WO2005082892A2 - Triazole compounds as antibacterial agents and pharmaceutical compositions containing them - Google Patents

Triazole compounds as antibacterial agents and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2005082892A2
WO2005082892A2 PCT/IB2005/000343 IB2005000343W WO2005082892A2 WO 2005082892 A2 WO2005082892 A2 WO 2005082892A2 IB 2005000343 W IB2005000343 W IB 2005000343W WO 2005082892 A2 WO2005082892 A2 WO 2005082892A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
mmol
difluoro
compound
Prior art date
Application number
PCT/IB2005/000343
Other languages
French (fr)
Other versions
WO2005082892A3 (en
Inventor
Jagattaran Das
Mohamed Takhi
Selvakumar Natesan
Sanjay Trehan
Javed Iqbal
Sitaram Kumar Magadi
Sreenivas Kandepu
Original Assignee
Dr. Reddy's Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2005082892A2 publication Critical patent/WO2005082892A2/en
Publication of WO2005082892A3 publication Critical patent/WO2005082892A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Novel triazole compounds as antibacterial agents and their pharmaceutical compositions containing them
  • the present invention relates to novel triazole compounds of formula (I),
  • the present invention also relates to a process for the preparation of the above said novel compounds.
  • MRSA methicillin-resistant Staphylococcus aureas
  • US 6054471 discloses fluorinated triazoles, which are reported for the treatment of neuropathic pain and associated hyperalgesia, including trigeminal and herpectic neuralgia, diabetic neuropathic pain, migraine, causalgia and deafferentation syndromes such as brachial plexus avulsion,
  • J. Med. Chem., 2843, 1991 discloses compound, which is an anticoccidiostat and also been found to have antiproliferative activity in several disease models and to posses antimetastatic activity in a model of ovarian cancer progression,
  • novel triazole compound ofthe present invention is useful for the treatment of various infections
  • novel triazole compounds ofthe general formula (I) as defined above their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them.
  • Another aspect of the present invention provides a process for the preparation of novel triazole compounds ofthe formula (I).
  • Yet another aspect ofthe pesent invention provides the use of novel compounds of formula (I) or their pharmaceutical compositions in the treatment of bacterial infections.
  • novel compounds of formula (I) or their pharmaceutical compositions in the treatment of bacterial infections.
  • the present invention relates to compounds having the general formula (I),
  • R 1 is isoindole-l,3-dione, azido, NHR where R represents (a) Hydrogen,
  • Optionally substituted groups selected from, (ii) Alkyl, (iii) Cycloalkyl, (iv) Alkoxy, (v) Cycloalkoxy, (vi) Alkenyl, (vii) Alkenyloxy, (viii) Aryl, (ix) Aryloxy, (x) Heteroaryl, (xi) ⁇ Heterocyclyl, (xii) Heteroaryloxy,
  • R 7 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, hydroxyalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, — C II — R 8
  • R 8 is optionally substituted group selected from alkyl, alkoxy, cycloalkyl, alkenyl, alkenyloxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, and Q represents oxygen or sulfur;
  • (xvi) -SR 8 wherein R 8 is as defined above, (xv) -S0 2 -alkyl;
  • R 2 and R 3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen, (iii) Cyano, (iv) Nitro, (v) Amino
  • R represents hydrogen or optionally substituted alkyl group
  • R b represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino;
  • 'Z' represents N, C or CH
  • R 4 represents hydrogen, cyano, alkyl,. cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalklyl, acyl, haloacyl, alkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, alkenyloxy, aryl, aryloxy, arylcarbonyl, aralkyl, aralkylcarbonyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heterocyclylalkyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, aralkyl, aralkoxyalkyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, aral
  • R 2 , R 3 , R 4 , R 5 , R ⁇ , R 7 and R 8 may take place 1 to 5 times, which may be same or different;
  • One aspect of the present invention provides compound of formula (I), where Z represents 'N', ' ' represents no bond, which is represented by compound of formula
  • Optionally substituted groups selected from, ( ⁇ ) ' Alkyl, (iii) Cycloalkyl, (iv) Alkoxy, (v) Cycloalkoxy, (vi) Alkenyl, (vii) Alkenyloxy,
  • R 2 and R 3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen,
  • R 4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkylamino, alkylaminoalldyl, acyl, haloacyl, aminocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, aryl, aryloxy, arylcarbonyl, . aralkyl, heterocyclyl, heterocyclylalkyl, .
  • substitutions on the possible groups represented by R 4 may take place 1 to 5 times, which may be same or different;
  • R 6 represents alkyl or alkoxy group
  • R and R which may be same or different, independently represent hydrogen or halogen
  • R represents
  • R e OH, OCH 3 , CH 3 , NH 2
  • R 2 and R 3 which may be same or different, independently represent hydrogen or halogen
  • R 4 represents
  • R' represents hydrogen or alkyl grou'p n represents 0-6;
  • R y represents alkyl or aryl Another embodiment of compound of formula (la), where Ri represents , wherein R represents alkyl or alkoxy group; R 2 and R 3 , which may be same or different, independently represent hydrogen or halogen; R represents cyano,
  • Another aspect of the present invention provides compound of formula (I), where
  • R 6 represents
  • R 2 and R 3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen,
  • R 4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, ammocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, aryl, aryloxy, arylcarbonyl, aralkyl, heterocyclyl, heterocyclylalkyl,- heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcaarbonyl, tert-butoxycarbonyl (BOC), alkenylcarbonyl, aralkyl, aralkyl
  • substitutions on the possible groups represented by R 4 may take place 1 to 5 times, which may be same or different; which is represented by compound of formula (Ia); their pharmaceutically acceptable salts their stereosiomers thereof, pharmaceutical compositions containing them
  • R 6 represents alkyl or alkoxy group
  • R 2 and R 3 which may be same or different, independently represent hydrogen or halogen
  • R represents
  • n 0-6;
  • R e OH, QCH 3 , CH 3 , NH 2
  • R y represents alkyl or aryl
  • R 6 represents alkyl or alkoxy group
  • R 2 -and R 3 which may be same or different, independently represent hydrogen or halogen
  • R represents alkyl or alkoxy group
  • R 2 and R 3 which may be same or different, independently represent hydrogen or halogen
  • R 4 represents
  • n 0-6;
  • R y represents alkyl or ' aryl
  • R represents alkyl or alkoxy group
  • R 2 and R 3 which may be same or different, independently represent hydrogen or halogen
  • R 4 represents cyano
  • 'Halogen' is fluorine, chlorine, bromine, or iodine
  • 'Alkyl' group is optionally substituted linear or branched ( -C 10 ) alkyl group.
  • exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t- butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like.
  • 'Haloalkyl' group is optionally substituted linear or branched monohalo(C
  • Exemplary alkyl groups include monohalomethyl, dihalomethyl, trihalomethyl, monohaloethyl, dihaloethylm trihaloehtylm tetrahaloethylm pentahaloethyl and the like.
  • 'Hydroxyalkyl' group is linear or branched hydroxy (Q-C ⁇ o)alkyl group.
  • exemplary alkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, hydroxyheptyl, hydroxyoctyl and the like.
  • 'Hydroxyalkylamino' group is linear or branched hydroxy(C ⁇ -C ⁇ o)alkylamino group.
  • exemplary hydroxyalkylamino groups include hydroxymethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxypentylamino, hydroxyhexylamino, hydroxyheptyl amino, hydroxyoctylamino and the like.
  • 'Cycloalkyl' group is (C 3 -C 8 ) cycloalkyl group.
  • exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • 'Alkylamino' group represents monoalkylamino or dialkylamino group.
  • 'Monoalkylamino' is (C ⁇ -C ⁇ o)alkylamino, where (C ⁇ -C ⁇ o)alkyl is as defined above.
  • Exemplary monoalkylamino groups include methylamino, ethylamino, propylamino, isoporpylamino and the like.
  • 'Dialkylamino' is di(C ⁇ -C 2 o)alkylamino, where (C1-C10) alkyl is as defined above.
  • Exemplary dialkylamino groups include dimethylamino, diethylamino, ethylmethylamino and the like.
  • Alkoxy' is ( -Cio) alkyl-O-, wherein the ( -C 1 0) alkyl group is as defined above.
  • Exemplary alkyl groups include methoxy, ethoxy, propoxy, butoxy, iso-propoxy and the like.
  • 'Cycloalkoxy' is (C3-C10) cycloalkoxy group.
  • exemplary cycloalkoxy groups include cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy and the like.
  • alkenyl' is (C 2 -C ⁇ o) alkenyl group.
  • alkenyl groups include ethenyl, propenyl, but-1-enyl, pentenyl, hexenyl and the like.
  • 'Cycloalkenyl' is (C 3 -C ⁇ o)cycloalkenyl group.
  • exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like.
  • alkylaminoalkyl' is (C ⁇ -C ⁇ o)alkylamino(C ⁇ -C ⁇ o)alkyl group, where alkyl group is as defined above.
  • alkylaminoalkyl groups include methylaminomethyl, methylaminoethyl, methylaminopropyl, methylaminobutyl, ethylaminomethyl, ethylaminoethyl, ethylaminopropyl, ethylaminobutyl, propylaminoethyl, propylaminobutyl, butylaminopropyl, butylaminobutyl, propylaminomethyl, butylaminomethyl, ethylaminobutyl, propylaminopropyl and the like.
  • alkylcarbonyl' is (C ⁇ -C ⁇ o)alkylcarbonyl group.
  • alkylcarbonyl groups include methylcarbonyl, ethylcarbonyl, propylcarbonyl, isoporpynylcarbonyl, butylcarbonyl and the like.
  • alkenylcarbonyl' is (C 2 -C ⁇ o)alkenyl-CO, wherein (C 2 -C ⁇ 0 ) alkoxy is as defined above.
  • alkenycarbonyl groups include ethenylcarbonyl, propenylcarbonyl, butenylcarbonyl, but-1-enylcarbonyl and the like.
  • alkoxyalkyl' is (C
  • alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxypropyl, ethoxybutyl, ethoxybutyl, ethoxypentyl, ethoxyhexyl, propoxyethyl, isopropoxyethyl, butoxyethyl, isobutoxyethyl and the like.
  • alkoxycarbonyl' is (C.-C 10 ) alkoxycarbonyl, wherein ( -C 1 0) alkoxy is as defined above.
  • alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl and the like.
  • Carboxy alkyl' is carboxy (C ⁇ -C . o)alkyl, where ( -C ⁇ o)alkyl group is as defined above.
  • Exemplary carboxyalkyl groups include carboxymethyl, carboxyethyl and the like.
  • alkylsulfonyl is (C ⁇ -C ⁇ o)alkylsulfonyl, where (C ⁇ -C ⁇ o)alkyl group is as defined above.
  • alkylsulfonyl groups include methylsulfonyl, ethylsulfonyl and the like
  • alkylsulfmyl is (C ⁇ -C ⁇ o)alkylsulfinyl, where (C ⁇ -C ⁇ o)alkyl group is as defined above.
  • alkylsulfmyl groups include methylsulfinyl, ethylsulfinyl and the like
  • 'Alkylsulfanyl' is (C ⁇ -C ⁇ o)alkylsulfanyl, where ( -C ⁇ o)alkyl group is as defined above.
  • Exemplary alkylsulfanyl groups include methylsulfanyl, ethylsulfanyl and the like
  • 'Alkylsulfonyloxy' is (C 1 -C 1 0) alkylsulfonyloxy, where (C ⁇ -C ⁇ o)alkyl group is as defined above.
  • Exemplary alkylsulfonyloxy groups include methylsulfonyloxy, ethylsulfonyloxy and the like.
  • 'Aryl' is monocylic or polycyclic ring system of about 6 to 14 carbon atoms.
  • exemplary groups include phenyl, naphthyl and the like.
  • 'Arylcarbonyl' is aryl-carbonyl group, where aryl group is as defined above.
  • arylcarbonyl groups include phenylcarbonyl, naphthylcarbonyl and the like.
  • 'Arylsulfonyl' is aryl-sulfonyl, where aryl group is as defined above.
  • Exemplary arylsulfonyl groups include phenylsulfonyl, naphthylsulfonyl and the like.
  • 'Arylsulfanyl' is aryl-sulfanyl, where aryl group is as defined above.
  • Exemplary arylsulfanyl groups include phenylsulfanyl, naphthylsulfanyl and the like.
  • 'Arylsulfinyl' is aryl-sulfinyl, where aryl group is as defined above.
  • arylsulf ⁇ nyl groups include phenylsulfinyl, naphthylsulfinyl and the like.
  • alkylcarbonylaminoalkyl is (C ⁇ -C ⁇ o)alkylcarbonylamino(C ⁇ -C ⁇ o)alkyl, where (Q- C ⁇ o)alkyl group is as defined above.
  • alkylcarbonylaminoalkyl groups include methylcarbonylaminomethyl, methylcarbonylaminoethyl and the like.
  • 'Arylcarbonylaminoalkyl' is arylcarbonylamino (C ⁇ -C ⁇ o)alkyl, where aryl and (Q- C ⁇ o)alkyl group are as defined above.
  • exemplary arylcarbonylaminoalkyl include phenylcarbonylaminomethyl, phenylcarbonylaminoethyl and the like.
  • alkyl carbonyloxyalkyl' is (C
  • exemplary alkylcarbonyloxyalkyl groups include methylcarbonyloxymethyl, ethylcarbonyloxymethyl and the like.
  • 'Hydroxyalkylcarbonyl' is hydroxyl-(C]-C ⁇ o)alkylcarbonyl, where (C ⁇ -C ⁇ o)alkyl group is as defined above.
  • exemplary hydroxyalkylcarbonyl groups include hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl and the like.
  • 'Aminoalkyl' is amino (C ⁇ -C ⁇ o)alkyl, where (C ⁇ -C ⁇ o)alkyl is as defined above.
  • exemplary amino alkyl groups include amino methyl, amino ethyl and the like.
  • aryl group is as defined above.
  • aryl amino groups include phenyl amino, naphthylamino and the like.
  • alkenyloxy' is (C3-C 1 0) alkenyl-O-, where the (C 2 -C ⁇ ) alkenyl group is as defined above.
  • alkenyl groups include ethenyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy and the like.
  • 'Acyl' is H-CO or (C ⁇ -C 20 ) alkyl-CO- group, where (C ⁇ -C 2 o)alkyl is as defined above.
  • exemplary acyl groups include acetyl, propionyl, wo-propionyl, tert-butionyl and the like.
  • Haloacyl' is Halogen-(C ⁇ -C ⁇ o) alkyl-CO- group, where (C ⁇ -C ⁇ o)alkyl is as defined above.
  • exemplary haloacyl groups include haloacetyl, halopropionyl and the like.
  • 'Acyloxy' is (C1-C10) acyl-O-, where acyl group is defined as H-CO- or (C 1 -C 10 ) alkyl-CO-, where (C1-C10) alkyl group is as defined above.
  • acyl groups include acetyl, propionyl, and the like.
  • acyloxy groups include acetyloxy, propionyloxy, t_. ⁇ -propionyloxy, tert-butionyloxyand the like.
  • 'Aryloxy' is optionally substituted aryl-O- group, where the aryl group is as defined above.
  • aryloxy groups include phenoxy, naphthyloxy and the like.
  • 'Aralkyl' is aryl-(C ⁇ -C ⁇ o) alkyl group, wherein aryl and (C1-C10) alkyl groups are as defined above.
  • Exemplary aralkyl groups include benzyl, 2-phenylethyl and the like.
  • 'Aralkylcarbonyl' is aralkyl-carbonyl group, wherein aralkyl group is as defined above.
  • exemplary aralkylcarbonyl groups include benzylcarbonyl, 2-phenylethylcarbonyl and the like.
  • 'Aralkoxy' is aralkyl-O- group, wherein the aralkyl group as defined above.
  • exemplary aralkoxy groups include bezyloxy, 2-phenethyloxy and the like.
  • 'Aralkoxyalkylcarbonyl' is aralkyl-0-(C ⁇ -C ⁇ o)alkyl-CO group, where aralkyl and (C ⁇ -C ⁇ o)alkyl groups are as defined above.
  • exemplary aralkoxyalkylcarbonyl groups include benzyloxymethylcarbonyl, benzyloxyethylcarbonyl, benzyloxypropylcarbonyl and the like.
  • Heterocyclyl' is non-aromatic saturated monocyclic or polycyclic ring system of about 5 to about 10 carbon atoms, having at least one hetero atom selected from O, S or N.
  • exemplary heterocyclyl groups include aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, oxazolidinyl, azepanyl, [1,3]- dioxanyl, 1,3-dioxolanyl, 1 ,4-dioxolanyl and the like.
  • Heterocyclylcarbonyl' is heterocyclylcarbonyl, where heterocyclyl is as defined above.
  • exemplary heterocyclylcarbonyl groups include aziridinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, thiazolidinylcarbonyl, oxazolidmylcarbonyl, azepanylcarbonyl, [l,3]-dioxanylcarbonylcarbonyl, 1,3-dioxolanylcarbonyl, 1 ,4-dioxolanylcarbonyl and the like.
  • Heterocyclylalkyl' is non-aromatic saturated monocyclic or polycyclic ring system of about 5 to about 10 carbon atoms, having at least one hetero atom selected from O, S or N.
  • exemplary heterocyclylalkyl groups include 4-ethylmorpholinyl, 4- propylmorpholinyl, 4-butylmorpholinyl, 4-pentylmo ⁇ holinyl, 4-ethyl-[l ,3]dioxolanyl, 4- propyl-[l,3]dioxolanyl, 4-butyl-[l,3]dioxolanyl, 4-pentyl-[l,3]dioxolanyl, 5-ethyl- oxazolidinyl, 5-propyl-oxazolidinyl, 5-butyl-oxazolidinyl, 5-pentyl-oxazolidinyl, 1-ethyl- pyrrolidine, 1-prop
  • Heteroaryl' is aromatic monocyclic or polycyclic ring system of about 5 to about 10 carbon atoms, having at least one heteroatom selected from O, S or N.
  • exemplary heteroaryl groups include as pyrazinyl, isothiazolyl, oxazolyl, isoxazolyl, lH-pyrazolyl, pyrrolyl, pyridazinyl, thienopyrimidyl, furanyl, lH-indolyl, isoindolyl, 1,3-benzodioxole, 1 ,3-benzoxathiole, quinazolinyl, pyridyl, thiophenyl and the like.
  • Heteroarylcarbonyl' is heteroarylcarbonyl.
  • exemplary heteroarylcarbonyl groups include as pyrazinylcarbonyl, isothiazolylcarbonyl, oxazolylcarbonyl, isoxazolylcarbonyl, lH-pyrazolylcarbonyl, pyrrolylcarbonyl, pyridazinylcarbonyl, thienopyrimidylcarbonyl, furanylcarbonyl, 1 H-indolylcarbonyl, isoindolylcarbonyl, 1,3 -benzodioxolecarbonyl, 1,3- benzoxathiolecarbonyl, quinazolinylcarbonyl, pyridylcarbonyl, thiophenylcarbonyl and the like.
  • Heteroaralkyl' is heteroaryl-(C ⁇ -C ⁇ o) alkyl group, wherein the heteroaryl and (C ⁇ - Cio) alkyl groups are as defined above.
  • Exemplary heteroaralkyl groups include 1-ethyl- 1 H-pyrazolyl, 1 -propyl- lH-pyrazolyl, 1 -butyl- 1 H-pyrazolyl, 1 -pentyl- 1 H-pyrazolyl, 1- ethyl-lH-imidazolyl, 1 -propyl- 1 H-imidazolyl, 1-butyl-lH-imidazolyl, 1-pentyl-lH- imidazolyl, 4-ethylpyridinyl, 4-propylpyridinyl, 4-butylpyridinyl, 4-pentylpyridinyl, 3- ethylpyridinyl, 3-propylpyridinyl, 3-butylpyridinyl
  • Heteroaryloxy' is heteroaryl-O-, wherein the heteroaryl group is as defined above.
  • exemplary heteroaryloxy groups include pyrazinyloxy, isothiazolyloxy, oxazolyloxy, pyrazolyloxy, phthalazinyloxy, indolyloxy, quinazolinyloxy, pyridyloxy, thienyloxy and the like.
  • Heteroaralkylcarbonyl' is heteroaralkyl-CO-group, where heteroaralkyl group is as defined above.
  • exemplary heteroaralkylcarbonyl groups include 1-ethyl-lH- pyrazolylcarbonyl, 1 -propyl- lH-pyrazolylcarbonyl, 1 -butyl- 1 H-pyrazolylcarbonyl, 1- pentyl- 1 H-pyrazolylcarbonyl, 1 -ethyl- 1 H-imidazolylcarbonyl, 1 -propyl- 1 H- imidazolylcarbonyl, 1 -butyl- 1 H-imidazolylcarbonyl, 1 -pentyl- 1 H-imidazolylcarbonyl, 4- ethylpyridinylcarbonyl, 4-propylpyridinylcarbonyl, 4-butylpyridinylcarbonyl, 4- pentylpyridinylcarbonyl, 3-e
  • Heterocyclylalkylcarbonyl' is heterocyclyl-CO-group, where heterocyclylalkyl group is as defined above.
  • exemplary heterocyclylalkylcarbonyl groups include 4- ethylmorpholinylcarbonyl, 4-propylmorpholinylcarbonyl, 4-butylmorpholinylcarbonyl, 4- pentylmo ⁇ holinylcarbonyl, 4-ethyl-[l,3]dioxolanylcarbonyl, 4-propyl-
  • Heteroarylsulfonyl' is heteroaryl-sulfonyl group
  • Exemplary heteroarylsulfonyl groups include pyrazinylsulfonyl, isothiazolylsulfonyl, oxazolylsulfonyl, pyrazolylsulfonyl, pyrrolylsulfonyl, pyridazinylsulfonyl, thienopyrimidylsulfonyl, furylsulfonyl, indolylsulfonyl, isoindolylsulfonyl, quinazolinylsulfonyl, pyridylsulfonyl, thiophenylsulfonyl and the like.
  • Carboxylic acid or its derivatives' may be amides or esters.
  • Exemplary carboxylic acid groups include CONH 2 , CONHMe, CONMe 2 , CONHEt, CONEt 2 , CONHPh, COOCH 3 , COOC 2 H 5 or COOC 3 H 7 .
  • 'Phosphoric acid or its derivates' include PO(OCH 3 ) 2 , PO(OC 2 H 5 ) 2 and the like.
  • Another embodiment of the present invention provides a process for the preparation of compound of formula (I), Where R represents R or R 4 , wherein R represents protecting group such as 't-butoxy carbonyl group (protecting group) and R 4 is as defined in description of compound of formula (I).
  • the compound of formula (2) represents compound of formula (I), when R 1 represents NHR 5 , R b represents R 4 and all other symbols are as defined in the description of compound of formula (I).
  • the compound of formula (2) represents compound of formula (I), when R 1 represents represents isoindole-l,3-dione, R b represents R 4 and all other symbols are as defined in the description of compound of formula (I).
  • the compound of formula (2) represents compound of formula (I), when R 1 represents NHR 5 wherein R 5 represents hydrogen atom, R b represents R 4 and all other symbols are as defined in the description of compound of formula (I), which comprises:
  • the compound of formula (2a) and and piperazine were stirred in a suitable solvent selected from tetrahydrofuran (THF), dimethylformamide (DMF), chloroform, acetonitrile and the like.
  • a suitable solvent selected from tetrahydrofuran (THF), dimethylformamide (DMF), chloroform, acetonitrile and the like.
  • the temperature of the reaction was maintained in the range of 20 °C to boiling temperature of the solvent used in the reaction.
  • the mixture was poured into cold water, and the mixture was cooled to ice temperature.
  • the material was filtered and dried or can be extracted from aqueous layer with a solvent such as ethyl acetate, DCM, chloroform and the like.
  • the above compound of formula (2b) was converted to a compound of formula (2c) by using a solvent such as DMF, THF, 1,4-dioxane and the like, and t- butoxycarbonylanhydride [(Boc) 2 0] in the presence of a base such as sodiumhydroxide (NaOH), potassiumhydroxide (KOH) and the like.
  • a base such as sodiumhydroxide (NaOH), potassiumhydroxide (KOH) and the like.
  • the temperature of the reaction was maintained in the range of 0 to 50 °C, and the duration ofthe reaction is in the range of 0.5 to 5 hours.
  • the resultant product was poured into water to obtain (t-butoxycarbonyl)'Boc' protected compound.
  • the compound of formula 2(c) was reduced to a compound of formula 2(d), by using a reducing agent such as palladium/carbon (Pd/C) or Platinum and hydrogen (H 2 ), sodium borohydrate/niclechloride (NaBE NiC ⁇ ) and the like.
  • a reducing agent such as palladium/carbon (Pd/C) or Platinum and hydrogen (H 2 ), sodium borohydrate/niclechloride (NaBE NiC ⁇ ) and the like.
  • the solvent used in the reaction was selected from methanol, ethanol, propanol, isopropanol, ethyl acetate and the like.
  • the compound of formula (2d) was converted to a compound of formula (2e) by using sodium nitrite (NaN0 2 ) in the presence of hydrochloride (HCI) or acetic acid (CH 3 COOH) followed by sodiumazide (NaN 3 ).
  • the temperature of the reaction may be maintained in the range of about -40 °C to boiling temperature of the solvent used, preferably in the range of 0 °C to boiling temperature.
  • the duration of the reaction may be in the range of about 0.5 to 15 hours, preferably in the range of about 0.5 to 5 hours
  • the compound of formula (2g) is reacted with a compound of formula (2h), to obtain a compound of formula (2i), when X represents halogen atom, by using (C 1 -C 10 ) alkyllithium such as methyllithium (MeLi), n-butyllithium (n-BuLi), secondary butyllithium (sec.BuLi), tertiary butyllithium (ter.BuLi) and the like, and the like.
  • the compound of formula (Ic), where X represents hydrogen atom is obtained by treating with CsF.
  • the solvent used in the reaction may be selected from tetrahydrofuran (THF), hexamethylphosphoramide (HMPA), diethylether and the like.
  • the temperature and duration of the reaction can be maintained in the range of about -78 to about 100 °C and about 30 min to about 1.5 h respectively.
  • the compound of formula (2i) is reacted with a compound of formula (2j), by using a reagent (Ci-Cio) alkyllithium such as methyllithium (MeLi), n-butyllithium (n- BuLi), secondary butyllithium (sec.BuLi), tertiary butyllithium (ter.BuLi) and the like.
  • a reagent (Ci-Cio) alkyllithium such as methyllithium (MeLi), n-butyllithium (n- BuLi), secondary butyllithium (sec.BuLi), tertiary butyllithium (ter.BuLi) and the like.
  • the solvent used in the reaction may be selected from THF, hexametaphosphoric (HMPA), diethyl ether, 1 ,4-dioxane and the like.
  • the temperature and duration of the reaction can be maintained in the range of about -78 to about 50
  • the resultant compound was treated with any of the reagents selected from cone HCI, p-toluene sulfonic acid (p-TSA), mesyl chloride & triethylamine, 1,2- diazabicyclo[5,4,0]undec-7-ene (DBU), phosphorous oxychloride (POCl 3 ),
  • the solvent used in the reaction is selected from pyridine, dichloromethane, acetonitrile, toluene and the like.
  • the temperature and duration of the reaction can be maintained in the range of about 0 to about 150 °C and about 30 min to about 24 h respectively.
  • the compound of formula (2k) in dil. HCI is reacted with NaN0 2 and NaN 3 or t- Butyl nitrile and NaN 3 , to obtain a compound of formula (21),
  • the temperature and duration of the reaction can be maintained in the range of about 0 to about 150 °C and about 30 min to about 24 h respectively.
  • the compound of formula (2f) and/or (21) was subjected to 1,3-dipolar cycloaddition with the corresponding acetylene derivative to obtain a compound of formula (2).
  • the solvent used in the reaction was selected from DMF, acetonitrile, THF, toluene and the like.
  • the reaction may be carried out in the presence of a catalyst such as Cul.
  • the temperature of the reaction was maintained in the range of 0 to 90 °C.
  • the duration of he reaction was maintained in the range of 0.5 to 6 hours.
  • the compound of formula (2f) and/or (2k) was converted to a compound of formula (2) by adopting the similar procedure as described above.
  • the compound of formula (3) was converted to a compound of formula (4) by using reagents such as hydrazine, dialkylamine, ethylenediamine and the like.
  • the solvents used in the reaction may be selected from methanol, ethanol, propanol, isopropanol and the like.
  • the temperature was maintained in the range of 20 °C to the boiling temperature of the solvent used in the reaction.
  • the duration of the reaction is in the range of 1 to 12 h.
  • the compound of formula (4) was converted to amide (where R 5 represents COR) by using the corresponding acid chloride and triethylamine or acid anhydride and base such as triethylamine, pyridine and the like.
  • the resultant amide can be further converted to thioamide by using sulfur transfer reagent such as La wesson's reagent or the amine can be converted to thiocyanate (NCS) by treating with thiophosgene and triethylamine, followed by refluxing in alcohol such as methanol, ethanol, propanol, isopropanol and the like.
  • the compound of formula (2f) and/or (21), where R represents 'Boc' was first deprotected with chloroethylchloroformate, dil. HCI or trifluoroacetic acid in a suitable solvent such as dichloromethane, 1 ,2-dichloroethane, THF, 1,4-dioxane, chloroform and the like.
  • a suitable solvent such as dichloromethane, 1 ,2-dichloroethane, THF, 1,4-dioxane, chloroform and the like.
  • the temperature of the reaction may be in the range of 0 to 40 °C.
  • the duration of the reaction may be in the range of 0.5 to 12 hours.
  • the resultant mixture was neutralized by sodium carbonate, sodium bicarbonate and the like, followed by extraction with a solvent such as ethylacetate, dichloromethane, chloroform and the like to obtain a free amine.
  • the free amine can be converted to
  • the deprotection can be carried out by using H 2 /Pd-C,
  • the solvent used may be selected from ethylacetate, methanol, ethanol, propanol and the like.
  • the temperature of the reaction may be in the range of 0 to 40 °C.
  • the duration of the reaction may be in the range of 0.5 to 12 hours.
  • the compound of formula 2(p) was converted to a compound of formulae or (5), by using the procedure as defined for the conversion of 2(f) and/or 2(1) to the compound of formulae (2) or (5).
  • Another aspect of the present invention provides an intermediate of formula (2f)
  • Another aspect ofthe present invention provides an intermediate of formula (21)
  • any reactive group in the substrate molecule may be protected according to conventional chemical practice.
  • Suitable protecting groups in any of the above mentioned reactions are tertiarybutyldimethylsilyl, methoxymethyl, triphenyl methyl, benzyloxycarbonyl, tetrahydropyran(THP) etc, to protect hydroxyl or phenolic hydroxy group; N-tert- butoxycarbonyl (N-Boc), N-benzyloxycarbonyl (N-Cbz), N-9-fluorenyl methoxy carbonyl (-N-FMOC), benzophenoneimine, propargyloxy carbonyl (POC) etc, for protection of amino or anilino group, acetal protection for aldehyde, ketal protection for ketone and the like.
  • the methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
  • a method of treating or preventing an bacterial infections in a subject is provided by administering an therapeutically effective amount of compound of formula (I).
  • terapéuticaally effective amount shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or patient that is being sought.
  • the pharmaceutically acceptable salts are prepared by reacting the compounds of formula (I) wherever applicable with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in the presence of a solvent like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used.
  • Organic bases like lysine, arginine, diethanolamine, choline, tromethamine, guanidine and their derivatives etc. may also be used.
  • acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in the presence of a solvent like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvent may also be used.
  • the salts of amino acid groups and other groups may be prepared by reacting the compounds of formula (I) with the respective groups in the presence of a solvent like alcohols, ketones, ether etc. Mixture of solvents may be used.
  • the present invention also provides pharmaceutical compositions, containing compounds of the general formula (I), their pharmaceutically acceptable salts
  • the pharmaceutical compositions according to this invention can be used for the treatment of bacterial infections. They can also be used for the treatment of bacterial infections associated with multidrug resistance.
  • the pharmaceutical compositions according to this invention can also be administered prophylatically for the prevention of bacterial infections in a patient at risk of developing a bacterial infection.
  • prodrugs comprise functional derivatives of the claimed compounds which are capable of being enzymatically activated or converted into the more active parent form.
  • administering encompasses the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs (1985). See also, Wihnan, 14 Biochem. Soc. Trans. 375-82 (1986); Stella et al., Prodrugs: A Chemical Approach to Targeted Drug Delivery in Directed Drug Delivery 241-61 (1985).
  • the regioisomers of compound of formula (I) may be prepared by modifying the reaction conditions, use of reagents like acid to base or base to acid or by reaction with free base hydrazine instead of its salt with diketone.
  • the molar proportion also can change the regioisomer formation.
  • the stereoisomers of the present invention include enatiomers such as (R), (S), a mixture of (R), (S), and mixture of (R) and (S).
  • the individual optical isomers or required isomers may be obtained by using reagents in such a way to obtain single isomeric form in the process wherever applicable or by conducting the reaction in the presence of reagents or catalysts in their single enantiomeric form.
  • Some of the preferred methods of resolution of racemic compounds include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in “Enantiomers, Racemates and Resolution” (Wiley Interscience, 1981).
  • the compounds of formula (I) may be resolved by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula (I) may be prepared by hydrolyzing the pure diastereomeric amide.
  • compositions may be in the forms normally employed, such as tablets, capsules, powders, dispersible granules, cachets, suppositories, syrups, solutions, suspensions and the like, may contain flavorants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions.
  • Such compositions typically contain from 0.5 to 90 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
  • Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions.
  • the active compounds will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above.
  • the compounds can be combined with a suitable solid, liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
  • the pharmaceutical compositions may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like.
  • the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds.
  • the injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
  • the compounds of the formula (I) or pharmaceutical compositions thereof as defined above are clinically administered to mammals, including human beings, via oral, parenteral and/or topical routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or abso ⁇ tion following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally.
  • the dosage is in the range of about 0.1 mg/kg to about 150 mg / kg, morepreferably about 3.0 mg/kg to about 100 mg/kg of body weight of the subject per day administered singly or as a divided dose.
  • the optimum dosage whether for prevention or treatment for the individual subject being treated will be determined by the person responsible for treatment, Initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administering, e.g. 2-6 times per day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used.
  • a topical treatment an effective amount of compound of formula (I) is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment.
  • Such creams and gels can be prepared by the procedures available in the literature and can include penetration enhancers.
  • N-Butyllithium (62 mL, 1.6M in hexane) was added drop wise to a solution of 3- fluoroaniline (5 grams, 45.1 mmol) in dry THF (100 mL) at -78 °C under nitrogen atmosphere and stirred for 30 minutes.
  • a solution of 1,2 -bis (chlorodimethylsilyl)-ethane (10.65 grams, 49.54 mmol) in dry THF (100 mL) was then added.
  • the reaction mixture was stirred at the same temperamre for 45 minutes and then warmed to 25-35 °C.
  • the reaction mixture was quenched with water (60 mL) and then extracted with diethyl ether. The combined organic layers were dried over sodium sulphate.
  • the title compound was prepared from 4-[(4-azido-2-fluoro-phenyl)-piperazine-l- carboxylic acid tert-butyl ester and 5-nitro-furoyl chloride, obtained in preparation 17, following the same procedure as described for the preparation of [4-(4-azido-2,6-difluoro- phenyl)-piperazin-l-yl]-(5-nitro-furan-2-yl)-methanone (Preparation 19).
  • IR (KBr, cm “1 ): 3118, 2928, 2822, 2323, 2203, 2117, 1746, 1648, 1572, 1505, 1430, 1356, 1281, 1237, 1196, 1152, 1027, 980.
  • CI-MS (m/z): 335 (M + +l), 306, 225, 151, 96, 90.
  • IR (KBr, cm “1 ): 3405, 2930, 2856, 1667, 1524, 1470, 1256, 11 19, 1045, 938, 859, 805, 779, 670, 605, 564.
  • CI-MS (m/z): 412 (M + +l), 383, 354, 326, 307, 231, 193, 144, 105, 91.
  • the title compound was prepared from 4-(l -Benzyl- 1, 2, 3, 6-tetrahydro-pyridin- 4-yl)-3, 5-difluoro-phenylamine (6 grams, 20 mmol), obtained from preparation 13, following the same procedure as described for the preparation of l-[4-(4-azido-2-fluoro - phenyl)-piperazin-l-yl] -ethanone (Preparation 7), in 62% yield.
  • aqueous layer was then extracted with ethyl acetate (50 mL x 4) and the combined organic layers were washed with water and brine and dried over sodium sulfate. Removal of volatiles left 1.6 grams (97%) of the title acid, which was used directly for the next step.
  • the desired product (600 mg) was obtained from 4-(4-azido-2, 6-difluoro-phenyl)- 1 , 2, 3, 6-tetrahydro-pyridine (687 mg, 2.91 mmol), obtained in preparation 27, by the same procedure as described for the preparation of [4-(4-azido-2-fluoro-phenyl)-3,6- dihydro-2H— pyridin-l-yl]-(2,2-dimethyl-[l,3]dioxolan-4-yl)-methanone (Preparation 30).
  • the title compound was prepared from was synthesized from l-(4-Azido-2,6- difluoro-phenyl)-piperazine, obtained in the process of preparation 19, and 2-amino-3- hydroxy-propionic acid methyl ester using the same procedure as described for synthesis of 3-[4-(4-Azido-2, 6-difluoro-phenyl)- piperazin-l-yl]-N-methyl-3-oxo-propionamide (preparation 36).
  • the title compound (250 mg, 53 %) was synthesized from (3-Hydroxy-phenyl)- acetic acid (191 mg, 1.25 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in example 27.
  • the title compound (490 mg, 58 %) was synthesized from (4-Nitro-phenyl)-acetic acid (379 mg, 2.09 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same described in example 27.
  • the title compound (87 mg, 1 1 %) was synthesized from hydroxyl phenyl-acetic acid (344 mg, 2.26 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine obtained in the process of preparation 20, applying the same procedure as described in example 27.
  • the title compound (700 mg, 29 %) was synthesized from 3-Chloromethyl- benzoyl chloride (1.78 mL, 12.6 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in preparation 34.
  • Preparation 56 l-[4-(4-Azido-2,6 -fluoro-phenyl)- piperazin-l-yl]-2-imidazoI-l-yI-ethanone
  • the title compound 400 mg, 55%o was synthesized from l-[4-(4-Azido-2,6- fluorb-phenyl)-piperazin-l-yl]-2-bromo-ethanone (750 mg, 2.08 mmol) obtained in preparation 47, and imidazole using the same procedure employed in preparation 45.
  • the title compound (630 mg, 50 %) was synthesized from acryloyl chloride (1.25 grams, 13.8 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20, following the same procedure as described in preparation 34.
  • n-Butyl lithium 0.41 mL, 1.6 M in hexane was added to a solution of tert-butyl hydroperoxide (TBHP). ( 0.2 mL, 4M in toluene) in THF ( 5 mL ) at -78 °C . The mixmre was stirred for 5 minutes. A solution of (l-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]- propenone (150 mg, 0.54 mmol) obtained in preparation 63, in dry THF (5 mL) was added to the reaction mixmre and stirred for 9 to 13 hours.
  • TBHP tert-butyl hydroperoxide
  • the title compound (100 mg, 50 %>) was synthesized from 2-Phenyl-[l,3]dioxane- 5-carboxylic acid (92 mg, 0.47 mmol) (Ref: J.Org.Chem., 62, 4029 - 4035, 1997) and 4- (4-azido-2,6-difluorophenyl)-l,2,3,6-tetrahydro-pyridine employing the procedure as described in example 27.
  • the title compound (1.3 grams, 69 %) was synthesized from pyrrolidine- 1 ,2- dicarboxylic acid 1 -tert-butyl ester (1 gram, 4.65 mmol) and l-(4-Azido-2-fluoro-phenyl)- piperazine, obtained in the process of preparation 20, following the same procedure as described in example 27.
  • the title compound (395 mg, 46 %) was synthesized from 1 -(4-Azido-2, fluoro- phenyl)-piperazine, obtained in the process of preparation 20, (720 mg, 3.26 mmol) applying the procedure as described in preparation 38.
  • the title compound (350 mg, 58 %) was synthesized from 4-pyridyl acetic acid (348 mg, 2 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in example 27.
  • Example 1 ⁇ l-[4-(4-Acetyl-piperazin-l-yl)-3-fluoro-phenyI]-l_?7-[l,2,3]triazol-4-ylmethyl ⁇ - thiocarbamic acid ⁇ ?-methyl ester
  • Example 8 ⁇ l-[3,5-Difluoro-4-(4-methanesulfonyl-piperazin-l-yl)-phenyl]-l_f7-[l,2,3]triazoI-4- ylmethylj-thiocarbamic acid O-methyl ester:
  • IR (KBr, cm “1 ): 3336, 3141 , 2920, 2855, 2361, 1747, 1520, 1451, 1408, 1322, 1268, 1207, 1 144, 1024, 958, 840, 783, 666, 517.
  • CI-MS (m/z): 447 (M+l), 415, 328.
  • IR (KBr, cm “1 ): 3404, 2930, 1590, 1518, 1454, 1393, 1355, 1233, 1143, 1023, 858, 811, 613.
  • CI-MS (m/z): 494 (M + +l), 462, 369, 337, 165, 158, 121.
  • reaction mixmre was washed with water followed by brine. Evaporation of volatiles left a residue, which was passed through a silica gel column (60-120 mesh; eluent: ethyl acetate: pet. ether) to produce the title compound (2.0 grams, 44%).
  • reaction mixmre was diluted with ethyl acetate (50 mL) followed by the addition of triethylamine (0.5 mL). Usual washings with water and brine and evaporation of the volatiles produced the title compound (550 mg, 73%).
  • the title compound was prepared from 4-(4-azido-2,6-difluoro-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester, obtained from preparation 18, and propargyl phthalimide following the same procedure as described for the preparation of 4- ⁇ 4-[4- (l,3-dioxo-l,3-dihydro-isoindol-2-ylmethyl)-[l,2,3]triazol-l-yl]-2-fluoro-phenyl ⁇ - piperazine-1 -carboxylic acid tert-butyl ester (Example 15).
  • IR (KBr, cm '1 ): 3416, 1718, 1637, 1519, 1467, 1396, 1279, 1232, 1211, 1027, 939, 855, 715,530.
  • CI-MS (m/z): 513 (M + +l), 483, 425, 315, 287, 229, 163, 91.
  • IR (KBr, cm “1 ): 3262, 3012, 2947, 2858, 1635, 1519, 1457, 1389, 1334, 1278, 1231, 1149, 1118, 1096, 1029, 857, 756.
  • CI-MS (m/z): 457 (M + +l), 425, 369, 320, 295, 245, 207, 183, 157, 128, 91.
  • reaction mixmre was diluted with water (30 mL) and then cooled to
  • reaction mixmre was diluted with dichloromethane (50 mL) washed with water followed by brine and dried over anhydrous sodium sulphate. The volatiles were removed under reduced pressure and the residue was purified by silica gel column chromatography

Abstract

The present invention relates to novel triazole compounds of formula (I), where all symbols are as defined in the detailed description; their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds.

Description

Novel triazole compounds as antibacterial agents and their pharmaceutical compositions containing them
Field of the Invention
The present invention relates to novel triazole compounds of formula (I),
Figure imgf000002_0001
where all symbols are as defined in the detailed description; their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them.
The present invention also relates to a process for the preparation of the above said novel compounds.
Background of the Invention
Since the discovery of penicillin, pharmaceutical companies have produced more than one hundred antibacterial agents to combat a wide variety of bacterial infections. In the past several years, there has been rapid emergence of bacterial resistance to several of these antibiotics. The multidrug resistance among these bacterial pathogens may also be due to mutation leading to more virulent clinical isolation; the most disturbing milestone has been the acquisition of resistance to vancomycin, an antibiotic generally regarded as the agent of last resort for serious Gram-positive infections. This growing multidrug resistance has recently rekindled interest in the search for new structural class of antibiotic that inhibit or kill these bacteria possibly by novel mechanisms.
A problem of larger dimension is the increasing incidence of the more virulent, methicillin-resistant Staphylococcus aureas (MRSA) among clinical isolates found worldwide. As with vancomycin resistant organisms, many MRSA strains are resistant to most of the known antibiotics, but MRSA strains have remained sensitive to vancomycin. However, in view of the increasing reports of vancomycin resistant clinical isolates and growing problem of bacterial resistance, there is an urgent need for new molecular entities effective against the emerging and currently problematic Gram-positive organisms.
Recently, several oxazolidinones have been discovered, which inhibit protein synthesis by binding to the 50S-ribosomal subunit which is close to the site to which chloramphenicol and lincomycin bind but their mode of action is mechanistically distinct from these two antibiotics. Various 1, 2, 3-triazoles, 1, 2, 4-triazoles and benzotriazoles have been reported to show various biological activities and have therefore found applications in medicinal chemistry. Some ofthe literature references are:
(a) Chem. Pharm. Bull. 48(12), 1935-1946 (2000) discloses the triazoles of reported as antifungal agents,
(b) US 6054471 discloses fluorinated triazoles, which are reported for the treatment of neuropathic pain and associated hyperalgesia, including trigeminal and herpectic neuralgia, diabetic neuropathic pain, migraine, causalgia and deafferentation syndromes such as brachial plexus avulsion,
(c) J. Med. Chem., 2843, 1991 discloses compound, which is an anticoccidiostat and also been found to have antiproliferative activity in several disease models and to posses antimetastatic activity in a model of ovarian cancer progression,
(d) J. Heterocycl. Chem., 609, 1989 discloses compound, which is reported for anti- inflammatory effects,
(e) EPO publication no 0304221 A2 discloses compounds, which are reported as antiproliferative reagents.
(f) PCT publication no. WO03/059894 (by Dr. Reddy's Laboratories Ltd.) discloses 1,2,3 -triazoles as antibacterial agents.
The novel triazole compound ofthe present invention is useful for the treatment of various infections
Summary ofthe Invention
According to one aspect of the present invention, there is provided novel triazole compounds ofthe general formula (I) as defined above, their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them.
Another aspect of the present invention provides a process for the preparation of novel triazole compounds ofthe formula (I).
Yet another aspect ofthe pesent invention provides the use of novel compounds of formula (I) or their pharmaceutical compositions in the treatment of bacterial infections. Detailed description of the Invention
The present invention relates to compounds having the general formula (I),
Where R1 is isoindole-l,3-dione, azido, NHR where R represents (a) Hydrogen,
6
(b) ~?XR Q
Where Q represents 'O' or 'S' R represents (i) Hydrogen,
Optionally substituted groups selected from, (ii) Alkyl, (iii) Cycloalkyl, (iv) Alkoxy, (v) Cycloalkoxy, (vi) Alkenyl, (vii) Alkenyloxy, (viii) Aryl, (ix) Aryloxy, (x) Heteroaryl, (xi) ■ Heterocyclyl, (xii) Heteroaryloxy,
(xiii) -NH-R7, where R7 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, hydroxyalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, — C II — R8
Q ' wherein R8 is optionally substituted group selected from alkyl, alkoxy, cycloalkyl, alkenyl, alkenyloxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, and Q represents oxygen or sulfur; (xiv) -N-[alkyl]2, (xv) -N(RcRd), wherem Rc and Rd together form an optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xvi) -SR8, wherein R8 is as defined above, (xv) -S02-alkyl;
R2 and R3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen, (iii) Cyano, (iv) Nitro, (v) Amino
Optionally substituted groups selected from (vi) Alkyl, (vii) Haloalkyl,
(viii) ORa where R represents hydrogen or optionally substituted alkyl group; (ix) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino;
'Z' represents N, C or CH;
' ' represents a bond or nobond;
R4 represents hydrogen, cyano, alkyl,. cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalklyl, acyl, haloacyl, alkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, alkenyloxy, aryl, aryloxy, arylcarbonyl, aralkyl, aralkylcarbonyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heterocyclylalkyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, aralkyl, aralkoxyalkyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfinyl, arylsulfonyl, arylsulfanyl, arylsulfmyl, tert-butoxycarbonyl, (BOC), heteroarylsulfonyl
R and R independently represent hydrogen, oxo (=0), thioxo (=S), amino, cynao, halogen, alkyl, alkoxy or haloalkyl; Substituents on R4, R6, R7, R8, independently selected from halogen, nitro, cyano, amino, hydroxy, cyano, oxo (=0), thioxo (=S), =N-CN, =N-ORx, where Rx represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfϊnyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, tert- butyl-dimethyl-silanyloxy)-acetyl chloride (TBDMSO), tert-butoxycarbonyl (BOC), N- hydroxyformamide, carboxylic acids or its derivatives, phosphoric acid or its derivates. Further optional substituents on the optionally substituted groups defined above are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), thioxo (=S), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives. Substitutents on R2 and R3 independently selected from hydroxy, halogen, nitro, amino, alkyl, haloalkyl, alkoxy, =0, =S, cyano group, or carboxylic acid or its derivatives, their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them.
Wherever substitutions are possible on the groups represented by R2, R3, R4, R5, Rδ, R7 and R8, they may take place 1 to 5 times, which may be same or different;
Representative compounds in accordance with the present invention are presented in Table 1. This table is not intended to be exclusive of the compounds of the present invention, but rather exemplary ofthe compounds that are encompassed by this invention
Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000007_0001
Figure imgf000007_0002
Figure imgf000007_0003
Figure imgf000007_0004
Figure imgf000007_0005
Figure imgf000007_0006
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000008_0004
Figure imgf000008_0005
Figure imgf000008_0006
Figure imgf000009_0001
Figure imgf000009_0002
Figure imgf000009_0003
Figure imgf000009_0004
:
Figure imgf000009_0005
Figure imgf000009_0006
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000010_0003
Figure imgf000010_0004
Figure imgf000010_0005
<
Figure imgf000010_0006
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000011_0003
Figure imgf000011_0004
Figure imgf000011_0005
Figure imgf000011_0006
Figure imgf000012_0001
Figure imgf000012_0002
Figure imgf000012_0003
Figure imgf000012_0004
Figure imgf000012_0005
Figure imgf000012_0006
Figure imgf000013_0001
Figure imgf000013_0002
Figure imgf000013_0003
Figure imgf000013_0004
Figure imgf000013_0005
.
Figure imgf000013_0006
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000014_0003
Figure imgf000014_0004
Figure imgf000014_0005
Figure imgf000014_0006
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000015_0003
Figure imgf000015_0004
Figure imgf000015_0005
Figure imgf000016_0001
Figure imgf000016_0002
Figure imgf000016_0003
Figure imgf000016_0004
Figure imgf000016_0005
Figure imgf000016_0006
Figure imgf000017_0001
Figure imgf000017_0002
Figure imgf000017_0003
Figure imgf000017_0004
Figure imgf000017_0005
Figure imgf000017_0006
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000018_0003
Figure imgf000018_0004
Figure imgf000018_0005
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
Figure imgf000019_0004
Figure imgf000019_0005
Figure imgf000019_0006
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000020_0003
Figure imgf000020_0004
Figure imgf000020_0005
Figure imgf000020_0006
Figure imgf000021_0001
Figure imgf000021_0002
Figure imgf000021_0003
Figure imgf000021_0004
Figure imgf000021_0005
Figure imgf000021_0006
their stereoisomers and their pharmaceutically acceptable salts thereof; One aspect of the present invention provides compound of formula (I), where Z represents 'N', ' ' represents no bond, which is represented by compound of formula
(Ia); their pharmaceutically acceptable salts their stereosiomers thereof, their pharmaceutical compositions containing them
Figure imgf000022_0001
Where R represents
— C-RD
II
Q Where Q represents 'S' Rδ represents (i) Hydrogen,
Optionally substituted groups selected from, (ϋ) ' Alkyl, (iii) Cycloalkyl, (iv) Alkoxy, (v) Cycloalkoxy, (vi) Alkenyl, (vii) Alkenyloxy,
R2 and R3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen,
R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkylamino, alkylaminoalldyl, acyl, haloacyl, aminocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, aryl, aryloxy, arylcarbonyl, . aralkyl, heterocyclyl, heterocyclylalkyl, . heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcaarbonyl, tert-butoxycarbonyl (BOC), alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfmyl, arylsulfonyl, arylsulfanyl, arylsulfinyl, heteroarylsulfonyl Substituents on R4 selected from halogen, nitro, cyano, amino, hydroxy, oxo (=0), =N- ' CN, =N-ORx, where Rx represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl; alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert-butyl-dimethyl-silanyloxy)-acetyl chloride (TBDMSO), tert-butoxycarbonyl (BOC), N-hydroxyformamide, carboxylic acid or its derivatives. The optional substituents on these groups are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives, phosphoric acid or its derivates;
The substitutions on the possible groups represented by R4, may take place 1 to 5 times, which may be same or different;
Another aspect of compound of formula (Ia), where Rj represents — C I I -R6
S , wherein R6 represents alkyl or alkoxy group; R and R , which may be same or different, independently represent hydrogen or halogen; R represents
Hydrogen, Cyanq H3
Figure imgf000024_0001
Figure imgf000024_0002
Figure imgf000025_0001
Re=OH, OCH3, CH3, NH2
Figure imgf000025_0002
Figure imgf000025_0003
Figure imgf000026_0001
Figure imgf000026_0002
Figure imgf000026_0003
OORy
Figure imgf000026_0004
Figure imgf000026_0005
Figure imgf000026_0006
Another embodiment of compound of formula (Ia), where R] represents
— C-R6 s , wherein R represents alkyl or alkoxy group;.
R2 and R3, which may be same or different, independently represent hydrogen or halogen;
R4 represents
Figure imgf000027_0001
where R'" represents hydrogen or alkyl grou'p n represents 0-6;
Figure imgf000027_0002
OH
Htf O Htf- O "Xv » 'NA- . πu * A v **
Ry represents alkyl or aryl Another embodiment of compound of formula (la), where Ri represents
Figure imgf000028_0001
, wherein R represents alkyl or alkoxy group; R2 and R3, which may be same or different, independently represent hydrogen or halogen; R represents cyano,
Figure imgf000028_0002
Another aspect of the present invention provides compound of formula (I), where
'Z' represents C, ' ' represents bond, which is represented by compound of formula
(lb); their pharmaceutically acceptable salts their stereosiomers thereof, pharmaceutical compositions containing them
Figure imgf000029_0001
Where R represents
— c- R6
Q
Where Q represents 'S'
R6 represents
(i) Hydrogen,
Optionally substituted groups selected from.
(ϋ) Alkyl,
(iϋ) Cycloalkyl,
(iv) Alkoxy,
(v) Cycloalkoxy,
(vi) Alkenyl,
(vii) Alkenyloxy,
R2 and R3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen,
R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, ammocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, aryl, aryloxy, arylcarbonyl, aralkyl, heterocyclyl, heterocyclylalkyl,- heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcaarbonyl, tert-butoxycarbonyl (BOC), alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfinyl, arylsulfonyl, arylsulfanyl, arylsulfϊnyl, heteroarylsulfonyl Substituents on R4 selected from halogen, nitro, cyano, amino, hydroxy, oxo (=0), =N- CN, =N-0Rx, where Rx represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert-butyl-dimethyl-silanyloxy)-acetyl chloride (TBDMSO), tert-butoxycarbonyl (BOC), N-hydroxyformamide, carboxylic acids or its derivatives. The optional substituents on these groups are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives, phosphoric acid or its derivates;
The substitutions on the possible groups represented by R4, may take place 1 to 5 times, which may be same or different; which is represented by compound of formula (Ia); their pharmaceutically acceptable salts their stereosiomers thereof, pharmaceutical compositions containing them
Another embodiment of compound of formula (lb), where Rj represents
— C-Rb s , wherein R6 represents alkyl or alkoxy group; R2 and R3, which may be same or different, independently represent hydrogen or halogen; R represents
Hydrogen, Cyanq H3
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000031_0001
n represents 0-6;
Figure imgf000031_0002
Re=OH, QCH3, CH3, NH2
Figure imgf000031_0003
Figure imgf000031_0004
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000033_0001
Ry represents alkyl or aryl
Figure imgf000033_0002
Another embodiment of compound of formula (Ia), where Rj represents
-C-R° s , wherein R6 represents alkyl or alkoxy group; R2-and R3, which may be same or different, independently represent hydrogen or halogen;
Another aspect of compound of formula (lb), where Ri represents
— C-R6 S , wherein R represents alkyl or alkoxy group;
R2 and R3, which may be same or different, independently represent hydrogen or halogen;
R4 represents
Hydrogen, Cyano,
Figure imgf000034_0001
Figure imgf000034_0002
n represents 0-6;
H
Figure imgf000034_0003
Figure imgf000035_0001
fe alkyl ort arey;lts
Figure imgf000035_0002
Figure imgf000035_0004
Figure imgf000035_0003
Ry represents alkyl or 'aryl
Another aspect of compound of formula (lb), where Ri represents
-C-R°
S , wherein R represents alkyl or alkoxy group; R2 and R3, which may be same or different, independently represent hydrogen or halogen;
R4 represents cyano,
Figure imgf000035_0005
Figure imgf000036_0001
Another aspect ofthe present invention provides examples of formula (I), where ' ....' represents no bond and Z represents 'N' and all other symbols are as defined earlier have given in the following table:
Figure imgf000036_0002
Figure imgf000036_0003
Figure imgf000036_0004
Figure imgf000037_0001
Figure imgf000037_0002
Figure imgf000037_0003
Figure imgf000037_0004
Figure imgf000037_0005
Figure imgf000037_0006
Figure imgf000038_0002
Figure imgf000038_0003
Figure imgf000038_0004
their stereoisomers and their pharmaceutically acceptable salts thereof;
Another aspect of the present invention provides examples of formula (I), where ' ....' represents bond and Z represents 'C and all other symbols are as defined earlier have given in the following table:
Figure imgf000038_0005
Figure imgf000039_0001
Figure imgf000039_0002
Figure imgf000039_0003
Figure imgf000039_0004
Figure imgf000039_0005
Figure imgf000039_0006
Figure imgf000040_0001
Figure imgf000040_0002
Figure imgf000040_0003
Figure imgf000040_0004
their stereoisomers and their prodrugs and their pharmaceutically acceptable salts thereof;
Another aspect ofthe present invention provides examples of formula (I), where '....' represents no bond and Z represents 'N' and all other symbols are as defined earlier have given in the following table:
Figure imgf000040_0005
Figure imgf000041_0001
Figure imgf000041_0002
Figure imgf000041_0003
Figure imgf000041_0004
Figure imgf000041_0005
Figure imgf000041_0006
Figure imgf000042_0001
Figure imgf000042_0002
,
Figure imgf000042_0003
:
Figure imgf000042_0004
Figure imgf000042_0005
Figure imgf000042_0006
their stereoisomers and their pharmaceutically acceptable salts thereof; Another aspect of the present invention provides examples of formula (I), where '....' represents a bond and Z represents 'C and all other symbols are as defined earlier have given in the following table:
Figure imgf000043_0001
Figure imgf000043_0002
Figure imgf000043_0003
Figure imgf000043_0004
Figure imgf000043_0005
Figure imgf000044_0001
Figure imgf000044_0002
Figure imgf000044_0003
Figure imgf000044_0004
Figure imgf000044_0005
their stereoisomers and their pharmaceutically acceptable salts thereof;
Definitions:
'Halogen' is fluorine, chlorine, bromine, or iodine;
'Alkyl' group is optionally substituted linear or branched ( -C10) alkyl group. Exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t- butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like. 'Haloalkyl' group is optionally substituted linear or branched monohalo(C|- Cio)alkyl group, dihalo(C|-Cιo)alkyl group, trihalo(Cι-Cιo)alkyl group, tetrahalo(Cι- Cιo)alkyl group, pentahalo(Cι-Cιo)alkyl group or hexahalo( -Cιo)alkyl group. Exemplary alkyl groups include monohalomethyl, dihalomethyl, trihalomethyl, monohaloethyl, dihaloethylm trihaloehtylm tetrahaloethylm pentahaloethyl and the like.
'Hydroxyalkyl' group is linear or branched hydroxy (Q-Cιo)alkyl group. Exemplary alkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, hydroxyheptyl, hydroxyoctyl and the like.
'Hydroxyalkylamino' group is linear or branched hydroxy(Cι-Cιo)alkylamino group. Exemplary hydroxyalkylamino groups include hydroxymethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxypentylamino, hydroxyhexylamino, hydroxyheptyl amino, hydroxyoctylamino and the like.
'Cycloalkyl' group is (C3-C8) cycloalkyl group. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
'Alkylamino' group represents monoalkylamino or dialkylamino group. 'Monoalkylamino' is (Cι-Cιo)alkylamino, where (Cι-Cιo)alkyl is as defined above. Exemplary monoalkylamino groups include methylamino, ethylamino, propylamino, isoporpylamino and the like. 'Dialkylamino' is di(Cι-C2o)alkylamino, where (C1-C10) alkyl is as defined above. Exemplary dialkylamino groups include dimethylamino, diethylamino, ethylmethylamino and the like.
Alkoxy' is ( -Cio) alkyl-O-, wherein the ( -C10) alkyl group is as defined above. Exemplary alkyl groups include methoxy, ethoxy, propoxy, butoxy, iso-propoxy and the like.
'Cycloalkoxy' is (C3-C10) cycloalkoxy group. Exemplary cycloalkoxy groups include cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy and the like.
'Alkenyl' is (C2-Cιo) alkenyl group. Exemplary alkenyl groups include ethenyl, propenyl, but-1-enyl, pentenyl, hexenyl and the like.
'Cycloalkenyl' is (C3-Cιo)cycloalkenyl group. Exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like.
'Alkylaminoalkyl' is (Cι-Cιo)alkylamino(Cι-Cιo)alkyl group, where alkyl group is as defined above. Exemplary alkylaminoalkyl groups include methylaminomethyl, methylaminoethyl, methylaminopropyl, methylaminobutyl, ethylaminomethyl, ethylaminoethyl, ethylaminopropyl, ethylaminobutyl, propylaminoethyl, propylaminobutyl, butylaminopropyl, butylaminobutyl, propylaminomethyl, butylaminomethyl, ethylaminobutyl, propylaminopropyl and the like.
'Alkylcarbonyl' is (Cι-Cιo)alkylcarbonyl group. Exemplary alkylcarbonyl groups include methylcarbonyl, ethylcarbonyl, propylcarbonyl, isoporpynylcarbonyl, butylcarbonyl and the like.
'Alkenylcarbonyl' is (C2-Cιo)alkenyl-CO, wherein (C2-Cι0) alkoxy is as defined above. Exemplary alkenycarbonyl groups include ethenylcarbonyl, propenylcarbonyl, butenylcarbonyl, but-1-enylcarbonyl and the like.
'Alkoxyalkyl' is (C|-Cι0)alkoxy(Cι-Cιo)alkyl group, where alkoxy and alkyl groups are as defined above. Exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxypropyl, ethoxybutyl, ethoxybutyl, ethoxypentyl, ethoxyhexyl, propoxyethyl, isopropoxyethyl, butoxyethyl, isobutoxyethyl and the like.
'Alkoxycarbonyl' is (C.-C10) alkoxycarbonyl, wherein ( -C10) alkoxy is as defined above. Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl and the like.
'Carboxy alkyl' is carboxy (Cι-C.o)alkyl, where ( -Cιo)alkyl group is as defined above. Exemplary carboxyalkyl groups include carboxymethyl, carboxyethyl and the like.
'Alkylsulfonyl' is (Cι-Cιo)alkylsulfonyl, where (Cι-Cιo)alkyl group is as defined above. Exemplary alkylsulfonyl groups include methylsulfonyl, ethylsulfonyl and the like
'Alkylsulfmyl' is (Cι-Cιo)alkylsulfinyl, where (Cι-Cιo)alkyl group is as defined above. Exemplary alkylsulfmyl groups include methylsulfinyl, ethylsulfinyl and the like
'Alkylsulfanyl' is (Cι-Cιo)alkylsulfanyl, where ( -Cιo)alkyl group is as defined above. Exemplary alkylsulfanyl groups include methylsulfanyl, ethylsulfanyl and the like 'Alkylsulfonyloxy' is (C1-C10) alkylsulfonyloxy, where (Cι-Cιo)alkyl group is as defined above. Exemplary alkylsulfonyloxy groups include methylsulfonyloxy, ethylsulfonyloxy and the like.
'Aryl' is monocylic or polycyclic ring system of about 6 to 14 carbon atoms. Exemplary groups include phenyl, naphthyl and the like.
'Arylcarbonyl' is aryl-carbonyl group, where aryl group is as defined above.. Exemplary arylcarbonyl groups include phenylcarbonyl, naphthylcarbonyl and the like.
'Arylsulfonyl' is aryl-sulfonyl, where aryl group is as defined above. Exemplary arylsulfonyl groups include phenylsulfonyl, naphthylsulfonyl and the like. 'Arylsulfanyl' is aryl-sulfanyl, where aryl group is as defined above. Exemplary arylsulfanyl groups include phenylsulfanyl, naphthylsulfanyl and the like.
'Arylsulfinyl' is aryl-sulfinyl, where aryl group is as defined above. Exemplary arylsulfϊnyl groups include phenylsulfinyl, naphthylsulfinyl and the like.
'Alkylcarbonylaminoalkyl' is (Cι-Cιo)alkylcarbonylamino(Cι-Cιo)alkyl, where (Q- Cιo)alkyl group is as defined above. Exemplary alkylcarbonylaminoalkyl groups include methylcarbonylaminomethyl, methylcarbonylaminoethyl and the like.
'Arylcarbonylaminoalkyl' is arylcarbonylamino (Cι-Cιo)alkyl, where aryl and (Q- Cιo)alkyl group are as defined above. Exemplary arylcarbonylaminoalkyl include phenylcarbonylaminomethyl, phenylcarbonylaminoethyl and the like.
'Alkyl carbonyloxyalkyl' is (C|-Cιo)alkylcarbonylamino(Cι-Cιo)alkyl, where ( - Cιo)alkyl group is as defined above. Exemplary alkylcarbonyloxyalkyl groups include methylcarbonyloxymethyl, ethylcarbonyloxymethyl and the like.
'Hydroxyalkylcarbonyl' is hydroxyl-(C]-Cιo)alkylcarbonyl, where (Cι-Cιo)alkyl group is as defined above. Exemplary hydroxyalkylcarbonyl groups include hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl and the like.
'Aminoalkyl' is amino (Cι-Cιo)alkyl, where (Cι-Cιo)alkyl is as defined above. Exemplary amino alkyl groups include amino methyl, amino ethyl and the like.
'Arylamino' where aryl group is as defined above. Exemplary aryl amino groups include phenyl amino, naphthylamino and the like.
'Alkenyloxy' is (C3-C10) alkenyl-O-, where the (C2-Cό) alkenyl group is as defined above. Exemplary alkenyl groups include ethenyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy and the like.
'Acyl' is H-CO or (Cι-C20) alkyl-CO- group, where (Cι-C2o)alkyl is as defined above. Exemplary acyl groups include acetyl, propionyl, wo-propionyl, tert-butionyl and the like.
'Haloacyl' is Halogen-(Cι-Cιo) alkyl-CO- group, where (Cι-Cιo)alkyl is as defined above. Exemplary haloacyl groups include haloacetyl, halopropionyl and the like.
'Acyloxy' is (C1-C10) acyl-O-, where acyl group is defined as H-CO- or (C1-C10) alkyl-CO-, where (C1-C10) alkyl group is as defined above. Exemplary acyl groups include acetyl, propionyl, and the like. Exemplary acyloxy groups include acetyloxy, propionyloxy, t_.ø-propionyloxy, tert-butionyloxyand the like.
'Aryloxy' is optionally substituted aryl-O- group, where the aryl group is as defined above. Exemplary aryloxy groups include phenoxy, naphthyloxy and the like. 'Aralkyl' is aryl-(Cι-Cιo) alkyl group, wherein aryl and (C1-C10) alkyl groups are as defined above. Exemplary aralkyl groups include benzyl, 2-phenylethyl and the like.
'Aralkylcarbonyl' is aralkyl-carbonyl group, wherein aralkyl group is as defined above. Exemplary aralkylcarbonyl groups include benzylcarbonyl, 2-phenylethylcarbonyl and the like.
'Aralkoxy' is aralkyl-O- group, wherein the aralkyl group as defined above. Exemplary aralkoxy groups include bezyloxy, 2-phenethyloxy and the like.
'Aralkoxyalkylcarbonyl' is aralkyl-0-(Cι-Cιo)alkyl-CO group, where aralkyl and (Cι-Cιo)alkyl groups are as defined above. Exemplary aralkoxyalkylcarbonyl groups include benzyloxymethylcarbonyl, benzyloxyethylcarbonyl, benzyloxypropylcarbonyl and the like.
'Heterocyclyl' is non-aromatic saturated monocyclic or polycyclic ring system of about 5 to about 10 carbon atoms, having at least one hetero atom selected from O, S or N. Exemplary heterocyclyl groups include aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, oxazolidinyl, azepanyl, [1,3]- dioxanyl, 1,3-dioxolanyl, 1 ,4-dioxolanyl and the like.
'Heterocyclylcarbonyl' is heterocyclylcarbonyl, where heterocyclyl is as defined above. Exemplary heterocyclylcarbonyl groups include aziridinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, thiomorpholinylcarbonyl, thiazolidinylcarbonyl, oxazolidmylcarbonyl, azepanylcarbonyl, [l,3]-dioxanylcarbonylcarbonyl, 1,3-dioxolanylcarbonyl, 1 ,4-dioxolanylcarbonyl and the like.
'Heterocyclylalkyl' is non-aromatic saturated monocyclic or polycyclic ring system of about 5 to about 10 carbon atoms, having at least one hetero atom selected from O, S or N. Exemplary heterocyclylalkyl groups include 4-ethylmorpholinyl, 4- propylmorpholinyl, 4-butylmorpholinyl, 4-pentylmoφholinyl, 4-ethyl-[l ,3]dioxolanyl, 4- propyl-[l,3]dioxolanyl, 4-butyl-[l,3]dioxolanyl, 4-pentyl-[l,3]dioxolanyl, 5-ethyl- oxazolidinyl, 5-propyl-oxazolidinyl, 5-butyl-oxazolidinyl, 5-pentyl-oxazolidinyl, 1-ethyl- pyrrolidine, 1-propyl-pyrrolidine, 1-butyl-pyrrolidine, 1 -pentyl-pyrrolidine, 2-ethyl- pyrrolidinyl, 2-propyl-pyrrolidinyl, 2 -butyl -pyrrolidinyl, 2-pentyl-pyrrolidinyl, 5 -ethyl - [l,3]dioxanyl, 5-propyl-[l,3]dioxanyl, 5-butyl-[l,3]dioxanyl, 1-ethyl-piperidyl, 1- propyl-piperidyl, 1 -butyl-piperidyl, 1-pentyl-piperidyl, 1 -ethyl-azepanyl, 1-propyl- azepanyl, 1 -butyl-azepanyl, 1 -pentyl-azepanyl and the like. 'Heteroaryl' is aromatic monocyclic or polycyclic ring system of about 5 to about 10 carbon atoms, having at least one heteroatom selected from O, S or N. Exemplary heteroaryl groups include as pyrazinyl, isothiazolyl, oxazolyl, isoxazolyl, lH-pyrazolyl, pyrrolyl, pyridazinyl, thienopyrimidyl, furanyl, lH-indolyl, isoindolyl, 1,3-benzodioxole, 1 ,3-benzoxathiole, quinazolinyl, pyridyl, thiophenyl and the like.
'Heteroarylcarbonyl' is heteroarylcarbonyl. Exemplary heteroarylcarbonyl groups include as pyrazinylcarbonyl, isothiazolylcarbonyl, oxazolylcarbonyl, isoxazolylcarbonyl, lH-pyrazolylcarbonyl, pyrrolylcarbonyl, pyridazinylcarbonyl, thienopyrimidylcarbonyl, furanylcarbonyl, 1 H-indolylcarbonyl, isoindolylcarbonyl, 1,3 -benzodioxolecarbonyl, 1,3- benzoxathiolecarbonyl, quinazolinylcarbonyl, pyridylcarbonyl, thiophenylcarbonyl and the like.
'Heteroaralkyl' is heteroaryl-(Cι-Cιo) alkyl group, wherein the heteroaryl and (C\- Cio) alkyl groups are as defined above. Exemplary heteroaralkyl groups include 1-ethyl- 1 H-pyrazolyl, 1 -propyl- lH-pyrazolyl, 1 -butyl- 1 H-pyrazolyl, 1 -pentyl- 1 H-pyrazolyl, 1- ethyl-lH-imidazolyl, 1 -propyl- 1 H-imidazolyl, 1-butyl-lH-imidazolyl, 1-pentyl-lH- imidazolyl, 4-ethylpyridinyl, 4-propylpyridinyl, 4-butylpyridinyl, 4-pentylpyridinyl, 3- ethylpyridinyl, 3-propylpyridinyl, 3-butylpyridinyl, 3-pentylpyridinyl, 3-ethyl-lH-indolyl, 3 -propyl- lH-indolyl, 3-butyl-lH-indolyl, 3 -pentyl- lH-indolyl, 2-ethylfuranyl, 2- propylfuranyl, 2-butylfuranyl, 5-ethylisoxazolyl, 5-propylisoxazolyl, 5-butylisoxazolyl, and the like.
'Heteroaryloxy' is heteroaryl-O-, wherein the heteroaryl group is as defined above. Exemplary heteroaryloxy groups include pyrazinyloxy, isothiazolyloxy, oxazolyloxy, pyrazolyloxy, phthalazinyloxy, indolyloxy, quinazolinyloxy, pyridyloxy, thienyloxy and the like.
'Heteroaralkylcarbonyl' is heteroaralkyl-CO-group, where heteroaralkyl group is as defined above. Exemplary heteroaralkylcarbonyl groups include 1-ethyl-lH- pyrazolylcarbonyl, 1 -propyl- lH-pyrazolylcarbonyl, 1 -butyl- 1 H-pyrazolylcarbonyl, 1- pentyl- 1 H-pyrazolylcarbonyl, 1 -ethyl- 1 H-imidazolylcarbonyl, 1 -propyl- 1 H- imidazolylcarbonyl, 1 -butyl- 1 H-imidazolylcarbonyl, 1 -pentyl- 1 H-imidazolylcarbonyl, 4- ethylpyridinylcarbonyl, 4-propylpyridinylcarbonyl, 4-butylpyridinylcarbonyl, 4- pentylpyridinylcarbonyl, 3-ethylpyridinylcarbonyl, 3-propylpyridinylcarbonyl, 3- butylpyridinylcarbonyl, 3-pentylpyridinylcarbonyl, 3-ethyl-l H-indolylcarbonyl, 3-propyl- 1 H-indolylcarbonyl, 3-butyl-l H-indolylcarbonyl, 3 -pentyl- 1 H-indolylcarbonyl,, 1,3- benzodioxolecarbonyl, 1,3-benzoxathiolecarbonyl, quinazolinylcarbonyl, pyridylcarbonyl, 2-ethylfuranylcarbonyl, 2-propylfuranylcarbonyl, 2-butylfuranylcarbonyl, 5- ethylisoxazolylcarbonyl, 5-propylisoxazolylcarbonyl, 5-butylisoxazolylcarbonyl, and the like.
'Heterocyclylalkylcarbonyl' is heterocyclyl-CO-group, where heterocyclylalkyl group is as defined above. Exemplary heterocyclylalkylcarbonyl groups include 4- ethylmorpholinylcarbonyl, 4-propylmorpholinylcarbonyl, 4-butylmorpholinylcarbonyl, 4- pentylmoφholinylcarbonyl, 4-ethyl-[l,3]dioxolanylcarbonyl, 4-propyl-
[l,3]dioxolanylcarbonyl, 4-butyl-[l,3]dioxolanylcarbonyl, 4-pentyl-
[l ,3]dioxolanylcarbonyl, 5-ethyl-oxazolidinylcarbonyl, 5-propyl-oxazolidinylcarbonyl, 5- butyl-oxazolidinylcarbonyl, 5-pe tyl-oxazolidinylcarbonyl, 1 -ethyl-pyrrolidinylcarbonyl, 1 -propyl-pyrrolidinylcarbonyl, 1 -butyl-pyrrolidinylcarbonyl, 1 -pentyl- pyrrolidinylcarbonyl, 2-ethyl-pyrrolidinylcarbonyl, 2-propyl-pyrrolidinylcarbonyl, 2- butyl-pyrrolidinylcarbonyl, 2-pentyl-pyrrolidinylcarbonyl, 5-ethyl-[l ,3]dioxanylcarbonyl, 5-propyl-[l ,3]dioxanylcarbonyl, 5-butyl-[ 1 ,3]dioxanylcarbonyl, 1 -ethyl- piperidylcarbonyl, 1 -propyl-piperidylcarbonyl, 1-butyl-piperidylcarbonyl, 1-pentyl- piperidylcarbonyl, 1 -ethyl-azepanylcarbonyl, 1-propyl-azepanylcarbonyl, 1-butyl- azepanylcarbonyl, 1 -pentyl-azepanylcarbonyl and the like.
'Heteroarylsulfonyl' is heteroaryl-sulfonyl group, Exemplary heteroarylsulfonyl groups include pyrazinylsulfonyl, isothiazolylsulfonyl, oxazolylsulfonyl, pyrazolylsulfonyl, pyrrolylsulfonyl, pyridazinylsulfonyl, thienopyrimidylsulfonyl, furylsulfonyl, indolylsulfonyl, isoindolylsulfonyl, quinazolinylsulfonyl, pyridylsulfonyl, thiophenylsulfonyl and the like.
'Carboxylic acid or its derivatives' may be amides or esters. Exemplary carboxylic acid groups include CONH2, CONHMe, CONMe2, CONHEt, CONEt2, CONHPh, COOCH3, COOC2H5 or COOC3H7.
'Phosphoric acid or its derivates' include PO(OCH3)2, PO(OC2H5)2 and the like.
Another embodiment of the present invention provides a process for the preparation of compound of formula (I), Where R represents R or R4, wherein R represents protecting group such as 't-butoxy carbonyl group (protecting group) and R4 is as defined in description of compound of formula (I).
The compound of formula (2) represents compound of formula (I), when R1 represents NHR5, Rb represents R4 and all other symbols are as defined in the description of compound of formula (I). The compound of formula (2) represents compound of formula (I), when R1 represents represents isoindole-l,3-dione, Rb represents R4 and all other symbols are as defined in the description of compound of formula (I).
The compound of formula (2) represents compound of formula (I), when R1 represents NHR5 wherein R5 represents hydrogen atom, Rb represents R4 and all other symbols are as defined in the description of compound of formula (I), which comprises:
Figure imgf000051_0001
The compound of formula (2a) and and piperazine were stirred in a suitable solvent selected from tetrahydrofuran (THF), dimethylformamide (DMF), chloroform, acetonitrile and the like. The temperature of the reaction was maintained in the range of 20 °C to boiling temperature of the solvent used in the reaction. After completion of the reaction the mixture was poured into cold water, and the mixture was cooled to ice temperature. The material was filtered and dried or can be extracted from aqueous layer with a solvent such as ethyl acetate, DCM, chloroform and the like.
The above compound of formula (2b) was converted to a compound of formula (2c) by using a solvent such as DMF, THF, 1,4-dioxane and the like, and t- butoxycarbonylanhydride [(Boc)20] in the presence of a base such as sodiumhydroxide (NaOH), potassiumhydroxide (KOH) and the like. The temperature of the reaction was maintained in the range of 0 to 50 °C, and the duration ofthe reaction is in the range of 0.5 to 5 hours. The resultant product was poured into water to obtain (t-butoxycarbonyl)'Boc' protected compound.
The compound of formula 2(c) was reduced to a compound of formula 2(d), by using a reducing agent such as palladium/carbon (Pd/C) or Platinum and hydrogen (H2), sodium borohydrate/niclechloride (NaBE NiC^) and the like. The solvent used in the reaction was selected from methanol, ethanol, propanol, isopropanol, ethyl acetate and the like.
The compound of formula (2d) was converted to a compound of formula (2e) by using sodium nitrite (NaN02) in the presence of hydrochloride (HCI) or acetic acid (CH3COOH) followed by sodiumazide (NaN3). The temperature of the reaction may be maintained in the range of about -40 °C to boiling temperature of the solvent used, preferably in the range of 0 °C to boiling temperature. The duration of the reaction may be in the range of about 0.5 to 15 hours, preferably in the range of about 0.5 to 5 hours
The compound of formula (2e) where R represents 'Boc' was first deprotected with dil. HCI or trifluoroacetic acid in a suitable solvent such as THF, 1,4-dioxane, chloroform and the like. The resultant mixture was neutralized by sodium carbonate, sodium bicarbonate and the like, followed by extraction with a solvent such as ethylacetate, dichloromethane, chloroform and the like to obtain a free amine. The free amine can be converted to suitable derivatives using conventional methods (eg: acid chloride / triethylamine).
The compound of formula (2g) is reacted with a compound of formula (2h), to obtain a compound of formula (2i), when X represents halogen atom, by using (C1-C10) alkyllithium such as methyllithium (MeLi), n-butyllithium (n-BuLi), secondary butyllithium (sec.BuLi), tertiary butyllithium (ter.BuLi) and the like, and the like. The compound of formula (Ic), where X represents hydrogen atom is obtained by treating with CsF. The solvent used in the reaction may be selected from tetrahydrofuran (THF), hexamethylphosphoramide (HMPA), diethylether and the like. The temperature and duration of the reaction can be maintained in the range of about -78 to about 100 °C and about 30 min to about 1.5 h respectively.
The compound of formula (2i) is reacted with a compound of formula (2j), by using a reagent (Ci-Cio) alkyllithium such as methyllithium (MeLi), n-butyllithium (n- BuLi), secondary butyllithium (sec.BuLi), tertiary butyllithium (ter.BuLi) and the like. The solvent used in the reaction may be selected from THF, hexametaphosphoric (HMPA), diethyl ether, 1 ,4-dioxane and the like. The temperature and duration of the reaction can be maintained in the range of about -78 to about 50 °C and about 4 to about 10 h respectively. The resultant compound was treated with any of the reagents selected from cone HCI, p-toluene sulfonic acid (p-TSA), mesyl chloride & triethylamine, 1,2- diazabicyclo[5,4,0]undec-7-ene (DBU), phosphorous oxychloride (POCl3), The solvent used in the reaction is selected from pyridine, dichloromethane, acetonitrile, toluene and the like. The temperature and duration of the reaction can be maintained in the range of about 0 to about 150 °C and about 30 min to about 24 h respectively. The above obtained compound is converted to compound of formula (2k), where ' ....' represents no bond, by treating with Et3SiH & BF3.OEt2, Et3SiH & CF3COOH, TMSC1, Nal, Me2SiI2) Bu3SnH and the like, under the above reaction conditions.
The compound of formula (2k) in dil. HCI, is reacted with NaN02 and NaN3 or t- Butyl nitrile and NaN3, to obtain a compound of formula (21), The temperature and duration of the reaction can be maintained in the range of about 0 to about 150 °C and about 30 min to about 24 h respectively.
The compound of formula (2f) and/or (21) was subjected to 1,3-dipolar cycloaddition with the corresponding acetylene derivative to obtain a compound of formula (2). The solvent used in the reaction was selected from DMF, acetonitrile, THF, toluene and the like. The reaction may be carried out in the presence of a catalyst such as Cul. The temperature of the reaction was maintained in the range of 0 to 90 °C. The duration of he reaction was maintained in the range of 0.5 to 6 hours. The compound of formula (2f) and/or (2k) was converted to a compound of formula (2) by adopting the similar procedure as described above. The compound of formula (3) was converted to a compound of formula (4) by using reagents such as hydrazine, dialkylamine, ethylenediamine and the like. The solvents used in the reaction may be selected from methanol, ethanol, propanol, isopropanol and the like. The temperature was maintained in the range of 20 °C to the boiling temperature of the solvent used in the reaction. The duration of the reaction is in the range of 1 to 12 h.
The compound of formula (4) was converted to amide (where R5 represents COR) by using the corresponding acid chloride and triethylamine or acid anhydride and base such as triethylamine, pyridine and the like. The resultant amide can be further converted to thioamide by using sulfur transfer reagent such as La wesson's reagent or the amine can be converted to thiocyanate (NCS) by treating with thiophosgene and triethylamine, followed by refluxing in alcohol such as methanol, ethanol, propanol, isopropanol and the like.
The compound of formula (2f) (where protecting group is present on nitrogen atom of piperzine ring) and/or (21) were also converted to a compound of formula (2p)
Figure imgf000054_0001
The compound of formula (2f) and/or (21), where R represents 'Boc' was first deprotected with chloroethylchloroformate, dil. HCI or trifluoroacetic acid in a suitable solvent such as dichloromethane, 1 ,2-dichloroethane, THF, 1,4-dioxane, chloroform and the like. The temperature of the reaction may be in the range of 0 to 40 °C. The duration of the reaction may be in the range of 0.5 to 12 hours. The resultant mixture was neutralized by sodium carbonate, sodium bicarbonate and the like, followed by extraction with a solvent such as ethylacetate, dichloromethane, chloroform and the like to obtain a free amine. The free amine can be converted to suitable derivatives using conventional methods (eg: acid chloride / triethylamine).
Alternatively, the deprotection can be carried out by using H2/Pd-C, The solvent used may be selected from ethylacetate, methanol, ethanol, propanol and the like. The temperature of the reaction may be in the range of 0 to 40 °C. The duration of the reaction may be in the range of 0.5 to 12 hours. The compound of formula 2(p) was converted to a compound of formulae or (5), by using the procedure as defined for the conversion of 2(f) and/or 2(1) to the compound of formulae (2) or (5).
Another aspect of the present invention provides an intermediate of formula (2f)
Figure imgf000055_0001
(2f) where Rb represents R or R4 where R represents tert-butoxy carbonyl (BOC and all other symbols are as defined in the description of compounds of formula (I).
Another aspect ofthe present invention provides an intermediate of formula (21)
Figure imgf000055_0002
(21) where R represents tert-butoxy carbonyl (BOC) and all other symbols are as defined in the description of compounds of formula (I).
It is appreciated that in any of the above-mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are tertiarybutyldimethylsilyl, methoxymethyl, triphenyl methyl, benzyloxycarbonyl, tetrahydropyran(THP) etc, to protect hydroxyl or phenolic hydroxy group; N-tert- butoxycarbonyl (N-Boc), N-benzyloxycarbonyl (N-Cbz), N-9-fluorenyl methoxy carbonyl (-N-FMOC), benzophenoneimine, propargyloxy carbonyl (POC) etc, for protection of amino or anilino group, acetal protection for aldehyde, ketal protection for ketone and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
A method of treating or preventing an bacterial infections in a subject is provided by administering an therapeutically effective amount of compound of formula (I).
The term "therapeutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or patient that is being sought.
The pharmaceutically acceptable salts are prepared by reacting the compounds of formula (I) wherever applicable with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in the presence of a solvent like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, tromethamine, guanidine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in the presence of a solvent like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvent may also be used. The salts of amino acid groups and other groups may be prepared by reacting the compounds of formula (I) with the respective groups in the presence of a solvent like alcohols, ketones, ether etc. Mixture of solvents may be used.
The present invention also provides pharmaceutical compositions, containing compounds of the general formula (I), their pharmaceutically acceptable salts The pharmaceutical compositions according to this invention can be used for the treatment of bacterial infections. They can also be used for the treatment of bacterial infections associated with multidrug resistance. The pharmaceutical compositions according to this invention can also be administered prophylatically for the prevention of bacterial infections in a patient at risk of developing a bacterial infection.
The compounds alternatively be formulated and administered in a prodrug form. In general, prodrugs comprise functional derivatives of the claimed compounds which are capable of being enzymatically activated or converted into the more active parent form. Thus, in the treatment methods of the present invention, the term "administering" encompasses the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs (1985). See also, Wihnan, 14 Biochem. Soc. Trans. 375-82 (1986); Stella et al., Prodrugs: A Chemical Approach to Targeted Drug Delivery in Directed Drug Delivery 241-61 (1985).
The regioisomers of compound of formula (I) may be prepared by modifying the reaction conditions, use of reagents like acid to base or base to acid or by reaction with free base hydrazine instead of its salt with diketone. The molar proportion also can change the regioisomer formation.
The stereoisomers of the present invention include enatiomers such as (R), (S), a mixture of (R), (S), and mixture of (R) and (S). The individual optical isomers or required isomers may be obtained by using reagents in such a way to obtain single isomeric form in the process wherever applicable or by conducting the reaction in the presence of reagents or catalysts in their single enantiomeric form. Some of the preferred methods of resolution of racemic compounds include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981). Where appropriate the compounds of formula (I) may be resolved by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula (I) may be prepared by hydrolyzing the pure diastereomeric amide.
The pharmaceutical compositions may be in the forms normally employed, such as tablets, capsules, powders, dispersible granules, cachets, suppositories, syrups, solutions, suspensions and the like, may contain flavorants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 0.5 to 90 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active compounds will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compounds can be combined with a suitable solid, liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like. For parenteral administration, the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
The compounds of the formula (I) or pharmaceutical compositions thereof as defined above are clinically administered to mammals, including human beings, via oral, parenteral and/or topical routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absoφtion following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range of about 0.1 mg/kg to about 150 mg / kg, morepreferably about 3.0 mg/kg to about 100 mg/kg of body weight of the subject per day administered singly or as a divided dose. However, the optimum dosage whether for prevention or treatment for the individual subject being treated will be determined by the person responsible for treatment, Initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administering, e.g. 2-6 times per day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. In a topical treatment an effective amount of compound of formula (I) is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Such creams and gels can be prepared by the procedures available in the literature and can include penetration enhancers.
The manner in which the compounds of this invention can be prepared is illustrated in the following examples, which demonstrate the preparation of typical species of the invention. In these examples, the identities of compounds, intermediates and final, were confirmed by infrared, nuclear magnetic spectral analyses as necessary. The examples are for the puφose of illustration only and should not be regarded as limiting the invention in any way. Preparation 1:
Prop-2-ynyl-thiocarbamic acid O-methyl ester
Figure imgf000059_0001
To an ice cooled solution of propargyl amine (10 grams, 182 mmol) and triethyl amine (38 mL, 273 mmol) in tetrahydrofuran (THF) (300 mL) was added drop wise a solution of carbon disulfide (13.8 mL, 218 mmol) in THF (100 mL) through an addition funnel over a period of 0.5 hours. A solution of ethylchloroformate (17.4 mL, 182 mmol) in THF (100 mL) was then added drop wise to the reaction mixture. The cooling bath was removed and the reaction mixture was allowed to stir at 25-35 °C for 15 minutes. The
precipitate formed was then filtered off and the filtrate was concentrated at 35 °C under reduced pressure. The resulting residue was diluted with methanol (200 mL) and the solution was refluxed for 2 hours. Evaporation of volatiles left a pasty mass, which was purified by passing through a silica gel column (petroleum ether/ethyl acetate, 1 :9) to obtain the title compound as white solid (13.6 grams, 56%).
Melting Point: 67-68 °C
Η NMR (CDC13): δ 6.65 & 6.30 (2 bs, IH, rotamers in a ratio of 1 :4), 4.35-4.25 (m, 2H),
4.04 & 3.96 (2s, 3H, rotamers in a ratio of 1 :4), 2.25 (t, J= 2.4 Hz, IH). IR (KBr, cm'1): 3237, 1542, 1214, 1148, 1074. CI-MS (m/z): 130 (M++l), 129, 114.
Preparation 2: 2-Prop-2-yny_-isoindoIe-l,3-dione
Figure imgf000059_0002
A mixture of potassium phthalimide (10 grams, 54 mmol) and propargyl bromide (7.65 grams, 65 mmol) was heated in dimethyl formamide (DMF) (50 mL) at 80 °C for 8 hours. The reaction mixture was then poured into ice cold water. White solid obtained was filtered on a Buchner funnel and washed with water and dried (yield is 8.95 grams, 90%). Melting Point: 138 °C . Η NMR (CDCI3): δ 7.95-7.85 (m, 2H), 7.75-7.68 (m, 2H), 4.46 (d, J = 2.5 Hz, 2H), 2.23
(t, J= 2.5 Hz, IH).
IR KBr. crn 1): 3294, 2925, 1771, 1725, 1397.
CI-MS (m z): 186 (M++l), 148.
Preparation 3: l-(2-Fluoro-4-nitro-phenyl)-piperazine
Figure imgf000060_0001
Piperazine (16.25 grams, 189 mmol) was added to a flask containing 3,4- difluoronitrobenzene (7 mL, 63 mmol) in acetonitrile (100 mL). The reaction mixture was refluxed for 2 hours. Acetonitrile was removed on rotavapor and the residue was diluted with water (30 mL) and extracted with ethyl acetate (3 x 150 mL). The combined organic layer was washed with water followed by brine and dried over sodium sulfate. Removal of volatiles yielded the title compound (12.8 grams, 90%).
Η NMR (CDCI3): δ 8.01-7.92 (m, 2H), 7.02-6.91 (t, J= 8.8 Hz, IH), 3.40-3.22 (m, 4H), 3.02-2.91 (m, 4H). IR (KBr, cm"1): 3438, 1330. CI-MS (m/z): 226 (M++l), 183.
Preparation 4: l-(2, 6-Difluoro-4-nitro-phenyI)-piperazine
Figure imgf000060_0002
Title nitro compound (25.3 grams, 92%) was obtained from 3,4,5- trifuoronitrobenzene (20 grams, 113 mmol) and piperazine (29 grams, 339 mmol) by following the same procedure as descibed for the prepration of l-(2-fiuoro-4-nitro- phenyl)-piperazine, obtained in preparation 3.
Η NMR (CDCI3): δ 7.76 (d, J= 10.0 Hz), 3.34 (bs, 4H), 3.02-2.97 (m, 4H) IR (KBr, cm-1): 3350, 3090, 2950, 2834, 2751, 1603, 1508, 1453, 1383, 1333, 1301, 1136, 1020, 779, 508. CI-MS (m/z): 244 (M++l), 228, 214, 196, 183, 155, 141, 1 12. Preparation 5: l-[4-(2-Fluoro-4-mtro-phenyl)-piperazin-l-yI]-ethanone
Figure imgf000061_0001
To a compound of l-(2-fluoro-4-nitro-phenyl)-piperazine (2.0 grams, 8.9 mmol), obtained in preparation 3, and pyridine (1.9 mL, 17.8 mmol) was added acetic anhydride
(10 mL, 106.8 mmol). The reaction mixture was stirred at 25-35 °C for 4 hours and then
diluted with ice cold water. The precipitate formed was filtered through a Buchner funnel and dried under vacuum to get the title compound (2.24 grams, 94%).
Η NMR (CDC13): δ 8.00 (d, J = 4.9 Hz, IH), 7.89 (d, J = 2.4 Hz, IH), 6.92 (t, J = 8.7 Hz,
IH), 3.79 (t, J= 5.0 Hz, 2H), 3.65 (t, J= 5.0 Hz, 2H), 3.32-3.22 (m, 4H), 2.15 (s, 3H).
IR(KBr, cm"1): 3440, 1949, 1337, 1240.
CI-MS (mz): 268 (M++l), 238, 204, 176, 144, 107, 97.
Preparation 6: l-(2-Fluoro-4-nitro-phenyl)-4-methanesulfonyl-piperazine
Figure imgf000061_0002
To an ice cooled solution of l-(2-fluoro-4-nitro-phenyl)-piperazine (2.0 grams, 8.9 mmol), obtained from preparation 3, in dichloromethane (40 mL) was added triethylamine (2.4 mL, 17.8 mmol) followed by the addition of methanesulfonyl chloride (1.02 mL,
13.35 mmol) at 0 °C. The reaction mixture was warmed to 25-35 °C and stirred for 2
hours. Concentration of the reaction mixmre and addition of ice cooled water to the reaction mixture led to the precipitation of light yellow product. The precipitate was filtered through Buchner funnel and dried under vacuum to get the title compound (2.6 grams, 96%).
Η NMR (CDCI3): δ 8.02-7.87 (m, 2H), 7.05 (t, J = 8.8 Hz, IH), 3.40 (bs, 4H), 2.88 (s,
4H).
IR (KBr, cm"1): 3407, 3089, 2925, 2853, 1601, 1514, 1340, 1162, 958, 779, 521.
CI-MS (mz): 304 (M++l). Preparation 7:
4-(2-FIuoro-4-nitro-phenyl)-piperazine-l-carboxyIic acid terf-butyl ester
Figure imgf000062_0001
To an ice cooled solution of l-(2-fluoro-4-nitro-phenyl)-piperazine (12.5 grams, 55.8 mmol), obtained in preparation 3, in 1,4-dioxane (108 mL) was added IN sodium hydroxide (NaOH) solution (54 mL) followed by the addition of di-tert-butyl dicarbonate
((BOC)20) (14 mL, 61.38 mmol). The reaction mixture was allowed to come to 25-35 °C
and stirred for 0.5 hour. It was then poured into ice cold water (200 mL) and the yellow precipitate formed was filtered through buchner funnel to get the desired compound (18.0 grams, 99%).
Η NMR (CDCU): δ 8.01-7.88 (m, 2H), 6.93 (t, J= 8.6 Hz, IH), 3.61 (t, J= 4.9 Hz, 4H),
3.24 (t, J= 4.9 Hz, 4H), 1.49 (s, 9H).
IR(KBr, cm"1): 3119, 1692, 1605, 1512.
CI-MS (m/z): 326 (M++l), 270, 240, 226, 195.183, 131, 96.
Preparation 8:
4-(2,6-Difluoro-4-nitro-phenyl)-piperazine-l-carboxyIic acid tert-butyl ester:
Figure imgf000062_0002
Title compound (30.3 grams, 86%) was obtained from l-(2,6-difluoro-4-nitro- phenyl)-piperazine (25 grams, 103 mmol), obtained in preparation 4, and (Boc)20 (26 mL, 113.2 mmol) following the same procedure as described for the preparation of 4-(2- fluoro-4-nitro-phenyl)-piperazine-l -carboxylic acid tert-butyl ester (Preparation 7). Η NMR (CDCI3): δ 6.56 (d, J= 9.6 Hz, 2H), 3.55-3.50 (m, 4H), 3.10- 3.00 (m, 4H), 1.58 (s, 9H). IR (KBr, cm"1) : 2121, 1695, 1501.
CI-MS: 340 (M++1), 314, 284, 258.
Preparation 9: 1 - [4-(4-Amino-2-fluoro -phenyl)-piper azin-1-yl] -ethanone
Figure imgf000063_0001
To a solution of l-[4-(2-fluoro-4-nitro-phenyl)-piperazin-l-yl]-ethanone (2.00 grams, 7.5 mmol), obtained in preparation 5, in a mixture of methanol and THF (4: 1, 40 mL) was added ammonium formate (1.9 grams, 30 mmol) followed by the addition of
10% palladium on charcoal (Pd-C) (400 mg, 3.75 mmol) and stirred at 25-35 °C for 4
hours. The reaction mixture was filtered through a pad of celite and washed thoroughly with methanol. Removal of volatiles on a rotavapor left a pasty residue, which was diluted with water and extracted with ethyl acetate (3 x 50 mL). The combined organic layer was washed with brine and dried over sodium sulfate. Title amine was obtained after removal of volatiles (1.7 grams, 94%).
Η NMR (CDC13): δ 6.86-6.76 (m, IH), 6.49-6.41 (m, 2H), 3.81-3.77 (m, 2H), 3.66-3.61
(m, 2H), 2.98-2.93 (m, 4H), 2.16 (s, 3H).
IR (KBr, cm"1): 3439, 3333, 3212, 2919, 1640, 1514, 1469.
CI-MS (mz): 238 (M++l), 220, 194, 165, 138, 124, 112.
Preparation 10:
4-(4-A_nino-2-fluoro-phenyl)-piperazine-l-carboxylic acid tert-butyl ester:
Figure imgf000063_0002
To a solution of 4-(2-fluoro-4-nitro-phenyl)-piperazine-l -carboxylic acid tert- butyl ester (9.00 grams, 27.7 mmol), obtained in preparation 7, in methanol and THF (4: 1 , 140 mL) was added ammonium formate (6.98 grams, 111 mmol) followed by the addition of 10% Pd-C (1.47 grams, 13.8 mmol) and stirred at 25-35 °C for 5 hours. The
reaction mixture was filtered through a pad of celite and washed thoroughly with methanol. Removal of volatiles left a pasty mass, which was diluted with water and extracted with ethyl acetate (150 mL x 3). The combined organic layer was washed with water followed by brine and dried over sodium sulfate. Evaporation of solvent produced the title amine (7.75 grams, 95%). lH NMR (CDCI3): δ 6.78 (t, J = 9.1 Hz, IH), 6.47-6.38 (m, 2H), 3.57 (t, J = 4.8 Hz, 4H),
2.90 (t, J= 4.8 Hz, 4H), 1.48 (s, 9H),
IR (KBr, cm"1): 3451, 3347, 1681.
CI-MS (m/z): 296 (M++l), 282, 240, 196.153, 106, 96.
Preparation 11:
4-(4-Amino-2, 6-difluoro-pheny_)-piperazine-l-carboxylic acid tert-butyl ester:
Figure imgf000064_0001
Title compound (20.5 grams, 75%) was prepared from 4-(2,6-difluoro-4-nitro- phenyl)-piperazine-l -carboxylic acid tert-butyl ester (30 grams, 87.5 mmol), obtained in preparation 8, ammonium formate (22.06 grams, 349.8 mmol) and 10% Pd-C (4.68 grams, 4.4 mmol) following the same procedure as described for the preparation of 4-(4- amino-2-fluoro-phenyl)-piperazine-l -carboxylic acid tert-butyl ester (Preparation 10). H NMR (CDCI3): δ 6.16 (ά, J = 10.5 Hz, 2H), 3.72 (bs, 2H), 3.53-3.48 (m, 4H), 3.02-
2.97 (m, 4H), 1.48 (s, 9H).
IR(KBr,cm"'): 3431, 3328,2976,2868, 1678, 1507, 1464, 1426, 1393, 1366, 1314, 1283,
1263, 1250, 1226, 1168, 1128, 1041, 1005, 958, 915, 837, 768, 734, 630, 579, 530.
CI-MS (m/z): 314 (M++l), 258, 214, 115, 100.
Preparation 12:
4-(l-Benzyl-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3-fluoro-phenylarnine
Figure imgf000064_0002
N-Butyllithium (62 mL, 1.6M in hexane) was added drop wise to a solution of 3- fluoroaniline (5 grams, 45.1 mmol) in dry THF (100 mL) at -78 °C under nitrogen atmosphere and stirred for 30 minutes. A solution of 1,2 -bis (chlorodimethylsilyl)-ethane (10.65 grams, 49.54 mmol) in dry THF (100 mL) was then added. The reaction mixture was stirred at the same temperamre for 45 minutes and then warmed to 25-35 °C. The reaction mixture was quenched with water (60 mL) and then extracted with diethyl ether. The combined organic layers were dried over sodium sulphate. The solvent was removed under vacuum to obtain l-(3-fluorophenyl)-2, 2, 5, 5-tetramethyl-[l, 2, 5] azadisilodine (1 1.4 grams) and this crude product was used in the next step without purification. To a solution of l-(3-fluoropheny_)-2,2,5,5-tetramethyl-[l,2,5] azadisilodine (11.4 grams, 45.1 mmol) in dry THF (120 mL) at -78 °C was added sec-butyl lithium (41.6 mL, 1.3 M in cyclohexane / hexane(92 / 8), 54.1 mmol) slowly under nitrogen and allowed the reaction mixture to stir for 5 hours at the same temperature. A solution of N-benzyl-4-piperidone (9.36 grams, 49.5 mmol) in dry THF (100 mL) was added to the reaction mixture and allowed to rise to 25-35 °C and stirred for 12 hours. Brought the reaction mixture to 0 °C
and acidified with concentrated hydrochloric acid (con.HCL). Washed the acidified reaction mixture with ether (2 x 100 mL). Then the reaction mixture was basified with 40%) aqueous sodium hydroxide solution to litmus blue and extracted with diethyl ether (3 x 160 mL). Organic layer was dried over sodium sulphate and evaporated under vacuum to get a brown residue, which was mixed with cone. HCI (150 mL) and heated at 90 °C for 9 to 13 hours. Brought the reaction temperature down to 0 °C and basified with ammonia solution and extracted with dichloromethane (3 x 150 mL). Removed the solvent under reduced pressure and was purified by silica gel column chromatography (10% ethyl acetate/petroluem ether) to obtain 4-(l -benzyl- 1, 2, 3, 6-tetrahydro-pyridin-4- yl)-3-fluoro-phenylamine as a brown solid (5.1 grams, 40%)
Η NMR (CDC13, 200 MHz): 7.44-7.20 (m, 5H), 7.03 (t, J = 8.8 Hz, IH), 6.44-6.22 (m, 2H), 5.96-5.78 (m, IH), 3.63 (s, 2H), 3.92-3.40 (m, 2H), 3.22-3.16 (m, 2H), 2.80-2.58 (m, 2H), 2.58-2.40 (m, 2H)
IR (KBr): 3463, 3381 , 3029, 2917, 2802, 1713, 1630, 1511, 1368, 1318, 1164 cm"1 CI-MS (m/e): 283 (M++l)
Preparation 13:
4-(l-Benzyl-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3, 5-difluoro-phenylamine
Figure imgf000065_0001
The title compound was prepared from 3,5-difluoroaniline (5 grams, 38.76 mmol) in 52% yield following the same procedure as described for the preparation of 4-(l- Benzyl-1, 2, 3, 6-tetrahydro-pyridin-4-yl)-3-fluoro-phenylamine (Preparation 12), in 52% yield.
Η NMR (CDC13, 200 MHz): δ 7.50-7.16 (m, 5H), 6.17 (d, J= 9.3 Hz, 2H), 5.82-5.67 (m, IH), 4.00-3.70 (m, 2H), 3.62 (s, 2H), 3.22-3.02 (m, 2H), 2.82-2.60 (m, 2H), 2.50-2.30 (m, 2H)
IR (KBr): 3391, 2921, 1647, 1454, 1160, 1019, 829 cm"1 CI-MS (m/e): (KBr): 301 (M+l)
Preparation 14: 3-Fluoro-4-(4-π_ethanesulfonyl-piperazin-l-y_)-phenylamine
Figure imgf000066_0001
Title amine (1.7 grams, 94%) was prepared from l-(2-fluoro-4-nitro-phenyl)-4- methanesulfonyl-piperazine (2.0 grams, 6.6 mmol), obtained from preparation 6, following the same procedure as described for the preparation of l-[4-(4-amino-2-fluoro - phenyl)-piperazin-l-yl] -ethanone (Preparation 9)..
Η NMR (CDCI3): δ 6.81 (t, J= 9.0 Hz, IH), 6.46-6.40 (m, 2H), 3.60 (bs, 4H), 3.39-3.36 (m, 2H), 3.09-3.07 (m, 2H), 2.83 (bs, 3H). IR (KBr, cm'1): 3451, 2922, 2852, 1633, 1316. CI-MS (m/z): 274 (M++l), 194.
Preparation 15: l-[4-(4-Azido-2-fluoro -phenyl)-piperazin-l-yl]-ethanone
Figure imgf000066_0002
To an ice cooled solution of l-[4-(4-amino-2-fluoro-phenyl)-piperazin-l-yl]- ethanone, (500 mg, 2.1 mmol), obtained in preparation 9, in 50% aquoes. HCI (2 mL) was added a samrated aqueous solution of sodium nitrite (291 mg, 4.21 mmol) drop wise. The reaction mixmre was then allowed to come to 25-35 °C and stirred for 1 hour. A solution of sodium acetate (3.5 grams, 42.2 mmol) and sodium azide (274 mg, 4.21 mmol) in water was added at 0 °C and stirred for 10 minutes. The precipitate formed was filtered through a Buchner funnel and dried under vacuum to get the title azide (360 mg, 65%).
Η NMR (CDC13): δ 6.94 (t, J= 8.8 Hz, IH), 6.79-6.72 (m, 2H), 3.88-3.75 (m, 2H), 3.66-
3.54 (m, 2H), 3.07-2.97 (m, 4H), 2.12 (s, 3H).
IR (KBr, cm"1): 3322, 2925, 2117, 1233, 1101, 758.
CI-MS (m/z): 264 (M++l), 252, 237, 235, 223, 210, 196.
Preparation 16: 3-Fluoro-4-(4-methanesulfonyl-piperazin-l-yl)-phenylazide
Figure imgf000067_0001
Title azide (975 mg, 89%) was obtained from 3-fluoro-4-(4-methanesulfonyl- piperazin-l-yl)-phenylamine (1.0 gram, 3.66 mmol), obtained from preparation 14, following the same procedure as described for the preparation of 1 -[4-(4-Azido-2-fluoro - phenyl)-piperazin-l-yl]-ethanone (Preparation 15)
Η NMR (CDCI3): δ 6.93-6.89 (m, IH), 6.79-6.72 (m, 2H), 3.40-3.37 (m, 4H), 3.16-3.12 (m, 4H), 2.83 (s, 3H).
IR (KBr, cm"1): 3423, 2929, 2840, 2124, 1507, 1326, 1154, 524. CI-MS (m z): 300 (M++l), 271.
Preparation 17:
4-(4-Azido-2-fluoro-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000067_0002
Sodium azide (1.32 grams, 20.34 mmol), moist with water (1 mL) was suspended in tert-butyl alcohol (25 mL) followed by the addition of 4-(4-amino-2-fluoro-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester (2.0 grams, 6.78 mmol), obtained in preparation 10, and tert-butyl nitrite1 (16 mL, 81 mmol) and heated at 70 °C for 3 hours. The reaction mixture was then diluted with water, extracted with ethyl acetate (2x 100 mL) and the combined organic layer was washed with brine and dried over sodium sulfate. Removal of volatiles under reduced pressure and chromatographic purification of the residue over silica gel (5:95 ethyl acetate/petroleum ether) afforded the title azide (1.5 grams, 70 %).
1. Vogel's Textbook of Practical Organic Chemistry, 5th Ed., 1989, Longman, UK.
Η NMR (CDC13): δ 6.93-6.84 (m, 2H), 6.70 (d, J= 4.4 Hz, IH), 3.59-3.54 (m, 4H), 2.98-
2.93 (m, 4H), 1.57 (s, 9H).
IR (KBr, cm"1): 2977, 2113, 1699, 1507, 1421, 1231, 1189,908.
CI-MS (m/z): 322 (M++l), 308, 293, 266, 237.
Preparation 18:
4-(4-Azido-2, 6-difluoro-phenyl)-piperazine-l-carboxylic acid tert-butyl ester:
Figure imgf000068_0001
Title compound (15.6 grams, 72%) was prepared from 4-(4-amino-2,6-difluoro- phenyl)-piperazine-l -carboxylic acid tert-butyl ester (20 grams, 63.9 mmol), obtained in preparation 11, and 10% aqueous.HCl, sodium nitrate (8.82 grams, 127.8 mmol), sodium azide (8.31 grams, 127.8 mmol) and sodium acetate (174 grams, 1278 mmol) following the same procedure as described for ttie preparation of l-[4-(4-azido-2-fluoro-phenyl)- piperazine-1-yl] -ethanone (Preparation 15).
Η NMR (CDC13): δ (d, J= 9.52 Hz, 2H), 3.53 (t, J= 4.88 & 5.13 Hz, 4H), 3.10-3.08 (m, 4H).
IR(KBr, cm"1): 3445, 2969, 2943, 2860, 2124, 1694, 1626, 1572, 1500, 1459, 1427, 1366, 1317,1283, 1250, 1169, 1133, 1073,1041,998,968,910,887,841,764,735,619,519. MS (m/z): 340 (M++l), 314, 284, 258, 240, 186, 149, 121, 97.
Preparation 19:
[4-(4-Azido-2, 6-difluoro phenyI)-piperazin-l-yl]-(5-nitro-furan-2-yl)-methanone
Figure imgf000068_0002
To an ice cooled solution of 4-(4-azido-2,6-difluoro-phenyl)-piperazine-l - carboxylic acid tert-butyl ester (1.0 grams, 2.95 mmol), obtained from preparation 18, was added trifluoroacetic acid (4 mL) and stirred at the same temperamre for 1 hour. Excess of trifluoroacetic acid was removed on rotavapor and the resulting salt was washed with petroleum ether and dried under vacuum. To the solution of the above salt in dichloromethane (15 mL) was added triethylamine (1.23 mL, 8.85 mmol) at 0 °C followed by the addition of 5-nitrofuroyl chloride (520 mg, 2.95 mmol). The reaction mixture was then allowed to stir 9 to 13 hours at 25-35 °C. Water was added to the reaction mixture
and extracted with ethyl acetate (3 x 30 mL). The combined organic portion was washed with water followed by brine and dried over sodium sulfate. The residue obtained upon concentration was purified by column chromatography (60-120 mesh silica gel, 1 :4, and ethyl acetate/pet ether) to obtain the title compound (500 mg, 45%).
Η NMR (CDC13): δ 7.38 (d, J = 3.9 Hz, IH), 7.23 (d, J = 3.4 Hz, IH), 6.60 (d, J = 9.3
Hz, 2H), 3.96 (bs, 4H), 3.26 (bs, 4H).
IR(KBr, cm"1): 3436, 3139, 3109, 2923,2851,2122, 1633, 1577, 1512, 1434, 1388, 1356,
1329, 1275, 1242, 1025, 973, 921, 838, 759, 607, 527, 497.
CI-MS (m/z): 379 (M++l), 351, 252, 210, 154, 140.
Preparation 20: [4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-(5-nitro-furan-2-yl)-methanone
0 Y ANΛ_ N3 o
The title compound was prepared from 4-[(4-azido-2-fluoro-phenyl)-piperazine-l- carboxylic acid tert-butyl ester and 5-nitro-furoyl chloride, obtained in preparation 17, following the same procedure as described for the preparation of [4-(4-azido-2,6-difluoro- phenyl)-piperazin-l-yl]-(5-nitro-furan-2-yl)-methanone (Preparation 19). "H NMR (CDCI3) : δ 7.34-7.21 (m, 2H), 6.91 (t, J = 8.8 Hz, lH),6.76-6.70 (m, IH), 6.37 (bs, IH), 4.15-3.91 (m, 4H), 3.12 (bs, 4H). IR (KBr, cm"1) : 2925, 2855, 2130, 1634, 1529, 1508. CI-MS : 361 (M++l), 333, 320, 205.
Preparation 21: l-(4-Azido-2, 6-difluoro-phenyI)-4-(5-nitro-furan-2-ylmethyI)-pipearazine:
Figure imgf000070_0001
The title compound was prepared from 4-[(4-azido-2-fluoro-phenyl)-piperazine-l- carboxylic acid tert-butyl ester (827 mg, 65%) and 5-nitro furyl mesylate (771.3 mg, 3.49 mmol) by following the same procedure as described for the preparation of [4-(4-azido- 2,6-difluoro-phenyl)-piperazin-l-yl]-(5-nitro-furan-2-yl)-methanone (Preparation 19). Η NMR (CDC13): δ 7.29 - 7.25 (m, IH), 6.58 - 6.48 (m, 3H), 3.68 (s, 2H), 3.17 (bs, 4H), 2.81 (bs, 4H).
IR (KBr, cm"1): 2831, 2115, 1629, 1573, 1501, 1443, 1389, 1357, 1236, 1137, 1028, 969, 928, 812, 739, 611. CI-MS (m/z): 365 (M++l), 348, 337, 318, 250.
Preparation 22: [4-(4-Azido-2,6-difluoro-phenyl)-pipearazin-l-yl]-isoxazol-5-yl-methanone:
Figure imgf000070_0002
The title compound was prepared from 4-[(4-azido-2-fluoro-phenyl)-piperazine-l- carboxylic acid tert-butyl ester (520 mg, 75.3%) and isoxazole carbonyl chloride (271 mg, 2.06 mmol), following the same procedure as described for the preparation of [4-(4-azido- 2, 6-difluoro phenyl)-piρerazin-l-yl]-(5-nitro-furan-2-yl)-methanone (Preparation 19). Η NMR (CDCI3): δ 8.34 (s, IH), 6.84 (s, IH), 6.58 (d, J = 9.3 Hz, 2H), 3.88 (bs, 4H). 3.23 (bs, 4H).
IR (KBr, cm"1): 3118, 2928, 2822, 2323, 2203, 2117, 1746, 1648, 1572, 1505, 1430, 1356, 1281, 1237, 1196, 1152, 1027, 980. CI-MS (m/z): 335 (M++l), 306, 225, 151, 96, 90.
Preparation 23: l-[4-(4-Azido-2,6-difluoro-phenyl)-piperzin-l-yl]-2-(tert-butyI-dimethyl-silanyloxy)- ethanone
Figure imgf000070_0003
The title compound was prepared from 4-[(4-azido-2-fluoro-phenyl)-piperazine-l- carboxylic acid tert-butyl ester and (450 mg, 75%) was obtained from (tert-Butyl- dimethyl-silanyloxy)-acetyl chloride2 (308 mg, 1.46 mmol) following the same procedure as described for the preparation of [4-(4-azido-2,6-difluoro-phenyl)-piperazin-l-yl]-(5- nitro-furan-2-yl)-methanone (Preparation 19). 2. Wilssner, A.; Grudzinskas, C. V.. J. Org. Chem., 1978, 43, 3972
Η NMR (CDC13): δ 6.45 (d, J = 9.3 Hz, 2H), 4.20 (s, 2H). 3.57 (bs, 4H), 3.02 (bs, 4H), 0.79 (s, 9H), 0.09 (s, 6H).
IR (KBr, cm"1): 3405, 2930, 2856, 1667, 1524, 1470, 1256, 11 19, 1045, 938, 859, 805, 779, 670, 605, 564. CI-MS (m/z): 412 (M++l), 383, 354, 326, 307, 231, 193, 144, 105, 91.
Preparation 24:
4-(4-Azido-2-fluoro-phenyl)-l-benzyl-l, 2, 3, 6-tetrahydro-pyridine:
Figure imgf000071_0001
The title compound was prepared from 4-(l -benzyl- 1, 2, 3, 6-tetrahydro-ρyridin-4- yl)-3-fluoro-phenylamine (6 grams, 21.2 mmol), obtained from preparation 12, by following the same procedure as described for l-[4-(4-Azido-2-fluoro -phenyl)-piperazin- 1-yl] -ethanone, in 38% yield. (Preparation 15).
Η NMR (CDCI3, 200 MHz): δ 7.45-7.18 (m, 6H), 6.82-6.62 (m, 2H), 6.01-5.96 (m, IH), 3.69 (s. 2H),'3.25-3.18 (m, 2H), 2.81-2.62 (m, 2H), 2.61-2.42 (m, 2H) IR fNeat): 3029, 2923, 2113, 1609, 1498, 1308 cm"1 CI-MS (m/e): 309 (M++l)
Preparation 25:
4-(4-Azido-2-fluoro-phenyI)-l, 2, 3, 6-tetrahydro-pyridine
Figure imgf000071_0002
l-Chloromethylchloro formate (3.89 mL, 35.71mmol.) was added to an ice cold solution of 4-(4-Azido-2-fluoro-phenyl)-l -benzyl- 1, 2, 3, 6-tetrahydro-ρyridine (10 grams, 32.46 mmol), obtained in preparation 24, in dichloromethane (DCM) (70 mL). This solution was allowed to stir at 0 °C for 1 hour. Solvent was evaporated under vacuum and the residue was refluxed in methanol for 2 hours. Then the solvent was removed under vacuum and the residue was purified by column chromatography (0.05:1 methanol: chloroform) to obtain desired product as yellow solid. (5 grams, 71%) Η NMR (CDCI3, 200MHz): 7.30-7.05 (m, IH), 6.80-6.62 (m, 2H), 6.00-5.86 (m IH), 3.97-3.75 (m, 2H), 3.57-3.30 (m, 2H), 2.97-2.75 (m, 2H). IR (KBr): 3425, 2926, 2116, 1498, 1309, 1206, 807, 600 cm"1 CI-MS (m e): 219 (M+l)
Preparation 26:
[4-{4-Azido-phenyl}-3, 6-dihydro-2H-pyridin-l-yI] - acetonitrile
Figure imgf000072_0001
To a solution of 4-(4-Azido-2-fluoro-phenyl)- 1 , 2, 3, 6-tetrahydro-pyridine (0.4 grams, 1.80 mmol), obtained in preparation 25, and potassium carbonate (0.79 grams, 5.5 mmol) in dry dimethyl formamide (DMF) (8 mL) was added bromoacetonitrile (2.2 grams, 18.30 mmol) at 0 °C . Allowed the reaction mixture to stir at 25-35 °C for 12
hours. The reaction mixmre was then diluted with ethyl acetate (15 mL), washed with water followed by brine solution. The organic layer was evaporated under reduced pressure and the residue was purified by column chromatography (0.1 :1 ethylacetate/pet.ether) to give the desired product as a yellow solid (0.09 grams, 36%) Η-NMR (CDC13, 200MHz): δ 7.28-7.19 (m, IH), 6.82-6.70 (m, 2H), 5.98-5.90 (m, IH), 3.67 (s, 2H), 3.34-3.30 (m, 2H), 2.87 (t, J=5.4 Hz, 2H), 2.70-2.58 (m, 2H). IR (Neat): 2924, 2113, 1616, 1500, 1208, 977, 860 cm"1 CI-MS (m/e): 258 (M+l)
Preparation 27:
4-(4-Azido-2, 6-difluoro-phenyl)-l, 2, 3, 6-tetrahydro-pyridine
Figure imgf000072_0002
The title compound (6 grams, 68%) was obtained from 4-(l -benzyl- 1, 2, 3, 6- tetrahydro-pyridin-4-yl)-3, 5-difluoro-phenylamine, obtained in preparation 13, using the same procedure as described for synthesis of 4-(4-azido-2-fluoro-phenyl)-l, 2, 3, 6- tetrahydro-pyridine (Preparation 25).
Η NMR (CDC13, 200MHz): δ 6.60(d, J=7.7 Hz, 2H), 6.02-5.89(m, IH), 3.40-3.28(m, 2H), 2.87(t, J= 5.5Hz, 2H), 2 60-2.48 (m, 2H). IR (KBr): 3421 , 2925, 2741, 2741, 2599, 2473, 21 17, 1613, 1206, 1095, 1035 cm"1
Preparation 28:
4-(l-Benzyl-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3,5-difluoro-pheny_azide :
Figure imgf000073_0001
The title compound was prepared from 4-(l -Benzyl- 1, 2, 3, 6-tetrahydro-pyridin- 4-yl)-3, 5-difluoro-phenylamine (6 grams, 20 mmol), obtained from preparation 13, following the same procedure as described for the preparation of l-[4-(4-azido-2-fluoro - phenyl)-piperazin-l-yl] -ethanone (Preparation 7), in 62% yield.
Η NMR (CDCI3, 200 MHz): δ 7.48-7.28 (m, 5H), 6.57 (d, J= 8.3 Hz, 2H), 5.89-5.72 (m, IH), 3.67 (s, 2H), 3.22-3.18 (m, 2H), 2.72 (t, J= 5.6 Hz, 2H), 2.59-2.32 (m, 2H) IR (KBr): 2920, 2801, 2115, 1632, 1570, 1492, 1436, 1436, 1342, 1235 cm"1 CI-MS (m/e): 327 (M+l), 298
Preparation 29:
(J?)-2,2-Dimethyl-l ,3-dioxolane-4-carboxylic acid
Figure imgf000073_0002
To a solution of methyl-(R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate (1.8 grams, 1 1.24 mmol) in THF (20 mL) was added an aqueous solution (20 mL) of lithium hydroxide monohydrate (0.71 grams, 16.9 mmol) drop wise over a period of 10 minutes at 0 °C and stirring was continued for another 1 hour. The reaction mixmre was diluted with 50 mL of water and extracted with ethyl acetate (50 mL), which was discarded. Further, the aqueous layer was acidified with 10 M phosphorous acid (H3P04) and the pH was brought to 2. The aqueous layer was then extracted with ethyl acetate (50 mL x 4) and the combined organic layers were washed with water and brine and dried over sodium sulfate. Removal of volatiles left 1.6 grams (97%) of the title acid, which was used directly for the next step.
Preparation 30:
[4-(4-Azido-2-fluoro-phenyl)-3,6-dihydro-2H-pyridin-l-yI]-((4S)-2,2-dimethyl-[l,3] dioxolan-4-yl)-methanone
Figure imgf000074_0001
To a solution of 2, 2-dimethyl-[l, 3] dioxolane-4-carboxylic acid, obtained in preparation 29, in dry THF (4 mL) was added isobutylchloroformate (103 mg, 0.757 mmol) and triethylamine (84 mg, 0.825 mmol) at 0 °C. The reaction mix re was stirred for 10 minutes, followed by the addition of 4-(4-Azido-2-fluoro-phenyl)-l, 2, 3, 6- tetrahydro-pyridine (150 mg, 0.688 mmol), obtained in preparation 25. The reaction mixture was allowed to stir for 16 hours at 25-35 °C after which it was diluted with ethyl
acetate (5 mL), washed with saturated sodium bicarbonate solution and brine. The organic layer was distilled off under vacuum and the residue was purified by column chromatography to furnish the desired product as a viscous liquid. (150 mg, 63%) Η NMR (CDC13, 200MHz): δ 7.30-7.15 (m, IH), 6.88-6.68 (m, 2H), 6.01-5.90 (m, IH), 4.80-4.66 (m, IH), 4.58-4.40 (m, IH), 4.40-4.24 (m, IH), 4.24-4.05 (m, 2H), 4.04-3.82 (m, 2H), 3.82-3.56 (m, IH), 2.76-2.36 (m, 2H), 1.43 (s, 6H); IR (Neat): 2959, 2114, 1646, 150, 1210, 1070, 845, 767 cm"1. CI-MS (m e): 347 (M+l);
Preparation 31:
[4-(4-Azido-2-fluoro-phenyl)-3,6-dihydro-2H-pyridin-l-yl]-((4R)-2,2-dimethyl-
[l,3]dioxolan-4-yl)-methanone
Figure imgf000074_0002
The title compound (260 mg) was synthesized from 4-(4-Azido-2-fluoro-phenyl)- 1, 2, 3, 6-tetrahydro-pyridine (300 mg, 1.376 mmol), obtained in preparation 25, by the same procedure as described for [4-(4-Azido-2-fluoro-phenyl)-3,6-dihydro-2H-pyridin-l- yl]-((4S)-2,2-dimethyl-[l,3] dioxolan-4-yl)-methanone (Preparation 30). Η NMR (CDC-3, 200MHz): δ 7.30-7.15(m, IH), 6.88-6.68(m, 2H), 6.01-5.90(m, IH), 4.80-4.66(m, IH), 4.55-4.40(m, IH), 4.40-4.24(m, IH), 4.24-4.05(m, 2H), 4.00-3.82(m, IH), 3.80-3.58 (m, IH), 2.66-2.40 (m, 2H), 1.42 (s, 6H). IR (Neat): 2987, 1644, 1449, 1374, 121 1, 1068, 847 cm"1 CI-MS (m/e): 347 (M+l)
Preparation 32:
[4-(4-Azido-2, 6-difluoro-phenyl)-3, 6-dihydro-2H-pyridin-l-yl]-((4S)-2.2-dimethy_-
[1, 3] dioxolan-4-yl)-methanone
Figure imgf000075_0001
The desired product (600 mg) was obtained from 4-(4-azido-2, 6-difluoro-phenyl)- 1 , 2, 3, 6-tetrahydro-pyridine (687 mg, 2.91 mmol), obtained in preparation 27, by the same procedure as described for the preparation of [4-(4-azido-2-fluoro-phenyl)-3,6- dihydro-2H— pyridin-l-yl]-(2,2-dimethyl-[l,3]dioxolan-4-yl)-methanone (Preparation 30). Η NMR (CDC13, 200MHz): δ 6.62 (d, J=4.8Hz, 2H), 5.90-5.70 (m, IH), 4.80-4.60 (m, IH), 4.60-4.42 (m, IH, 4.42-4.27 (m, IH), 4.27-4.05 (m, 2H), 4.05-3.85 (m, IH, 3.85-3.62 (m, IH), 2.70-2.28 (m,2H), 1.43(s, 6H). IR (Neat): 2988, 1633, 1438, 1343, 1057, 928, 732 cm"1 CI-MS (m e): 365 (M+l)
Preparation 33:
[4-(4-Azido-2, 6-difluoro-phenyI)-3, 6-dihydro-2H-pyridin-l-yl]-((4R)-2, 2-dimethyl-
[1, 3] dioxolan-4-yl)-methanone
Figure imgf000075_0002
The title compound (770 mg) was obtained from 4-(4-azido-2, 6-difluoro-phenyl)- 1, 2, 3, 6-tetrahydro-pyridine (500 mg, 3.42 mmol), obtained in preparation 27, and (S)- 2,2-dimethyl-l,3-dioxalane-4-carboxylic acid, by the same procedure as described for the preparation of [4-(4-azido-2-fluoro-phenyl)-3,6-dihydro-2H~pyridin-l -yl]-(2,2-dimethyl- [l,3]dioxolan-4-yl)-methanone (Preparation 30).
Η NMR (CDC13, 200MHz): δ 6.59(d, J=7.8Hz, 2H), 5.90-5.70(m, IH), 4.73(t, J=6.3Hz, IH), 4.60-4.41(m, IH), 4.41-4.25(m, IH), 4.25-4.08(m, 2H), 4.08-3.85(m, IH), 3.80- 3.60(m, IH), 2.72-2.30(m, 2H), 1.42(s, 6H). IR(Neat): 2988, 2202, 2117, 1570. 1449, 1344, 1059, 981 cm"1 CI-MS (m/e):.365 (M+l)
Preparation 34:
3-[4-(4-Azido-2,6-difluoro-phenyI)- piperazin-l-yl]-3-oxo-propionic acid ethyl ester
Figure imgf000076_0001
To a stirred solution of l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19 (500 mg, 2.1 mmol) in dry dichloromethane (DCM) (15 mL) was added triethylamine (0.9 ml, 6.3 mmol) and ethylmalonyl chloride (0.53 mL, 4.18 mmol) and 4-Dimethylamino-pyridine (DMAP) catalytic amount at 0 °C . The reaction mixmre was diluted with DCM and washed with water (2 x 15mL), brine, dried over sodium sulfate. (Na2S04) The organic solvent was distilled off under vacuum and the residue was purified by column chromatography (4:6 ethyl acetate/pet.ether) to give the title compound (600 mg, 81%).
'H NMR (CDCI3, 400 MHz): δ 6.56 (d, J = 9.7 Hz, 2H), 4.22 (q, J = 7.0 Hz, 2H), 3.76 (t, J = 4.8 Hz, 2H), 3.56 (t, J = 4.8 Hz, 2H), 3.50 (s, 2H), 3.18 - 3.1 1 (m, 4H), 1.30 (t, J = 7.3 Hz, 3H).
IR (KBr): 2923, 2116, 1739, 1652, 1504, 1443, 1237, 1154, 1028,846 cm"1. CI-MS (m/e): 354 (M++l), 328
Preparation 35: 3-[4-(4-Azido-2,6-difluoro-phenyI)-piperazin-l-yl]-3-oxo-propionicacid
Figure imgf000077_0001
To a stirred solution of 3-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-yl]-3-oxo- propionic acid ethyl ester (100 mg, 0.28 mmol) obtained in preparation 34, in THF:H20 (4:1) solution was added lithium hydroxide (9 mg, 0.37 mmol) in minimum amount of water and stirred for 2 hours at 25-35 °C. The reaction mixture was acidified with ortho
phosphoric acid till pH = 2 and the extracted with ethyl acetate and concentrated under vacuum to yield the corresponding free acid which was pure enough to carry next step (60 mg, 65%).
Η NMR (CDCh, 400 MHz): 8 6.69 (d, J = 9.4 Hz, 2H), 3.82 (t, J = 4.8 Hz, 2H), 3.60 (t, J
= 4.8 Hz, 2H), 3.42 (s, 2H), 3.21 - 3.15 (m, 4H).
IR (neat): 2922, 2854, 2117, 1736, 1610, 1504, 1445, 1237, 1033, 756 cm"1
CI-MS (m/e): 282, 256
Preparation 36:
3-[4-(4-Azido-2, 6-difluoro-phenyI)- piperazin-l-yl]-N-methyl-3-oxo-propionamide
Figure imgf000077_0002
To a stirred solution of 3-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-yl]-3- oxo-propionic acid (150 mg, 0.46 mmol) obtained in preparation 35, in dry DMF (8 mL) was added methylamine in THF (29 mg, 0.92 mmol), N -Methyl moφholine (47 mg, 0.46 mmol) and Benzotriazol-1-yloxytris (dimethyl-amino) phosphonium hexafluorophosptate (BOP) (204 mg, 0.46 mmol) portion wise at 0 °C. The reaction mixture was stirred for 9 to
13 hours at 25-35 °C. Then the reaction mixmre was diluted with ethyl acetate (20 mL)
and washed with water (2 x 10 mL), brine and dried (Na2S0 ). The solvent was removed under vacuum and the residue was purified by column chromatography (1% CH3OH CHCI3) to furnish the title compound (90 mg, 57%).
Η NMR (CDCI3, 400 MHz): δ 7.44 (bs, IH), 6.56 (d, J = 9.1 Hz, 2H), 3.75 (t, J = 4.8 Hz, 2H), 3.66 (t, J = 4.6 Hz, 2H), 3.36 (s, 2H), 3.18 -3.10 (m, 4H), 2.84 (d, J = 4.8 Hz, 3H). IR (KBr): 3320, 2923, 2115, 1632, 1505, 1451, 1240, 1031, 834 cm"1. CI-MS (m/e): 339 (M++l), 310
Preparation 37:
2(S)-{3-[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]-3-oxo-propionyImino}-3- hydroxy-propionic acid methyl ester
Figure imgf000078_0001
The title compound was prepared from was synthesized from l-(4-Azido-2,6- difluoro-phenyl)-piperazine, obtained in the process of preparation 19, and 2-amino-3- hydroxy-propionic acid methyl ester using the same procedure as described for synthesis of 3-[4-(4-Azido-2, 6-difluoro-phenyl)- piperazin-l-yl]-N-methyl-3-oxo-propionamide (preparation 36).
Η NMR (CDC13, 400 MHz): δ 8.01 (d, J = 6.4 Hz, IH), 6.58 (d, J = 9.5 Hz, 2H), 4.70 - 4.65 (m, IH), 4.05 - 3.96 (m, 2H), 3.80 (s, 3H), 3.78 (t, J = 5.0 Hz, 2H), 3.63 (t, J = 5.6 Hz, 2H), 3.44 (d, J = 2.5 Hz, 2H), 3.21- 3.11 (m, 4H). IR (KBr): 3319, 2115, 1746, 1630, 1504, 1442, 1235, 1033, 754 cm"1 CI-MS (m/e): 427 (M++l), 409
Preparation 38: [4-(4-Azido-2,6-difluoro-pheny_)-piperazin-l-yl]-acetonitrile
Figure imgf000078_0002
To a stirred solution of l-(4-Azido-2,6 -difluoro-phenyl)-piperazine, obtained in the process of preparation 19, (1.5 grams, 6.27 mmol) in dry DMF (10 mL) was added anhydrous potassium carbonate (K2C03) (5.2 grams, 37.6 mmol) and stirred at for 5 minutes. Then bromoacetonitrile was added drop wise at 25-35 °C and stirred for 9 to 13
hours. The reaction mixmre was diluted with ethylacetate and washed with water (2 x25 mL), brine and dried over Na2S0 . The organic layer was concentrated under vacuum and the purified by column chromatography (8:2 ethyl acetate (EtOAc)φet ether) to give the title product (1 gram, 59 %) Η NMR (CDC13, 200 MHz): δ 6.55 (d, J = 9.7 Hz, 2H), 3.57 (s, 2H), 3.25 - 3.18 (m,
4H), 2.73-2.69 (m, 4H).
IR (Neat): 2831, 2116, 1503, 1235, 1009, 780 cm"1
CI-MS (m/e): 279 (M++l), 252, 226
Preparation 39: l-[4-(4-Azido-2, 6-difluoro-phenyl) - piperazin-l-yl]-2-pyridin-3-yl-ethanone
Figure imgf000079_0001
The title compound (200 mg, 67%) was synthesized from pyridin-3-yl-acetic acid (145 mg, 0.84 mmol) using the same procedure as described in example 27. Η NMR (CDCh, 400 MHz): δ 8.56 -8.51 (m, 2H), 7.66 (d, J = 7.8 Hz, IH), 7.32 - 7.27 (m, IH), 6.55 (d, J = 9.4 Hz, 2H), 3.78 - 3.75 (m, 2H), 3.76 (s, 2H), 3.59 (t, J = 4.8 Hz, 2H), 3.12 - 3.09 (m, 2H), 3.10 - 3.05 (m, 2H).
IR (KBr): 2115, 1645, 1574, 1504, 1441, 1238, 1152, 1029, 846, 712 cm"1 CI-MS (m/e): 359 (M++l), 330
Preparation 40: l-[4-(4-Azido-2,6-difluoro-phenyl) - piperazin-l-yl]-2-(3-hydroxy-phenyl)-ethanone
Figure imgf000079_0002
The title compound (250 mg, 53 %) was synthesized from (3-Hydroxy-phenyl)- acetic acid (191 mg, 1.25 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in example 27.
Η NMR (CDC13, 400 MHz): δ 7.17 (t, J = 7.8 Hz, IH), 6.86 (t, 2.1Hz, IH), 6.78 - 6.73 (m, 2H), 6.53 (d, J = 9.7 Hz, 2H), 3.78 - 3.72 (m, 2H), 3.73 (s, 2H), 3.55 (t, J = 4.8 Hz, 2H), 3.09 (t, J = 4.8 Hz, 2H), 2.97 - 2.95 (m, 2H). IR (KBr): 3277, 2113, 1640, 1509, 1442, 1240, 1030, 836, 679 cm"1. CI-MS (m/e): 373 (Iv ) Preparation 41: l-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-yI]-2-(4-hydroxy-phenyl )-ethanone
Figure imgf000080_0001
The title compound (160 mg, 81%>) was synthesized from (4-Hydroxy-phenyl)- acetic acid (80 mg, 0.53 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, applying the same procedure as described in example 27. Η NMR (CDC13, 400 MHz): δ 7.10 (d, J = 8.6 Hz, 2H), 6.79 -6.75 (d, J = 8.5 Hz, 2H), 6.56 - 6.51 ( d, J = 9.6 Hz, 2H), 5.19 (s, IH), 3.75 (t, J = 4.8 Hz, 2H), 3.69 (s, 2H), 3.55 (t, J = 4.8 Hz, 2H), 3.15 - 3.05 (m, 2H), 3.01 - 2.95 (m, 2H). IR (KBr): 3246, 2116, 1631, 1509, 1443, 1237, 1029, 730 cm"1. CI-MS (m/e): 373 (M+), 345
Preparation 42: l-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-yl]-2-(2-nitro-phenyl)- ethanone
Figure imgf000080_0002
The title compound (470 mg, 56 %) was synthesized from (2-nitro-phenyl)-acetic acid (379 mg, 2.09 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtainted in the process of preparation 19, using the same procedure as described in example 27. Η NMR (CDCI3, 200 MHz): δ 8.10 (d, = 8.1 Hz, IH), 7.63 -7.34 (m, 3H), 6.56(d, J = 9.7 Hz, 2H), 4.10 (s, 2H), 3.80-3.62 (m, 4H), 3.30-3.21(m, 2H), 3.20-3.06 (m, 2H). IR (KBr): 2113, 1653, 1575, 1524, 1504, 1440, 1352, 1237, 1155, 1026, 728 cm"1. CI-MS (m/e): 403 (M++l), 377
Preparation 43: l-[4-(4-Azido-2,6-difluoro-pbenyl)- piperazin-l-yl]-2-(4-nitro-phenyl)- ethanone
Figure imgf000080_0003
The title compound (490 mg, 58 %) was synthesized from (4-Nitro-phenyl)-acetic acid (379 mg, 2.09 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same described in example 27. Η NMR (CDC13, 400 MHz): δ 8.22-8.19(m, 2H), 7.44(d, J=8.9 Hz, 2H), 6.60-6.53(m, 2H), 3.85(s, 2H), 3.77(t, J = 5.1 Hz, 2H), 3.58(t, J= 4.8 Hz, 2H), 3.12(t, J= 4.6 Hz, 2H), 3.10-3.05(m, 2H).
IR (KBr): 2118, 1651, 1575, 151 1, 1441, 1349, 1288, 1022, 739 cm"1 CI-MS (m/e): 402 (M+), 374, 346
Preparation 44: l-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yI]-2-bromo-ethanone
Figure imgf000081_0001
To a stirred solution of l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20 (400 mg, 1.81 mmol) in dry DCM at 0 °C was added triethylamine (0.8 mL) followed by the drop wise addition of bromoacetyl bromide (0.3 mL) and catalytic amount of DMAP. The mixture was stirred 9 to 13 hours at 25-35 °C.
The solvent was removed under vacuum and the residue was purified by column chromatography (1 :9 EtOAc/Pet. Ether) to afford desired product (140 mg, 23%).
Η NMR (200 MHz, CDC13): δ 7.14 - 6.84 (m, 2H), 6.78 - 6.72(m IH), 3.89 (s, 2H), 3.84
- 3.76 (m, 2H), 3.75 - 3.60 (m, 2H), 3.22 - 2.94 (m, 4H). IIRR ((KKBBrr)):: 33443388,, 22885533,, 22111144,, 1166f55, 1509, 1435, 1294, 1224, 1162, 1032, 808, 753 cm- CI-MS (m/e): 344 (M++2), 303
Preparation 45: l-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-2-dimethyIamino-ethanone
Figure imgf000081_0002
To a stirred mixmre of N,N-dimethylamine (0.26 mL, 2M solution in methanol), potassium carbonate (170 mg, 1.23 mmol) and dry DMF (2 mL) was added l-[4-(4- Azido-2-fluoro-phenyl)-piperazin-l-yl]-2-bromo-ethanone (140 mg, 0.40 mmol) obtained in preparation 44, in dry DMF (3 mL) drop wise at room te,perature and stirred for 9 to 13 hours. Then the reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (2 x 15 mL), brine and dried over Na2S04. The solvent was removed under vacuum and the residue was purified by column chromatography (3.5: 6.5 EtOAc/pet ether) to furnish the title compound (100 mg, 80 %).
Η NMR (200 MHz, CDC13): δ 7.16-6.82 (m, 2H), 6.81-6.65 (m, IH), 3.92-3.62 (m, 4H),
3.18 (s, 2H), 3.16-2.92 (m, 4H), 2.32 (s, 6H).
IR(Neat): 2825, 2114, 1648, 1506, 1460, 1232, 1147, 1029, 859, 755 cm"1.
CI-MS (m/e): 307(M++1), 281, 266.
Preparation 46: l~[4-(4-Azido-2-difluoro-phenyl)- piperazin-l-yl]-2(R)-hydroxy-2-phenyl- ethanone
Figure imgf000082_0001
The title compound (87 mg, 1 1 %) was synthesized from hydroxyl phenyl-acetic acid (344 mg, 2.26 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine obtained in the process of preparation 20, applying the same procedure as described in example 27. Η NMR (200 MHz, CDCI3): δ 7.48 - 7.30 (m, 5H), 7.14 - 6.84 (m, 2H), 6.76 (t, J = 8.5 Hz, IH), 5.24 (d, J = 5.3 Hz, IH), 4.74 (bs, IH), 4.12 - 3.82 (m, IH), 3.80 - 3.62 (m, IH), 3.56 - 3.22 (m, 2H), 3.20 - 2.66 (m, 4H).
IR (Neat): 3407, 2113, 1644, 1505, 1450, 1386, 1234, 1025, 763, 703 cm"1. CI-MS (m/e): 356 (M++l), 328, 314, 299
Preparation 47: l-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-yl]-2-bromo-ethanone
The title compound (1.12 grams, 37%) was synthesized from bromo acetyl bromide (1.5 mL, 16.7 mmol) and l -(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the the same procedure as described in preparation 44. Η NMR (200 MHz, CDC13): δ 6.57 (d, J = 9.5 Hz, 2H), 3.89 (s, 2H), 3.82 - 3.68 (m, 2H),
3.66 - 3.58 (m, 2H), 3.28 - 3.04 (m, 4H).
IR (KBr): 3423, 2114, 1745, 1635, 1504, 1446, 1236, 1028, 971, 846 cm"1.
CI-MS (m/e): 362 (M++2), 360
Preparation 48: l-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-yl]-2-pyrazol-l-yl-ethanone
Figure imgf000083_0001
The title compound (160 mg, 47%) was synthesized from l-[4-(4-Azido-2,6- difluoro-phenyl)- piperazin-l-yl]-2-bromo-ethanone (350 mg, 0.97 mmol) obtained in preparation 47, employing the same procedure as described in preparation 45. Η NMR (200 MHz, CDCI3): δ 7.58 (s, IH), 7.25 (s, IH), 6.56 (d, J=9.3 Hz, 2H), 6.34 (s, IH), 5.04(s, 2H), 3.78-3.58 (m, 4H), 3.18-2.98 (m, 4H). IR (KBr): 3108, 2118, 1656, 1570, 1506, 1237, 1 150, 1034, 819, 771 cm"1 CI-MS (m/e): 348 (M++l)
Preparation 49: l-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-2-pyrazol-l-yl-ethanone
Figure imgf000083_0002
Using the same procedure as described in preparation 45, the title compound (162 mg, 53 %) was synthesized from 1 -[4-(4-Azido-2-fluoro-phenyl) - piperazin-l-yl]-2- bromo-ethanone (322 mg, 0.94 mmol) obtained in preparation 44.
Η NMR (200 MHz, CDCI3): δ 7.56 (s, 2H), 6.98 - 6.68 (m, 3H), 6.38 (s, IH), 5.04 (s, 2H), 3.86 - 3.64 (m, 4H), 3.12 - 2.92 (m, 4H).
IR (KBr): 3102, 2117, 1663, 1509, 1308, 1239, 1212, 1156, 1095, 1026, 814, 772 cm-1. CI-MS (m e): 330 (M++l), 304, 289
Preparation 50: 3-Chloromethyl-N,N-dimethyl-benzamide
Figure imgf000084_0001
To a stirred solution 3-chloromethyl benzoyl chloride (0.07ml, 0.53 mmol) in DCM at 0 °C was added dimethylamine (1.6 mL, 2M in methanol) drop wise and stirred for 9 to 13 hours at 25-35 °C. The solvent was removed under vacuum and the residue
was purified by column chromatography (1.5:8.5 EtOAc/pet ether) to afford the title product (85 mg, 81 %).
Η NMR (200MHz, CDC13): δ 7.45-7.32 (m, 4H), 4.59 (s, 2H), 3.18 (s, 3H),
2.94 (s, 3H).
IR (Neat): 3419, 2926, 1743, 1633, 1393, 1264, 1173, 1078, 710 cm"1.
CI-MS (m/e): 198 (M++l), 153
Preparation 51: 3-[4-(4-Azido-2,6-difluoro-phenyl)- piperazin-l-ylmethyl]-N,N-dimethyl- benzamide
Figure imgf000084_0002
To a stirred solution of l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19 (80 mg, 0.33 mmol) in dry DMF (3 mL) was added potassium carbonate (138 mg, 1 mmol) at 25-35 °C followed by the drop wise addition of
3-chloromethyl-N,N-dimethyl-benzamide (99 mg, 0.5 mmol) obtained in preparation 50, as a solution in DMF (3 mL). The reaction mixture was stirred at 25-35 °C 9 to 13 hours.
The mixmre was diluted with EtOAc (25 mL) and washed with water (2 x 20 mL) and brine. The organic layers were dried over sodium sulphate and concentrated under vacuum. The residue was purified by column chromatography (3:7 EtOAc/ Pet. ether) to afford title compound (85 mg, 63%>).
Η NMR (400MHz, CDCI3): δ 8.09 - 7.98 (m, 2H), 7.48 - 7.24 (m, 2H), 6.56 (d, J = 9.2 Hz, 2H), 3.59 (s, 2H), 3.22 - 3.09 (m, 2H), 3.03 - 2.94 (m, 2H), 2.86 (s, 6H), 2.64 - 2.50 (m, 4H). IR (Neat): 2817, 2113, 1636, 1502, 1449, 1391, 1238, 1027, 927, 772 cm"1. CI-MS (m/e): 401 (M++l), 372
Preparation 52: [4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]-(3-chIoromethyl-phenyl)-methanone
Figure imgf000085_0001
The title compound (700 mg, 29 %) was synthesized from 3-Chloromethyl- benzoyl chloride (1.78 mL, 12.6 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in preparation 34.
Η NMR (200MHz, CDC13): δ 7.78-7.28 (m, 4H), 6.58 (d, J=9.5 Hz, 2H), 5.02 (s, 2H), 4.26-3.78 (m, 2H), 3.64-3.48 (m, 2H), 3.42-3.24 (m, 2H), 3.24-2.98 (m, 2H). IR (KBr): 3420, 2115, 1634, 1503, 1388, 1238, 1207, 1024, 829, 710 cm"1. CI-MS (m/e): 392 (M++l)
Preparation 53:
[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]- (3-dimethylaminomethyl-phenyl)- methanone
Figure imgf000085_0002
To a stirred solution of [4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]-(3- chloromethyl-phenyl)-methanone (700 mg, 1.78 mmol) obtained in preparation 52, in DCM was added N,N-dimethylamine (5.4 mL) drop wise at 0 °C and stirred for 9 to 13 hours at 25-35 °C. The solvent was removed under vacuum and the residue was purified
by column chromatography (7:3 EtOAc/pet.ether) to afford the title product (250 mg, 35
%).
Η NMR (200MHz, CDCI3): δ 7.42-7.22 (m, 4H), 6.58 (d, J=8.9 Hz, 2H), 3.88-3.72 (m,
2H), 3.70-3.36 (m, 2H), 3.50(s, 2H), 3.38-3.02 (m, 4H), 2.38(s, 6H).
IR (KBr): 2114, 1636, 1574, 1503, 1239, 1027, 844, 744 cm"1. CI-MS (m/e): 401 (M++l)
Preparation 54: [4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yI]-pyridin-4-yl-methanone
Figure imgf000086_0001
The title compound (143 mg, 49 %) was synthesized from Isonicotinic acid (112 mg, 0.91 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine obtained in the process of preparation 20, applying the same procedure as described in example 27. Η NMR (200MHz, CDC13): δ 8.82 - 8.86 (m, 2H), 7.35 (d, J = 4.8 Hz, 2H), 7.14 - 6.78 (m, 3H), 4.08 - 3.84 (m, 2H), 3.64 - 3.42 (m, 2H), 3.30 - 2.88 (m, 4H). IR (KBr): 2114, 1641, 1505, 1437, 1286, 1233, 1159, 1018, 922, 834, 756, 638 cm"1. CI-MS (m/e): 327 (M++l), 286
Preparation 55: l-[4-(4-Azido-2-fluoro-phenyl)- piperazin-l-yl]-2-imidazol-l-yl-ethanone
Figure imgf000086_0002
The title compound (72 mg, 47%) was synthesized from l-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-2-bromo-ethanone (161 mg, 0.47 mmol) obtained in preparation 44, and imidazole following same procedure as described in preparation 45. Η NMR (200 MHz, CDC13): δ 7.59 (s, IH), 7.19 - 6.72 (m, 5H), 4.86 (s, 2H), 3.94 - 3.78 (m, 2H), 3.76 - 3.58 (m, 2H), 3.19 - 2.96 (m, 4H), IR (Neat): 2115, 1661, 1507, 1428, 1232, 1033, 810, 755, 662 cm"1 CI-MS (m/e): 330 (M++l), 304, 289
Preparation 56: l-[4-(4-Azido-2,6 -fluoro-phenyl)- piperazin-l-yl]-2-imidazoI-l-yI-ethanone
Figure imgf000087_0001
The title compound (400 mg, 55%o) was synthesized from l-[4-(4-Azido-2,6- fluorb-phenyl)-piperazin-l-yl]-2-bromo-ethanone (750 mg, 2.08 mmol) obtained in preparation 47, and imidazole using the same procedure employed in preparation 45. Η NMR (200MHz, CDC13): δ 7.62 (s, IH), 7.15 (s, IH), 7.07 (s, IH), 6.57 (d, J = 9.5 Hz, 2H), 4.82 (s, 2H), 3.84 -3.66 (m, 2H), 3.64 - 3.44 (m, 2H), 3.22 - 3.04 (m, 4H). IR (KBr): 2124, 1666, 1505, 1440, 1242, 1036, 834, 662 cm"1. CI-MS (m/e): 348 (M++l), 322
Preparation 57: [4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yI]-Pyridin-3-yl-methanone
Figure imgf000087_0002
The title compound (178 mg, 60 %) was synthesized from nicotinic acid (111 mg, 0.91 mmol) and l-(4-Azido-2-f_uoro-phenyl)-piperazine, obtained in the process of preparation 20, following the same procedure as described in example 27. Η NMR (200MHz, CDCI3): δ 8.80 - 8.59 (m, 2H), 7.88 - 7.72 (m, IH), 7.49 - 7.29 (m, IH), 7.18 - 6.84 (m, 2H), 6.80 - 6.64 (m, IH), 4.18 - 3.44 (m, 4H), 3.36 - 2.64 (m, 4H). IR (KBr): 2114, 1637, 1505, 1436, 1285, 1236, 1159, 1012, 814, 755 cm"1. CI-MS (m/e): 327 (M++l), 301, 286
Preparation 58:
5(R)-[4-(4-Azido-2, 6-difluoro-phenyl)-piperazine-l-carbonyl]-2,2-dimethyl
- [1, 3] dioxolane-4(R) -carboxylic acid methyl ester
Figure imgf000087_0003
The title compound (10 grams, 47 %>) was synthesized from 2,2-Dimethyl- [l ,3]dioxolane-4 (R),5 (R) -dicarboxylic acid monomethyl ester (12 grams, 41.8 mmol) and l-(4-Azido-2,6-difluoro-pheny_)-piperazine, obtained in the process of preparation 19, using the procedure as described in example 27.
Η NMR (CDC1 , 200 MHz): δ 6.56 (d, J = 9.6 Hz, 2H), 5.35 (d, J = 6.0 Hz, IH), 4.93 (d,
J = 4.0 Hz, IH), 4.81 (s, 3H), 4.36 - 4.18 (m, 4H), 3.24 - 3.12 (m, 4H).
CI-MS (m/e): 411(M+-15), 397(M+-28).
Preparation 59:
[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yI]-(5(S)-hydroxymethyl-2,2- dimethyl-[l, 3] dioxolan-4(R)-yl)-methanone
Figure imgf000088_0001
To a stirred solution of 5-[4-(4-Azido-2,6-difluoro-phenyl)-piperazine-l- carbonyl]-2,2-dimethyl-[l,3]dioxolane-4-carboxylic acid methyl ester (2 grams, 4.7 mmol) obtained in preparation 58, in methanol at 0 °C was added sodium borohydride
(356 mg, 9.4 mmol) portion wise and stirred at 25-35 °C for 3 - 4 hours. The methanol
was removed under vacuum and the residue was purified by column chromatography (0.3:1 EtOAc/pet ether) to give title compound (1 gram, 55%).
Η NMR (CDCI3, 200 MHz): δ 6.57 (d, J = 9.6 Hz, 2H), 4.76 - 4.64 (m, IH), 4.54 (d, J = 7.2 Hz, IH), 3.99 - 3.54 (m, 6H), 3.38 - 2.96 (m, 4H), 1.46 (s, 3H), 1.41 (s, 3H). CI-MS (m e): 398 (M+ + 1), 372
Preparation 60:
2-(2-Amino-phenyl)-l-[4-(4-azido-2, 6-fluoro-phenyl)-piperazin-l-yl]-ethanone
Figure imgf000088_0002
The title compound (60 mg, 63%>) was synthesized from l-[4-(4-azido-2,6- difluoro-phenyl)- piperazin-l-yl]-2-(2-nitro-phenyl)- ethanone (100 mg, 0.25 mmol) obtained in preparation 42, using the same procedure as described in example 95. Η NMR (CDCI3, 200 MHz): δ 7.16-6.92 ( m, 2H ), 6.80 - 6.62 (m, 2H), 6.54 (d, J=9.5 Hz, 2 H ), 3.80 - 3.58 (m, 6 H ), 3.18 - 2.91 (m, 4 H). CI-MS (m/e): 373 (M+ + l) Preparation 61:
Acetic acid (2-{2-[4-(4-azido-2,6-fluoro-phenyl)-piperazin-l-yI]-2-oxo-ethyI}- phenylcarbamoyl)-methyl ester
Figure imgf000089_0001
To a stirred solution of 2-(2-Amino-phenyl)-l-[4-(4-azido-2, 6-fluoro-phenyl)- piperazin-l-yl]-ethanone (60 mg, 0.16 mmol) obtained in preparation 60, was added triethylamine (0.06 mL) and acetoxy acetylchloride (0.03 mL) and catalytic amount of DMAP at 0 °C . The reaction mixmre was diluted with DCM and washed with water (2 x 10 mL), brine and then dried over sodium sulphate. The solvent was removed under vacuum and the residue was purified by column chromatography (2.5: 7.5 EtOAc/Pet.Ether) to yield title product (50 mg, 65%).
Η NMR (CDC-3,400 MHz): δ 10.48 (bs, IH), 7.99 (d, J = 8.1 Hz, IH), 7.36-7.29(m, IH), 7.16 - 7.08 (m, 2H), 6.56 (d, J=9.3 Hz, 2H), 4.77 (s, 2H), 3.81 (t, J=4.7 Hz, 2H), 3.72 (s, 2 H), 3.72 - 3.64 ( m, 2 H), 3.21-3.04 (m, 4H), 2.16 (s, 3H). CI-MS (m/e): 473 (M+ + 1), 447
Preparation 62:
N-(2-{2-[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yI]-2-oxo-ethyl}-phenyl)-2- hydroxy-acetamide
Figure imgf000089_0002
To a stirred solution of acetic acid (2-{2-[4-(4-azido-2,6-fluoro-phenyl)-piperazin- l-yl]-2-oxo-ethyl}-phenylcarbamoyl)-methyl ester (50 mg, 0.11 mmol) obtained in preparation 61, in methanol at 0 °C was added aqueous ammonia (2 to 3 drops) and stirred for 3 - 4 hours. The methanol was removed under vacuum and the residue was purified by column chromatography (0.6:1 EtOAc/pet ether) to give the title product (25 mg, 54%). O 2005/082892
Η NMR (CDC.3,400 MHz): δ 10.13 (bs, IH), 8.03 (d, J = 8.0 Hz, IH), 7.38-7.30 (m,
IH), 7.19-7.09 ( m, 2H), 6.55(d, J= 9.6 Hz, 2H), 4.30 (s, 2H), 3.76 (s, 2H), 3.74-3.65(m,
4H), 3.12-3.08 (m, 4H).
CI-MS (m/e): 431 (M+ + 1), 405
Preparation 63: l-[4-(4-Azido-2-fluoro-phenyI)-piperazin-l-yI]-propenone
Figure imgf000090_0001
The title compound (630 mg, 50 %) was synthesized from acryloyl chloride (1.25 grams, 13.8 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20, following the same procedure as described in preparation 34.
Η NMR (CDC13, 200 MHz): δ 7.18 - 6.82 (m, 2H), 6.80 - 6.44 (m, 2H), 6.31 (dd, J, =
1.9 Hz, = 16.8 Hz, IH), 5.73 (dd, J, = 1.9 Hz, J2 = 10.3 Hz, IH), 3.98 - 3.54 (m, 4H),
3.22 - 2.84 (m, 4H).
CI-MS (m/e): 276 (M+ + 1), 250, 235
Preparation 64: [4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-oxiranyI-methanone
Figure imgf000090_0002
n-Butyl lithium ( 0.41 mL, 1.6 M in hexane) was added to a solution of tert-butyl hydroperoxide (TBHP). ( 0.2 mL, 4M in toluene) in THF ( 5 mL ) at -78 °C . The mixmre was stirred for 5 minutes. A solution of (l-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]- propenone (150 mg, 0.54 mmol) obtained in preparation 63, in dry THF (5 mL) was added to the reaction mixmre and stirred for 9 to 13 hours. Sodium sulfite (21.6 mg, 0.1 mmol) was added and stirred for 20 minutes. The reaction mixmre was diluted with DCM (30 mL) and filtered through celite bed. The filtrate was concentrated under vacuum and the residue was purified by column chromatography (0.6: 1 EtOAc: Pet Ether) to yield the title compound (30 mg, 18 %).
Η NMR (CDCI3, 200 MHz): δ 7.28 - 6.82 (m, 3H), 3.99 - 3.72 (m, 4H), 3.66 (t, J = 3.3 Hz, IH), 3.24 - 3.06 (m, 4H), 3.01 (d, J = 3.0 Hz, 2H). CI-MS (m/e): 292 (M+ + 1), 251 Preparation 65: l-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-y_]-2-hydroxy-3-morpholin-4-yl-propan- 1-one
Figure imgf000091_0001
[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-Oxiranyl-methanone (85 mg, 0.292 mmol) obtained in preparation 64, and moφholine ( 9 mg, 0.1 mmol) were refluxed in isopropanol ( 10 mL) for 1 hour . The reaction mixture was further heated at 50 °C for 2 hours. Then it was allowed to come to 25-35 °C for 9 to 13 hours. The solvent was
removed under vacuum and the residue was purified by column chromatography (0.7: 1 EtOAc: Pet Ether) to obtain the desired product (80 mg, 12 % ).
Η'VMR (CDC13, 400 MHz): δ 6.97 - 6.89 (m, 2H), 6.80 - 6.72 (m, IH), 4.60 - 4.48 (m, IH), 3.94 - 3.86 (m, IH), 3.82 - 3.62 (m, 8H), 3.16 - 3.02 (m, 4H), 2.78 - 2.54 (m, 6H). CI-MS (m/e): 379 (M+ + 1), 353, 338
Preparation 66:
[4-(4-Azido-2,6-difluoro-phenyI)-3,6-dihydro-2H-pyridin-l-yl]-(2-phenyl-
[l,3]dioxan-5-y_)-methanone
Figure imgf000091_0002
The title compound (100 mg, 50 %>) was synthesized from 2-Phenyl-[l,3]dioxane- 5-carboxylic acid (92 mg, 0.47 mmol) (Ref: J.Org.Chem., 62, 4029 - 4035, 1997) and 4- (4-azido-2,6-difluorophenyl)-l,2,3,6-tetrahydro-pyridine employing the procedure as described in example 27.
Η NMR (CDCI3, 200 MHz): δ 7.58 - 7.44 (m, 2H), 7.44 - 7.31 (m, 3H), 6.60 (d, J = 8.4 Hz, 2H) 5.94 - 5.80 (m, IH), 5.57 (s, IH), 4.48 - 4.11 (m, 6H), 3.81 (t, J = 5.3 Hz, 2H), 3.55 - 3.31 (m, IH), 2.60 - 2.36 (m, 2H).
IR(KBr): 3423,2113, 1626, 1569, 1437, 1388, 1237, 1150, 1093, 1028, 753 cm"1. CI-MS (m/e): 398 (M+-28), 292. Preparation 67: l-[4-(4-Azido-2-fluoro-phenyI)-piperazin-l-yl]-2-hydroxy-propan-l-one
Figure imgf000092_0001
The title compound (90 mg, 13 %) was synthesized from 2-hydroxy-propionic acid
(200 mg, 2.26 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20, following the same procedure as described in example 27.
IH NMR (CDC13, 200 MHz): δ 7.15 - 6.98 (m, IH), 6.97 - 6.82 (m, IH), 6.81 - 6.66
(m, IH), 4.57 - 4.38 (m, IH), 4.01 - 3.66 (m, 3H), 3.64 - 3.46 (m, 2H), 3.18 - 2.92 (m,
4H), 1.36 (d, J = 6.5 Hz, 3H).
IR(Neat): 3423, 2924, 2115, 1644, 1507, 1443, 1230, 1129, 1037, 936, 876, 726 cm"1.
ES-MS(m/e): 294 (M++l)
Preparation 68: l-[4-(4-Azido-2-fluoro-p_ιenyl)-piperazin-l-yl]-2,2-dif_uoro-ethanone
Figure imgf000092_0002
The title compound (110 mg, 28 %) was synthesized from difluoro acetic acid (130 mg, 1.35 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20, using the same procedure as described in example 27. Η NMR (CDCI3, 200 MHz): δ 7.16 - 6.99 (m, IH), 6.92 (t, J = 8.7 Hz, IH), 6.76 (d, J = 10.9 Hz, IH), 6.13 (t, J = 53.6 Hz, IH), 3.90 - 3.66 (m, 4H), 3.10 - 2.97 (m, 4H). IR (KBr): 3449, 2829, 2116, 1674, 1507, 1235, 1137, 1031, 844, 725, 564 cm"1. CI-MS (m e): 300 (M++l), 274, 259
Preparation 69:
2(S)-[4-(4-Azido-2-fluoro-phenyl)-piperazine-l-carbonyl]-pyrrolidine-l -carboxylic acid tert-butyl ester
Figure imgf000093_0001
The title compound (1.3 grams, 69 %) was synthesized from pyrrolidine- 1 ,2- dicarboxylic acid 1 -tert-butyl ester (1 gram, 4.65 mmol) and l-(4-Azido-2-fluoro-phenyl)- piperazine, obtained in the process of preparation 20, following the same procedure as described in example 27.
IH NMR (CDC13, 200 MHz): δ 7.16 - 6.82 (m, 2H), 6.81 - 6.67 (m, IH), 4.80 - 4.50 (m, IH), 3.94 - 3.30 (m, 6H), 3.26 - 2.90 (m, 4H), 2.20 - 1.98 (m, 2H), 1.96 - 1.76 (m, 2H), 1.46 (s, 9H).
IR (Neat): 3481, 2976, 2113, 1695, 1659, 1506, 1450, 1400, 1229, 1162, 1126, 1033, 755, 663 cm"1. CI-MS (m/e): 419 (M++l), 393, 378, 337, 322, 293
Preparation 70:
[4-(4-Azido-2-fluoro-pheny_)-piperazin-l-yl]-acetonitrile
Figure imgf000093_0002
The title compound (395 mg, 46 %) was synthesized from 1 -(4-Azido-2, fluoro- phenyl)-piperazine, obtained in the process of preparation 20, (720 mg, 3.26 mmol) applying the procedure as described in preparation 38.
Η NMR (400 MHz, CDC13): δ 7.10 - 7.00 (m, IH), 7.00 - 6.90 (m, IH), 6.80 - 6.76 (m, IH), 3.56 (s, 2H), 3.18 - 3.09 (m, 4H), 2.82 - 2.75 (m, 4H).
IR (Neat): 3419, 2941, 2830, 2114, 1575, 1507, 1454, 1384, 1230, 1 148, 1012, 912, 861, 812, 601 cm"1. CI-MS (m e): 260 (M+), 232
Preparation 71: [4-(4-Azido-2-fluoro-phenyI)-piperazin-l-yl]-cyclopropyl-methanone
Figure imgf000093_0003
To a stirred solution of cyclopropyl carboxylic acid (134 mg, 1.58 mmol) and was added isobutylchloroformate (0.2 mL, 1.55 mmol) in dry DCM at 0 °C To this solution was added drop wise stirred solution of l-(4-Azido-2, fluoro-phenyl)-piperazine (345 mg,
1.56 mmol) and triethylamine (0.32 mL, 3.10 mmol) in dry DCM and stirred at 25-35 °C
for 9 to 13 hours. The reaction mixmre was diluted with DCM and washed with water (2 xl5 mL), brine and dried over Na2S0 . The organic layer was concentrated under vacuum and the residue was purified by column chromatography (4:6 EtOAc/pet ether) to give the title product (235 mg, 52%).
Η NMR (400 MHz, CDC13): δ 6.99 - 6.90 (m, 2H), 6.82 - 6.73 (m, IH), 3.92 - 3.75 (m, 4H), 3.15 - 2.95 (m, 4H), 1.79 - 1.75 (m, IH), 1.05 - 1.00 (m, 2H), 0.82 - 0.75 (m, 2H). IR (KBr): 2922, 2112, 1640, 1505, 1438, 1229, 1035, 906, 804, 758 cm"1. CI-MS (m/e): 290 (M++l), 249
Preparation 72: N-{2-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-acetamide
Figure imgf000094_0001
The title compound (40 mg, 15 %) was synthesized from N-acetyl glycine (105 mg, 0.89 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20, using the same procedure as described in example 27. Η NMR (200 MHz, CDC13): δ 7.08 - 6.80 (m, 2H), 6.80 - 6.74 (m, IH), 6.73 - 6.39 (m, IH), 4.10 (d, J = 3.9 Hz, 2H), 3.90 - 3.78 (m, 2H), 3.65 - 3.58 (m, 2H), 3.15 - 2.95 (m, 4H), 2.06 (s, 3H).
IR (Neat): 3336, 2924, 2115, 1642, 1505, 1442, 1384, 1232, 1033, 773 cm"1. CI-MS (m/e): 321 (M++l), 295, 280
Preparation 73: 3-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yI]-3-oxo-propionitrile
Figure imgf000094_0002
The title compound (95 mg, 37%) was synthesized from cyano acetic acid (92 mg, 1.08 mmol) and l-(4-Azido-2-fluoro-phenyl)-piperazine, obtained in the process of preparation 20, using the same procedure as described in example 27. Η NMR (200 MHz, CDC13): δ 7.11 - 6.70 (m, 3H), 3.90 - 3.75 (m, 2H), 3.70 - 3.60 (m, 2H), 3.52 (s, 2H), 3.20 - 3.02 (m, 4H).
IR (Neat): 3424, 2923, 2358, 2114, 1653, 1586, 1506, 1039, 897, 761 cm"1. CI-MS (m/e): 289 (M++l), 263, 248.
PreparatioH 74:
{2-[4-(4-Azido-2-fluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-carbamic acid tert- butyl ester
Figure imgf000095_0001
The title compound (315 mg, 62%) was synthesized from N-Boc glycine (286 mg, 1.63 mmol) and l-(4-Azido-2-fmoro-phenyl)-piperazine, obtained in the process of preparation 20, using the same procedure as described in example 27. Η NMR (200 MHz, CDCI3): δ 7.07 - 6.83 (m, 2H), 6.80 - 6.70 (m, IH), 5.55 - 5.45 (m, IH), 4.00 (d, J = 4.2 Hz, 2H), 3.99 - 3.79 (m, 2H), 3.79 - 3.55 (m, 2H), 3.15 - 2.98 (m, 4H), 1.45 (s, 9H).
IR (Neat): 3418, 2978, 2114, 1712, 1659, 1508, 1464, 1367, 1231, 1164 cm"1. CI-MS (m/e): 379 (M++l), 353
Preparation 75: [4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]-Pyridin-3-yl-methanone
Figure imgf000095_0002
The title compound (130mg, 18 %) was synthesized from nicotinic acid (500 mg, 2.09 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine,obtained in the process of preparation^, using the procedure as described in example 27. Η NMR (200 MHz, CDC13): δ 8.70 - 8.67 (m, 2H), 7.79 (d, J = 7.3 Hz, IH), 7.41 - 7.37 (m, IH), 6.57 (d, J = 9.5 Hz, 2H), 4.00 - 3.80 (m, 2H), 3.70 - 3.50 (m, 2H), 3.30 - 3.00
(m, 4H). IIRR ((NNeeaatt): 3415, 2923, 21 16, 1682, 1503, 1206, 1031, 836, 725 cm" CI-MS (m/e): 345 (M++l), 319, 304
Preparation 76: l-[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]-propan-2-one
Figure imgf000096_0001
The title compound (410mg, 54 %) was synthesized from chloroacetone (0.4 mL,
5.13 mmol) and l-(4-azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, following the same procedure as described as described in preparation 38.
Η NMR (400 MHz, CDCI3): δ 6.54 (d, J = 9.7 Hz, 2H), 3.23 - 3.19 (m, 6H), 2.61 - 2.59
(m, 4H), 2.18 (s, 3H). IIRR ((NNeeaatt)):: 33338833,, 22882210, 2114, 1717, 1575, 1503, 1356, 1238, 1139, 1026, 928, 842 cm"'. CI-MS (m e): 296 (M++l), 268
Preparation 77: l-[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yI]-propan-2-one oxime
Figure imgf000096_0002
To a stirred solution of l-[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]- propan-2-one (70 mg, 0.24 ) obtained in preparation 76, in methanol was added drop wise solution of hydroxylamine hydrochloride (33 mg, 0.47 mmol) and sodium bicarbonate (40 mg, 0.47 mmol) in water and stirred at 25-35 °C for 9 to 13 hours. The reaction mixmre
was diluted with DCM and washed with water, brine and dried over Na2S04. The organic layer was concentrated under vacuum and the residue was purified by column chromatography (5.5:4.5 ethyl acetate/petroleum ether) to furnish the desired compound
(45 mg, 59 %).
Η NMR (400 MHz, CDC13): δ 6.54 (d, J = 8.3 Hz, 2H), 3.20 - 3.17 (m, 4H), 3.06 (s, 2H),
2.59 - 2.52 (m, 4H), 1.95 (s, 3H).
IR (KBr): 3436, 2836, 2121, 1629, 1572, 1508, 1444, 1257, 1109, 942, 837, 609 cm"1.
CI-MS (m/e): 311 (M++l), 293, 263
Preparation 78: l-[4-(4-Azido-2, 6-difluoro-phenyl) - piperazin-l-yl]-2-pyridin-4-yl-ethanone
Figure imgf000097_0001
The title compound (350 mg, 58 %) was synthesized from 4-pyridyl acetic acid (348 mg, 2 mmol) and l-(4-Azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in example 27. Η NMR (400 MHz, CDC13): δ 8.65 - 8.55 (m, 2H), 7.22 (d, J = 5.4 Hz, 2H), 6.56 (d, J = 8.2 Hz, 2H), 3.80 - 3.73 (m, 2H), 3.75 (s, 2H), 3.54 (t, J = 4.9 Hz, 2H), 3.11 (t, J = 4.8 Hz, 2H), 3.02 (t , J = 4.5 Hz, 2H)
IR (Neat): 3382, 2920, 2114, 1646, 1503, 1441, 1236, 1031, 965, 843, 769 cm"1. CI-MS (m/e): 359 (M++l), 333
Preparation 79:
{2-[4-(4-Azido-2, 6-difluoro-pheny_)-piperazin-l-yI]-2-oxo-ethyl}-carbamic acid tert- butyl ester
Figure imgf000097_0002
The title compound (2.2 grams, 48 %) was synthesized from N-Boc glycine (2.6 grams, 14.9 mmol) and l-(4-azido-2,6-difluoro-phenyl)-piperazine, obtained in the process of preparation 19, using the same procedure as described in example 27. Η NMR (200 MHz, CDC13): δ 6.57 (d, J = 9.5 Hz, 2H), 5.55 - 5.45 (m, IH), 3.99 (d, J =
4.2 Hz, 2H), 3.74 (t, J = 4.9 Hz, 2H), 3.55 - 3.45 (m, 2H), 3.20 - 3.10 (m, 4H), 1.45 (s,
9H).
IR (KBr): 3306, 2973, 2114, 1710, 1653, 1502, 1554, 1447, 1366, 1279, 1165, 1028, 967,
840 cm"1.
CI-MS (m e): 398 (M++2), 369, 341, 297
Preparation 80:
Acetic acid {2-[4-(4-azido-2,6-difluoro-phenyI)-piperazin-l-yl]-2-oxo- ethylcarbamoyl}-methyl ester
Figure imgf000098_0001
{2-[4-(4-Azido-2, 6-difluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester (1 grams, 2.5 mmol) obtained in preparation 79, was treated with 60%)
TFA in DCM and stirred at 25-35 °C for 30 minutes and the reaction mixmre was co-
evaporated with toluene (2 x 20 mL) and extracted with ethyl acetate and concentrated to give 2-amino-l-[4-(4-azido-2,6-difluoro-phenyl)-piperazin-l-yl]-ethanone ,which was pure enough to be taken for further step directly To a stirred solution of 2-amino-l-[4-(4- azido-2,6-difluoro-phenyl)-piperazin-l-yl]-ethanone (730 mg, 2.5 mmoL) in dry DCM at 0 °C was added triethyl amine (1.0 mL, 7.4 mmol), acetoxy acetyl chloride (0.8 mL, 7.4 mmol) drop wise and stirred at 25-35 °C for 9 to 13 hours. The reaction mixture was
diluted with DCM and washed with water, brine and dried over Na2S04. The organic layer was concentrated under vacuum and the residue was purified by column chromatography
(4:6 ethyl acetate/petroleum ether) to give the title product (670 mg, 68%).
Η NMR (200 MHz, CDC13): δ 7.40 - 7.30 (m, IH), 6.57 (d, J = 9.5 Hz, 2H), 4.62 (s, 2H),
4.15 (d, J = 3.9 Hz, 2H), 3.76 (t, J = 4.8 Hz, 2H), 3.54 (t, J = 4.8 Hz, 2H), 3.20 - 3.05 (m,
4H), 2.17 (s, 3H).
IR (Neat): 3392, 2924, 2855, 2207, 2116, 1753, 1653, 1572, 1504, 1441, 1373, 1235,
1162, 1031,843,700 cm"1.
CI-MS (me): 397 (M++l), 368 Preparation 81:
N-{2-[4-(4-Azido-2,6-difluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-2-hydroxy- acetamide
Figure imgf000099_0001
To a stirred solution of acetic acid {2-[4-(4-azido-2,6-difluoro-phenyl)-piperazin- l-yl]-2-oxo-ethylcarbamoyl} -methyl ester (210 mg, 0.53mmol) obtained in preparation 80, in methanol at 0 °C was added aqueous ammonia drop wise (5 to 6 drops) and stirred at 25-35 °C for lhour. The solvent was removed and the residue was purified by column
chromatography (7.5:2:5 ethyl acetate/ pet ether) to give the title product (175 mg, 93%) Η NMR (400 MHz, DMSO): δ 7,71 (t, J=4.8 Hz, IH), 6.94 (d, J=9.9 Hz, 2H), 5.68-5.60 (m, 2H), 4.09 (d, J=5.1 Hz, 2H), 3.85 (s, 2H), 3.60-3.48 (m, 4H), 3.10-3.00 (m, 4H). IR (Neat): 3382, 2924, 2854, 2116, 1645, 1573, 1504, 1441, 1238, 1076, 1030, 579 cm"1. CI-MS (m/e): 355 (M++l), 326, 240
Preparation 82: 2-Phenyl-[l,3]dioxane-5-carboxyIic acid
Figure imgf000099_0002
This compound was synthesized according to the procedure reported in J. Org. Chem. 1997, (52, 4029-4035.
Preparation 83: (S)-2-Oxo-oxazolidine-5-carboxylic acid
HN = .OH
O This compound was synthesized from (S)-malic acid following the procedure reported in Synlett. 2002, 2101-2103.
Example 1: {l-[4-(4-Acetyl-piperazin-l-yl)-3-fluoro-phenyI]-l_?7-[l,2,3]triazol-4-ylmethyl}- thiocarbamic acid <?-methyl ester
Figure imgf000100_0001
To an ice cooled solution of l-[4-(4-azido-2-fluoro-phenyl)-piperazin-l-yl]- ethanone (300 mg, 1.14 mmol) in DMF (5 mL), obtained in preparation 15, were added prop-2-ynyl-thiocarbamic acid O-methyl ester (176 mg, 1.37 mmol), diisopropylethylamine (198 μL, 1.14 mmol) and cuprous iodide (238 mg, 1.14 mmol) successively at 0 °C. The reaction mixmre was stirred at 25-35 °C for 1 hour and then
quenched with samrated ammonium chloride solution followed by 2-3 drops of ammonia and extracted with 5% methanol in chloroform (100 mL). The organic layer was washed successively with water and brine and then dried over sodium sulfate. The solvent was evaporated to afford the title compound (180 mg, 40%).
Η NMR (DMSO-d6): δ 9.65 (bs, IH), 8.64 (d, J= 7.8 Hz, IH), 7.84-7.67 (m, 2H), 7.21 (t, J= 8.9 Hz, IH), 4.71 & 4.44 (2d, rotamers in a ratio of 4:1, J= 5.5 Hz, 2H), 3.95 & 3.88 (2s, rotamers in a ratio of 1 :4, 3H), 3.61 (bs, 4H), 3.18-3.03 (m, 4H). IR (KBr, cm"1): 3428, 2926, 1636, 1520, 1440, 1226, 1059, 615. CI-MS (m/z): 393(M++1), 361, 319, 274, 257, 229, 181, 162, 130, 114.
Example 2:
{l-[3-Fluoro-4-(4-methanesuIfonyl-piperazin-l-yl)-phenyl]-liϊ-[l,2,3]triazol-4- ylmethyl}-thiocarbamic acid O-methyl ester:
Figure imgf000100_0002
Title compound (415 mg, 58%) was prepared from 3-fluoro-4-(4-methanesulfonyl- piperazin-l-yl)-phenylazide (500 mg, 1.67 mmol), obtained in preparation 16, following the same procedure as descibed in the prepration of {l-[4-(4-acetyl-piperazin-l-yl)-3- fluoro-phenyl]-lH-[l ,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester (Example 1) Η NMR (CDCI3): δ 8.07 (s, IH), 7.56-7.42 (m, 2H), 7.06 (t, J= 8.8 Hz, IH), 4.93 & 4.67 (2d, rotamers in a ratio of 4: 1, J- 5.4 Hz, 2H), 4.13 & 4.01 (2s, rotamers in a ratio of 1 :4, 3H), 3.47-3.43 (m, 4H), 3.29-3.26 (m, 4H), 2.87 (s, 3H).
IR (KBr, cm"1): 3415, 2925, 2854, 1658, 1519, 1324, 1152, 1060, 969, 786, 518. CI-MS (m/z): 429 (M++l), 397, 381, 355, 310, 289, 259, 229.
Example 3:
4-{2-Fluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l, 2, 3] triazol-l-yl]-phenyl}- piperazine-1-carboxylic acid tert-butyl ester
Figure imgf000101_0001
Title compound (388 mg, 46%) was obtained from 4-(4-azido-2-fluoro-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester (600 mg, 1.87 mmol), obtained in preparation 17, prop-2-ynyl-thiocarbamic acid O-methyl ester (288 mg, 2.24 mmol), obtained in preparation 1, diisopropylethyl amine (326 μL, 1.87 mmol) and cuprous iodide (356 mg, 1.87 mmol) following the same procedure descibed for the prepration of {l-[4-(4-acetyl- piperazin- 1 -y_)-3-fluoro-phenyl]- lH-[ 1 ,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester (Example 1).
Η NMR (CDCI3): δ 8.04 & 7.81 (2s, rotamers in 4:1 ratio, IH), 7.52-7.39 (m, 2H), 7.02- 6.95 (m, 2H), 4.91 & 4.39 (2d, rotamers in 4:1 ratio, J = 5.9 Hz, 2H), 4.11 & 3.99 (2s, rotamers in 1:4 ratio, 3H), 3.62 (t, J= 4.6 Hz, 4H), 3.10 (t, J= 4.6 Hz. 4H), 1.49 (s, 9H). IR (KBr, cm"1): 3300, 3134, 2976, 2926, 2856, 1689, 1519, 1422, 1245, 1165, 1124, 1042, 994, 875, 826. CI-MS (m/z): 451 (M++l), 419, 363, 276, 232, 194,
Example 4:
4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazoI-l-yl]- phenyl}-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000101_0002
Title compound (880 mg, 32%) was prepared from 4-(4-azido-2,6-difluoro- phenyl)-piperazine-l -carboxylic acid tert-butyl ester (2.0 grams, 2.9 mmol), obtained in preparation 18 and following the same procedure as described for the preparation of {1- [4-(4-acetyl-piperazin-l-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (Example 1). Melting Point: 158-160 °C
Η NMR (CDC13): δ 8.04 & 7.81 (2s, rotamers in 4:1 ratio, IH), 7.31-7.26 (rn, 2H), 6.91 (bs, IH), 4.90 & 4.65 (2d, rotamers in 4:1 ratio, J- 5.8 Hz, 2H), 4.11 & 3.99 (2s, rotamers in 1 :4 ratio, 3H), 3.55 (bs, 4H), 3.18 (bs, 4H), 1.48 (s, 9H). IR (KBr, cm"1): 3199, 2925, 1688, 1518, 1170, 864, 555. CI-MS (m/z): 469 (M++l), 437, 413, 381, 294, 250, 163, 91.
Example 5:
[l-(3-Fluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000102_0001
To an ice cold solution of 4-{2-fluoro-4-[4-(methoxythiocarbonylamino-methyl)- [1, 2, 3]triazol-l-yl]-phenyl}-piperazine-l-carboxylic acid tert-butyl ester (550 mg, 1.22 mmol), obtained in Example 3, in DCM (1 mL) was added trifluoroacetic acid (2 mL) and stirred for 3 hours. The reaction mixture was then brought to pH = 8 by the addition of aqueous sodium bicarbonate and extracted with ethyl acetate (50 mL x 3). Combined ethyl acetate portion was washed with water followed by brine and dried over sodium sulfate. Evaporation of volatiles and purification of the residue by column chromatography (silica gel 60-120, 15:85 methanol/chloroform) yielded the title compound (260 mg, 61%). Η NMR (CDCI3): δ 8.73 (bs, IH), 7.92 & 7.90 (2s, rotamers in 4:1 ratio, IH), 7.27-7.12 ( , 2H), 6.73 (m, IH), 4.46 & 4.19 (2s, rotamers in 4:1 ratio, 2H), 3.66 & 3.58 (2s, rotamers in 1:4 ratio, 3H), 3.06 (m, 8H). IR (KBr, cm"1): 3415, 2256, 1643, 1026, 1000, 827, 766, 538. CI-MS (m/z): 351 (M++l), 319, 303, 262, 232, 165, 147, 93.
Example 6: 2005/082
[l-(3,5-Difluoro-4-piperazin-l-yl-phenyl)-l_r7-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000103_0001
The title compound was prepared from 4-{2,6-difluoro-4-[4- (methoxythiocarbonylamino-methyl)-[ 1 ,2,3]triazol- 1 -yl] -phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, obtained in example 4, and following the same procedure as described for the preparation of [l-(3-fluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4- ylmethyl]-thιocarbamic acid -methyl ester (Example 5).
Η NMR (CDC13) : δ 8.04 & 7.81 (2s, rotamers in ratio of 4:1, IH), 7.33-7.22 (m, 2H), 7.07 (bs, IH), 4.90 & 4.60 (2s, rotamers in ratio of 4:1, 2H), 4.11 & 3.99 (2s, rotamers in ratio of 1:4, 3H), 3.23-3.03 (m, 4H), 3.01-2.99 (m, 4H). IR (KBr, cm"1): 2837, 1516, 1401, 1201, 1137. CI-MS: 369 (M++l), 337, 295, 250.
Example 7;
(l-{3-Fluoro-4-[4-(5-nitro-furan-2-carbonyl)-piperazin-l-yl]-phenyl}-liy [1,2,3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000103_0002
The title compound (150 mg, 28%) was obtained from [4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-(5-nitro-furan-2-yl)-methanone (400 mg, 1.11 mmol), obtained in preparation 20, followed by the same procedure as described in the preparation of { 1 -[4- (4-acetyl-piperazin-l-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (Example 1).
Η NMR (CDCI3): δ 8.06 (s, IH), 7.55 (s, IH), 7.49-7.38 (dd, J= 5.5 & 9.4 Hz, 2H), 4.90 (d, J= 5.9 Hz, 2H), 4.11-3.99 (m, 7H), 3.99 (bs, 4H). IR (KBr, cm"1): 3252, 2924, 1638, 1520. CI-MS (m/z): 490 (M++l), 458, 426, 393, 292.
Example 8: {l-[3,5-Difluoro-4-(4-methanesulfonyl-piperazin-l-yl)-phenyl]-l_f7-[l,2,3]triazoI-4- ylmethylj-thiocarbamic acid O-methyl ester:
Figure imgf000104_0001
To an ice cold solution of 4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino- methyl)-[l,2,3]triazol-l-yl]-phenyl}-piperazine-l-carboxylic acid tert-butyl ester (200 mg, 0.43 mmol), obtained in example 4, in DCM (5 mL) was added 10 N HCI (0.43 mL, 4.27 mmol) and stirred for 15 minutes. An aqueous solution of sodium bicarbonate (717 mg) was then added to the reaction mixmre. Resulting biphasic system was treated with methanesufonyl chloride (0.04 mL, 0.51 mmol) and stirred for 1 hour. Organic phase was separated, washed with water and brine successively and dried over sodium sulfate. Evaporation of the volatiles and purification ofthe resulting residue (silica gel 60-120, 1:1 acetone/chloroform) yielded the title compound (135 mg, 71%).
Η NMR(CDC13): δ 8.06 &7.80 (2s, IH, rotamers in 4:1 ratio), 7.32 (d, J = 9.3 Hz, 2H), 6.89-6.91 (m, IH), 4.91 & 4.66 (2d, J = 5.9 Hz, 2H, rotamers in 4:1 ratio), 4.12 & 4.00 (2s, rotamers in 1 :4 ratio, 3H), 3.36 (s, 8H), 2.85 (s, 3H).
IR (KBr, cm"1): 3336, 3141 , 2920, 2855, 2361, 1747, 1520, 1451, 1408, 1322, 1268, 1207, 1 144, 1024, 958, 840, 783, 666, 517. CI-MS (m/z): 447 (M+l), 415, 328.
Example 9:
(l-{3,5-Difluoro-4-[4-(5-nitro-furan-2-carbonyI)-piperazin-l-yl]-phenyl}-l_f7- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000104_0002
The title compound (60 mg, 64%) was obtained from [4-(4-azido-2,6-difluoro phenyl)-piperazin-l -yl]-(5-nitro-furan-2-yl)-methanone, obtained in preparation 19, following the same procedure as described for the preparation of {l-[4-(4-acetyl- piperazin-l-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O- methyl ester (Example 1).
Η NMR (CDC13): δ 8.06 & 7.80 (2s, rotamers in 4:1 ratio, IH), 7.52 (d, J= 12.4 Hz, IH), 7.44 (d, J= 9.4 Hz, IH), 7.37 (d, J= 3.8 Hz, IH), 7.24 (d, J= 5.4 Hz, IH), 7.05 (t, J= 8.9 2005/082892
Hz, IH), 6.90 (bs, IH), 4.91 & 4.68 (2d, rotamers in 4: 1 ratio, J= 5.9 Hz), 4.11-3.99 (m,
7H), 3.26 (bs, 4H).
IR (KB^cm"1): 3252, 2924, 1740, 1638, 1582, 1521, 1436, 1384, 1351, 1243, 1149, 1022,
971, 873, 812, 749.
CI-MS (m/z): 490, 458, 426, 393, 319, 292, 278, 251, 163, 116, 100.
Example 10:
(l-{3,5-Difluoro-4-[4-(5-nitro-furan-2-ylmethyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyI)-thiocarbamic acid -methyl ester:
Figure imgf000105_0001
Title compound (135 mg, 25%) was prepared from 1 -(4-azido-2,6-difluoro- phenyl)-4-(5-nitro-furan-2-ylmethyl)-pipearazine (500 mg, 1.32 mmol), obtained in preparation 21, following the same procedure as described for the preparation of {l-[4-(4- acetyl-piperazin-l-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester (Example 1).
Η NMR (CDC13): δ 8.01 & 7.71 (2s, rotamers in 4:1 ratio, IH), 7.26 (d, J= 6.4 Hz, 2H), 6.85 (bs, IH), 6.52 (d, J= 3.4 Hz, IH), 4.88 & 4.62 (2d, rotamers in 4: 1 ratio, J= 6.35 Hz, 2H), 4.09 & 3.97 (2s, rotamers in 1 :4 ratio, 3H), 3.71 (s, 2H), 3.28 (bs, 4H), 2.67 (bs, 4H). IR (KBr, cm"1): 3404, 2930, 1590, 1518, 1454, 1393, 1355, 1233, 1143, 1023, 858, 811, 613. CI-MS (m/z): 494 (M++l), 462, 369, 337, 165, 158, 121.
Example 11:
(l-{3,5-Difluoro-4-[4-(isoxazole-5-carbonyl)-piperazin-l-yI]-phenyl}-l_?7- [l,2,3]triazol-4-yImethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000105_0002
The title compound (400 mg, 66.4%) was prepared from [4-(4-azido-2,6-difluoro- phenyl)-pipearazin-l-yl]-isoxazol-5-yl-methanone, obtained in preparation 22, following the same procedure as described for the preparation of {l-[4-(4-acetyl-piperazin-l-yl)-3- fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester (Example
1).
Η NMR (CDC13): δ 8.35 (d, J= 1.5 Hz, IH), 8.07 & 7.83 (2s, rotamers in 4:1 ratio, IH),
7.34 (ά, J = 8.8 Hz, 2H), 6.94 (bs, IH), 6.85 (s, IH), 4.92 & 4.67 (2d, rotamers in 4:1 ratio, J= 5.9 Hz, 2H), 4.12 & 4.01 (2s, 3H, rotamers in 1:4 ratio), 3.91 (bs, 4H), 3.34 (bs,
4H).
IR (KBr, cm"1): 3441, 2924, 1645, 1520, 1456, 1261, 1201, 1148, 1033, 981, 862, 755.
CI-MS (m/z): 464 (M++l), 432, 369, 337, 309, 295, 250, 214, 196, 174, 149, 133, 92.
Example 12: (l-{3-Fluoro-4-[4-(2-hydroxy-acetyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000106_0001
To an ice cooled solution of 4-{2-fluoro-4-[4-(methoxythiocarbonylamino- methyl)-[l, 2, 3] triazol-l-yl]-phenyl}-piperazine-l-carboxylic acid tert-butyl ester (235 mg, 0.5 mmol), obtained in example 3, was added trifluoroacetic acid (2 mL) and stirred at the same temperature for 1 hour. Excess of trifluoroacetic acid was removed on rotavapor and the resulting salt was washed with petroleum ether and dried under vacuum. To a solution of the salt in dichloromethane (10 mL) was added triethylamine (0.14 mL, 1 mmol) at 0 °C followed by the addition of tert-butyl dimethylsilyloxy acetyl chloride (120 mg, 0.5 mmol). The reaction mixmre was then allowed to stir 9 to 13 hours at 25-35 °C.
Water was added to the reaction mixmre and extracted with ethyl acetate (30 mL x 2). The combined organic portion was washed with water followed by brine and dried over sodium sulfate. The solvent was concentrated and the residue was dissolved in tetrahydro furan (5 mL) and tetrabutyl ammonium fluoride (160 mg, 0.5 mmol) was added to it. Stirring was continued for 2 hours. The reaction mixture was diluted with ethyl acetate and washed with water and brine successively. Organic layer was dried over sodium sulfate and volatiles were evaporated. The residue formed was passed through a silica gel column (60-120 mesh, eluent: ethyl acetate) to get 50 mg (25%) ofthe title compound. Η NMR (CDC13): δ 8.11 & 7.95 (2s, rotamers in 4:1 ratio, IH), 7.51 (d, J= 12.7 Hz, IH), 7.43 (d, J= 9.3 Hz, IH), 7.02 (t, J= 8.8 Hz, IH), 4.87 & 4.60 (2d, rotamers in 4:1 ratio, J = 5.9 Hz, 2H), 4.22 (d, J = 3.9 Hz, 2H), 4.11 & 3.98 (2s, rotamers in 1 :4 ratio, 3H), 3.85
(bs, 2H), 3.72 (bs, IH), 3.50 (bs, 2H), 3.17 (bs, 4H)
IR (KBr, cm"1): 3307, 3146, 2923, 2853, 1654, 1522, 1437, 1237, 1027, 982, 936, 867,
572.
CI-MS (m/z): 409 (M++l), 377, 345, 320, 290, 190, 163, 146, 1 17, 103, 91.
Example 13:
[l-(4-{4-[2-(tert-Butyl-dimethyI-silanyloxy)-acetyl]-piperazin-l-yl}-3,5-difuoro- phenyl)-l_?-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000107_0001
Title compound (200 mg, 38%) was obtained from l-[4-(4-azido-2,6-difluoro- phenyl)-piperzin-l-yl]-2-(tert-butyl-dimethyl-silanyloxy)-ethanone (400 mg, 0.97 mmol), obtained in preparation 23, following the same procdure as described for the preparation of {l-[4-(4-acetyl-piperazin-l-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl}- thiocarbamic acid O-methyl ester (Example 1).
Η NMR (CDC13): δ 8.02 & 7.76 (2s, rotamers in 4: 1 ratio, IH), 7.27 (d, J= 9.3 Hz, 2H), 6.85 (bs, IH), 4.87 & 4.62 (2d, rotamers in 4:1 ratio, J= 5.9 Hz, 2H), 4.30 (s, 2H), 4.08 & 3.96 (2s, rotamers in 1:4 ratio, 3H), 3.69 (bs, 4H), 3.20 (bs, 4H), 0.89 (s, 9H), 0.09 (s, 6H).
IR(KBr, cm"1): 3426, 3237, 2932, 2857, 1644, 1522, 1464, 1362, 1228, 1203, 1131, 1024, 842,780,581. CI-MS (m/z): 541 (M++l), 509, 483, 451, 423, 406, 364, 179, 93.
Example 14:
(l-{3,5-Difluoro-4-[4-(2-hydroxy-acetyl)-piperazin-l-yl]-phenyl}-l_/-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000107_0002
Title compound (125 mg, 79%) was prepared from [l-(4-{4-[2-(tert-butyl- dimethyl-silanyloxy)-acetyl]-piperazin- 1 -yl } 3 , 5-difuoro-phenyl)- lH-[ 1 ,2 ,3 ]triazol-4- ylmethyl]thiocarbamic acid O-methyl ester (200 mg, 0.77 mmol), obtained in example 13, upon treating with tetra-butyl ammonium fluoride (140 mg, 0.45 mmol) in THF (5 mL) at
25-35 °C for 2 hours. Extraction with ethylaceate and removal of volatiles under vacuum
left a residue, which was passed through silica gel column (60% ethyl acetate: pet. ether) to give the title compound.
Η NMR (CDC13): δ 8.08 & 7.85 (2s, rotamers in 1 :4 ratio, IH), 7.33 (d, J= 9.3 Hz, 2H),
7.05 (bs, IH), 4.92 & 4.65 (2d, rotamers in 4:1 ratio, J= 5.9 Hz, 2H), 4.22 (d, J= 4.4 Hz,
2H), 4.11 & 3.99 (2s, rotamers in 1 :4 ratio, 3H), 3.82 (bs, IH), 3.41 (d, J = 4.4 Hz, 2H),
3.25 (bs, 4H).
IR (KBr, cm"1): 3353, 3202, 3148, 3043, 2947, 2853, 1537, 1593, 1522, 1456, 1365, 1248,
1200, 1029, 982, 855, 770, 576.
CI-MS (m/z): 427(M++1), 395, 369, 353, 308, 186, 142.
Example 15:
4-{4-[4-(l,3-Dioxo-l,3-dihydro-isoindol-2-ylmethyl)-[l,2,3]triazoI-l-yl]-2-fluoro- phenyl}-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000108_0001
To a solution of 4-(4-azido-2-fluoro-phenyl)-piperazine-l -carboxylic acid tert- butyl ester (10 grams, 31.15 mmol), obtained in preparation 17, _V-ethyldiisoproρyl amine (8.3 mL, 46.7 mmol) and propargyl phthalimide (6.4 grams, 34.3 mmol) in DMF (50 mL) was added cuprous iodide (3.25 grams, 15.58 mmol) in small batches at 25-35 °C and
allowed to stir for 3 hours. Samrated ammonium chloride solution containing 10% ammonium hydroxide was added and stirred for 15 minutes. The aqueous layer was extracted with ethyl acetate (50 mL x 3) and the combined extracts were washed with water and brine successively and dried over sodium sulfate. Evaporation of volatiles left a residue, which was crystallized from 50%> ethyl acetate: pet.ether system to get 15 grams of title compound (95%). H NMR (CDCI3): 7.96 (s, IH), 7.83-7.90 (m, 2H), 7.71-7.77 (m, 2H), 7.27-7.50 (m, 2H), 6.99 (t, J = 8.7 Hz, IH), 5.07 (s, 2H), 3.61 (t, J = 5.0 Hz, 4H), 3.07 (t, J = 4.9 Hz, 4H), 1.49 (bs, 9H).
IR (KBr, cm"1): 3469, 1721, 1685, 1523, 1425, 1397, 1232. CI-MS (m/z): 507, 451, 407.
Example 16:
2-{l-[4-(4-Acrolyl-piperazin-l-yl)-3-fluoro-phenyl]-lΛr-[l,2,3]triazol-4-ylmethyl}- isoindole-l,3-dione
R
O / \ )=\ N; N ° X==\ v A"~i " .]^A o To 4-{4-[4-(l,3-dioxo-l,3-dihydro-isoindol-2-ylmethyl)-[l,2,3]triazol-l-yl]-2- fluoro-phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester (2.9 grams, 4.94 mmol), obtained in example 15, was added trifluoro acetic acid (4 mL) and the resulting solution was stirred for 1 hour. Trifluoroaceticacid was evaporated and the residue formed was washed with ether. The solid obtained was dissolved in dichloromethane (20 mL) and trietheylamine (2.42 mL, 17.26 mmol) was added at ice temperamre followed by the addition of acrolyl chloride (0.44 mL, 5.4 mmol). Upon stirring for 16 hours at 25-35 °C
the reaction mixmre was washed with water followed by brine. Evaporation of volatiles left a residue, which was passed through a silica gel column (60-120 mesh; eluent: ethyl acetate: pet. ether) to produce the title compound (2.0 grams, 44%). Η NMR (CDCI3): δ 7.97 (s, IH), 7.84-7.90 (m, 2H), 7.71-7.77 (m, 2H), 7.38-7.52 (m, 2H), 6.99 (t, J = 8.8 Hz, IH), 6.28-6.68 (m, 2H), 5.72-5.78 (dd, J = 2.0 & 10.2 Hz, IH), 5.07 (s, 2H), 3.78-3.89 (m, 4H), 3.12-3.22 (m, 4H) IR (KBr, cm"1): 3427, 1723, 1152, 1085. CI-MS (m z): 503, 461, 142, 127. Example 17:
2-(l-{4-[4-(2,3-Dihydroxy-propionyl)-piperzin-l-yl]-3-fluoro-phenyl}-l-f7- [l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione
Figure imgf000109_0001
To a solution of 2-{l-[4-(4-acrolyl-piperazin-l-yl)-3-fluoro-phenyl]-l-1 - [l,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (1.2 grams, 1.52 mmol), obtained in example 16, in 50% acetone : water (40 mL) were added N-methyl moφholine iV-oxide (351 mg, 2.6 mmol) and 1%> osmium tetroxide (66 mg, 0.26 mmol) in tert-butanol (6.6 mL) and stirred at 25-35 °C for 4 hours. The reaction mixture was extracted with ethyl
acetate (50 mL x 2) and the combined organic layer was washed with brine and dried over sodium sulfate. Evaporation of volatiles left a residue, which was passed through a silica gel column (60-120 mesh; eluent, 1:9; methanol/chloroform) to produce the title compound (1.15 grams, 90%).
"H NMR (CDC13): δ 8.37 (s, IH), 7.77-7.90 (m, 2H), 7.52-7.62 (m, 2H), 7.06 (t, J = 8.7 Hz, IH), 5.01 (s, 2H), 4.46-4.58 (m, 3H), 3.79 (bs, 4H), 3.67 (bs, IH), 3.15 (bs, 4H). IR (KBr, cm"1): 3417, 2922, 1723, 1632, 1398, 1241, 529. CI-MS (m z): 503, 477, 435, 407.
Example 18:
2-(l-{4-[4-(2,2-Dimethyl-[l,3]dioxoIane-4-carbonyI)-piperazin-l-yl]-3-fluoro- phenyl}-li7-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione
Figure imgf000110_0001
To a solution of 2-(l-{4-[4-(2,3-dihydroxy-propionyl)-piperzin-l-yl]-3-fluoro- phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione (750 mg, 1.52 mmol), obtained in example 17, in benzene (10 mL) were added 2,2-dimethoxy propane (317 mg, 3.04 mmol) and pyridinium-p-toluenesulphonate (50 mg) and refluxed for 2 hours. The reaction mixmre was diluted with ethyl acetate (50 mL) followed by the addition of triethylamine (0.5 mL). Usual washings with water and brine and evaporation of the volatiles produced the title compound (550 mg, 73%).
Η NMR (CDCU): δ 7.96 (s, IH), 7.84-7.89 (m, 2H), 7.70-7.74 (m, 2H), 7.37-7.50 (m, 2H), 6.99 (t, J= 8.7 Hz, IH), 5.06 (s, 2H), 4.7 (t, J= 6.4 Hz, IH), 4.49 (t, J= 8.3 Hz, IH), 4.14 (t, J= 8.1 Hz, IH), 4.06-3.68 (m, 4H), 3.11 (m, 4H), 1.41 (s, 6H). IR (KBr, cm"1): 3443, 2925, 2854, 1718, 1649, 1521, 1237, 1046, 715, 532. CI-MS (m z): 535, 272, 254, 224, 1 18. Example 19:
{4-[4-(4-Aminomethyl-[l,2,3]triazol-l-yl)-2-fluoro-phenyl]-piperazin-l-yl}-(2,2- dimethyl- [1 ,3] dioxolan-4-yl)methanone
Figure imgf000111_0001
To a solution of 2-(l-{4-[4-(2,2-dimethyl-[l,3]dioxolane-4-carbonyl)-piperazin-l- yl]-3-fluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione (500 mg, 0.936 mmol), obtained in example 18, in methanol (10 mL) was added hydrazine hydrate (0.3 mL) and refluxed for 4 hours. Removal of methanol by distillation left a residue, which was triturated with ether (50 mL x 3) and the combined ether layer was washed with water and brine successively. Evaporation of the ether gave 350 mg (93%) of product. Η NMR (CDC13): δ 8.43 (s, IH), 7.49-7.71 (m, 2H), 7.09 (t, J= 8.9 Hz, IH), 4.78 (t, J = 6.1 Hz, lH), 4.42 (t, J= 6.4 Hz, IH), 3.34 (s, 4H), 3.19 (bs, 4H), 1.48 (s, 6H). IR (KBr, cm"1): 3439, 2925, 1649, 1523, 1239, 1065, 866. CI-MS (m/z): 405, 391, 364, 283, 179, 147.
Example 20: (l-{4-[4-(2,3-Dihydroxy-propionyl)-piperazin-l-yl]-3-fluoro-phenyI}-lJ_T-
[l,2,3]triazol-4-yImethyl)-thiocarbamic acid O-methyl ester
Figure imgf000111_0002
To a solution of {4-[4-(4-aminomethyl-[l ,2,3]triazol-l-yl)-2-fluoro-phenyl]- piperazin-l-yl}-(2,2-dimethyl-[l,3]dioxalan-4-yl)methanone (350 mg, 0.87 mmol), obtained in example 19, in chloroform (10 mL) were added samrated sodium bicarbonate solution (10 mL) followed by the addition of thiophosgene (0.066 mL) at ice temperamre and stirred for 2 hours. Organic layer was separated and aqueous layer was extracted with chloroform. Combined organic phases were washed with brine and dried over sodium sulfate. Evaporation of the volatiles gave a residue, which was diluted with methanol (10 mL) and refluxed for 16 hours. Methanol was evaporated and the residue formed was 2005/08289 passed through a silica gel column (60-120 mesh; eluent: 1:9, methanol/chloroform) to give 300 mg (79%) of the title compound.
Η NMR (CDC13): δ 8.05 & 7.82 (2s, rotamers in 4:1 ratio, IH), 7.5 (d, J = 12.6 Hz, IH),
7.41 (d, J = 7.8 Hz, IH), 7.03 (bs, IH), 7.01 (t, J = 8.6 Hz, IH), 4.91 & 4.66 (2d, raotamers in 4:1 ratio, J = 6.2 Hz, 2H) 4.52 (bs, IH), 4.12 & 3.99 (2s, rotamers in 1 :4 ratio, 3H), 3.92-3.69 (m, 7H), 3.14 (bs, 4H), 2.57 (bs, 4H).
IR (KBr, cm"1): 3425, 2924, 1635, 1522, 1455, 1230, 1 145, 1027, 864, 817, 696.
CI-MS (m/z): 435, 389, 373, 347, 319, 294, 277, 238, 206, 187, 174, 137, 102, 93.
Example 21:
4-{4- [4-(l ,3-Dioxo-l ,3-dihydro-isoindol-2-ylmethyl)- [1 ,2,3] triazol-1 -yl] -2,6-difuoro- phenyl}-piperazine-l -carboxylic acid tert-butyl ester
Figure imgf000112_0001
The title compound was prepared from 4-(4-azido-2,6-difluoro-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester, obtained from preparation 18, and propargyl phthalimide following the same procedure as described for the preparation of 4-{4-[4- (l,3-dioxo-l,3-dihydro-isoindol-2-ylmethyl)-[l,2,3]triazol-l-yl]-2-fluoro-phenyl}- piperazine-1 -carboxylic acid tert-butyl ester (Example 15).
Η NMR (CDCI3) : δ 7.95 (s, IH), 7.89-7.85 (m, 2H), 7.75-7.71 (m, 2H), 7.27 (d, J = 8.9 Hz, 2H), 5.06 (s, 2H), 3.55-3.53 (m, 4H), 3.17-2.96 (m, 4H), 1.68 (s, 9H). IR (KBr, cm"1) : 2924, 1716, 1522, 1397. CI-MS : 525 (M++1), 469, 425, 314, 258, 148, 105.
Example 22:
2-{l-[4-(4-Acrolyl-piperazin-l-yl)-3,5-difluoro-phenyI]-l-fi -[l,2,3]triazol-4-ylmethyl}- isoindole-1 ,3-dione
Figure imgf000112_0002
Title compound (2.4 grams, 88%) was prepared from 4-{4-[4-(l,3-dioxo-l,3- dihydro-isoindol-2-ylmethyl)-[ 1 ,2,3]triazol- 1 -yl]-2,6-fluoro-phenyl} -piperazine- 1 - carboxylic acid tert-butyl ester (3.0 grams, 5.73 mmol), obtained in example 21, acroloyl 2005 0 chloride (0.51 mL, 6.3 mmol) and rriethyl amine (2.4 mL, 17.2 mmol) following the same procedure as descibed for the prepration of 2-{l-[4-(4-acrolyl-piperazin-l-yl)-3-fluoro- phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (Example 16).
Η NMR (CDC13): δ 7.96 (s, IH), 7.89-7.71 (m, 4H), 7.28 (d, J = 9.1 Hz, 2H), 6.64 &
6.56 (2d, J = 10.5 Hz, IH), 6.32 (d, J => 16.9 Hz, IH), 5.73 (d, J = 10.2 Hz, IH), 5.06 (s,
2H), 3.81 (bs, 2H), 3.69 (bs, 2H), 3.23 (bs, 4H).
IR (KBr, cm"1): 3439, 3085, 2853, 1719, 1644, 1518, 1465, 1438, 1395, 1231, 1032, 856,
715, 530.
CI-MS (m/z): 479 (M++l), 450, 425, 366, 297, 211, 194, 165, 121, 92.
Example 23: 2-(l-{4-[4-(2,3-Dihydroxy-propionyl)-piperzin-l-yl]-3,5-difluoro-phenyI}-l _'-
[ 1 ,2,3] triazol-4-ylπ_ethy_)-isoindole-l,3-dione
Figure imgf000113_0001
Title compound (1.0 gram, 47%) was prepared from 2-{l-[4-(4-acrolyl-piperazin- l-yl)-3,5-difluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (2.0 grams, 4.2 mmol), obtained in example 22, 1% osmiumtetroxide in tert-butanol (107 mg, 0.42 mmol) and N-methyl moφholine-N-oxide (567 mg, 4.2 mmol) following the same procedure as described for the preparation of 2-(l-{4-[4-(2,3-dihydroxy-propionyl)- piperzin-1 -yl]-3-fluoro-phenyl}-lH-[l ,2,3]triazol-4-ylmethyl)-isoindole-l ,3-dione (Example 17).
Η ΝMR (CDCI3): δ 7.96 (s, IH), 7.90-7.72 (m, 4H), 7.29 (d, J = 1 1.8 Hz, 2H), 5.07 (s, 2H), 4.49-4.48 (m, IH), 3.81-3.62 (m, 6H), 3.25 (bs, 4H).
IR(KBr, cm"1): 3416, 1718, 1637, 1519, 1467, 1396, 1279, 1232, 1211, 1027, 939, 855, 715,530. CI-MS (m/z): 513 (M++l), 483, 425, 315, 287, 229, 163, 91.
Example 24:
2-(l-{4-[4-(2,2-Dimethyl-[l,3]dioxolane-4-carbonyl)-piperazin-l-yl]-3,5-difluoro- phenyl}-l_f7-[l,2,3]triazoI-4-ylmethyl)-isoindoIe-l,3-dione 2005/082892
Figure imgf000114_0001
Title compound (0.9 gram, 83%) was obtained from 2-(l-{4-[4-(2,3-dihydroxy- propionyl)-piperzin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole- 1,3-dione (1.0 gram, 1.95 mmol), obtained in example 23, 2,2-dimethoxy propane (0.5 mL, 3.91 mmol) and pyridinium />-tolunesulfonate (50 mg, 0.195 mmol) following the same procedure as described for the preparation of 2-(l-{4-[4-(2,2-dimethyl- [ 1 ,3]dioxolane-4-carbonyl)-piperazin- 1 -yl]-3-fluoro-phenyl} -lH-[ 1 ,2,3]triazol-4- ylmethyl)-isoindole-l,3-dione (Example 18).
Η NMR (CDC13): δ 7.96 (s, IH), 7.90-7.72 (m, 4H), 7.29 (d, J = 11.8 Hz, 2H), 5.07 (s, 2H), 4.49-4.48 (m, IH), 3.81-3.62 (m, 6H), 3.25 (bs, 4H).
IR (KBr, cm'1): 3416, 1718, 1637, 1519, 1467, 1396, 1279, 1232, 1211, 1027, 939, 855, 715,530. CI-MS (m/z): 513 (M++l), 483, 425, 315, 287, 229, 163, 91.
Example 25:
{4-[4-(4-Aminomethyl-[l,2,3]triazol-l-yl)-2,6-difluoro-phenyI]-piperazin-l-yl}-(2,2- dimethyl-[l,3]dioxalan-4-yl)methanone
Figure imgf000114_0002
Title compound (550 mg, 80%) was prepared from 2-(l-{4-[4-(2,2-dimethyl- [l,3]dioxolane-4-carbonyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-isoindole-l,3-dione (900 mg, 1.62 mmol), obtained in example 24, and hydrazine hydrate (0.5 mL) following the procedure as described for the preparation of {4-[4-(4-aminomethyl-[l,2,3]rriazol-l-yl)-2-fluoro-phenyl]-piperazin-l-yl}-(2,2- dimethyl-[l,3]dioxalan-4-yl)methanone (Example 19).
Η NMR (CDCI3): δ 7.84 (s, IH), 7.33 (d, J = 9.3 Hz, 2H), 4.72 (t, J= 6.2 Hz, IH), 4.51 (dd, J= 8.3 Hz & 5.8 Hz, IH), 4.16 (dd, J= 8.3 Hz & 6.8 Hz, IH), 4.07 (s, IH), 3.94-3.63 (m, 4H), 3.24 (d, J= 4.6 Hz), 1.43 (d, J= 1.9 Hz, 6H). IR (KBr, cm"1): 3442, 2988, 2924, 2856, 1844, 1520, 1460, 1381, 1279, 1230, 1154, 1038,
1001, 933, 855, 701, 616, 565, 533.
CI-MS (m z): 423 (M++l), 365, 342, 320, 265, 236, 407, 192, 163, 101, 91.
Example 26:
(l-{4-[4-(2,3-Dihydroxy-propionyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-l_f7- [l,2,3]triazol-4-ylmetbyI)-thiocarbamic acid O-methyl ester
Figure imgf000115_0001
Title compound (270 mg, 45%>) was prepared from {4-[4-(4-aminomethyl- [l,2,3]triazol-l-yl)-2,6-difluoro-phenyl]-piperazin-l-yl}-(2,2-dimethyl-[l,3dioxalan-4- yl)methanone (550 mg, 1.3 mmol), obtained in example 25, using thiophosgene (115 mL, 1.43 mmol) and sodium bicarbonate (1.1 grams, 13 mmol) following the same procedure as described for the preparation of (l-{4-[4-(2,3-dihydroxy-propionyl)-piperazin-l-yl]-3- fluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (Example 20).
Η NMR (CDC13): 8.07 & 7.81 (2s, rotamers in 4:1 ratio, IH), 7.32 (d, J- 9.3 Hz, 2H), 6.96 (bs, IH), 4.91 & 4.65 (2d, rotamers in 4:1 ratio, J = 5.9 Hz, 2H), 4.51 (bs, IH), 4.12 & 4.00 (2s, rotamers in 1:4 ratio, 3H), 3.92-3.63 (m, 7H), 3.25 (bs, 4H), 2.50 (bs, IH). IR (KBr, cm"1): 3262, 3012, 2947, 2858, 1635, 1519, 1457, 1389, 1334, 1278, 1231, 1149, 1118, 1096, 1029, 857, 756. CI-MS (m/z): 457 (M++l), 425, 369, 320, 295, 245, 207, 183, 157, 128, 91.
Example 27: (R)-(l-{4-[4-(2,2-dimethyl-[l,3]dioxolane-4-carbonyl)-piperazin-l-yI]-3,5-difluoro- phenyl}-l 7-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000115_0002
To a solution of (R)-2,2-dimethyl-l,3-dioxolane-4-carboxylic acid (876 mg, 6.0 mmol), obtained in preparation 29, in DCM (15 mL) were added l-(3,5-difluoro-4- piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester (2.0 grams, 5.43 mmol), obtained in example 6, and N-methyl moφholine (604 mg, 6.0 mmol) at 0 °C N-(3-dimethylaminopropyl)--V-ethyl carbodiimide hydrochloride (1.15 grams, 6.0 mmol) was added to the reaction mixmre portion wise and stirring was continued at 0 °C for additional 1 hour and then at 25-35 °C 9 to 13 hours. Reaction
mixture was then diluted with ethyl acetate (250 mL) and the organic portion was washed with water followed by brine and dried over sodium sulfate. Removal of volatiles and purification of the resulting residue by column chromatography (methanol/chloroform, 1 :9) yielded the title compound (2.17 grams, 75%).
Η ΝMR (CDC13) : δ 8.06 & 7.81 (2s, rotamers in ratio of 4:1, IH), 7.31 (d, J = 93 Hz, 2H), 6.91 (bs, IH), 4.90 (d, J = 6.2 Hz, 2H), 4.71-4.68 (m, IH), 4.41-4.61 (m, IH), 4.15- 4.11 (m, IH), 3.99 (s, 3H), 3.69-3.85 (m, 4H), 3.10-3.30 (m, 4H), 1.42 (s, 6H). IR (KBr, cm"1) : 3248, 1631, 1519, 1372. CI-MS : 497 (M++1), 465, 433, 408, 380, 280.
Example 28:
(l-{4-[4-(2(R),3-Dihydroxy-propionyI)-piperazin-l-yl]-3,5-difluoro-phenyl}-l_/- [l,2,3]triazo_-4-y_methyl)-thiocarbamic acid O-methyl ester
Figure imgf000116_0001
To an ice-cooled suspension of (R)-(l-{4-[4-(2,2-dimethyl-[l,3]dioxolane-4- carbonyl)-piperazin- 1 -yl] -3,5 -difluoro-phenyl } - 1 H- [ 1 ,2, 3 ] triazol-4-ylmethy 1 ] thiocarbamic acid O-methyl ester (3.3 grams, 6.65 mmol), obtained in example 27, in methanol (25 mL) was added 50% aqueous HCI (25 mL) drop wise and stirred at 25-35
°C for 9 to 13 hours. Reaction mixmre was diluted with water (30 mL) and then cooled to
ice temp. pH of the reaction mixmre was brought to 7 by the addition of solid sodium bicarbonate and extracted with chloroform. Combined organic portions were dried over sodium sulfate and the residue obtained after removal of volatiles was purified by column chromatography (silica gel 60-120, eluent; methanol/chloroform, 3: 97) to get the title compound (1.75 grams, 58%>).
Η ΝMR (CDCI3): δ 8.06 & 7.82 (2s, rotamers in 4: 1 ratio, IH), 7.32 (d, J= 9.1 Hz, 2H), 6.99 (bs, IH), 4.91 & 4.65 (2d, rotamers in 4:1 ratio, J= 5.9 Hz, 2H), 4.51 (dd, J= 6.2 & 9.7 Hz, IH), 4.10 & 3.99 (2s, rotamers in 1:4 ratio, 3H), 3.92-3.64 (m, 7H), 3.25 (bs, 4H),
2.53 (bs, IH)
IR (KBr, cm"1): 3266, 1638, 1519, 1463, 1278, 1203, 1026, 853, 736.
CI-MS (m/z): 457 (M++l), 425, 393, 383, 369, 340, 302, 280, 268, 238, 195, 165, 123,
106, 92.
Example 29:
(S)-(l-{4-[4-(2,2-dimethyI-{l,3]dioxolane-4-carbonyl)-piperazin-l-yl]-3,5-difluoro- phenyl}-lH-[l,2,3]triazol-4-ylmethyI]-thiocarbamic acid O-methyl ester
Figure imgf000117_0001
To a solution of (S)-2,2-dimethyl-l,3-dioxolane-4-carboxylic acid (890 mg, 6.1 mmol), obtained from the corresponding methyl ester, in THF (20 mL) was added triethyl amine (2.12 mL, 15 mmol) followed by the addition of isobutylchloroformate (0.8 mL, 6.1 mmol) at ice temperamre and stirring was continued for 20 minutes. A solution of 1- (3,5-difluoro-4-piperazin-l -yl-phenyl)- lH-[ 1 ,2,3]triazol-4-ylmethyl]-thiocarbamic acid -methyl ester (1.86 grams, 5.0 mmol), obtained in example 6, in THF (10 mL) was then added to the above reaction mixmre and it was further stirred 9 to 13 hours. The reaction mixmre was diluted with water and extracted with ethyl acetate. Combined ethyl acetate extract was washed with water followed by brine and dried over sodium sulfate. Removal of volatiles and purification of the resulting residue by column chromatography (methanol/chloroform, 1:9) yielded the title compound (700 mg, 30%). Η NMR (CDC13) : δ 8.05 & 7.81 (2s, rotamers in ratio of 4: 1, IH), 7.34-7.28 (m, 2H), 6.91 (bs, IH), 4.91 & 4.65 (d, J= 6.0 Hz, rotamers in ratio of 4: 1, 2H), 4.70 (t, J= 6.3 Hz, IH), 4.53-4.49 (m, IH), 4.17-4.1 1 (m, IH), 4.01 (s, 3H), 3.60-3.91 (m, 4H), 3.10-3.30 (m, 4H), 1.41 (s, 6H).
IR (KBr, cm"1) : 3250, 1632, 1522, 1205. CI-MS : 497 (M++l), 465, 433, 408, 380, 280.
Example 30:
(l-{4-[4-(2(S),3-Dihydroxy-propionyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-l__T- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000118_0001
Title compound (0.8 gram, 27%) was obtained from (S)-(l-{4-[4-(2,2-dimethyl- [l,3]dioxolane-4-carbonyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4- ylmethyl] -thiocarbamic acid O-methyl ester (3.2 grams, 8.72 mmol), obtained in example 29, following the same procedure as described for the preparation of (l-{4-[4-(2(R),3- dihydroxy-propiony l)-piperazin- 1 -yl] -3 , 5 -difluoro-phenyl } - 1 H- [ 1 ,2, 3 ] triazol-4-ylmethyl)- thiocarbamic acid O-methyl ester (Example 28).
Η NMR (CDC13): δ 8.07 & 7.83 (2s, rotamers in 4:1 ratio, IH), 7.31 (d, J= 9.1 Hz, 2H), 7.11 (t, J = 5.4 Hz, IH), 4.91 & 4.65 (2d, rotamers in 4: 1 ratio, J = 5.9 Hz, 2H), 4.51 (bs, IH), 4.11 & 3.99 (2s, rotamers in 1 :4 ratio, 3H), 3.96-3.64 (m, 7H), 3.25 (bs, 4H), 2.65 (bs, IH).
IR(KBr, cm"1): 3240, 3129, 2942, 2857, 1740, 1634, 1518, 1461, 1399, 1336, 1277, 1202, 1055, 1026,851,694. CI-MS (m/z): 457 (M++l), 425, 407, 383, 369, 340, 302, 169, 106, 92.
Example 31:
(l-{4-[4-(2(_R),3-Dihydroxy-propionyl)-piperazin-l-yl]-3-fluoro-phenyI}-l_f7- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000118_0002
The title compound was synthesized from [l-(3-fluoro-4-piperazin-l-yl-phenyl)- lH-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 5, following the same procedure as described for the preparation of (l-{4-[4-(2(R),3- dihydroxy-propiony -piperazin-l-yll-S.S-difluoro-phenylJ-lH-fl
Figure imgf000118_0003
thiocarbamic acid O-methyl ester (Example 28).
Η NMR (DMSO-d6) : δ 9.64-9.59 (m, IH), 8.64 & 8.60 (2s, rotamers in ratio of 4:1, IH),
7.79 (dd, J = 8.1 & 2.4 Hz, IH), 7.68 (dd, J = 6.2 & 1.6 Hz, IH), 7.22 (t, J= 9.1 Hz, IH),
4.96 (d, J = 5.4 Hz, IH), 4.72 & 4.44 (2d, rotamers in ratio of 4:1, J = 5.6 Hz, 2H), 4.70
(bs, IH), 4.38 (d, J = 4.6 Hz, IH), 3.95 & 3.89 (2s, rotamers in ratio of 1 :4, 3H), 3.72-3.69
(m, 2H), 3.58-3.49 (m, 2H), 3.08 (s, 4H). IR (KBr, cm"1) : 3457, 1727, 1628, 1526. CI-MS : 439 (M++l), 389, 291, 181, 108.
Example 32:
(l-{4-[4-(2(S),3-Dihydroxy-propionyl)-piperazin-l-yl]-3-fluoro-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000119_0001
The title compound was synthesized from (S)-(l-{4-[4-(2,2-dimethyl- [l,3]dioxolane-4-carbonyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4- ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 29, following the same procedure as described for the preparation of (l-{4-[4-(2(S),3-dihydroxy-propionyl)- piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester (Example 30).
Η NMR (CDCl3+DMSO-d6) : δ 9.10 (s, IH), 8.25 & 8.10 (2s, rotamers in ratio of 4:1, IH), 7.20-7.61 (m, 2H), 7.07 (t, J= 8.8 Hz, IH), 4.83 & 4.56 (2d, rotamers in ratio of 4: 1, J = 5.7 Hz, 2H), 4.41-4.59 (m, 3H), 4.04 & 3.97 (2s, rotamers in ratio of 1:4, 3H), 3.79- 3.69 (m, 4H), 3.16-3.06 (m, 4H). IR (KBr, cm"1) : 3226, 1624, 1523, 1442, 1233, 1049. CI-MS : 439 (M++l), 389, 351, 319, 195, 102.
Example 33:
2-{l[4-BenzyI-l,2,3,6-tetrahydro-pyridin-4-yl)-3-fluoro-phenyl]-l-? -[l,2,3]triazol-4- ylmethyl isoindole-l,3-dione :
Figure imgf000119_0002
To a solution of 4-(4-azido-2-fluoro-phenyl)-l -benzyl- 1,2,3, 6-tetrahydro-pyridine (100 mg, 0.324 mmol), obtained in preparation 24, in acetonitrile (10 mL) was added N- Ethyldiisopropylamine (0.11 mL, 0.64 mmol) followed by the addition of 2-proρ-2-ynyl- isoindole-l,3-dione (0.09 grams, 0.48 mmol), obtained in preparation 2, and cuprous iodide (0.067 grams, 0.35 mmol) and stirred at 25-35 °C for 2 hours. The reaction mixture
was filtered through a celite bed, which was washed thoroughly with 10% methanol in chloroform. The filtrates were concentrated under vacuum and the crude product was purified by silica gel column chromatography (50% ethyl acetate/pet. ether) to get desired product as a yellow solid (150 mg, 93%>).
Η NMR (CDCb, 200 MHz): δ 8.01 (s, IH), 7.93-7.80 (m, 2H), 7.80-7.64 (m, 2H), 7.52-
7.19 (m, 8H), 6.11-6.00 (m, IH), 5.07 (s, 2H), 3.65 (s, 2H), 3.28-3.10 (m, 2H), 2.80-2.62
(m, 2H), 2 62-2.44 (m, 2H)
IR (KBr): 3434, 2925, 1721, 1393 cm"1
CI-MS (m/e): 494 (M++l), 408, 400
Example 34:
2- {1- [3-Fluoro-4-(l ,2,3,6-tetrahydro-pyridin-4-yl)-phenyl] -IH- [1 ,2,3] triazol-4-yl methyl}- isoindole-l,3-dione
Figure imgf000120_0001
To a solution of 2-{l[4-Benzyl-l,2,3,6-tetrahydro-pyridin-4-yl)- 3-fluoro-phenyl]- \H- [1,2,3] triazole-4-ylmethyl isoindole-l,3-dione (300 mg, 0.608 mmol), obtained in example 33, in dry dichloromethane (10 mL) at 0 °C added drop wise 1-chloroethyl chloroformate (0.067 mL, 0.611 mmol) and allowed the reaction mixmre to stir at the same temperamre for 1.5 hours. Evaporated the solvent on rotavapor and dissolved the residue in methanol (20 mL). Refluxed the reaction mixmre for 0.5 hours. The solvent was evaporated and the residue was purified by silica gel column chromatography (5 % methanol/chloroform) to get the desired product as a white solid (150 mg, 61%>). Η NMR (DMSO-d6 + MeOH-d4, 200 MHz): δ 8.70 (s, IH), 7.99-7.72 (m, 6H), 7.60 (t, J = 8 Hz, IH), 6.16-6.13 (m, IH), 5.00 (s, 2H), 3.92-3.72 (m, 2H), 3.39 (t, J= 6.1 Hz, 2H), 2.84-2.64 (m, 2H)
IR (KBr): 3435, 2925, 1711, 1618, 1396 cm"1 CI-MS (m/e): 403 (M++l)
Example 35: 2-{l-[4-(l-Acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3-fluoro-phenyl]-l_fϊ-[l,2,3]triazol- 4-ylmethyl}-isoindole-l,3-dione
Figure imgf000121_0001
To a solution of 2-{l-[3-fluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-l_t - [l,2,3]triazol-4-yl methyl} -isoindole-l,3-dione (150 mg, 0.372 mmol), obtained in example 34, in dry dichloromethane (10 mL), added triethylamine (0.103 mL, 0.744 mmol) followed by the addition of acetyl chloride (0.029 mL, 0.409 mmol) and 4- dimethylaminopyridine (5 mg, 0.037 mmol) and allowed the reaction mixmre to stir for
10 hours at 25-35 °C. Solvent was evaporated and the residue purified by silica gel
column chromatography (70 % ethyl acetate/pet. ether) to yield desired product as white solid (100 mg, 61%).
Η NMR (CDC13, 200 MHz): δ 8.03 (s, IH), 7.96-7.80 (m, 2H), 7.80-7.67 (m, 2H), 7.55-
7.30 (m, 3H), 6.10-5.98 (m, IH), 5.07 (s, 2H), 4.35-4.20 (m, IH), 4.20-4.08 (m, IH), 3.81
(t, J= 5.6 Hz, IH), 3.66 (t, J= 5.6 Hz, IH), 2.72-2.42 (m, 2H), 2.17 (s, 3H)
CI-MS (m/e):.446 (M++l)
IR (KBr): 3453, 2924, 1710, 1651, 1459 cm"1
Example 36:
7V-{l-[4-(l-Acetyl-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3-fluoro-phenyl]-li7-[l, 2, 3] triazol-4-ylmethyl}-thioacetamide
Figure imgf000121_0002
To 2-{l-[4-(l-acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3-fluoro-phenyl]-lH-
[l ,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (100 mg, 0.224 mmol), obtained in example 35, in methanol (20 mL) was added hydrazine hydrate (0.096 mL) and refluxed the reaction mixmre for 2 hours. Concentrated the reaction mixmre and residue obtained was purified by silica gel column chromatography (5% methanol/chloroform) to yield 1- {4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)2-fluoro-phenyl]-3,6-dihydro-2H-pyridin-l-yl}- ethanone as a white solid (65 mg). Then it was dissolved in TΗF (5 mL), cooled to 0 °C was added triethylamine (0.057 mL, 0.412 mmol) followed by the addition of ethyl dithioacetate (0.03 mL, 0.267 mmol). The reaction mixmre was brought to 25-35 °C and
stirred for 12 hours. Evaporated the solvent on rotavapor and purified the residue by silica gel column chromatography (80 % ethyl acetate/pet.ether) to yield the desired product as a white solid (70 mg, 89%).
Melting Point: 132-135 °C .
Η NMR (CDC13, 400 MHz): δ 8.12 (s, 2H), 7.58-7.42 (m, 2H), 7.41-7.35 (m, IH), 6.08-
6.01 (m, IH), 5.00 (d, J= 5 Hz, 2H), 4.30- 4.22 (m, IH), 4.18-4.14 (m, IH), 3.86-3.78 (m,
IH), 3.72-3.60 (m, IH), 2.60 (s, 3H), 2.64-2.52 (m, 2H), 2.16 (s, 3H)
IR (KBr): 3446, 2924, 2853, 1623, 1461 cm"1
CI-MS (m/e): 374 (M++l)
Example 37:
{l-[4-(l-Acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3-fluoro-phenyl]-lH-[l,2,3] triazol-4- ylmethylj-thiocarbamic acid O-methyl ester
Figure imgf000122_0001
To a solution of l-{4-[4-(4-Aminomethyl-[l,2,3]triazol-l-yl)2-fluoro-phenyl]-3,6- dihydro-2H-pyridin-l-yl} -ethanone (0.1 gram, 0.317 mmol), in THF (5 mL) was added triethylamine (0.09 mL, 0.634 mmol) and brought the reaction temperamre down to 0 °C . To this solution was added carbon disulphide (0.023 mL, 0.38 mmol) and allowed the reaction mixmre to stir at the same temperamre for 4 hours, after which ethylchloroformate (0.032 mL, 0.348 mmol) was added and the reaction was continued for another 1 hour at 0 °C. The solvent was evaporated and methanol (8 mL) was added to the residue and the reaction mixture was refluxed for 12 hours. Methanol was removed by evaporation and the residue was purified by silica gel column chromatography (70 % ethyl acetate/pet.ether) to afford the desired product as white solid (100 mg, 81%). Melting Point: 155-157 "C .
Η NMR (CDCI3, 400 MHz): δ 8.12 and 7.84 (two s, IH, rotamers in ratio of 4: 1), 7.58- 7.44 (m, 2H), 7.42-7.38 (m, IH), 6.94-6.86 (m, IH), 6.08-6.00 (m, IH), 4.93 and 4.68 (two d, J= 5.8 Hz, 2H, rotamers in the ratio of 4: 1), 4.32-4.28 (m, IH), 4.20-4.12 (m, IH), 4.00 (s, 3H), 3.82 (t, J = 5.3 Hz, IH), 3.68 (t, J = 5.3 Hz, IH), 2.64-2.52 (m, 2H), 2.18 (s,
3H)
IR (KBr): 3184, 2925, 1634, 1515, 1429, 1240 cm"1
CI-MS (m/e): 390 (M++l), 358
Example 38:
2-(l-{3-Fluoro-4-[l-(5-nitro-furan-2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- phenyl}-l_f7-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione :
Figure imgf000123_0001
To a solution of 2-{l-[3-fluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-lH- [l,2,3]triazol-4-yl methyl} -isoindole-l,3-dione (1 gram, 2.48 mmol), obtained in example 34, in dry dichloromethane (15 mL) was added triethylamine (1.04 mL, 7.44 mmol) and cooled the reaction mixmre to 0 °C . At this temperamre added 2-nitro-5-furoyl chloride
(0.52 grams, 2.97 mmol) to the reaction mixmre and left it to stir at 25-35 °C for 12 hours.
The reaction mixmre was diluted with dichloromethane (50 mL) washed with water followed by brine and dried over anhydrous sodium sulphate. The volatiles were removed under reduced pressure and the residue was purified by silica gel column chromatography
(70 % ethyl acetate/pet.ether) to yield the titled compound as a yellow solid (1 gram,
75%)
Η NMR (CDC13, 200 MHz):_ δ 8.04 (s, IH), 7.96-7.80 (m, 2H), 7.80-7.65 (m, 2H), 7.58-
7.30 (m, 5H), 6.18-6.00 (m, IH), 5.09 (s, 2H), 4.64-4.50 (m, IH), 4.50-4.32 (m, IH),
4.14- 3.92 (m, 2H), 2.84-2.72 (m, 2H)
IR (KBr): 3436, 2924, 1717, 1631 cm"1
CI-MS (m/e): 543 (M++l), 513, 494, 400
Example 39:
_V-(l-{3-Fluoro-4-[l-(5-nitro-furan-2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- phenyl}-l_7-[l,2,3]triazol-4-ylmethyl)-thioacetamide :
Figure imgf000123_0002
To a solution of 2-(l-{3-fluoro-4-[l-(5-nitro-furan-2-carbonyl)-l,2,3,6-tetrahydro- pyridin-4-yl]-phenyl}-l/ -[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione (1 gram, 1.84 mmol), obtained in example 38, in methanol (20 mL) was added hydrazine hydrate (0.79 L) and refluxed the reaction mixmre for 2 hours. Allowed the reaction mixmre to stir for
12 hours at 25-35 °C. Evaporated the solvent and the residue was purified by silica gel
column chromatography (10 % methanol/chloroform) to furnish l-{4-[4-(4-aminomethyl- [l,2,3]triazol-l-yl)2-fluoro-phenyl]-3,6-dihydro-2H-pyridin-l-yl}-(5-nitro-furan-2-yl)- methanone as a white solid (640 mg) which was pure enough to carry out further step. Then a solution this amine (150 mg, 0.364 mmol) in THF (10 mL) was cooled to 0 °C, added triethylamine (0.101 mL, 0.728 mmol) followed by addition of ethyl dithioacetate
(0.054 mL, 0.473 mmol). Allowed the reaction mixmre to stir at 25-35 °C for 12 hours.
Solvent was removed under vacuum and the residue was purified by silica gel column chromatography (70 % ethyl acetate/pet.ether) to get desired compound as a yellow solid
(60 mg, 35%)
Melting Point : 112-114 °C .
Η NMR (CDCl3+DMSO-d6, 200 MHz): δ 10.24-10.10 (m, IH), 8.37 (s, IH), 7.70-7.54
(m, 2H), 7.54-7.40 (m, 2H), 7.24 (d, J= 3.6 Hz, IH), 6.21-6.04 (m, IH), 4.98 (d, J= 5.37
Hz, 2H), 4.68-4.34 (m, 2H), 4.12-3.92 (m, 2H), 2.86-2.62 (m, 2H), 2.55 (s, 3H).
IR(KBr): 3441, 2924, 1631, 1502, 1429, 1353 cm"1
ES-MS (m/e): 471 (M+l)
Example 40:
(l-{3-Fluoro-4-[l-(5-nitro-furan-2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yI]- phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000124_0001
To an ice cooled solution of l-{4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)2-fluoro- phenyl]-3,6-dihydro-2H-pyridin-l-yl}-(5-nitro-furan-2-yl)-methanone (220 mg, 0.533 mmol), in dry THF (10 mL) was added triethylamine (0.09 mL, 0.639 mmol) and carbon disulphide (0.064 mL, 1.066 mmol) and allowed the reaction mixmre to stir at 0 °C for 4 hours, after which ethyl chloroformate (0.049 mL, 0.533 mmol) was added and the reaction was continued for another 1 hour at 0 °C. The solvent was evaporated and methanol (20 mL) was added to the residue and the reaction mixmre was refluxed for 12 hours. Methanol was removed by evaporation and the residue was purified by silica gel column chromatography (3% methanol/chloroform) to get the desired compound as a white solid (90 mg, 35%).
Melting Point : 164-166 *C
Η NMR (DMSO-d6, 400 MHz): δ 9.71-9.60 (m, IH), 8.75 and 8.72 (two s, IH, rotamers in a ratio of 4: 1), 7.89 (dd, J = 1.9 and 12.2 Hz, IH), 7.84- 7.76 (m, 2H), 7.61 (t, J = 8.3
Hz, IH), 7.38-7.34 (m, IH), 6.24- 6.08 (m, IH). 4.74 (d, J = 5.8 Hz, 2H), 4.56-4.40 (m,
2H), 4.39- 4.20 (m, IH), 3.98-3.81 (m, IH), 3.95 and 3.89 (two s, 3H, rotamers in a ratio
1 :3), 2.76-2.52 (m, 2H).
IR (KBr): 3281, 2925, 1623, 1516, 1435, 1354, 1253 cm"1
CI-MS (m/e): 487 (M++l), 455, 423, 338, 191, 100
Example 41:
2-{l-[4-Benzyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenyl]-l_? - [ 1 ,2,3] triazoIe-4-yl methyl}-isoindole-l ,3-dione
Figure imgf000125_0001
The title compound was prepared from 4-(l -benzyl- 1,2,3, 6-tetrahydro-pyridin-4- yl)-3,5-difluoro-phenylazide (3 grams, 9.2 mmol), obtained in preparation 28, following the same procedure as described for the preparation of 2-{l[4-Benzyl-l,2,3,6-tetrahydro- pyridin-4-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4-ylmethyl isoindole-l ,3-dione in 67% yield (Example 33).
Η NMR (CDC13, 200 MHz): δ 8.00 (s, IH), 7.98-7.80 (m, 2H), 7.80-7.62 (m, 2H), 7.41- 7.20 (m, 7H), 5.95-5.82 (m, IH), 5.10 (s, 2H), 3.66 (s, 2H), 3.25-3.18 (m, 2H), 2.79-2.62 (m, 2H), 2.58-2.38 (m, 2H). IR (KBr): 1721, 1429, 1397, 1026, 711 cm"1 CI-MS (m/e): 522 (M+l), 418, 148
Example 42:
2-{l-[3,5-Difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-l^r-[l,2,3]triazol-4-yl methyl}-isoindole-l,3-dione
Figure imgf000126_0001
The title compound was prepared from 2-{l-[4-benzyl-l,2,3,6-tetrahydro-pyridin- 4-yl)- 3,5-difluoro-phenyl]-l -[l,2,3]triazole-4-yl methyl }-isoindole-l , 3 -di one (2 grams, 3.9 mmol), obtained in example 41, following the same procedure as described for the preparation of 2-{l-[3-fluoro-4-(l,2,3,6-tefrahydro-pyridin-4-yl)-phenyl]-lH-
[l,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (Example 34), in 60% yield. Η NMR (DMSO-d6, 200 MHz): δ 8.87 (s, IH), 7.96-7.85 (m, 4H), 7.76 (d, J = 8.3 Hz, 2H), 7.62-7.48 (m, IH), 5.99-5.84 (m, IH), 4.93 (s, 2H), 3.50-3.32 (m, 2H), 3.04-2.84 (m, 2H), 2.36-2.18 (m, 2H)
IR (KBr): 3443, 2924, 1772, 171, 1632, 1509, 1455, 1432, 1397, 1288, 1033 cm'1 CI-MS (m/e): 422 (M+l), 348
Example 43:
4-{4-[4-(l,3-Dioxo-l,3-dihydro-isoindole-2-yImethyl)-[l,2,3]-triazol-l-yl]-2,6- difluoro-phenyI}-3,6-dihydro-2H-pyridin-l-carboxylic acid tert-butyl ester
Figure imgf000126_0002
To a solution of 2-{l-[3, 5-difluoro-4-(l, 2, 3, 6-tetrahydro-pyridin-4-yl)-phenyl]- 1/ -[1 , 2, 3] triazol-4-ylmethyl}-isoindole-l,3-dione (150 mg, 0.356mmol), obtained in example 42, in dichloromethane (7 mL), added triethylamine (0.14 mL) followed by di- tert-butyldicarbonate (194 mg, 0.89 mmol) and allowed the reaction mixmre to stir for 3 hours at 25-35 °C. Solvent was evaporated and the residue purified by column
chromatography over silica gel (ethyl acetate/pet.ether, 3:2) to obtain the title compound as a light brown solid (100 mg, 54%o).
Η NMR (CDC13, 200 MHz): δ 8.01 (s, IH), 7.92-7.80 (m, 2H), 7.80-7.64 (m, 2H), 7.32
(d, J = 7.5 Hz, 2H), 5.96-5.84 (m, IH), 5.08 (s, 2H), 4.16-4.03 (m, 2H), 3.64 (t, J = 5.4
Hz, 2H), 2.51-2.32 (m, 2H), 1.50 (s, 9H)
IR (KBr): 3460, 2926, 1720, 1428, 1366, 1238, 1179, 1044, 864, 714 cm"1
CI-MS (m/e): 522 (M+l), 46, 422 Example 44:
4-[4-(4-AminomethyI-[l,2,3] triazol-l-yl)-2,6-difluorophenyl]-3,6-dihydro-2i_r- pyridin-1-carboxylic acid tert-butyl ester
Figure imgf000127_0001
To 4-{4-[4-(l ,3-dioxo-l,3-dihydro-isoindole-2-ylmethyl)-[l,2,3]triazol-l-yl]-2,6- difluoro-phenyl}-3,6-dihydro-2_r -pyridin-l-carboxylic acid tert-butyl ester (100 mg, 0.192 mmol), obtained in example 43, in methanol (5 mL) was added hydrazine hydrate (0.08 L) and refluxed the reaction mixmre for 2 hours. Allowed the reaction mixture to cool and filtered over a celite pad, added silica gel (300 mg) to the filtrate, evaporated solvent and purified the residue by column chromatography (3% methanol/chloroform) to get the required product as a yellow solid (50 mg, 66%).
Η NMR (CDC13, 400 MHz):_δ 7.89 (s, IH), 7.33 (d, J = 7.3 Hz, 2H), 5.94-5.83 (m, IH), 4.16-3.98 (m, 4H), 3.69-3.58 (m, 2H), 2.49-2.36 (m, 2H), 1.26 (s, 9H). IR (KBr): 3441, 2926, 1694, 1422, 1 139, 1175, 1051, 863 cm"1 CI-MS (m e): 392 (M+l), 336
Example 45:
4-{2,6-Difluoro-4-[4-(thioacetylamino-methyl)-[l,2,3]triazol-l-yl]-phenyl}-3,6- dihydro-2iϊ-pyridin-l-carboxylic acid tert-butyl ester
Figure imgf000127_0002
To an ice cooled solution of 4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6- difluorophenyl] -3, 6-dihydro-2H-pyridin-l -carboxy lie acid tert-butyl ester (70 mg, 0.179 mmol), obtained in example 44, in THF (5 mL) was added triethylamine (0.06 mL, 0.448 mmol) followed by the addition of ethyl dithioacetate (0.05 mL, 0.447 mmol). The reaction mixmre was brought to 25-35 °C and stirred for 12 hours. Evaporated the solvent
on rotavapor and purified the residue by column chromatography over silica gel (ethyl acetate/pet. ether 2:3) to afford the required compound as a pale yellow solid (57 mg,
71%).
Melting Point: 158-160 °C .
Η NMR (CDC1 , 200 MHz): δ 8.12 (s, IH), 8.12-7.98 (m, IH), 7.33 (d, J = 7.8 Hz, 2H),
5.98-5.84 (m, IH), 5.02 (d, J = 5.4 Hz, 2H), 4.18-4.04 (m, 2H), 3.65 (t, J = 5.4 Hz, 2H),
2.62 (s, 3H), 2.52-2.36 (m, 2H),1.51 (s, 9H).
IR (KBr):_3434, 2926, 1695, 1426, 1172, 1050, 860, 538cm"1
CI-MS (m/e): (M+l) 450, 394, 365
Example 46:
N-{l-[3,5-Difluoro-4-(l,2,3,6-tertrahydro-pyridin-4-yl)-phenyl]-l _'-[l,2,3]triazoI-4- ylmethyl}-thioacetamide
Figure imgf000128_0001
A 60% solution of trifluoroacetic acid in dichloromethane (10 mL) was added to 4-{2,6-difluoro-4-[4-(thioacetylamino-methyl)-[l,2,3]triazol-l-yl]-phenyl}3,6-dihydro- 2-r -pyridin-l -carboxylic acid tert-butyl ester (100 mg, 0.22 mmol), obtained in example
45. The reaction mixmre was allowed to stir at 25-35 °C for 3 hours. Toluene (15 mL)
was added into the reaction mixmre and evaporated to dryness on rotavapor. The residue was purified by column chromatography over silica gel (10% methanol-chloroform) to obtain the desired compound as a brown solid (52 mg, 66%).
Melting Point: 186-188 °C
Η ΝMR (DMSO-d6): δ 10.62-10.42 (m, IH), 9.22-8.98 (m, 2H), 8.86 (s, IH), 7.88 (d, J =
8.5 Hz, 2H), 6.08 - 5.96 (m, IH), 4.87 (d, J = 5.4 Hz, 2H), 3.90-3.72 (m, 2H), 3.42-3.24
(m, 2H), 2.68-2.45 (m, 2H), 2.42 (s, 3H).
IR (KBr): 3358, 2928, 1387, 1219, 1036, 761cm"1
CI-MS (m/e): 350 (M+l)
Example 47:
4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-3,6-dihydro-2i-T-pyridine-l-carboxylic acid tert-butyl ester
Figure imgf000129_0001
To a solution of 4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6-difluorophenyl]-3,6- dihydro-2H-pyridin-l -carboxylic acid tert-butyl ester (100 mg, 0.26 mmol), obtained in example 44, in THF (10 mL) was added triethylamine (0.07 mL) and brought the reaction temperamre down to 0 °C. To this solution added carbon disulphide (0.02 mL, 0.31 mmol) and allowed the reaction mixmre to stir at the same temperamre for 4 hours, after which ethylchloroformate (0.02 mL, 0.26 mmol) was added and the reaction was continued for a further 1 hour at 0 °C . The solvent was removed on a rotavapor and the residue was dissolved in methanol (15 mL). The mixmre was refluxed for 12 hours. Methanol was removed by evaporation and the residue was chromatographed over silica gel (25% ethyl acetate/pet.ether) to obtain the desired product as a creamy solid (61 mg, 52%). Η NMR (CDC13, 200 MHz): δ 8.16 and 7.87( two s, IH, in 3: 1 ratio), 7.35 (d, J= 7.3Hz, 2H), 7.09-6.87 (m, IH), 6.00-5.80 (m, IH), 4.92 and 4.67 (two d, J = 5.9 Hz, 2H,in 3: 1 ratio), 4.24-4.02 (m, 2H), 3.98 (s, 3H), 3.76-3.32 and 3.32-3.20 ( two m, 2H in 6: 1 ratio), 2.54-2.34 (m, 2H), 1.50 (s, 9H).
IR (KBr): 3442, 1692, 1515, 1423, 1239, 1161, 1116, 1015, 854 cm"1 CI-MS (m/e): 466 (M+l), 434, 410, 378.
Example 48:
{l-[3,5-Difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-l_f/-[l,2,3]triazol-4- ylmethyl}-thiocarbamic acid O-methyl ester:
Figure imgf000129_0002
A 60% solution of trifluoroacetic acid in dichloromethane (5 mL) was added to 4- {2,6-difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]-phenyl}-3,6- dihydro-2H-pyridine-l -carboxylic acid tert-butyl ester (60 mg, 0.12 mmol), obtained in example 47, and allowed to stir at 25-35 °C for 3 hours. Toluene (15 mL) was added into
the reaction mixture and evaporated to dryness under vacuum. The residue was purified by column chromatography over silica gel (9%>methanol-chloroform) to get a brown solid
(45 mg, 95%)
Melting Point : 120-122 °C.
Η NMR (CDCl3+DMSO-d6, 200 MHz): δ 9.20-9.02 (m, IH), 8.39 and 8.30 (two s, IH, rotamers in 3: 1 ratio), 7.49 (d, J = 7.8 Hz, 2H), 5.98-5.88 (m, IH), 4.85 (d, J = 5.4 Hz,
2H), 4.62-4.50 (m, IH), 4.05-3.98 (two s, 3H, rotamers in 1 :3 ratio), 3.80-3.68 (m, 2H),
3.34-3.16 (m, 2H), 2.64-2.44 (m, 2H)
IR (KBr): 3432, 1680, 1414, 1203 cm"1
CI-MS (m e): 366 (M+l), 334, 318
Example 49:
2-{l-[4-(l-Acrolyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenyl}-l_?ϊ-[l,2,3] triazole-4-yl} isoindole-l,3-dione
Figure imgf000130_0001
To an ice cooled solution of 2-{l-[3,5-difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)- phenyl]-lH-[l,2,3]triazol-4-yl methyl }-isoindole-l, 3 -dione (1.08 grams, 2.37 mmol), obtained in example 42, in dichloromethane (20 mL), was added triethylamine (0.5 mL) followed by acryloyl chloride (0.231 mL, 2.85 mmol) and then mixture was stirred at 25-
35 °C for 12 hours. The reaction mixture was diluted with dichloromethane (40 mL) and
washed with water followed by brine. Evaporation of the organic layer and purification of the resulting residue by flash chromatography (1% methanol-chloroform) yielded the desired compound (800 mg, 71%) as a white solid.
Η NMR (CDC1 , 200 MHz): δ 8.02 (s, IH), 7.90-7.85 (m, 2H), 7.75-7.71 (m, 2H), 7.33
(d, J = 7.8 Hz, 2H), 6.70-6.56 (m, IH), 6.55-6.22 (m, IH), 6.00-5.80 (m, IH), 5.79-5.62
(d, J = 11.7 Hz, IH), 5.07 (s, 2H), 4.32-4.26 (m, 2H), 3.89-3.77 (m, 2H), 2.56-2.38 (m,
2H).
IR (KBr): 2925, 1721, 1642, 1434, 1045, 713 cm"1
CI-MS (m e): 476 (M+l)
Example 50: 2-(l-{4-[2,3-Dihydroxy-propionyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro- phenyI}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione
Figure imgf000131_0001
The title compound was prepared from 2-{l-[4-(l-acryloyl-l,2,3,6-tetrahydro- pyridin-4-yl)-3,5-difluoro-phenyl}-lH-[l,2,3]triazole-4-yl}isoindole-l,3-dione (500 mg, 1.05 mmol), obtained in example 49, following the same procedure as described for the preparation of 2-(l-{4-[4-(2,3-dihydroxy-propionyl)-piperzin-l-yl]-3-fluoro-phenyl}-lH- [l ,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione (Example 15), in 56% yield. Η NMR (CDCl3+DMSO-d6, 200 MHz): δ 8.47 (s, IH), 7.90-7.64 (m, 4H), 7.52 (d, J = 8.0 Hz, 2H), 6.00-5.82 (m, IH), 5.04 (s, 2H), 4.57-4.20 (m, 5H), 3.90-3.60 (m, 4H), 2.40- 2.20 (m, 2H)
IR (KBr): 3423, 2926, 1716, 1631, 1396, 1047, 858 cm"1 CI-MS (m/e): 510 (M+), 480, 422.
Example 51:
2-(l-{4-[4,4-Dimethyl-[l,3]dioxolane-2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- 3,5-difluoro-phenyl}-l_r7-[1.2.3]triazol-4-ylmethyl)-isoindoIe-l,3-dione :
Figure imgf000131_0002
The title compound was prepared from 2-(l-{4-[l,2,3-dihydroxy-propionyl)- l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)- isoindole-l,3-dione (500 mg, 0.98 mmol), obtained in example 50, following the same procedure as described for the preparation of 2-(l-{4-[4-(2,2-dimethyl-[l,3]dioxolane-4- carbonyl)-piperazin-l-yl]-3-fluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3- dione (Example 18), in 84% yield.
Η NMR (CDCh, 200 MHz): δ 8.01 (s, IH), 7.90-7.85 (m, 2H), 7.7.5-7.7.1 (m, 2H), 7.33 (d, J= 7.8 Hz, 2H), 5.99-5.82 (m.lH), 5.07 (s, 2H), 4.70 (t, J= 6.2 Hz, IH), 4.60-4.22 (m, 2H), 4.22-3.84 (m, 3H), 3.82-3.60 (m, IH), 2.60-2.38 (m, 2H), 1.42 (s, 6H) IR (KBr):.1719, 1633, 1454, 1396, 1045, 859, 758 cm"1 CI-MS (m e): 550 (M+), 377, 148
Example 52:
{4-[4-(4-Aminomethyl-[l,2,3]triazol-l-yl)-2,6-difluoro-phenyl]-3,6-dihydro-2^- pyridin-l-yl}-(4,4-dimethyl-[l,3]dioxoIane-2-yI)-methanone
Figure imgf000132_0001
The title compound was prepared from 2-(l-{4-[4,4-dimethyl-[l,3]dioxolane-2- carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}-l-t_'-[1.2.3]triazol-4- ylmethyl)-isoindole-l,3-dione (320 mg, 0.58 mmol), obtained in example 51, following the same procedure as described for the preparation of {4-[4-(4-aminomethyl- [l,2,3]triazol-l-yl)-2-fluoro-phenyl]-piperazin-l-yl}-(2,2-dimethyl-[l,3]dioxolan-4- yl)methanone (Example 19).
Η NMR (CDC13+ DMSO-d6, 200 MHz): δ 8.40 (s, IH), 7.50 (d, J = 7.8 Hz, 2H), 5.99- 5.86 (m, IH), 4.90-4.78 ( , IH), 4.50-4.20 ( , 3H), 4.20-4.06 (m, 2H), 4.05-3.84 (m, 2H), 3.84-3.67 (m, IH), 2.50 (m, 2H), 1.40 (s, 6H) IR (KBr): 3433, 2924, 1635, 1450, 1235, 1027, 858 cm"1 CI-MS (m e): 420 (M+), 163
Example 53:
_V-(l-{4-[l-(2,2-Dimethyl-[l,3]dioxolane-4-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-
3,5-difluoro-phenyl}-l_r7-[l,2,3]triazol-4-ylmethyl)-thioacetamide
F s
To an ice cooled solution of{4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6- difluoro-phenyl]-3,6-dihydro-2H-pyridin-l-yl}-(4,4-dimethyl-[l,3]dioxolane-2-yl)- methanone (120 mg, 0.285 mmol), obtained in example 52, in THF (15 mL) was added triethylamine (0.59 mL, 0.516 mmol) and ethyl dithioacetate ( 0.36 mL, 0.314 mmol). The reaction was left to stir at 25-35 °C for 12 hours. Solvent was removed under reduced pressure and the residue was purified by chromatography over silica gel (60% ethyl acetate/pet.ether) to get the title compound as a white solid (50 mg, 37%>).
Η NMR (CDC13, 200 MHz): δ 8.38-8.21 (m, IH), 8.16 (s, IH), 7.35 (d, J= 7.8 Hz, 2H),
5.96-5.82 (m, IH), 5.00 (d, J = 5.4Hz, 2H), 4.75 (t, J = 6.3 Hz, IH), 4.60-4.27 (m, 2H),
4.22-4.08 (m, 2H), 4.08-3.91 (m, IH), 3.90-3.60 (m, IH), 2.60 (s, 3H), 2.60-2.30 (m, 2H),
1.43 (s, 6H)
IR(KBr): 3440, 1633, 1453, 1043, 858 cm"1
CI-MS (m/e): 478 (M+l), 405, 350, 294, 228
Example 54:
N-(l-{4-[l-(2,3-Dihydroxy-propionyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro- phenyl}-l_f7-[l,2,3]triazol-4-ylmethyl)-thioacetamide :
Figure imgf000133_0001
To a solution of -V"-(l-{4-[l-(2,2-dimethyl-[l,3]dioxolane-4-carbonyl)-l,2,3,6- tetrahydro-pyridin-4-yl]-3,5-difluoro-ρhenyl}-lH-[l,2,3]triazol-4-ylmethyl)- thioacetamide (180 mg, 0.376 mmol), obtained in example 53, in THF (8 mL) and added
IN HCI (2 mL). And mixmre was allowed to stand at 25-35 °C for 6 days. Evaporated the
solvent on a rotavapour and purified the residue by column chromatography over silica gel (methanol/chloroform, 0.03: 1) to obtain the desired product as a white solid (80 mg, 49%)
Melting Point : 158 °C
Η NMR (DMSO-d6, 400 MHz): δ 10.54-10.44 (m, IH), 8.88 (s, IH), 7.85 (d, J = 8.4 Hz, 2H), 6.01-5.98 (m, IH), 5.08-4.99 (m, IH), 4.84 (d, J = 5.4 Hz, 2H), 4.78-4.70 (m, IH), 4.45-4.20 (m, 2H), 4.20-4.16 (m, IH), 3.95-3.63 (m, 2H), 3.62-3.50 (m, IH), 3.50-3.40 (m, IH), 2.50-2.30 (m, 2H), 2.49 (s, 3H) IR (KBr): 3421, 1756, 1638, 1241, 1055, 1025 cm"1 CI-MS (m/e): 438 (M+l), 420, 260
Example 55:
(l-{4-[l-(2,2-Dimethyl-[l,3]dioxolane-4-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- 3,5-difluoro-phenyl}-li?-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000134_0001
To a solution of{4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6-difluoro-phenyl]- 3,6-dihydro-2H-pyridin-l-yl}-(4,4-dimethyl-[l,3]dioxolane-2-yl)-methanone (300 mg, 0.72 mmol), obtained in example 52, in THF (15 mL) was added triethylamine (0.19 mL, 1.43 mmol) and brought the reaction temperamre down to 0 °C . To this solution added carbon disulphide (0.052 mL, 0.86 mmol) and allowed the reaction mixmre to stir at the same temperature for 4 hours, after which methylchloroformate (0.06 mL, 0.72 mmol) was added and the reaction was continued for another 1 hour at 0 °C The solvent was removed on a rotavapor. Methanol (15 mL) was added to the residue and the mixture was refluxed for 12 hours. Methanol was removed by evaporation and the residue was chromatographed over silica gel (ethyl acetate/pet.ether, 7:3) to obtain the desired product as a cream color solid (256 mg, 73%).
Η NMR (CDC13, 200 MHz): δ 8.07 (s, IH), 7.32 (d, J =7.8 Hz, 2H), 6.89-6.76 (m, IH), 5.96-5.83 (m, IH), 4.89 (d, J = 5.9 Hz, 2H), 4.70 (t, J = 6.3 Hz, 2H), 4.56-4.40 (m, IH), 4.40-4.24 (m, IH), 4.24-4.04 (m, 2H), 3.97 (s, 3H), 3.84-3.58 (m, IH), 2,50-2.37 (m, 2H), 1.53 (s, 3H), 1.34 (s, 3H)
IR(KBr): 2926, 1634, 1512, 1454, 1203, 3413, 858 cm"1 CI-MS (m/e):.494 (M+l), 462
Example 56:
{4-[l-((4S)2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4- yl)-3-flouro-phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000134_0002
N, N-Disopropylamine (0.05 mL, 0.289 mmol.), prop-2-ynyl-thiocarbamic acid-O- methyl ester (100 mg, 0.210 mmol), obtained in preparation 1, and copper iodide (28 mg, 0 .144 mmol) were added to a solution of [4-(4-Azido-2-fluoro-phenyl)-3,6-dihydro-2H- pyridin-l-yl]-((4S)-2,2-dimethyl-[l,3] dioxolan-4-yl)-methanone (100 mg, 0.289 mmol.), obtained in preparation 30, in DMF (5 mL) and stirred at 25-35 °C for 2 hours. The
solvent was removed partially under reduced pressure. The residual solvent was diluted with ethyl acetate (5 mL) and washed with water followed by brine. The organic layer was dried over anhydrous sodium sulphate and evaporated under vacuum. The residue was purified by column chromatography (0.1:1 methanol/chloroform) to give the title product (250 mg, 44%).
Η NMR (CDC13, 200MHz): δ 8.00 and 7.92 (2s, IH, rotamers in 3: 1 ratio), 7.59-7.342 (m, 2H), 7.12-6.98 (m, IH), 6.12-6.00 (m, IH), 4.92 (d, J=5.8Hz, 2H), 4.80-4.60 (m, IH), 4.56-4.26 (m, 2H), 4.26-2.08 (m, 2H), 4.08-3.90 (m, 4H), 3.80-3.60 (m, IH), 2.72-2.42 (m, 2H), 1.43 (s, 6H)
IR (KBr): 3250, 2937, 1639, 1453, 1370, 1207, 1152, 1046, 871, 757 cm"1 CI-MS (m/e): 476(M+1), 444 (M-31)+
Example 57:
{4-[l-((4R)-2-2-Dimethyl-[l, 3] dioxoIane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4- yl)-3-flouro-phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000135_0001
Using the same procedure as described for the preparation of {4-[l-((4S)2-2- Dimethyl-[1, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3-flouro- phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester, obtained in example 56, the title product (250 mg, 73%o) was obtained as a white solid (250 mg, 44%) from [4-(4-azido-2-fluoro-phenyl)-3,6-dihydro-2H-pyridin-l-yl]-((4R)-2,2-dimethyl- [l ,3]dioxolan-4-yl)-methanone (250 mg, 0.723 mmol), obtained in preparation 31. Η NMR (CDCI3, 400MHz): δ 8.13 and 8.00 (2s, IH, rotamers in 4: 1 ratio), 7.59-7.48 (m, 2H), 7.39 (t, J=7.8Hz, IH), 6.93-6.85 (m, IH), 6.10-6.02 (m, IH), 4.92 & 4.66 (two d, 2H, rotamers in the ratio 3: 1), 4.73 (dd, J,=6.3Hz, J2=13.3Hz, IH), 4.55-4.45 (m, IH), 4.45- 4.27 (m, IH), 4.20-4.10 (m, 2H), 4.00 (s, 3H), 4.12-3.92 (m, 2H), 3.80-3.67 (m, IH), 2.60-2.48 (m, 2H), 1.48 (s, 6H) IR (Neat): 3248, 1639, 1452, 1207, 1048, 871 cm"1 CI-MS (m e): 476 (M+l), 444 (M-31)+
Example 58:
(l-{4[l-((4S)-2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin- 4-yl)-3, 5-diflouro-phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester
Figure imgf000136_0001
Using the same procedure as described for the preparation of {4-[l-((4R)-2-2- Dimethyl-[1, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3-flouro- phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (Example 57), the title compound (250 mg) was obtained from [4-(4-azido-2, 6-difluoro-phenyl)-3, 6- dihydro-2H-pyridin-l-yl]-((4S)-2, 2-dimethyl-[l, 3] dioxolan-4-yl)-methanone (420 mg), obtained in preparation 32.
Η NMR (CDC13, 200MHz): δ 8.12 and 7.88 (2s, IH, rotamers in 3:1 ratio), 7.36(d, J=7.8 Hz, 2H), 7.05-6.88 (m, IH), 6.06-5.88 (m,lH), 4.92-4.68 (two d, J=5.8 Hz, 2H, rotamers in the ratio 3: 1), 4.75 (t, J=6.3 Hz, IH), 4.60-4.48 (m, IH), 4.48-4.30 (m, IH), 4.30-4.17 (m, 2H), 4.12 & 4.00 (two s, 3H, rotamers in the ratio 1 :3), 4.10-3.92 (m, IH), 3.85-3.62 (m, IH), 2.80-2.38 (m, 2H), 1.43 (s, 6H)
IR (KBr): 3378, 3139, 2361, 1636, 1455, 1283, 1074, 987, 857 cm"1 CI-MS (m/e): 494 (M+l), 462 (M-31)+
Example-59:
(l-{4[l-((4R)-2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4- yI)-3, 5-diflouro-phenyl}-lH-[l, 2, 3] triazol-4-yl-methyl)-thiocarbamic acid O-methyl ester
Figure imgf000136_0002
Using the same procedure as described for the preparation of {4-[l-((4S)2-2- Dimethyl-[1, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3-flouro- phenyl} -1H-[1, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (Example 56), the title compound (460 mg) was synthesized from [4-(4-azido-2, 6-difluoro-phenyl)-3, 6- dihydro-2H-pyridin-l-yl]-((4R)-2, 2-dimethyl-[l,3] dioxolan-4-yl)-methanone, which is obtained in preparation 33.
Η NMR (CDC13, 200 MHz): δ 8.02 and 7.87(two s, rotamers in the ratio 3: 1, IH), 7.38 (d, J= 7.3 Hz, 2H), 7.01 -6.92 (m, IH), 6.01-5.90(m, IH), 4.92 & 4.68(two d, J=6.3Hz, rotamers in the ratio 3: 1, 2H), 4.74(t, J=6.3Hz, IH), 4.30-4.17(m, 2H), 4.12 & 4.00(two s, rotamers in the ratio 1 :3, 3H), 4.10-3.92(m, IH), 3.85(m, IH), 2.75-2.35(m, 2H), 1.43(s, 6H). IR (Neat): 3257, 2923, 1633, 1512, 1453, 1205, 1148, 1047, 987 cm"1 CI-MS (m/e): 494 (M+l)
Example 60:
(l-{4-[l-(2,3-Dihydroxy-propionyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro- phenyl}-l_f/-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000137_0001
To a solution of (l-{4-[l-(2,2-dimethyl-[l,3]dioxolane-4-carbonyl)-l,2,3,6- tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (256 mg, 0.52 mmol), obtained in example 55, in THF ( 8 mL) added
IN HCI (3 mL) and reaction mixmre was allowed to stand at 25-35 °C for 6 days.
Evaporated the solvent on a rotavapour and purified the residue by column chromatography over silica gel (methanol/chloroform, 0.04: 1) to furnish the desired product as a white solid (180 mg, 77%>)
Melting Point: 132-134 °C
Η NMR (CDCI3, 400 MHz): δ 9.04-8.98 and 8.98-8.88 (two m, IH in 1 :2 ratio), 8.35 and
8.25 (two s, IH in 4: 1 ratio), 7.48 (d, J - 7.8 Hz, 2H), 5.98-5.88 (m, IH), 4.86 and 4.60
(two d, J = 5.9 Hz, 2H in 4:1 ratio), 4.56-4.45 (m, IH), 4.42-4.32 (m, IH), 4.32-4.18 (m,
2H), 4.07 and 3.98 (two s, 3H, rotamers inl: 4 ratio), 3.84-3.66 (m, 5H ), 2.58-2.48 (m,
2H)
IR (KBr):3428, 2927, 1637, cm"1
CI-MS (m/e): 454(M+1), 422, 380 Example 61:
(l-{4-[l-(2(S), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]-3-fluoro- phenyl}-lH-[l, 2, 3] triazol-4-yImethyl)-thiocarbamic acid O-methyl ester
Figure imgf000138_0001
To a solution of {4-[l-((4S)-2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l,2,3,6- tetrahydro-pyridin-4-yl)-3-flouro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (200 mg, 0.42 mmol.), obtained in example 56, was added 2N HCI (5 mL). The reaction mixmre was kept at 25-35 °C for 48 hours. The solvent was removed
under reduced pressure and the crude residual product was purified by column chromatography (0.1 :1 methanol: chloroform) to get the product as a brown solid (130 mg, 71%).
Η NMR (CDC13, 200MHz): δ 9.25-9.10 ( m, IH), 8.36& 8.27 (s, IH, rotamers in the ratio 3: 1), 7.69-7.50 (m, 2H), 7.48-7.38 (m, IH), 6.18-6.03 (m, IH), 4.84 & 4.57 (two d,
2H, rotamers in the ratio 3: 1), 4.54-4.32 (m, 3H), 4.34-4.21 (m, 2H), 4.04 & 3.96 ( two s,
3H, rotamers in the ratio 3:1), 3.83-3.60(m, 4H), 2.72-2.50 (m, 2H)
IR (KBr): 3423, 2926, 210, 1623, 1541, 1541, 1438, 1231, 1044, 867, 812 cm"1
Example 62: l-{4-[l-(2(R), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]-3-fluoro- phenyI}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid 0-methyl ester
Figure imgf000138_0002
{4-[l-((4R)-2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin- 4-yl)-3-flouro-phenyl}-lH-[l , 2, 3] triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (250 mg, 0.526 mmol.), obtained in example 57, was reacted using the same procedure as described for the preparation of (l-{4-[l-(2(S), 3-dihydroxy-propionyl)-l, 2,3,6- tetrahydro-pyridin-4-yl]-3-fluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (Example 61), to yield the desired product (140 mg, 61%) as a brown solid (140 mg, 61%)
Η NMR (CDC13, 200MHz): δ 8.33 and 8.22 (2s, IH, rotamers in 3:1 ratio), 7.69-7.50 (m,
2H), 7.48-7.38 (m, IH), 6.18-5.98 (m, IH), 4.85 & 4.57 ( two d, 2H, rotamers in the ratio
3:1), 4.54-4.32 (m, 3H), 4.32-4.25 (m, 2H), 4.01 & 3.97 (two s, 3H, rotamers in the ratio
1 :3), 3.80-3.58 (m, 4H), 2.72-2.49 (m, 3H).
IR (KBr): 3424, 2925, 1626, 1402, 1324, 1198, 1046, 867, 695cm"1
CI-MS (m/e): 404 (M-31)+
Example 63:
(l-{4-[l-(2(S), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]-3,5-difluoro- phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid 0-methyl ester
Figure imgf000139_0001
Using the same procedure as described for the preparation of (l-{4-[l-(2(S), 3- dihydroxy-propionyl)- 1 ,2,3,6-tetrahydro-pyridin-4-yl]-3-fluoro-phenyl}- 1 H-[ 1 ,2,3] triazol-4-ylmethyl)-thiocarbamic acid 0-methyl ester (Example 61), the title compound was synthesized from (l-{4[l-((4S)-2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l, 2, 3, 6- tetrahydro-pyridin-4-yl)-3,5-diflouro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester, obtained in example 58.
Η NMR (CDCI3, 200 MHz): δ 9.58-9.35 (m, IH), 8.63 and 8.60 (2s, IH, rotamers in 4:1 ratio), 7.65 (d, J=7.8Hz, 2H), 6.05-5.85 (m, IH), 4.79 (d,J=5.8Hz, 2H), 4.70-4.55 (m, IH), 4.55-4.22 (m, 2H), 4.39-4.19 (m, 2H), 4.01& 3.94 (two s, 3H, rotamers in the ratio 1 :3), 3.90- 3.75 (m, IH), 3.75-3.55 (m, 2H), 2.61-2.39 (m, 2H). IR (Neat): 3268, 2945, 1630, 1453, 1202, 1049, 859 cm'1 CI-MS (m e):. 454 (M+l), 422 (M-31)+
Example 64:
2-(l-{3,5-Difluoro-4-[l-(5-nitro-thiophene-2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4- yl]-phenyI}-lf_r-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione O 2005/082892
Figure imgf000140_0001
A solution of 5-nitro-thiophene-2-carboxylic acid (600 mg, 4.26 mmol) in thionyl- chloride (15 mL) was refuxed for 1 hour. Evaporated thionyl chloride on rotavapor and dried the residue under high vacuum. To a solution of the residue in dry THF (20 L) added triethylamine (0.29 mL, 2.1 mmol) and a solution of 2-{l-[3,5-difluoro-4-(l,2,3,6- tetrahydro-pyridin-4-yl)-phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione, (600 mg, 1.425 mmol), obtained in example 42, in dry THF (20 mL) under nitrogen atmosphere at 0 °C and left the reaction mixmre to stir at 25-35 °C for 12 hours. Diluted
the reaction mixmre with dichloromethane (30 mL) and washed with water followed by brine. Evaporated the organic solvent on a rotavapor and purified the residue over silica gel by column chromatography (1% methanol/chloroform) to obtain the title compound as a brown solid (659 mg, 80%)
Η NMR (CDC13, 400 MHz): δ 8.02 (s, IH), 7.90-7.85 (m, 3H), 7.76-7.7 (m, 2H), 7.36(d,
J = 7.9 Hz, 2H), 7.25 (d, J = 4.3 Hz, IH), 6.00-5.96 (m, IH), 5.08 (s, 2H), 4.41-3.97 (m,
2H), 3.97-3.86 (m, 2H), 2.63-2.57 (m, 2H)
IR (KBr): 3422, 2926, 1721, 1625, 1529, 1241, 768 cm"1
ES-MS (m/e): 577 (M+l), 301, 255
Example 65:
_V-(l-{3, 5-Difluoro-4-[l-(5-n_tro-thiophene-2-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-
4-yl]-phenyl}-l_?y-[l, 2, 3] triazoI-4-ylmethyl)-thioacetamide
Figure imgf000140_0002
The title compound was prepared from 2-(l-{3,5-difluoro-4-[l-(5-nitro-thiophene- 2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)- isoindole-l,3-dione (659 mg, 1.14 mmol), obtained in example 64, following the same procedure as described for the preparation of N-(l-{3-fluoro-4-[l-(5-nitro-furan-2- carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)- thioacetamide (Example 39), in 41% yield.. Η NMR (CD3OD, 200 MHz): δ 8.59 (s, IH), 7.98 (d, J = 4.0 Hz, IH), 7.62 (d, J = 7.5 Hz, 2H), 7.47 (d, J = 4.0 Hz, IH), 6.06-5.94(m, IH), 4.98-4.92 (m, 2H), 4.48-4.36 (m, 2H), 4.02-3.92 (m, 2H), 2.68-2.52 (m, 2H), 2.50 (s, 3H) IR (KBr): 3440, 1630, 1338, 1048, 640 cm"1 ES-MS (m e):. 505 (M+l)
Example 66:
2-{l-[4-(l-Acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenyl]-l_/-[l,2,3] triazoI-4-ylmethyl)-isoindole-l,3-dione
Figure imgf000141_0001
To an ice cooled solution of 2-{l-[3,5-difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)- phenyl]-lH-[l ,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (100 mg, 0.237 mmol), obtained in example 42, in dichloromethane (10 mL) was added triethylamine (0.008 mL) followed by acetyl chloride (0.02 mL, 0.285 mmol). The reaction mixmre was left to stir for 12 hours at 25-35 °C To the reaction mixture added dichloromethane (20 mL) and
washed with water followed by brine. Removed the solvent on rotavapor and chromatographed the residue over silica gel (2.5% methanol/chloroform) to obtain the required product as a white solid (80 mg, 73%).
Η NMR (CDCI3, 200 MHz): δ 8.01 (s, IH), 7.90-7.80 (m, 2H), 7.80-7.62 (m, 2H), 7.30 (d, J = 7.3 Hz, 2H), 5.99-5.81 (m, IH), 5.06 (s, 2H), 4.30-4.10 (m, 2H), 3.81 (t, J = 5.4 Hz, IH), 3.65 (t, J= 5.4 Hz, IH), 2.58-2.40 (m, 2H), 2.14 (s, 3H) IR (KBr): 3433, 1711, 1632, 1428, 1040, 856 cm"1 CI-MS (m/e):( M+l) 464
Example 67:
N-{l-[4-(l-acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenyl]-lJff-[l,2,3] triazol-4-ylmethyl)-thioacetamide
Figure imgf000141_0002
The title compound was prepared from 2-{l-[4-(l-acetyl-l,2,3,6-tetrahydro- pyridin-4-yl)-3,5-difluoro-phenyl]-l_t/"-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione (450 mg, 0.97 mmol), obtained in example 66, following the same procedure as described for the preparation of N-{l-[4-(l-acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3-fluoro-phenyl]- lH-[l ,2,3]triazol-4-ylmethyl}-thioacetamide in 50% yield. Melting Point: 182 °C .
Η ΝMR (CDCl3+DMSO-d6, 200 MHz):.δ 10.22-10.11 (m, IH), 8.44 (s, IH), 7.50 (d, J = 7.8 Hz, 2H), 6.01-5.89 (m, IH), 4.95 (d, J=5.4 Hz, 2H), 4.30-4.19(m, 2H), 3.81(t, J = 5.4 Hz, IH), 3.71 (t, J= 5.4 Hz, IH), 2.62-2.40 (m, 2H), 2.54 (s, 3H), 2.20 (s, IH) IR (KBr): 3437, 1615, 1451, 1035, 846 cm"1 CI-MS (m/e):. 392 (M+l), 363, 289
Example 68:
{l-[4-(l-Acetyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenyl]-l_r/- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000142_0001
To an ice cooled solution of l-{4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6- difluoro-phenyl]-3,6-dihydro-2H-pyridin-l-yl}-ethanone (200 mg, 0.60 mmol), in THF (10 mL) was added triethylamine (0.1 mL) followed by carbon disulphide ( 0.04 mL, 0.72 mmol) and allowed the reaction mixmre to stir at the same temperamre for 4 hours, after which ethylchloroformate (0.05 mL, 0.54 mmol) was added and the reaction was continued for another 1 hour at 0 °C . The solvent was removed under reduced pressure, methanol (15 mL) was added to the residue and the reaction mixture was refluxed for 12 hours. Methanol was removed by evaporation and the residue was chromatographed over silica gel (1% methanol/chloroform) to obtain the desired product as a white solid (68 mg, 28%).
Melting Point: 174 °C .
Η ΝMR (CDC13, 200 MHz): δ 8.12 and 7.88 (two s, IH, rotamers in 4: 1 ratio), 7.35 (d, J = 7.5 Hz, 2H), 7.08-6.90 (m, IH), 6.00-6.82 (m, IH), 4.91 and 4.70 (d, J = 5.9 Hz, 2H, rotamers in 4: 1 ratio), 4.35-4.20 (m, IH), 4.20-4.05 (m, IH), 4.10 and 4.00 (two s, 3H, rotamers in 1 :4 ratio), 383 (t, J= 5.4 Hz, IH), 3.68 (t, J= 5.4 Hz, IH), 2.50-2.40 (m, 2H), 2.18 (s, 3H) IR (KBr): 3420, 2925, 1633, 1453, 1273, 1053 CI-MS (m/e): 408 (M+l), 376
Example 69:
N-{l-[4-(l-Benzyl-l, 2, 3, 6-tetrahydro-pyridin-4-yl)-3, 5-difluro-phenyl]-li/-[l,2,3] triazol-4-ylmethyl}-thioacetamide
Figure imgf000143_0001
To a solution of 2-{l-[4-benzyl-l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro- phenyl]-lH-[l,2,3]triazole-4-ylmethyl isoindole-l,3-dione (500 mg, 0.97 mmol), obtained in example 41, in methanol (10 mL) was added hydrazinehydrate (0.42 mL) and refluxed the reaction mixture for 2 hours. The reaction mixmre was allowed to stir for 6 hours at ambient temperamre. Filtered the reaction mixture over a celite pad and the filtrates were concentrated. The residue was chromatographed over silica gel (9%> methanol/chloroform) to obtain { l-[4-(l -benzyl- 1,2,3, ό-tefrahydro-pyridin^-yl^.S-difluoro-phenyl]-!//- [l,2,3]triazol-4-yl}methylamine as a creamy solid (370 mg). To an ice cooled solution of this amine (100 mg, 0.263 mmol) in dry THF (3 mL) was added triethylamine (0.09 mL), followed by ethyl dithioacetate (0.08 mL, 0.657 mmol) and allowed the reaction mixmre to warm up to 25-35 °C and stirred for 12 hours. The reaction mixmre was concentrated
under vacuum and the residue purified by column chromatography over silica gel (40% ethyl acetate/pet.ether) to furnish the desired compound as a white solid (80 mg, 70%>).
Melting Point: 140-142 °C .
Η ΝMR (CDC13, 200 MHz):_δ 8.29-8.04 (m, IH), 8.11 (s, IH), 7.46-7.16 (m, 7H), 5.96-
5.84 (m, IH), 5.01 (d, J= 5.4 Hz, 2H), 3.68 (s, 2H), 3.28-3.18 (m, 2H), 2.82-2.63 (m, 2H),
2.62 (s, 3H), 2.48-2.38 (m, 2H)
IR (KBr): 3220, 1631, 1454, 1218, 1043, 757, 700, cm"1
CI-MS (m/e): 440 (M+l)
Example 70:
2-(l-[3.5-Difluoro-4-[l-(5-nitro-furan-2-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]- phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-isoindole-l, 3-dione
Figure imgf000144_0001
To a solution of 2-{l-[3,5-difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]- lH-[l ,2,3]triazol-4-yl methyl}-isoindole-l,3-dione (420 mg, 0.99 mmol), obtained in example 42, in dry dichloromethane (15 mL) was added triethylamine (0.413 mL, 2.97 mmol) and cooled the reaction mixmre to 0 °C . At this temperamre, added 2-nitro-5- furoyl chloride (210 mg, 1.19 mmol) to the reaction mixmre and stirred at 25-35 °C for 12
hours. The reaction mixture was diluted with dichloromethane (50 mL) washed with water followed by brine and then dried over sodium sulphate. The volatiles were removed under reduced pressure and the residue was purified by column chromatography over silica gel
(40% ethyl acetate/pet.ether) to get the title compound as a pale yellow solid (410 mg,
73%)
Η NMR (CDC13, 200 MHz): δ 8.02 (s, IH), 7.88-7.82 (m, 2H), 7.82-7.70 (m, 2H), 7.40-
7.20 (m, 4H), 6.02-5.84 (m, 2H), 5.06 (s, 2H), 4.62-4.42(m, IH), 4.42-4.30 (m, IH), 4.12-
3.90 (m, 2H), 2.70-2.50 (m, 2H)
IR (KBr):.1720, 1630, 1432, 1355, 1039, 713 cm"1
ES-MS (m/e): 561 (M+l)
Example 71:
7V-(l-[3.5-Difluoro-4-[l-(5-nitro-furan-2-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- phenyl}-l_? -[l, 2, 3] triazol-4-ylmethyl)-thioacetamide
Figure imgf000144_0002
The title compound was prepared from 2-(l-[3.5-difluoro-4-[l-(5-nitro-furan-2- carbonyl)- 1 ,2,3 ,6-tetrahydro-pyridin-4-yl]-phenyl} - lH-[ 1 ,2,3]triazol-4-ylmethyl)- isoindole-l,3-dione (410 mg, 0.732 mmol), obtained in example 70, following the same procedure as descibed for the prepration of /V-(l-{3-fluoro-4-[l-(5-nitro-furan-2- carbonyl)- 1,2,3, 6-tetrahydro-pyridin-4-yl]-ρhenyl}-lH-[l,2,3]triazol-4-ylmethyl)- thioacetamide (Example 39) in 48%> yield. Melting Point: 193 °C . Η NMR (CDCI3, 400 MHz): δ 8.32 -8.21 (m, IH), 8.19 (s, IH), 7.39-7.36 (m, 3H), 7.30- 7.22 (merged with CDC13 peak, IH), 6.02-5.98 (m,lH), 5.05 (d, J = 5.4 Hz, 2H), 4.70- 4.58 (m, IH), 4.50-4.40 (m, IH), 4.10-3.90 (m, 2H), 2.70-2.60 (m, 2H), 2.60(s, 3H) IR (KBr): 1630, 1529, 1437, 1355, 1037, 846 cm"1 CI-MS (m/e): 489 (M+l), 457, 350
Example 72: l-{3.5-Difluoro-4-[l-(5-nitro-furan-2-carbonyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]- phenyl}-l/y-[l, 2, 3] triazol-4-ylmethyI)-thiocarbamic acid O-methyl ester
Figure imgf000145_0001
To an ice cooled solution of {4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6- difluoro-phenyl]-3,6-dihydro-2H-pyridin-l-yl}-(5-nitro-furan-2-yl)-methanone (150 mg, 0.345 mmol) in dry THF (10 mL), was added triethylamine (0.058 mL, 0.418 mmol) and carbon disulphide (0.025 mL, 0.418 mmol) and allowed the reaction mixmre to stir at 0 °C for 4 hours. Ethylchloroformate (0.39 mL, 0.418 mL) was then added to the reaction mixture and allowed to stir for another 1 hour at the same temperamre. The reaction mixmre was diluted with ethyl acetate (20 mL), washed with water followed by brine, and dried over sodium sulphate. Evaporated the organic layer under vacuum and passed the residue through a column of silicagel (50% ethyl acetate/pet.ether) and refluxed the compound attained in methanol (15 mL) for 12 hours. Methanol was removed on a rotavapor and the residue was purified by column chromatography over silica gel (40%) ethyl acetate/pet.ether) to get the title compound (60 mg, 63%>),. Melting Point: 210 °C.
Η NMR (CDCI3, 200 MHz): δ 8.11 (s, IH), 7.42-7.30 (m, 3H), 7.25 (merged with CDC13 peak, IH), 6.90-6.82 (m, IH), 6.02-5.90 (m, IH), 4.91(d, J = 5.7 Hz, 2H), 4.70-4.50 (m, IH), 4.48-4.32 (m, IH), 4.20-4.00(m, 2H), 4.00 (s, 3H), 2.67 (m, 2H) IR (KBr):.3408, 1628, 1029, 762 cm "' CI-MS (m/e):_ 505 (M+l), 473, 441
Example 73:
2-(l-{4-[l-(2-Benzyloxy-acetyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}- 1H-[1,2,3] triazol-4-ylmethyl)-isoindole-l,3-dione
Figure imgf000146_0001
To a solution of 2-{l-[3,5-difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]- lH-[l,2,3]triazol-4-ylmethyl}-isoindole-l,3-dione (350 mg, 0.831 mmol), obtained in example 42, was added dry dichloromethane (10 mL), triethylamine (0.346 mL, 2.49 mmol) and reaction mixmre was cooled down to 0 °C . Benzyloxy acetylchloride (0.155 mL, 0.997 mmol) was added at this temperamre and the reaction mixmre was left to stir at
25-35 °C for 12 hours. It was then diluted with chloroform (25 mL), washed with water
followed by brine, and dried over sodium sulphate. The chloroform layer was evaporated on rotavapor and the residue was chromatographed over silica gel (55% ethyl acetate/pet.ether) to obtain the desired product as a white solid (430 mg, 91%>) Η NMR (CDC13, 200 MHz): δ 8.02 (s, IH), 7.98-7.81 (m, 2H), 7.81-7.68 (m, 2H), 7.40- 7.20 (m, 7H), 6.00-5.80 (m, IH), 5.07 (s, 2H), 4.63 (s, 2H), 4.30-4.10(m, IH), 4.30 (s, 3H), 3.90-3.79 (m, IH), 3.78-3.60 (m, IH), 2.50-2.39 (m, 2H) IR (KBr): 1723, 1634, 1455, 1100, 719 cm"1 CI-MS (m/e): 570 (M+l), 464, 174
Example 74: l-{4-[4-(4-Aminomethyl-[l,2,3]triazol-l-yl)-2,6difluoro-phenyl]-3,6-dihydro-pyridin- l-yl]-2-benzyloxyethanone :
Figure imgf000146_0002
To a solution of 2-(l-{4-[ 1 -(2-benzyloxy-acetyl)- 1,2,3, 6-tetrahydro-pyridin-4-yl]- 3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole-l,3-dione (130 mg, 0.228 mmol), obtained in example 73, in methanol (5 mL) was added hydrazine hydrate (0.1 mL) and refluxed the reaction mixmre for 2 hours. Allowed the reaction mixture to stir for
8 hours at 25-35 °C. Filtered the precipitate over a celite pad and concentrated the filtrates
under reduced pressure. The residue was chromatographed over silica gel (5% methanol/chloroform) to obtain the required product (70 mg, 70%>) Η NMR (CDCI3, 200 MHz): δ 7.93 (s, IH), 7.47-7.16 (m, 7H), 6.02-5.80 (m, IH), 4.64 (s, 2H), 4.34-4.02 (m, 4H), 4.22 (s, 2H), 3.91-3.76 (m, IH), 3.76-3.63 (m, IH), 2.54-2.36 (m, 2H) IR (KBr):.3361, 2926, 1633, 1453, 1032, 858, 752 cm"1
Example 75:
Λ?-(l-{4-[l-(2-Benzyloxy-acetyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro- phenyl}-l -[l,2,3]triazoI-4-ylmethyl)-thioacetamide
Figure imgf000147_0001
To a solution of l-{4-[4-(4-aminomethyl-[l,2,3]triazol-l-yl)-2,6-difluoro-phenyl]- 3,6- dihydro-pyridin-l-yl]-2-benzyloxyethanone (125 mg, 0.285 mmol), obtained in example 74, in THF (10 mL) was added triethylamine (0.059 mL, 0.427mmol). Cooled the reaction mixture to 0 °C and added ethyl dithioacetate (0.036 mL, 0.313 mmol) and then allowed the reaction mixture to stir at 25-35 °C for 12 hours. Evaporated the solvent
on rotavapor and purified the residue by column chromatography over silica gel (40% ethyl acetate/pet.ether) to get the title compound as a white solid (70 mg, 50%>). Melting Point: 125 °C
Η NMR (CDCI3, 200 MHz): δ 8.58-8.44 (bs, IH), 8.16 (s, IH), 7.40-7.20 (m, 7H), 6.00- 5.82 (m, IH), 5.01 (d, J = 5.4 Hz, 2H), 4.63 (s, 2H), 4.28-4.18 (m, 2H), 4.26 (s, 2H), 3.86-3.78 (m, IH), 3.78-3.67 (m, IH), 2.60 (s, 3H), 2.58 (m, 2H) IR (KBr): 3242, 1634, 1453, 1217, 1039, 756 cm"1 CI-MS (m/e): 498 (M+l)
Example 76:
(l-{4-[l-(2-Benzyloxy-acetyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}- l//-[l,2,3]triazol-4-yImethy_)-thiocarbamic acid O-methyl ester
Figure imgf000147_0002
To an ice cooled solution of l-{4-[4-(4-aminomethyl-[l,2,3]triazol-lyl)-2,6- difluoro- phenyl]-3,6-dihydro-pyridin-l-yl]-2-benzyloxyethanone (220 mg, 0.50 mmol), obtained in example 74, in dry THF (15 mL) was added triethylamine (0.123 mL, 0.89 mmol) and carbon disulphide (0.054 mL, 0.89 mmol) and allowed the reaction mixmre to stir at 0 °C for 4 hours. Ethylchloroformate (0.085 mL, 0.89 mL) was then added to the reaction mixmre and allowed to stir for further 1 hour at the same temperamre. The reaction mixmre was then diluted with ethyl acetate (50 mL), washed with water followed by brine and dried over sodium sulphate. Evaporated the organic layer on rotavapor and passed the residue through a column of silica gel to remove minor impurities. The resulting isothiocyanate derivative was refluxed in methanol (15 mL) for 12 hours. Methanol was removed under vacuum and the residue was purified by column chromatography over silica gel (50% ethyl acetate/pet.ether) to afford the title compound as a pale yellow semisolid (70 mg, 65%).
Η NMR (CDC13, 200 MHz): δ 8.12 (s, IH), 7.44-7.18 (m, 7H), 7.00-6.85 (m, IH), 6.08- 5.82 (m, IH), 4.93 (d, J = 6.1 Hz, 2H), 4.64 (m, 2H), 4.26 and 4.12 (two s, 3H, rotamers in 4:1 raio), 4.23-4.18 (m, IH), 4.00 (s, 2H), 3.92-3.82 (m, IH), 3.80-3.62 (m, IH), 3.58- 3.40 (m, IH), 2.58-2.40 (m, 2H).
IR (KBr): 3393, 2927, 1632, 151 1, 1453, 1364, 1201, 1041, 858, 751 cm"1 CI-MS (m/e): 514 (M+l), 482.
Example 77:
2-(l-[3,5-Difluoro-4-[l-(5-nitro-furan-2-ylmethyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- phenyI}-l_f/-[l,2,3]triazol-4-ylmethyl)-isoindole-l, 3-dione
Figure imgf000148_0001
To a suspension of 2-{l-[3,5-difluoro-4-(l,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]- lH-[l,2,3]triazol-4-yl methyl} -isoindole-1, 3-dione (0.2 grams, 0.425 mmol) in dry THF (15 mL) was added molecular sieves (4 A0) followed by 5-nitro-2-furfural (87 mg, 0.618 mmol), obtained in example 42. The reactiom mixmre was stirred at 25-35 °C for 1.5
hours. Sodium triacetoxy borohydride (0.402 gram, 1.900 mmol) was added to the reaction mixture and then allowed to stir 9 to 13 hours at ambient temperamre. The reaction mixture was filtered and the residue was washed with dichloromethane. The organic layer was then washed with water and dried over sodium sulphate. The solvent was evaporated and the residue was purified by column chromatography over silica gel
(40% ethyl acetate/pet.ether) to give the desired product as a white solid (95 mg, 37%).
Η NMR (CDC13, 200 MHz): δ 8.01(s, IH), 7.94-7.82 (m, 2H), 7.82-7.68 (m, 2H), 7.40-
7.28 (m, 3H), 6.55 (d, J= 3.4 Hz, IH), 5.92-5.84 (m, IH), 5.08 (s, 2H), 3.81 (s, 2H), 3.36-
3.24 (m, 2H), 2.83(t, J= 5.6Hz, 2H), 2.58-2.44 (m, 2H)
IR (KBr): 3431, 3132, 2925, 2854, 1717, 1493, 1395, 1244 cm"1
CI-MS (m e): 547 (M+l), 422, 295, 222
Example 78
/V-(l-{3,5-Difluoro-4-[l-(5-nitro-furan-2-ylmethyl)-l,2,3,6-tetrahydro-pyridin-4-yl] phenyl}-l_f7-[l,2,3]triazol-4-ylmethyI)-thioacetamide
Figure imgf000149_0001
2-(l-[3,5-Difluoro-4-[l-(5-nitro-furan-2-ylmethyl)-l,2,3,6-tetrahydro-pyridin-4- yl]-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-isoindole-l, 3-dione (95 mg, 0.174 mmol), obtained in example 77, was suspended in methanol and hydrazine hydrate (0.07 mL) was added to the reaction mixmre. It was refluxed for 2 hours and brought to 25-35 °C
and stirred for 4 hours. The reaction mixmre was filtered and the residue washed with 5% methanol/chloroform (30 mL). The filtrate was then concentrated and the residue purified by column chromatography over silica gel (10% methanol/chloroform) to yield (l-{3,5- difluoro-4-[l-(5-nitro-furan-2-ylmethyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-phenyl}-l/ - [l,2,3]triazol-4-yl)methylamine as a cream colour sticky solid (40 mg). The amine prepared by following afore mentioned method (225 mg, 0.54 mmol) was taken in THF (10 mL) and cooled to 0 °C. To the reaction mixmre added triethylamine (0.15 mL, 1.08 mmol) followed by ethyl dithioacetate (0.07 mL, 0.649 mmol) and stirred for 10 hours at
25-35 °C. The reaction mixmre was concentrated under vacuum and purified by column
chromatography over silica gel (2 % methanol/chloroform) to afford the title compound as a white solid (110 mg, 43%) Melting Point: 120-122 °C Η NMR (CDCI3, 200 MHz): δ 8.12 (s, IH), 7.99-7.90 (m, IH), 7.40-7.28 (m, 3H), 6.56 (d, J = 3.5 Hz, IH), 5.96-5.84 (m, IH), 5.02 (d, J = 6.0 Hz, 2H), 3.83 (s, 2H), 3.36-3.28
(m, 2H), 2.85 (t, J= 5.5 Hz, 2H), 2.60 (s, 3H), 2.60-2.46 (m, 2H) IR (KBr): 3431, 2925, 2855, 1626, 1502 cm'1 CI-MS (m/e): 475 (M+l), 444, 350, 346
Example 79:
(l-{3,5-Difluoro-4-[l-(5-nitro-furan-2-ylmethyl)-l,2,3,6-tetrahydro-pyridin-4-yl]- phenyl}-l_f7-[l,2,3]triazol-4-yImethyl)-thiocarbamic acid O-methyl ester
Figure imgf000150_0001
( 1 - {3 ,5-difluoro-4-[ 1 -(5-nitro-furan-2-ylmethyl)-l ,2,3 ,6-tetrahydro-pyridin-4-yl]- phenyl}-lH-[l,2,3]triazol-4-yl)methylamine (225 mg, 0.910 mmol), was taken in THF (15 mL) and cooled to 0 °C . To the reaction mixmre was added triethylamine (0.14 mL, 1 mmol) followed by carbon disulphide (0.11 mL, 1.82 mmol) and allowed to stir for 4 hours at 0 °C. Ethyl chloroformate (0.09 L, 0.190 mmol) was then added to the reaction mixture and stirred for another 1 hour. The reaction mixture was then warmed to 25-35 °C
and concentrated under vacuum. The residue was chromatographed over silica gel (2% methanol/chloroform) and resulting isothiocyanate derivative was refluxed in methanol for 16 hours. Reaction mixmre was concentrated and the residue was purified by column chromatography over silica gel (1% methanol/chloroform) to yield the desired compound as a white solid (65 mg, 26%)
Melting Point: 156-158 °C .
Η NMR (CDCI3. 200 MHz): δ 8.01 (s, IH), 7.40-7.26 (m, 3H), 6.94-6.80 (m, IH), 6.55
(d, J = 3.5 Hz, IH), 5.96-5.84 (m, IH), 4.92 (d, J = 5.9 Hz, 2H), 4.00 (s, 3H), 3.82 (m,
2H), 3.38-3.24 (m, 2H), 2.84 (t, J= 5.5 Hz, 2H), 2.58-2.42 (m, 2H)
IR(KBr): 3426, 2925, 1502, 1456, 1351 cm"1
CI-MS (m/e): 491 (M+l), 459, 366
Example 80:
{l-[4-(l-cyanomethyl-l, 2, 3, 6-tetrahydro-pyridinyl)-3-fluoro-phenyI]-lH-[l, 2, 3] triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester
Figure imgf000151_0001
To a solution of [4-{4-azido-phenyl}-3, 6-dihydro-2H-pyridin-l-yl]-acetonitrile (0.04 grams, 0.16 mmol), obtained in preparation 26, in dry DMF (2 mL) was added N- Ethyldiisopropylamine (0.02 grams, 0.16 mmol), prop-2-ynyl-thiocarbamic acid-O-methyl ester (0.02 grams, 0.18 mmol) and copper iodide (0.015 grams, 0.08 mmol) were added.
The reaction mixmre was allowed to stir for 20 minutes at 25-35 °C. It was then diluted
with ethyl acetate (4 mL) and washed with an aqueous solution of ammonium chloride and ammonium hydroxide (1 : 1). The organic solvent was removed under vacuum and the residue was purified using column chromatography (0.2: 1 ethyl acetate/pet. Ether) to give the title compound as a white crystalline solid (0.04 grams, 65%>)
Η NMR (CDC13, 200MHz): δ 8.19 & 7.90(two s, IH , rotamers in the ratio 4: 1,), 7.60- 7.36(m, 3H), 7.00-6.82(m, IH), 6.17-6.00 (m, IH), 4.92 and 4.66 (2d, J=6.4 Hz, 2H, rotamers in 4:1 ratio), 4.12 & 4.00 (two s, 3H, rotamers in the ratio 1:3 ), 3.69 (s, 2H), 3.42-3.35 (m, 2H), 2.90 (t, J=5.4 Hz, 2H), 2.75-2.60 (m, 2H). IR (Neat): 2924, 1515, 1459, 123e0, 1146, 1045, 978, 875, 757 cm"1 CI-MS (m/e): 387(M+1)
Example 81:
(l-{4-[l-(2(R), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]-3,5- difluoro-phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid 0-methyl ester
Figure imgf000151_0002
(l-{4-[l-((4R)-2-2-Dimethyl-[l, 3] dioxolane-4-carbonyl)-l, 2, 3, 6-tetrahydro- pyridin-4-yl)-3, 5-diflouro-phenyl}-lH-[l, 2, 3] triazol-4-yl-methyl)-thiocarbamic acid O- methyl ester (300 mg, 0.61 mmol), obtained in example 59, was reacted using the same procedure as for (l-{4-[l-(2(S), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4- yl]-3-fluoro-phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)-thiocarbamic acid-O-methyl ester
(Example 61) to yield the desired product (130 mg, 47%).
Η NMR (CDC13, 200MHz): δ 9.63-9.52(m, IH), 8.78 and 8.70 (two s, rotamers in the ratio 3: 1, IH), 7.77 (d, J=7.8Hz, 2H), 6.02-5.85 (m, IH), 4.99-4.88(m, IH), 4.80-4.58 (m,
3H), 4.50-4.23( m, 3H), 4.23-4.10 (m, IH), 3.96 and 3.89 (two s, rotamers is the ratio 1:3,
3H), 3.96-3.65 (m, IH), 3.65-3.40 (m, 2H), 2.58-2.30 (m, 2H)
IR (Neat): 3345, 2943, 1630, 1512, 1453, 1201, 1048, 756, 619 cm"1
CI-MS (m/e):.454 (M+l), 422 (M-31)+
Example 82:
(l-{3,5-Difluoro-4-[4-(2-methylcarbamoyl-acetyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester ,
Figure imgf000152_0001
The title compound was prepared in 72% yield from 3-[4-(4-azido-2,6-difluoro- phenyl)- piperazin-l-yl]-N-methyl-3-oxo-propionamide (80 mg, 0.24 mmol), obtained in preparation 36, and prop-2-ynyl-thiocarbamic acid-O-methyl ester (37 mg, 0.29 mmol) by following the same procedure as described in example 1.
Η NMR (CDCI3 + CD3OD, 400 MHz): δ 8.91 and 8.82 (2t, J = 5.5 Hz, IH, rotamers in the ratio 1 :3), 8.25 and 8.13 (2s, IH, rotamers in the ratio 4:1), 7.65 (bs, IH ), 7.40 (d, J = 9.4 Hz, 2H, rotamers in the ratio 3:1), 4.85 and 4.58 (2s, 3H, rotamers in the ratio 1 :3), 3.76(t, J = 4.8 Hz, 2H), 3.71 (t, J = 4.6 Hz, 2H), 3.39 (s, 2H), 3.37-3.19 (m, 4H), 2.79 (d, J = 4.8 Hz, 3H).
IR (KBr): 3354, 2924, 1648, 1629, 1516, 1466, 1201, 1036, 858 cm"1. ES-MS (m/e): 490 (M++ 23), 468 (M++l)
Example 83:
4-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-2(S)- hydroxy-4-oxo-butyric acid methyl ester
Figure imgf000152_0002
The title compound was prepared from 2-hydroxy-succinic acid 1 -methyl ester (483 mg, 3.26 mmol) and [l-(3,5-Difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4- ylmethyl]-thiocarbamic acid O-methyl ester (1 gram, 2.72 mmol), obtained in example 6, by following the same procedure as described in example 27.
Η NMR (DMSO, 400 MHz): δ 9.67 - 9.62 (m, IH), 8.72 and 8.67 (2s, IH, rotamers in the ratio 3:1), 7.75 (d, J = 10.1 Hz, 2H), 5.54 (d, J = 6.3 Hz, IH ), 4.72 and 4.36 (2d, I = 5.5 Hz, 2H, rotamers in the ratio 2:1), 4.50 - 4.39 (m, IH), 3.94 and 3.89 (2s, 3H, rotamers in the ratio 1:3), 3.64 (s, 3H), 3.59 - 3.56 (m, 4H), 3.20 - 3.18 (m, 2H), 3.18 - 3.10 (m, 2H), 2.75 (d, 6.0 Hz, 2H).
IR (KBr): 3271, 2923, 1737, 1638, 1518, 1444, 1267, 1207, 856 cm"1. CI-MS (m/e): 499 (M++l), 467
Example 84:
2(S)-[3-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l- yl]-phenyl}-piperazin-l-yl)-3-oxo-propionyIamino]-3-hydroxy-propionic acid methyl ester
Figure imgf000153_0001
The title compound was obtained from 2(S)-{3-[4-(4-azido-2,6-difluoro-phenyl)- piperazin-l-yl]-3-oxo-propionylmino}-3-hydroxy-propionic acid methyl ester (200 mg, 0.47 mmol), obtained in preparation 37, by following the procedure as described in example 1.
Η NMR (DMSO, 400 MHz): δ 9.99 - 9.61 (m, IH), 8.72 and 8.67 (2s, IH, rotamers in the ratio 3:1), 8.44 (d, J = 7.8 Hz, IH), 7.74 (d, J = 9.9 Hz, 2H), 5.06 (t, J = 5.6Hz, IH), 4.72, 4.43 (d, J = 5.6 Hz, 2H, rotamers in the ratio 3: 1), 4.40 - 4.36(m, IH), 3.95 and 3.89 (2s, 3H, rotamers in the ratio 1 :3), 3.75 - 3.98 (m, 2H), 3.64 (s, 3H), 3.62 - 3.51 (m, 4H), 3.46 (d, J = 6.9 Hz, 2H), 3.19 - 3.17 (m, 2H), 3.16 - 3.10 (m, 2H).
IR (KBr): 3285, 1739, 1654, 1521, 1447.2, 1228, 1035, 859 cm"1. CI-MS (m/e): 556 (M++l), 538, 524, 506
Example 85: O 2005/082892
{l-[4-(4-Cyanomethyl-piperazin-l-yl)-3,5-difluoro-phenyI]-lH-[l,2,3]triazol-4- yImethyl}-thiocarbamic acid O-methyl ester
Figure imgf000154_0001
The title compound (400 mg, 27%) was synthesized from 4-(4-azido-2,6-difluoro- phenyl)-piperazine-l-carbonitrile (1 gram, 3.6 mmol), obtained in preparation 38, by following the procedure as described in example 1.
Η NMR (CDC13, 400 MHz): δ 8.04 and 7.80 (2s, IH, rotamers in the ratio 4: 1), 7.28 (d, J = 9.8 Hz, 2H), 6.92 (bs, IH ), 4.90 and 4.65 (2d, J = 5.8 Hz, 2H, rotamers in the ratio 4:1), 4.12, 3.99 (2s, 3H, rotamers in the ratio 1:4), 3.59 (s, 2H), 3.35 - 3.21 (m, 4H), 2.74 (t, J = 4.7 Hz, 4H).
IR (KBr): 3432, 2923, 1630, 1517, 1454, 1353, 1288, 1212, 1 131, 1027, 856, 617, 527 cm" . CI-MS (m/e): 376 (M+-31), 349
Example 86:
(l-{3,5-Difluoro-4-[4-(N-hydroxycarbamimidoylmethyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbaπ_ic acid O-methyl ester
Figure imgf000154_0002
To a stirred solution of {l-[4-(4-cyanomethyl-piperazin-l-yl)-3,5-difluoro- phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester (350 mg, 0.86 mmol), obtained in example 85, in ethanol (20 mL) was added hydroxylamine hydrochloride (239 mg, 3.44 mmol) and sodium carbonate (274 mg, 2.58 mmol) in minimum amount of water and refluxed for 9 to 13 hours at 60-70 °C. Ethanol was removed under vacuum and the residue was diluted with ethylacetate (20 mL) and washed with water, brine and dried over Na2S04. The solvent was removed under vacuum and the residue was purified by column chromatography (7:3 ethyl acetate/pet ether) to give the title compound (80 mg, 21%).
Η NMR (DMSO, 400 MHz): δ 9.65 - 9.61 (m, IH), 8.98 (s, IH), 8.70 and 8.66 (2s, lH,rotamers in the ratio 4:1), 7.71 (d, J = 9.9 Hz, 2H), 5.25 (s, 2H), 4.72 and 4.43 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 4: 1), 3.94 and 3.88 (2s, 3H, rotamers in the ratio 1 :4),
3.29 - 3.16 (m, 4H), 2.91 (s, 2H), 2.52 - 2.49 (m, 4H).
CI-MS (m/e): 441 (M++l), 425, 393, 369, 337
IR (KBr): 3394, 2924, 1672, 1517, 1458, 1228, 1 144, 1036, 860 cm"1.
Example 87:
(l-{3,5-Difluoro-4-[4-(2-lH-indol-3-yl-acetyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000155_0001
The title compound (130 mg, 54 %) was synthesized from (lH-indol-3-yl)-acetic acid (81 mg, 0.46 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol- 4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27.
Η NMR (CDC13, 400 MHz): δ 8.09 (s, IH), 8.01 and 7.76 (2s, IH, rotamers in the ratio 4: 1), 7.64 (d, J = 8.1 Hz, IH), 7.38 (d, J = 8.1 Hz, IH), 7.29 - 7.13 (m, 5H), 6.84 (bs, IH), 4.90 and 4.64 (d, J = 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :6), 3.90 (s, 2H), 3.82 - 3.78 (m, 2H), 3.63 - 3.58 (m, 2H), 3.23 - 3.18 (m, 2H), 3.10 - 3.01 (m, 2H).
IR (KBr): 3409, 2929, 1629, 1518, 1450, 1218, 1 148, 1034, 856, 745 cm"1. ES-MS (m/e): 548 (M++ 23), 526 (M++l)
Example 88:
(l-{3,5-Difluoro-4-[4-(2-pyridin-3-yl-acetyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000155_0002
The title compound (150 mg, 58%) was synthesized from l-[4-(4-azido-2,6- difluoro-phenyl)- piperazin-l-yl]-2-pyridin-3-yl-ethanone (190 mg, 0.53 mmol), obtained in preparation 39, by following the procedure as described in example 1. Η NMR (CDCI3, 400 MHz): δ 8.56 - 8.51 (m, 2H), 8.04 and 7.79 (2s, IH, rotamers in the ratio 3: 1) 7.66 (dd, Ji = 1.9 Hz, J2 = 6.0 Hz, IH), 7.33 - 7.26 (m, 3H), 6.94 (bs, IH),
4.90 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4: 1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 3.81 - 3.79 (m, 2H), 3.77 (s, 2H), 3.63 (t, J = 4.8 Hz, 2H), 3.22
- 3.20 (m, 2H), 3.19 - 3.14 (m, 2H).
IR (KBr): 3135, 2857, 1646, 1582, 1521, 1438, 1205, 1147, 1032, 850 cm"1.
ES-MS (m/e): 510 (M++ 23), 489 (M++2)
Example 89:
(l-{4-[4-(3(S),4-Dihydroxy-butyryl)-piperazin-l-yl]-3,5-difluoro-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000156_0001
To a stirred solution of 4-(4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino- methyl)-[l,2,3]triazol-l-yl]-phenyl}-piperazin-l-yl)-2(S)-hydroxy-4-oxo-butyric acid methyl ester (100 mg, 0.2 mmol), obtained in example 83, in methanol was added sodium borohydride (16 mg, 63.6 %>) portion wise at 0 °C . The reaction mixmre was stirred for 6 hours at same temperamre. Methanol was removed under vacuum and the residue was purified by column chromatography (2% methanol/chloroform) to yield the title compound (60 mg, 64%).
Η NMR (CDCI3, 400 MHz): δ 8.05 and 7.80 (2s, IH, rotamers in the ratio 5: 1), 7.31 (d, J = 9.1 Hz, 2H), 6.96 - 6.82 (m, IH), 4.90 and 4.65 (2d, J = 6.2 Hz, 2H, rotamers in the ratio 4: 1), 4.22 - 4.16 (m, IH), 4.1 1 and 4.00 (2s, 3H, rotamers in the ratio 1 :6), 3.78 - 3.73 (m, 3H), 3.62 - 3.56 (m, 3H), 3.25 - 3.19 (m, 4H), 2.64 - 2.52 (m, 2H). IR (KBr): 3358, 2924, 1624, 1500, 1445, 1229, 1033, 857, 754 cm"1. CI-MS (m/e): 471 (M++l), 453, 439, 421
Example 90:
[l-(4-{4-[2-(3,4-Dihydroxy-phenyl)-acetyl]-piperazin-l-yl}-3,5-difluoro-phenyl)-lH- [l,2,3]triazol-4-ylmethyI]-thiocarbamic acid O-methyl ester O 2005/082892
Figure imgf000157_0001
The title compound (200 mg, 57%) was synthesized from (3,4-dihydroxy-phenyl)- acetic acid (114 mg, 0.68 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27.
Η NMR (CDC13, 400 MHz): δ 8.03 and 7.83 (2s, IH, rotamers in the ratio 4:1), 7.25 (d, J = 8.9 Hz, 2H), 7.05 (t, J = 5.9 Hz, IH), 6.88 (d, J = 1.9 Hz, IH), 6.80 (d, 8.1Hz, IH), 6.60 (dd, Ji = 1.9 Hz, J2 = 8.1 Hz, IH), 4.89 and 4.66 (2d, J = 6.2 Hz, 2H, rotamers in the ratio 5:1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1:4), 3.78 (t, J = 4.6 Hz, 2H), 3.69 (s, 2H), 3.61 (t, J = 4.6 Hz, 2H), 3.22 - 3.18 (m, 2H), 3.12 - 3.06 (m, 2H). IR (KBr): 3255, 1624, 1519, 1445, 1282, 1231, 1035, 858 cm"1. ES-MS (m/e): 519 (M++l), 541 (M++ 23).
Example 91:
{l-[4-(4-Cyano-piperazin-l-yl)-3, 5- difluoro-phenyl]-lH-[l,2,3]triazol- 4-ylmethyl}- thiocarbamic acid O-methyl ester
Figure imgf000157_0002
To a solution of [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4- ylmethyl]-thiocarbamic acid O-methyl ester (500 mg, 1.36 mmol), obtained in example 6, and sodium acetate (602 mg, 7.34 mmol) in methanol (40 mL) was treated during 5 minutes, with a methanol (10 mL) solution of cyanogen bromide (173 mg, 1.63 mmol) at 0 °C and stirred at same temperamre for 2 hours. The methanol was removed under vacuum and the residue was washed with sodium bicarbonate and extracted with dichloromethane (DCM) and washed with water, dried over Na2S04 and concentrated and purified by column chromatography (3:7 ethyl acetate/petroleum ether) to give the title compound (120 mg, 23%).
Η NMR (CDCI3, 400 MHz): δ 8.05 and 7.80 (2s, IH, rotamers in the ratio 4: 1), 7.31 (d, J = 9.1 Hz, 2H), 6.95 - 6.85 (m, IH), 4.90 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1:5), 3.40 - 3.37 (m, 4H), 3.36 - 3.30 (m, 4H).
IR (KBr): 3283, 2215, 1518, 1451, 1384, 1331, 1204, 1139, 1040, 857, 756 cm"1. CI-MS (m/e): 394 (M++l), 362, 275
Example 92:
[l-(3,5-Difluoro-4-{4-[2-(3-hydroxyphenyl)-acetyl]-piperazin-l-yl}-phenyl)-lH- [l,2,3]triazol-4-yImethyl] -thiocarbamic acid O-methyl ester
Figure imgf000158_0001
-
The title compound (220 mg, 68%) was synthesized from 1 -[4-(4-azido-2,6- difluoro-phenyl)-piperazin-l-yl]-2-(3-hydroxy-phenyl)-ethanone (240 mg, 0.64 mmol), obtained in preparation 40, by following the procedure as described in example 1. Η NMR (CDC13, 400 MHz): δ 8.03 and 7.81 (2s, IH, rotamers in the ratio 4:1), 7.27 - 7.17 (m, 3H), 7.00 - 6.89 (m, IH), 6.84 (s, IH), 6.79 - 6.74 (m, 2H), 4.90, 4.65 (2d, J = 6.2 Hz, 2H, rotamers in the ratio 4:1), 4.11, 3.99 (2s, 3H, rotamers in the ratio 1 :4), 3.81 - 3.76 (m, 2H), 3.75 (s, 2H), 3.61 - 3.58 (m, 2H), 3.20 - 3.17 (m, 2H), 3.10 - 3.00 (m, 2H). IR (KBr): 3284, 1627, 1518, 1456, 1230, 1151, 1036, 857, 774 cm"1. ES-MS (m/e): 503 (M++l)
Example 93:
[l-(3,5-Difluoro-4-{4-[2-(4-hydroxyphenyl)-acetyl]-piperazin-l-yl}-phenyl)-lH- [l,2,3]triazol-4-ylmethyl] -thiocarbamic acid O-methyl ester
Figure imgf000158_0002
The title compound (79 mg, 40%) was synthesized from l-[4-(4-azido-2,6- difluoro-ρhenyl)-piperazin-l-yl]-2-(4-hydroxy-phenyl)-ethanone (150 mg, 0.40 mmol), obtained in preparation 41, by following the procedure as described in example 1. Η NMR (CDC13) 400 MHz): δ 8.03 and 7.78 (2s, IH, rotamers in the ratio 5:1), 7.28 (d, J = 9.5 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 6.88 - 6.83 (m, IH), 6.80 (d, J = 8.6 Hz, 2H), 5.02 (s, IH), 4.90 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :4), 3.77 (t, J = 4.8 Hz, 2H), 3.70 (s, 2H), 3.61 - 3.56 (m,
2H), 3.22 - 3.18 (m, 2H), 3.10 - 3.02 (m, 2H).
IR (KBr): 3380, 2923, 1624, 1516, 1444, 1231, 1149, 1035, 857 cm"1.
CI-MS (m/e): 471 (MA31), 384, 107
Example 94:
[l-(3,5-Difluoro-4-{4-[2-(2-nitro-phenyl)-acetyl]-piperazin-l-yl}-phenyl)-lH- [l,2,3]triazol-4-y!methyl]-thiocarbamic acid O-methyl ester
Figure imgf000159_0001
The title compound (450 mg, 79%) was synthesized from l-[4-(4-azido-2,6- difluoro-phenyl)-piperazin-l-yl]-2-(2-nitro-phenyl)-ethanone (430 mg, 1.07 mmol) obtained in preparation 42, by following the same procedure as described in example 1. Η NMR (CDCI3, 400 MHz): δ 8.13 and 8.11 (dd, J,=l .l Hz, J2 = 8.3 Hz, IH ), 8.04 and 7.80 (2s, IH, rotamers in the ratio 3:1), 7.62-7.58(m, IH), 7.47( t, J = 7.0 Hz, IH), 7.37(d, J = 7.5 Hz, IH), 7.31 (d, J = 9.4 Hz, 2H), 6.92-6.88 (m, IH), 4.91 and 4.65(2d, J=5.9Hz, 2H, rotamers in the ratio 4: 1), 4.12 (s, 2H), 4.00 (s,3H), 3.82-3.76 (m, 2H), 3.75-3.69(m, 2H), 3.39-3.30(m, 2H), 3.30-3.21(m, 2H).
IR (KBr): 3267, 1640, 1522, 1444, 1340, 1206, 1141, 1031, 859, 730 cm"1. CI-MS (m/e): 500 (M+-31), 383, 337
Example 95:
[l-(4-{4-[2-(2-Amino-phenyl)-acetyl]-piperazin-l-yl}-3, 5-difluoro-phenyl)-lH-[l, 2,3] triazol-4-ylmethyl] -thiocarbamic acid O-methyl ester
Figure imgf000159_0002
To a stirred solution of [l-(3,5-difluoro-4-{4-[2-(2-nitro-phenyl)-acetyl]-piperazin- l-yl}-phenyl)-lH-[l,2,3] triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester (200 mg, 0.38 mmol), obtained in example 94, and ammonium chloride (202 mg, 3.8 mmol) in ethanol: water (2:1) solution was heated to 80-90 °C and then added iron (63 mg, 1.13 mmol) portion wise and heated at same temperamre for 3 hours. Ethanol was removed under vacuum and the reaction mixmre was extracted with ethylacetate. The organic layer was washed with water (2 x 20 mL), brine and dried over Na2S0 . The organic layer was concentrated under vacuum and the residue was purified by column chromatography (1%
CH3OH/CHCI3) to give the title product (135 mg, 72 %).
Η NMR (CDCI3, 400 MHz): δ 8.03 and 7.78 (2s, IH, rotamers in the ratio 5: 1), 7.32 -
7.26 (m, 2H), 7.11 - 7.06(m, IH), 7.03 (d, J = 7.2 Hz, IH), 6.99 - 6.86 ( , IH), 6.73 (d, J
= 7.5 Hz, 2H), 4.90 and 4.64 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 5:1), 4.11 and 3.99
(2s, 3H, rotamers in the ratio 1 :5), 3.78 - 3.73 (m, 2H), 3.71 (s, 2H), 3.21 - 3.18 (m, 2H),
3.18 - 3.12 (m, 2H).
IR (KBr): 3355, 1525, 1517, 1457, 1205, 1147, 1035, 855, 753 cm"1.
CI-MS (m/e): 502 (M++l), 470, 452, 369
Example 96:
[l-(3,5-D_fluoro-4-{4-[2-(3-nitro-phenyl)-acetyl]-piperazin-l-yl}-phenyl)-lH- [l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000160_0001
The title compound (320 mg, 74 %) was synthesized from (3-nitro-phenyl)-acetic acid (148 mg, 0.82 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [l ,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester (300 mg, 0.82 mmol), obtained in example 6, by following the procedure as described in example 27. Η NMR (CDCI3, 400 MHz): δ 8.15 (dd, J, = 1.1 Hz, J2=6.9 Hz, 2H ), 8.05 and 7.81 (2s, IH, rotamers in the ratio 5:1), 7.63 (d, J=7.8 Hz, IH), 7.55-7.51 (m, IH), 7.3 l(d, J=9.1 Hz, 2H), 6.96 (t, J=5.4 Hz, IH), 4.90 and 4.65 (2d, J=6.1Hz, 2H, rotamers in the ratio 4: 1),4.1 1 and 3.99(2s, 3H, rotamers in the ratio 1:5), 3.87(s, 2H), 3.80 (t, J= 4.8 Hz, 2H), 3.65(t, J = 4.6 Hz, 2H), 3.25-3.18 (m, 4H).
IR (KBr): 3250, 1638, 1527, 1455, 1349, 1229, 1033, 856, 730 cm"1. CI-MS (m/e): 500 (M+-31), 470, 443, 413
Example 97:
[l-(4-{4-[2-(3-Amino-phenyl)-acetyl]-piperazin-l-yl}-3,5-difluoro-phenyl)-lH- [l,2,3]triazol-4-yImethyl]-thiocarbamic acid O-methyl ester
Figure imgf000161_0001
The title compound (200 mg, 71 %) was synthesized from [l-(3,5-difluoro-4-{4- [2-(3 -nitro-phenyl)-acetyl] -piperazin- 1 -yl} -phenyl)- 1 H-[ 1 ,2,3]triazol-4-ylmethyl]- thiocarbamic acid O-methyl ester (300 mg, 0.56 mmol), obtained in example 96, by following the procedure as described in example 95.
Η NMR (CDC13, 400 MHz): δ 8.02 and 7.78(2s, IH, rotamers in the ratio 5:1), 7.27(d, J=9.7 Hz, 2H), 7.1 l(t, J=8.1Hz, IH), 6.87-6.83(m, IH), 6.65-6.62(m, 2H), 6.58(dd, J, = 2.1 Hz, J2=7.8Hz, IH ), 4.90 and 4.64(2d, J=5.9Hz, 2H, rotamers in the ratio 5:1), 4.11 and 3.99(2s, 3H, rotamers in the ratio 1 :5), 3.77 (t, J=4.8 Hz, 2H), 3.69 (s, 2H), 3.56 (t, J=4.6 Hz, 2H), 3.22-3.18 (m, 2H), 3.08-3.01 (m, 2H). IR (KBr): 3358, 2924, 1629, 1518, 1461, 1230, 1151, 1038, 858 cm"1 ES-MS (m/e): 524 (M++ 23), 502 (M++l)
Example 98:
[l-(3,5-Difluoro-4-{4-[2-(4-nitro-phenyl)-acetyl]-piperazin-l-yl}-phenyl)-lH- [l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000161_0002
The title compound (460 mg, 71%>) was synthesized from l-[4-(4-azido-2,6- difluoro-phenyl)-piperazin-l-yl]-2-(4-nitro-phenyl)-ethanone (490 mg, 1.22 mmol), obtained in preparation 43, by following the procedure as described in example 1. !H NMR (CDCI3, 400 MHz): δ 8.21 (d, J=8.6 Hz, 2H), 8.04 and 7.90 (2s, IH, rotamers in the ratio 5:1), 7.45 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 9.1 Hz, 2H), 6.92 (bs, IH), 4.90 and 4.65(2d, , J=5.9 Hz, 2H, rotamers in the ratio 3:1), 4.1 1 and 3.99(2s, 3H, rotamers in the ratio 1 :5), 3.87 (s, 2H), 3.79 (t, J = 4.8 Hz, 2H), 3.61(t, J = 4.6 Hz, 2H), 3.23-3.20(m, 2H), 3.18-3.15(m, 2H) .
IR (KBr): 3279, 1643, 1515, 1451, 1343, 1280, 1226, 1207, 1149, 1032, 857 cm'1. CI-MS (m/e): 500 (M -31), 470
Example 99: [l-(4-{4-[2-(4-Amino-phenyl)-acetyl]-piperazin-l-yl}-3,5-difluoro-phenyl]-piperazin- l-yl}-phenyl)-lH-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester
Figure imgf000162_0001
The title compound (65 mg, 69 %) was synthesized from [l-(3,5-difluoro-4-{4-[2- (4-nitro-phenyl)-acetyl]-piperazin-l-yl} -phenyl)- 1H-[1, 2,3]triazol-4-ylmethyl]- thiocarbamic acid O-methyl ester (100 mg, 0.19 mmol), obtained in example 98, by employing the same procedure as described in example 95.
Η NMR (CDC13, 400 MHz): δ 8.02 and 7.77(2s, IH, rotamers in the ratio 3: 1), 7.30- 7.24(m, 2H), 7.04 (d, J= 8.6 Hz, 2H), 6.87(bs,lH), 6.66(d, J = 8.6 Hz, 2H), 4.90 and 4.65(2d, J= 5.9 Hz, 2H, rotamers in the ratio 4: 1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 3.76(t, J = 4.8 Hz, 2H), 3.66( s, 2H), 3.56 ( t, J=4.6 Hz, 2H), 3.20-3.18 (m, 2H), 1.70(bs,2H).
IR (KBr): 3351 , 2921, 1630, 1517, 1448, 1217, 1149, 1033, 852, 688 cm"1. ES-MS (m/e): 524 (M++ 23), 502 (M++l)
Example 100:
(l-{4-[4-(2-Dimethylamino-acetyI)-piperazin-l-yl]-3-fluoro-phenyl}-lH- [l,2,3]triazol-4-yImethyl)-thiocarbamic acid O-methyl ester
Figure imgf000162_0002
The title compound (42 mg, 30 %>) was synthesized from l-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-2-dimethylamino-ethanone (100 mg, 0.32 mmol), obtained in preparation 45, by following the procedure as described in example 1. Η NMR ( 200 MHz, CDCI3): δ 8.04 and 7.81 (2s, IH, rotamers in the ratio 4:1), 7.53- 7.43 (m, 2H), 7.01(t, J=8.7 Hz, 2H), 4.89 and 4.64 (2d, J= 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.19 and 4.01(2s, 3H, rotamers in the ratio 1 :4), 3.89 - 3.78 (m, 4H), 3.26-3.09 (m, 6H), 2.30 (s, 6 H).
IR (KBr): 3448, 3194, 3136, 2942, 1640, 1522, 1455, 1229, 1147, 1049, 1018, 863 cm"1 ES-MS (m/e): 458 (M++23), 436.3 (M++l). Example 101:
(l-{3-Fluoro-4-[4-(2(R)-hydroxy-2-phenyl-acetyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyI)-thiocarbamic acid O-methyl ester
Figure imgf000163_0001
The title compound (70 mg, 59 %) was synthesized from 1 -[4-(4-azido-2-difluoro- phenyl)- piperazin-1-yl] -2 -hydroxy-2 -phenyl -ethanone (87 mg, 0.25 mmol), obtained from preparation 46, by following the procedure as described in example 1. Η NMR (200MHz, CDC13): δ 8.02 and 7.78 (2s, IH, rotamers in the ratio 4:1), 7.48 - 7.25 (m, 8H), 7.00 - 6.82 (m, 2H), 5.29 (d, J = 6.2 Hz, IH), 4.89 and 4.76 (2d, J = 5.8 Hz, 2H, rotamers in the ratio 4:1), 4.01 and 3.99 (2s, 3H, rotamers in the ratio 1 :4), 3.85 - 3.60 (m, 2H), 3.61 - 3.30 (m, 2H), 3.12 - 2.84 (m, 4H). IR (Neat): 3263, 3009, 2946, 1644, 1520, 1448, 1388, 1242, 1025, 756 cm"1. CI-MS (m e): 485 (M++l), 453.
Example 102:
(l-{3,5-Difluoro-4-[4-(2-pyrazol-l-yl-acetyl)-piperazin-l-yI]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000163_0002
The title compound (65 mg, 34 %) was synthesized from l-[4-(4-azido-2,6- difluoro-phenyl)- piperazin-l-yl]-2-pyrazol-l-yl-ethanone (140 mg, 0.40 mmol), obtained in preparation 48, following the same procedure as described in example 1. Η NMR (200MHz, CDCI3): δ 8.04 and 7.80 (2s, IH, rotamers in the ratio 4: 1), 7.54 (s, 2H), 7.29 (d, J= 9.3 Hz, 2H), 6.93 (bs, IH), 6.34 (s, IH), 5.06 (s, 2H), 4.89 and 4.64 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4: 1), 4.09 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 3.82 - 3.62 (m, 4H), 3.28 - 3.08 (m, 4H).
IR (KBr): 3435, 2926, 1668, 1517, 1456, 1225, 1199, 1146, 1033, 854, 753 cm"1. CI-MS (m/e): 445 (M+-31), 413, 388 Example 103:
(l-{3-Fluoro-4-[4-(2-pyrazol-l-yl-acetyl)-piperazin-l-yI]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
θCH3
Figure imgf000164_0001
The title compound (150 mg, 67 %) was synthesized from l-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-2-pyrazol-l-yl-ethanone (160 mg, 0.49 mmol), obtained in preparation 49, following the same procedure as described in example 1. Η NMR (200MHz, CDC13): δ 8.09 and 7.82 (2s, IH, rotamers in the ratio 5:1), 7.62 - 7.50 (m, 2H), 7.50 - 7.30 (m, 2H), 7.10 - 7.05 (m, IH), 6.98 (t, J = 8.9 Hz, IH), 6.38 - 6.22 (m, IH), 5.10 (s, 2H), 4.91 and 4.68 (2d, J = 5.8 Hz, 2H, rotamers in the ratio 5:1), 4.14 and 4.10 (2s, 3H, rotamers in the ratio 1 :3), 3.94 - 3.64 (m, 4H), 3.19 - 3.02 (m, 4H). IR (KBr): 3241, 2944, 1660, 1519, 1238, 1149, 1032, 869, 754 cm"1. CI-MS (m/e): 427 (M+-31)
Example 104:
(l-{4-[4-(4-Dimethylamino-butyryl)- piperazin-l-yl]-3,5-difluoro-phenyl }-lH-
[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000164_0002
The title compound (200 mg, 35 %) was synthesized from 4-dimethylamino- butyric acid (157 mg, 1.19 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [1,2,3] triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27.
Η NMR (200 MHz, DMSO): δ 9.71 (bs, IH), 8.76 and 8.72 (2s, IH, rotamers in the ratio 3:1), 7.79 (d, J = 9.8 Hz, 2H), 4.79 and 4.59 (2d, J = 5.7 Hz, 2H, rotamers in the ratio 4: 1), 3.99 and 3.92 (2s, 3H, rotamers in the ratio 1 :5), 3.76 - 3.56 (m, 4H), 3.54 - 3.30 ( , 4H), 2.50 - 2.30 (m, 4H), 2.25 (s, 6H). IR (KBr): 2930, 1634, 1519, 1453, 1214, 1147, 1032, 855, 758 cm"1. 2005/082892
CI-MS (m/e): 482 (M++l), 450
Example 105:
(l-{4-[4-(3-Dimethylcarbamoyl-benzyI)-piperazin-l-yI]-3,5-difluoro-phenyl}-lH- [l,2,3]triazoI-4-ylmethyI)- thiocarbamic acid O-methyl ester
Figure imgf000165_0001
The title compound (150 mg, 29 %) was synthesized from 3-[4-(4-azido-2,6- difluoro-phenyl)- piperazin-l-ylmethyl]-N,N-dimethyl- benzamide (400 mg, 1.0 mmol) obtained in preparation 51 , by following the procedure as described in example 1. Η NMR (400MHz, CDC13): δ 8.04 and 7.78 (2s, IH, rotamers in the ratio 5:1), 7.46 - 7.28 (m, 6H), 6.89 - 6.81 (m, IH), 4.89 and 4.64 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 5 :1), 4.12 and 3.99 (2s, 3H, rotamers in the ratio 1:6), 3.58 (s, 2H), 3.34 - 3.22 (m, 4H), 3.12 (s, 3H), 2.99 (s, 3H), 2.64 - 2.52 (m, 4H).
IR (KBr): 3221, 2940, 1626, 1517, 1455, 1396, 1204, 1140, 1038, 858, 753 cm"1. CI-MS (m/e): 530 (M++l), 498
Example 106:
(l-{4-[4-(3,4-Dihydroxy-benzoyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-lH- l,2,3]triazol-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000165_0002
The title compound (50 mg, 12 %) was synthesized from 3,4-dihydroxy-benzoic acid (151 mg, 0.99 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27.
Η NMR (400MHz, DMSO): δ 9.68-9.58 (m, IH), 9.28 (s, IH), 9.16 (s,lH), 8.72 and 8.67 (2s, IH, rotamers in the ratio 3:1), 7.76 ( d, J=10.2 Hz, 2H), 6.84 (s, IH), 6.80-6.74 (m, 2H), 4.72 and 4.43 (2d, , J = 5.6 Hz, 2H, rotamers in the ratio 3:1), 3.94 and 3.88 (2s, 3H, rotamers in the ratio 1 :4), 3.66-3.54 (m, 4H), 3.24 - 3.12 (m, 4H). IR (KBr): 3268, 1596, 1517, 1442, 1288, 1227, 1148, 1025, 851 cm"1. ES-MS (m/e): 527 (M++23), 505 (M++l).
Example 107:
(l-{4-[4-(4-Amino-3-hydroxy-benzoyl)-piperazin-l-yI]-3,5-difluoro-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000166_0001
The title compound (100 mg, 18 %) was synthesized from 4-amino-3 -hydroxy - benzoic acid (200 mg, 1.30 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [l ,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27.
Η NMR (400MHz, DMSO): δ 9.66 - 9.60 (m, IH), 9.24 (bs, IH), 8.72 and 8.70 (2s, IH, rotamers in the ratio 3: 1), 7.75 (d, J = 9.9 Hz, 2H), 6.79 (s, IH), 6.78 - 6.70 (m, IH), 6.58 (d, J = 7.8 Hz, IH), 4.92 (bs, 2H), 4.73 and 4.24 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 3: 1), 3.95 and 3.88 ( 2s, 3H, rotamers in the ratio 1 :3), 3.66 - 3.54 (m, 4H), 3.24 - 3.09 (m, 4H).
IR (KBr): 3373, 1612, 1518, 1440, 1289, 1230, 1148, 1023, 854, 564 cm"1. ES-MS (m/e): 526 (M++23), 504 (M++l)
Example 108:
(l-{4-[4-(3-Dimethylaminomethyl-benzoyl)-piperazin-l-yl]-3,5-difluoro- phenyl}-lH- [l,2,3]triazol-4-yImethyI)-thiocarbamic acid O-methyl ester
Figure imgf000166_0002
The title compound (40 mg, 12 %) was synthesized from [4-(4-azido-2,6-difluoro- phenyl)-piperazin-l-yl]-(3-dimethylaminomethyl-phenyl)-methanone (250 mg, 0.63 mmol), obtained in preparation 53, by following the procedure as described in example 1. Η NMR (200MHz, CDC13): δ 8.04 and 7.82 (2s, IH, rotamers in the ratio 4: 1), 7.54 - 7.18 (m, 6H), 7.00 - 6.82 (m, IH), 4.89 and 4.68 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 4:1), 4.16 and 3.99 (2s, 3H, rotamers in the ratio 1 :6), 3.78 - 3.39 (m, 4H), 3.54 (s, 2H), 3.36 - 3.08 (m, 4H), 2.28 (s, 6H). IR (KBr): 3422, 2924, 1628, 1517, 1458, 1201, 1024, 850, 700 cm"1. CI-MS (m/e): 530 (M++l), 498
Example 109:
(l-{3-FIuoro-4-[4-(pyridine-4-carbonyl)-piperazin-l-yI]-phenyl}-lH-[l, 2, 3] triazol- 4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000167_0001
The title compound (66 mg, 36 %) was synthesized from [4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-pyridin-4-yl-methanone (133 mg, 0.41 mmol), obtained in preparation 54, using the same procedure as described in example 1. Η NMR (200MHz, CDC13): δ 8.69 (d, J = 5.6 Hz, 2H), 8.04 and 7.82 (2s, IH, rotamers in the ratio 4:1), 7.59 - 7.39 (m, 2H), 7.32 (d, J = 5.9 Hz, 2H), 7.19 - 6.98 (m, IH), 6.97 - 6.88 (m, IH), 4.91 and 4.64 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.18 and 4.02 (2s, 3H, rotamers in the ratio 1:4), 4.11 - 3.84 (m, 2H), 3.62 - 3.49 (m, 2H), 3.30 - 3.01 (m, 4H).
IR (KBr): 3431, 2924, 1635, 1520, 1440, 1243, 1149, 1016, 756 cm"1. CI-MS (m/e): 456 (M++l), 424
Example 110:
(l-{3-Fluoro-4-[4-(2-imidazol-l-yl-acetyl)-piperazin-l-yl]-phenyl} -lH-[l,2,3]triazol-
4-ylmethyI)-thiocarbamic acid O-methyl ester
Figure imgf000167_0002
The title compound (26 mg, 26 %) was synthesized from l-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-2-imidazol-l-yl-ethanone (72 mg, 0.22 mmol), obtained in preparation 55, by using the same procedure as described in example 1. Η NMR (200 MHz, CDCI3): δ 8.06 and 7.81 (2s, IH, rotamers in the ratio 4:1), 7.64 - 7.45 (m, IH), 7.42 - 7.38 (m, 2H), 7.19 - 6.82 (m, 2H), 6.81 - 6.68 (m, IH), 4.91 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 5:1), 4.85 (s, 2H), 4.61 and 4.01 (2s, 3H, rotamers in the ratio 1:5), 3.89 - 3.78 (m, 2H), 3.74 - 3.49 (m, 2H), 3.20 - 3.09 (m, 4H). IR (KBr): 3422, 2925, 1656, 1518, 1234, 1148, 1033, 866 cm"1. ES-MS (m/e): 481 (M++23), 459 (M++l)
Example 111:
(l-{3,5-Difluoro-4-[4-(2-imidazoI-l-yI-acetyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000168_0001
The title compound (75 mg, 8%) was synthesized from 1 -[4-(4-azido-2-fluoro- phenyl)- piperazin-l-yl]-2-imidazol-l-yl-ethanone (660 mg, 1.90 mmol), obtained in preparation 56, following the same procedure as described in example 1. Η NMR (200MHz, CDC13): δ 8.09 (s, IH), 7.58 (s, IH), 7.39 - 7.29 (m, 2H), 7.19 - 7.09 (m, IH), 7.03 - 6.94 (m, IH), 4.94 (d, J = 5.8 Hz, 2H), 4.84 (s, 2H), 4.12 and 4.01 (2s, 3H, rotamers in the ratio 1 :5), 3.92 - 3.74 (m, 2H), 3.68 - 3.54 (m, 2H), 3.36 - 3.18 (m, 4H). IR (KBr): 3426, 1653, 1517, 1427, 1233, 1 154, 1032, 857, 756, 663 cm"1. CI-MS (m/e): 477 (M++l), 455
Example 112:
(l-{3-Fluoro-4-[4-(pyridine-3-carbonyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4- y!methyl)-thiocarbamic acid O-methyl ester
Figure imgf000168_0002
The title compound (40 mg, 16 %) was synthesized from [4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-pyridin-4-yl-methanone (178 mg, 0.55 mmol), obtained in preparation 57, by following the procedure as described in example 1. Η NMR (200 MHz, CDC13): δ 8.77 - 8.64 (m, 2H), 8.05 (s, IH), 7.84 - 7.74 (m, IH), 7.58 - 7.38 (m, 3H), 7.03 (t, J = 8.9 Hz, IH), 7.00 - 6.90 (m, IH), 4.91 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 5: 1), 4.08 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 4.32 - 3.48 (m, 4H), 3.32 - 3.04 (m, 4H). CI-MS (m/e): 424 (M+-31), 367
IR (KBr): 3424, 2927, 1649, 1529, 1438, 1243, 1149, 1011, 864, 810 cm"1. CI-MS (m/e): 424 (M+-31), 367 Example 113:
(l-{3,5-Difluoro-4-[4-(5(S)-hydroxymethyI-2,2-dimethyl-[l,3]dioxolane-4(R)- carbonyl)piperazin-l-yl]phenyl}-lH-[l,2,3]triazoI-4-ylmethyl)-thiocarbamicacid O- methyl ester
Figure imgf000169_0001
The title compound (100 mg, 25%) was synthesized from [4-(4-azido-2,6-difluoro- phenyl)-piperazin-l-yl]-(5-hydroxymethyl-2,2-dimethyl-[l,3]dioxolan-4-yl)-methanone (300 mg, 0.75 mmol), obtained in preparation 59, by following the procedure as described in example 1.
Η NMR (DMSO, 400 MHz): δ 8.04 and 7.81 (2s, IH, rotamers in the ratio 4: 1), 7.31 (d, J = 9.4 Hz, 2H), 6.86 - 6.81 (m, IH), 4.90 and 4.65 (2d, J = 6.1 Hz, 2H, rotamers in the ratio 5: 1), 4.74 - 4.69 (m, 2H), 4.55 (d, J = 7.5 Hz, IH), 4.11 and 4.00 (2s, 3H, rotamers in the ratio 1 :6), 3.96 - 3.82 (m, 2H), 3.77 - 3.65 (m, 4H), 3.25 - 3.19 (m, 4H), 1.47 (s, 3H), 1.42 (s, 3H).
IR (Neat): 3374, 2928, 1640, 1518, 1448, 1384, 1210, 1153, 1038, 856 cm"1. ES-MS (m/e): 549 (M+ + 23), 527 (M+ + 1)
Example 114:
(l-{3,5-Difluoro-4-[4-(2(R),3(S),4-trihydroxy-butyryl)-piperazin-l-yl]-phenyI}-lH [l,2,3]triazo_-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000169_0002
(l-{3,5-Difluoro-4-[4-(5(S)-hydroxymethyl-2,2-dimethyl-[l,3]dioxolane-4(R)- carbonyl)piperazin- 1 -yl]phenyl} - 1 H-[ 1 ,2,3]triazol-4-ylmethyl)-thiocarbamicacid-0- methyl ester (350 mg, 0.66 mmol), obtained in example 113, was dissolved in 60 % TFA in DCM (10 mL) at 0 °C . The reaction mixmre was stirred for 2 to 3 hours at 25-35 °C.
The solvent was removed under vacuum and the reaction mixmre was co-evaporated with toluene (2 x 10 mL) and the residue was purified by preparative thin layer chromatography (TLC) to yield the title compound (80 mg, 25%>). Η NMR (DMSO, 400 MHz): δ 9.67 - 9.59 (m, IH), 8.71 and 8.67 (2s, IH, rotamers in the ratio 4:1), 7.75 (d, J = 9.9 Hz, 2H), 4.73 (d, J = 5.6 Hz, IH), 4.62 - 4.58 (m, 2H), 4.46
- 4.44 (m, 2H), 3.94 and 3.88 (2s, 3H, rotamers in the ratio 1 :4), 3.67 - 3.59 (m, 5H), 3.49
- 3.42 (m, IH), 3.36 - 3.31 (m, IH), 3.23 - 3.11 (m, 5H).
IR (Neat):3353, 2926, 1633, 1518, 1453, 1390, 1330, 1276, 1229, 1120, 1029, 857, 757 cm"1.
ES-MS (m/e): 509 (M+ + 23), 487 (M+ + 1)
Example 115:
{l-[3,5-Difluoro-4-(4-{2-[2-(2-hydroxy-acetylamino)-phenyl]-acetyl}-piperazin-l-yl)- phenyl]-lH-[l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester
Figure imgf000170_0001
The title compound (200 mg, 38 %) was synthesized from N-(2-{2-[4-(4-azido- 2,6-difluoro-phenyl)-piperazin- 1 -yl]-2-oxo-ethyl} -phenyl)-2-hydroxy-acetamide (400 mg, 0.93 mmol), obtained in preparation 62, by following the procedure as described in example 1.
Η NMR (DMSO, 400 MHz): δ 9.71 (s, IH), 9.68 - 9.61 (m, IH), 8.71 and 8.67 (2s, IH, rotamers in the ratio 3: 1), 7.70 (d, J = 10.2 Hz, 2H), 7.68 (d, J = 8.0 Hz, IH), 7.30 - 7.23 (m, 2H), 7.10 (dt, J, = 1.2 Hz, J2 = 7.2 Hz, IH), 5.79 (t, J=5.9 Hz, IH), 4.70 and 4.43 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 3:1), 3.99 (d, J = 5.9 Hz, 2H), 3.94 and 3.88 (2s, 3H, rotamers in the ratio 1 :3), 3.77 (s, 2H), 3.76 - 3.68 (m, 2H), 3.67 - 3.58 (m, 2H), 3.21
- 3.15 (m, 2H), 3.15 - 3.08 (m, 2H).
IR (KBr): 3420, 1631, 1520, 1456, 1228, 1153, 1036, 856, 758, 491 cm"1. CI-MS (m/e): 560 (M++l), 528 (M+-31).
Example 116:
[2-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-2-oxo-ethyl]-phosphonic acid dimethyl ester
Figure imgf000170_0002
The title compound (180 mg, 64 %) was synthesized from (dimethoxy- phosphoryl)-acetic acid (136 mg, 0.82 mmol) and l-(3,5-difluoro-4-piperazin-l-yl- phenyl)-lH-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27. Η NMR (CDCI3, 200 MHz): δ 8.05 and 7.81 (2s, IH, rotamers in the ratio 4:1), 7.30 (d, J = 9.4 Hz, 2H), 6.98 - 6.86 (m, IH), 4.90 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :4), 3.86 (s, 2H), 3.80 (s, 3H), 3.78 - 3.65 (m, 4H), 3.38 - 3.19 (m, 4H), 3.13 (d, J = 22.0 Hz, 2H). IR (KBr): 3227, 2924, 1638, 1517, 1457, 1368, 1250, 1209, 1148, 1031, 982, 850, 809, 566 cm"1. ES-MS (m/e): 519.2
Example 117:
5(R)-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazine-l-carbonyI)-2,2-dimethyl-[l,3]dioxolane-4(R)-carboxylic acid methyl ester
Figure imgf000171_0001
The title compound (300 mg, 38 %>) was synthesized from 5-[4-(4-azido-2,6- difluoro-phenyl)-piperazine-l-carbonyl]-2,2-dimethyl-[l,3]dioxolane-4-carboxylic acid methyl ester (600 mg, 1.41 mmol), by following the procedure as described in example 1
Η NMR (CDC13,200 MHz): δ 8.06 and 7.84 (2s, IH, rotamers in the ratio 4: 1), 7.31 (d, J = 9.1 Hz, 2H), 7.12 - 6.92 (m, IH), 5.39 (d, J = 5.3 Hz, IH), 4.90 (t, J = 5.9 Hz, 3H), 4.64 (rotameric doublet, J = 6.0 Hz), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :4), 3.81 (s, 3H), 4.00 - 3.56 (m, 4H), 3.39 - 3.30 (m, 4H), 1.50 (s, IH), 1.45 (s, 3H) CI-MS (m/e): 555(M++1), 522
Example 118:
(l-{3,5-Difluoro-4-[4-(5(R)-hydroxycarbamoyl-2,2-dimethyl-[l,3]dioxolane-4(R)- carbonyl)-piperazin-l-yl]-phenyI}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000172_0001
NaOH (3.8 M in methanol, 2.7 mL) was added to hydroxylamine hydrochloride (1.6 M in methanol, 4 mL) at 0 °C and stirred for 2 hours. This hydroxylamine solution was added to a stirred solution of 5-(4-{2,6-difluoro-4-[4-methoxythiocarbonylamino- methyl)-[ 1 ,2,3 ]triazol- 1 -yl]-phenyl } -piperazine- 1 -carbonyl)-2,2-dimethyl-[l ,3]dioxolane- 4-carboxylic acid methyl ester (500 mg, 0.9 mmol), obtained in example 117, in methanol at 0 °C by filtration. The reaction mixture was stirred at 25-35 °C for 45 minutes. The
solvent was removed and the residue was purified by column chromatography (0.02:1 methanol/chloroform) to furnish the title compound (180 mg, 36%).
*H NMR (DMSO, 200 MHz): δ 10.91 (s, IH), 9.78 - 9.58 (m, IH), 9.01 (s, IH), 8.73 and 8.68 (2s, IH, rotamers in the ratio 3:1), 7.76 (d, J = 9.9 Hz, 2H), 5.01 (d, I = 5.6 Hz,
IH), 4.83 (d, J = 5.6 Hz, IH), 4.72 and 4.44 (2ό, J = 5.6 Hz, 2H, rotamers in the ratio 4:1),
3.94 and 3.88 (2s, 3H, rotamers in the ratio 1:3), 3.74 - 3.52 (m, 4H), 3.22 - 3.00 (m, 4H),
1.42 (s, 3H), 1.34 (s, 3H).
IR (Neat): 3262, 2927, 1644, 1617, 1447, 1383, 1211, 1149, 1033, 859, 755, 616 cm"1.
ES-MS (m/e): 578 (M+ + 23), 556 (M+ +1)
Example 119:
4-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)- 2(R),3(R) -dihydroxy-4-oxo-butyric acid methyl ester
Figure imgf000172_0002
Using the same procedure as described in example 114, the title product (90 mg, 32 %) was synthesized from 5-(4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino- methyl)-[l,2,3]triazol-l-yl]-phenyl}-piperazine-l-carbonyl)-2,2-dimethyl-[l,3]dioxolane- 4-carboxylic acid methyl ester ( 300 mg, 0.54 mmol), obtained in example 117. Η NMR (CDC13,400 MHz): δ 8.05and 7.80 (2s, IH, rotamers in the ratio 4 :1), 7.32 (d, J=9.4 Hz, 2H), 6.91-6.84 (m, IH), 4.90 and 4.65(2d, J=6.1 Hz, 2H, rotamers in the ratio 4:1), 4.78 (d, J=1.8 Hz, IH), 4.69 (d, J=1.6Hz, IH), 4.11 and 4.00 (2s, 3H, rotamers in the ratio 1:3), 3.88 (s, 3H), 3.79-3.62 (m, 4H),3.35-3.22 (m, 4H). IR (Neat): 3266, 2928, 1642, 1518, 1447, 1384 cm"1. CI-MS (m/e): 514(M+), 486, 396
Example 120:
( 1 - {3-Fluoro-4-[4-(2-hydroxy-3-morpholin-4-yl-propionyl)-piperazin- 1 -y l]-phenyl} - 1 H- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000173_0001
The title compound (13 mg, 13%) was prepared from l-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-2-hydroxy-3-mo holin-4-yl-propan-l-one (75 mg, 0.2 mmol), obtained in preparation 65, by following the same procedure as described in example 1.
Η NMR (CDC-3,400 MHz): δ 8.04 and 7.81 (2s, IH, rotamers in the ratio 3: 1), 7.51 (dd,
J, = 2.6, J2 = 12.6 Hz, IH), 7.48 - 7.39 (m, IH), 7.03 (t, J = 8.8 Hz, IH), 6.94 - 6.84 (m,
IH), 4.91 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4:1), 4.58 - 4.49 (m, IH),
4.11 and 4.00 (2s, 3H, rotamers in the ratio 1 :4), 3.99 - 3.86 (m, IH), 3.84 - 3.62 (m, 8H),
3.26 - 3.08 (m, 4H), 2.78 - 2.51 (m, 6H).
IR (Neat): 3254, 2924, 2854, 1640, 1520, 1453, 1388, 1235, 1116, 1027, 1008, 984, 867,
757,667, 618 cm"1.
ES-MS (m/e): 508 (M+ + 1).
Example 121:
(l-{3,5-Difluoro-4-[l-(2-phenyI-[l,3]dioxane-5-carbonyl)-l,2,3,6-tetrahydro-pyridin- 4-yl]-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000173_0002
The title compound (42 mg, 36%>) was synthesized from [4-(4-azido-2,6-difluoro- phenyl)-3,6-dihydro-2H-pyridin-l-yl]-(2-phenyl-[l,3]dioxan-5-yl)-methanone (90 mg, 0.21 mmol) obtained in preparation 66, by following the procedure as described in example 1.
Η NMR (DMSO, 400 MHz): δ 9.66 (t, J = 5.9 Hz, IH), 8.80 and 8.75 (2s, IH, rotamers in the ratio 3:1), 7.83 (d, J = 8.5 Hz, 2H), 7.48 - 7.41 (m, 2H), 7.41 - 7.34 (m, 3H), 6.04 - 5.97 ( , IH), 5.57 (s, IH), 4.74 and 4.45 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 4:1), 4.41 -4.36 and 4.15 - 4.09 (2m, 2H), 4.27 (dd, J, = 4.5 Hz, J2 = 11.5 Hz, 2H), 4.09 - 4.00 (m, 2H), 3.95 and 3.89 (2s, 3H, rotamers in the ratio 1:4), 3.84 - 3.77 and 3.72 - 3.65 (2m, 2H), 3.50 - 3.32 (m, IH), 2.54 - 2.44 ( , IH), 2.39 - 2.32 (m, IH). ES-MS (m/z): 556 (M"+l)
Example 122:
(l-{3,5-Difluoro-4-[l-(3-hydroxy-2-hydroxymethyl-propionyl)-l,2,3,6-tetrahydro- pyridin-4-yI]-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000174_0001
To a solution of (l-{3,5-difluoro-4-[l-(2-phenyl-[l,3]dioxane-5-carbonyl)- 1 ,2,3 ,6-tetrahydro-pyridin-4-yl]-phenyl} - 1 H-[ 1 ,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (40 mg, 0.07 mmol), obtained in example 121, in tetrahydrofuran (THF) (3 mL), HCI ( 3N, 0.2 mL ) was added and the solution was stirred for 24 hours at 25-35 °C.
The reaction mixmre coevaporated with toluene (2 x 5 mL) under reduced pressure. The residue was purified by column chromatography (4:6 methanol/ chloroform) to afford the desired product (20 mg, 59 %).
Η NMR (DMSO, 400 MHz): δ 9.66 (t, J = 5.9 Hz, IH), 8.79 and 8.75 (2s, IH, rotamers in the ratio 3:1), 7.82 (dd. J, = 4.8 Hz, J2 = 13.4 Hz, 2H), 6.04 - 5.95 (m, IH), 4.74 and
4.45 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 4:1), 4.66 - 4.55 (m, 2H), 4.35 - 4.28 and
4.21 - 4.13 (2m, 2H), 3.95 and 3.89 (2s, 3H, rotamers in the ratio 1:4), 3.82 - 3.69 (m,
2H), 3.61 - 3.48 ( , 4H), 3.18 - 3.02 (m, IH), 2.52 - 2.33 (m, 2H).
IR (KBr): 3384, 2940, 1618, 1511, 1453, 1364, 1203, 1148, 1033, 859, 756 cm"1.
CI-MS (m/e): 467 (M+), 432 (M+-32), 387
Example 123:
5-(R) -(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazine-l-carbonyl)-2,2-dimethyl-[l,3]dioxolane-4(R)-carboxylic acid ethyl ester
Figure imgf000175_0001
The title compound (160 mg, 37 %) was synthesized from 2,2-dimethyl- [l,3]dioxolane-4,5-dicarboxylic acid monoethyl ester (254 mg, 1.23 mmol) and [l-(3,5- difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O- methyl ester obtained in example 6, by following the same procedure as described in example 27.
Η NMR (CDC13, 400 MHz): δ 8.05 and 7.81 (2s, IH, rotamers in the ratio 8:1), 7.31 (d. J = 9.1 Hz, 2H), 6.97 (t, J = 5.6 Hz, IH), 5.36 (d, J = 6.1 Hz, IH), 4.94 (d, J = 5.1 Hz, IH), 4.90 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 7:1), 4.30 - 4.23 (m, 2H), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1:9), 3.97 - 3.88 (m, 2H), 3.75 - 3.64 (m, 2H), 3.33 - 3.18 (m, 4H), 1.50 (s, 3H), 1.45 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H).
IR (KBr): 3251, 1754, 1636, 1517, 1466, 1366, 1254, 1211, 1148, 1114, 1038, 982, 855, 698 cm"1. ES-MS (m/e): 569.3 (M++l).
Example 124:
4-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-2( R ), 3( R ) - dihydroxyr4-oxo-butyric acid ethyl ester
Figure imgf000175_0002
By following the procedure as described in example 114, the title compound (60 mg, 40 %) was obtained from 5-(R)-(4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino- methyl)-[ 1 ,2,3]triazol-l -yl]-phenyl } -piperazine- 1 -carbonyl)-2,2-dimethyl-[ 1 ,3]dioxolane- 4(R)-carboxylic acid ethyl ester (150 mg, 0.29 mmol) obtained in example 123. *H NMR (CDCI3, 200 MHz): δ 8.06 and 7.83 (2s, IH, rotamers in the ratio of 5:1), 7.32 (d, J = 9.2 Hz, 2H), 7.06 - 6.90 (m, IH), 4.91 and 4.65 (2d, J = 5.8 Hz, 2H, rotamers in the ratio 4:1), 4.81 (s, IH), 4.50 - 4.24 (m, 3H), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 4.05 - 3.83 (m, IH), 3.83 - 3.58 (m, 3H), 3.44 - 3.15 (m, 4H), 1.35 (t, J = 7.3 Hz, 3H). IR (KBr): 3408, 2943, 1743, 1646, 1514, 1459, 1392, 1332, 1231, 1124, 1030, 838 cm"1. CI-MS (m/e): 529 (M++l), 425, 369.
Example 125:
(l-{3,5-Difluoro-4-[4-(3-nitro-benzenesulfonyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3] triazo--4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000176_0001
To a stirred solution of [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [l ,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester (120 mg, 0.54 mmol), obtained in example 6, in dry DCM at 0 °C was added triethylamine (0.15 mL, 1.08 mmol), 3 -nitrobenzene sulphonyl chloride (120 mg, 0.54 mmol) and stirred at 25-35 °C
for 9 to 13 hours. The reaction mixmre was diluted with DCM and washed with water (2 x 10 mL), brine and dried over sodium sulphate. The organic layer was concentrated under vacuum and the residue was purified by column chromatography (0.7: 0.3 ethyl acetate/petroleum ether) to obtain the title product as a bright yellow solid (200 mg, 71%). Η NMR (DMSO, 400 MHz): δ 9.68 - 9.58 (m, IH), 8.69 and 8.64 (2s, IH, rotamers in the ratio 3:1), 8.57 (d, J = 8.3 Hz, IH), 8.42 (t, J = 1.8 Hz, IH), 8.23 (dd. J, = 1.6 Hz, J2 = 7.7 Hz, IH), 7.99 (t, J = 8.1 Hz, IH), 7.72 (d, I = 10.0 Hz, 2H), 4.71 and 4.42 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 4: 1), 3.93 and 3.87 (2s, 3H, rotamers in the ratio 1 :4), 3.38 - 3.19 (m, 4H), 3.19 - 3.04 (m, 4H).
IR (KBr): 3262, 2922, 1526, 1459, 1357, 1263, 1233, 1176, 1 135, 1044, 950, 714, 575 cm"1' ES-MS (m/e): 554.3 (M++l).
Example 126:
(l-{4-[4-(3-Amino-benzenesulfonyl)-piperazin-l-yl]-3,5-dif_uoro-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000176_0002
To a suspension of tin chloride (563 mg, 2.34 mmol) in methanol (MeOH) (10 ml), Cone. HCI (2 mL) was added and the mixmre was cooled to -10 °C . A solution of 1 - {3,5-difluoro-4-[4-(3-nitro-benzenesulfonyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester (130 mg, 0.25 mmol), obtained in example 125, in MeOH (5 mL) was transferred to the above mixmre and the reaction mixmre was stirred for over night at 25-35 °C. Reaction mixmre was quenched with sodium
bicarbonate solution (20%, 20 mL) and extracted with DCM (2 x 30 mL). The organic layer was washed with water, brine and dried over Na2S04. The organic layer was concentrated under vacuum and the residue was purified by column chromatography (4:6 methanol/chloroform) to give the title product as light yellow solid (70 mg, 57%).
Η NMR (DMSO, 400 MHz): δ 9.63 (t, J = 5.6 Hz, IH), 8.69 and 8.65 (2s, IH, rotamers in the ratio 4:1), 7.72 (d, J = 9.9 Hz, 2H), 7.27 (t, J = 7.7 Hz, IH), 6.94 (t, J = 2.1 Hz, IH),
6.90 - 6.82 (m, 2H), 5.66 (s, 2H), 4.71 and 4.42 (2d, J = 5.6 Hz, 2H, rotamers in the ratio
4:1), 3.93 and 3.98 (2s, 3H, rotamers in the ratio 1 :4), 3.28 - 3.21 (m, 4H), 3.04 - 2.97 (m,
4H).
IR (KBr): 3375, 2855, 1518, 1453, 1317, 1270, 1231, 1207, 1158, 1043, 948, 859, 733,
580 cm"1
ES-MS (m/e): 524.3 (M++l), 546.3 (M++23).
Example 127:
(l-{3-Fluoro-4-[4-(2-hydroxy-propionyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000177_0001
The title compound (50 mg, 45 %) was synthesized from l-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-2-hydroxy-propan-l-one (80 mg, 0.27 mmol), obtained in preparation 67, by following the procedure as described in example 1. IH NMR (CDC13 & CD3OD, 200 MHz): δ 8.14 and 7.89 (2s, IH, rotamers in the ratio 5:1), 7.58 - 7.40 (m, 2H), 7.04 (t, J = 9.0 Hz, IH), 4.86 and 4.63 (2s, 2H, rotamers in the ratio 5:1), 4.51 (q, J = 4.7 Hz, IH), 4.10 and 3.99 (2s, 3H, rotamers in the ratio 1:5), 3.96 - 3.86 (m, IH), 3.69 - 3.57 (m, 4H), 3.28 - 3.03 (m, 4H), 1.37 (d, J = 6.4 Hz, 3H). IR (KBr): 3206, 2924, 1633, 1526, 1443, 1226, 1151, 1050, 1014, 981, 862, 769 cm"1. ES-MS (m/e): 445 (M++23), 423 (M++l) Example 128:
(l-{4-[4-(2,2-Difluoro-acetyl)-piperazin-l-yl]-3-fluoro-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000178_0001
The title compound (80 mg, 57 %>) was synthesized from (l-{4-[4-(2, 2-difluoro- aceryl)-piperazin- 1 -yl] -3 -fluoro-phenyl } - 1 H-[ 1 ,2,3 ]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (100 mg, 0.33 mmol), obtained in preparation 68, by following the same procedure as described in example 1.
IH NMR (CDC13, 200 MHz): δ 8.06 and 7.82 (2s, IH, rotamers in the ratio 5:1), 7.60 - 7.36 (m, 2H), 7.02 (t, J = 8.7 Hz, IH), 7.02 - 6.90 (m, IH), 6.15 (t, J = 53.6 Hz, IH), 4.90 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 5: 1), 4.12 and 4.00 (2s, 3H, rotamers in the ratio 1:5), 3.92 - 3.76 (m, 4H), 3.26 - 3.10 (m, 4H).
IR (KBr): 3443, 3196, 2932, 1661, 1521, 1228, 1149, 1126, 1063, 978, 846, 725 cm"1. ES-MS (m/e): 451 (M++23), 429 (M++l)
Example 129:
(l-{3,5-Difluoro-4-[4-(lH-imidazole-4-carbonyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
The title compound (50 mg, 41 %) was synthesized from lH-imidazole-4- carboxylic acid (60 mg, 0.54 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH-
[1 ,2,3] triazol-4-yl-methyl]-thiocarbamic acid O-methyl ester, obtained in example 6, by following the procedure as described in example 27.
IH NMR (DMSO, 400 MHz): δ 12.57 - 12.39 (bs, IH), 9.69 - 9.57 (m, IH), 8.72 and
8.67 (2s, IH, rotamers in the ratio 3: 1), 7.82 - 7.70 (m, 4H), 4.72 and 4.43 (2d, J = 5.6 Hz,
2H, rotamers in the ratio 3:1), 3.95 and 3.89 (2s, 3H, rotamers in the ratio 1 :3), 3.29 -
3.25 (m, 4H), 3.22 - 3.18 (m, 4H).
IR (KBr): 3421, 3219, 2922, 1601, 1517, 1441, 1274, 1198, 1029, 851, 757, 684 cm"1.
ES-MS (me): 485 (M++23), 463 (M++l) Example 130: 2(S)-(4-{2-F_uoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazoI-l-yl]- phenyl}-piperazine-l-carbonyl)-pyrro!idine-l-carboxylic acid tert-butyl ester
Figure imgf000179_0001
The title compound (100 mg, 5 %) was synthesized from 2-[4-(4-azido-2-fluoro- phenyl)-piperazine-l-carbonyl]-pyrrolidine-l -carboxylic acid tert-butyl ester (1.3 grams, 3.11 mmol), obtained in preparation 69, by following the same procedure as described in example 1.
IH NMR (CDC13, 200 MHz): δ 8.05 and 7.81 (2s, IH, rotamers in the ratio 5: 1), 7.56 - 7.34 (m, 2H), 7.08 - 6.86 (m, 2H), 4.90 (d, J = 5.9 Hz, 2H), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 3.92 - 3.36 (m, 6H), 3.28 - 3.00 (m, 4H), 2.24 - 1.63 (m, 4H), 1.47 (s, 9H).
IR (Neat): 3243, 2975, 1685, 1520, 1444, 1043, 1366, 1231, 1161, 1038, 865, 755 cm"1. ES-MS (m/e): 570 (M++23), 548 (M++l)
Example 131:
(l-{3-FIuoro-4-[4-(pyrrolidine-2(S)-carbonyl)-piperazin-l-yI]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000179_0002
The title compound (50 mg, 62 %) was synthesized from 2-(4-{2-fluoro-4-[4- (methoxythiocarbonylamino-methyl)-[ 1 ,2,3]triazol- 1 -yl]-phenyl} -piperazine- 1 -carbonyl)- pyrrolidine-1 -carboxylic acid tert-butyl ester (100 mg, 0.18 mmol), obtained in example
130, by using trifluoroacitic acid at 25-35 °C
IH NMR (CDC13, 200 MHz): δ 8.06 (s, IH), 7.60 - 7.32 (m, 2H), 7.01 (t, J = 8.7 Hz, IH), 4.91 ( d, J = 5.1 Hz, 2H), 4.76 - 4.56 (m, IH), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 3.84 - 3.54 (m, 4H), 3.40 - 3.28 (m, 4H), 3.27 - 3.04 (m, 3H), 2.22 - 1.76 (m,
4H).
IR (Neat): 3286, 1611. 1520, 1450, 1199, 1 128, 1052, 865, 757, 720 cm"1.
ES-MS (m/e): 470 (M++23), 448 (M++l)
Example 132:
{l-[4-(4-CyanomethyI-piperazin-l-yI)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4- ylmethyl} -thiocarbamic acid O-methyl ester
.
Figure imgf000180_0001
The title compound (20 mg, 9 %) was synthesized from [4-(4-Azido-2-fluoro- phenyl)-piperazin-l-yl]-acetonitrile (150 mg, 0.58 mmol), obtained in preparation 70, by using the same procedure as described in example 1.
Η NMR ( 200 MHz, CDC13) : δ 8.03 and 7.81 (2s, IH, rotamers in the ratio 3:1), 7.51 - 7.26 (m, 2H), 7.02 ( t, J = 8.7 Hz, IH), 7.00 - 6.92 (m, IH), 4.90 and 4.65 (2d, I = 6.0 Hz, 2H, rotamers in the ratio 3: 1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :3), 3.59 (s, 2H), 3.30 - 3.19 (m, 4H), 2.88 - 2.78 (m, 4H).
IR (Neat): 3318, 2942, 2833, 2113, 1757, 1519, 1453, 1385, 1324, 1245, 1205, 1142, 1010 cm"1. CI-MS (m/e): 391 (M++2), 358, 331, 301
Example 133:
(l-{3-Fluoro-4-[4-(N-hydroxycarbamimidoylmethyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazoI-4-ylmethyl)-thiocarbamic acid-O-methyl ester
Figure imgf000180_0002
The title compound (35 mg, 32 %>) was synthesized from compound (100 mg, 0.26 mmol), obtained in example 132, by following the procedure as described in example 86. Η NMR (200 MHz, DMSO): δ 9.75 - 9.65 (m, IH), 9.01 (s, IH), 8.65 and 8. 59 (2s, IH, rotamers in the ratio 3: 1), 7.84 - 7.60 (m, 2H), 7.22 (t, J = 8.9 Hz, IH), 5.26 (s, 2H), 4.72 and 4.42 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 3:1), 3.94 and 3.88 (2s, 3H, rotamers in the ratio 1:3), 3.18 - 3.10 (m, 4H), 2.91 (s, 2H), 2.60 - 2.40 (m, 4H). IR (KBr): 3460, 3359, 2924, 1674, 1521, 1441, 1405, 1338, 1228, 1194, 1060, 924 cm'1. ES-MS (m/e): 445.3 (M++23), 423.4 (M++l)
Example 134:
{l-[4-(4-Cyclopropanecarbonyl-piperazin-l-yl)-3-fluoro-phenyl]-lH-[l,2,3]triazol-4- ylmethyl}-thiocarbamic acid O-methyl ester
Figure imgf000181_0001
The title compound (100 mg, 30 %) was synthesized from compound [4-(4-azido- 2-fluoro-phenyl)-piperazin-l-yl]-cyclopropyl-methanone (235 mg, 0.73 mmol), obtained in preparation 71, by following the same procedure as described in example 1. Η NMR (400 MHz, CDC13): δ 8.04 and 7.80 (2s, IH, rotamers in the ratio 3: 1), 7.50 (dd, J, = 2.6 Hz, J2 = 12.6 Hz, IH), 7.41 (dd, J, = 1.1 Hz, J2 = 3.5 Hz, IH), 7.03 (t, J = 8.8 Hz, IH), 6.91 (bs, IH), 4.91 and 4.65 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 3:1), 4.11 and 4.00 (2s, 3H, rotamers in the ratio 1:3), 3.91 - 3.80 (m, 4H), 3.21 - 3.10 (m, 4H), 1.81 - 1.75 (m, IH), 1.06 - 1.00 (m, 2H), 0.85 - 0.78 (m, 2H).
IR (KBr): 3444, 3224, 1614, 1521, 1443, 1327, 1233, 1144, 1039, 982, 871 cm"1. CI-MS (m e): 419 (M++l), 387,
Example 135:
4-{2-Fluoro-4-[4-(methoxythiocarbonyIamino-methyl)-[l,2,3]triazol-l-yl]-phenyl}- piperazine-1-carboximidothioic acid methyl ester, compound with acetonitrile
Figure imgf000181_0002
To a stirred solution of [l-(3-fluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4- ylmethyl]-thiocarbamic acid O-methyl ester (100 mg, 0.29 mmol), obtained in example 5, in ethanol was added dimethyl cyano dithioimino carbonate (46 mg, 0.31 mmol) and heated 9 to 13 hours at 60 °C . Ethanol was removed under vacuum and the residue was diluted with ethylacetate and washed with water, brine and dried over Na2S0 . The organic layer was concentrated and the residue was purified by column chromatography
(7:3 ethyl acetate/petroleum ether) to give the title product (32 mg, 25%>).
Η NMR (200 MHz, DMSO + CDC13): δ 9.55 - 9.45 (m, IH), 8.52 and 8.47 (2s, IH, rotamers in the ratio 3: 1), 7.80 - 7.60 (m, 2H), 7.16 (t, J = 8.8 Hz, IH), 4.75 and 4.47 (2d,
J = 5.8 Hz, 2H, rotamers in the ratio 3:1), 4.10 - 4.01 (m, 4H), 3.98 and 3.91 (2s, 3H, rotamers in the ratio 1 :3), 3.39 - 3.19 (m, 4H), 2.76 (s, 3H).
IR (KBr): 3417, 2182, 1555, 1509, 1437, 1361, 1323, 1233, 1151, 876 cm"1.
CI-MS (m/e): 449 (M++l), 417
Example 136:
(l-{4-[4-(2-Acetylamino-acetyl)-piperazin-l-yl]-3-fluoro-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000182_0001
The title compound (65 mg, 19 %) was synthesized from N-{2-[4-(4-azido-2- fluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-acetamide (250 mg, 0.78 mmol), obtained in preparation 72, by following the procedure as described in example 1. Η NMR (200 MHz, DMSO + CDC13): δ 9.42 (bs, IH), 8.45 and 8.39 (2s, IH, rotamers in the ratio 3: 1), 7.90 - 7.80 (m, IH), 7.75 - 7.57 (m, 2H), 7.11 (t, J = 8.9 Hz, IH), 4.77 and 4.49 (2d, J = 5.7 Hz, 2H, rotamers in the ratio 3:1), 4.06 (d, J = 5.0 Hz, 2H), 4.00 and 3.92 (2s, 3H, rotamers in the ratio 1:3), 3.78 - 3.60 (m, 4H), 3.35 - 3.05 (m, 4H), 1.96 (s, 3H). IR (Neat): 3286, 1644, 1580, 1439, 1236, 1151, 1031, 868, 760 cm"1. CI-MS (m/e): 450 (M++l), 418
Example 137:
(l-{4-[4-(2-Cyano-acetyl)-piperazin-l-yl]-3-fluoro-phenyI}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000182_0002
The title compound (70 mg, 51 %) was synthesized from 3-[4-(4-azido-2-fluoro- phenyl)-piperazin-l-yl]-3-oxo-propionitrile (95 mg, 0.33 mmol), obtained in preparation 73, by following the procedure as described in example 1
Η NMR (200 MHz, DMSO + CDC13): δ 9.15 - 9.05 (m, IH), 8.24 and 8.12 (2s, IH, rotamers in the ratio 3: 1), 7.60-7.45 (m, 2H), 7.07 (t, J = 8.5 Hz, IH), 4.83 and 4.57 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 3:1), 4.04 and 3.97 (2s, 3H, rotamers in the ratio 1 :3), 3.82 - 3.70 (m, 4H), 3.65 - 3.60 (s, 2H), 3.25 - 3.03 (m, 4H). IR (Neat): 3383, 1594, 1579, 1385, 1039 cm"1. CI-MS (m/e): 418 (M++l), 386
Example 138:
[2-(4-{2-fluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]-phenyl}- piperazin-l-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester
Figure imgf000183_0001
The title compound (200 mg, 47 %) was synthesized from {2-[4-(4-azido-2- fluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester (315 mg, 0.83 mmol), obtained in preparation 74, by following the procedure as described in example 1. Η NMR (200 MHz, CDCI3): δ 8.04 and 7.80 (2s, IH, rotamers in the ratio 3:1), 7.58 - 7.40 (m, 2H), 7.10 - 6.90 (m, 2H), 5.55 - 5.45 (m, IH), 4.90 and 4.65 (2d, J = 5.8 Hz, 2H, rotamers in the ratio 3: 1), 4.11 and 4.02 (2s, 3H, rotamers in the ratio 3:1), 3.91 (d, J = 7.0 Hz, 2H), 3.90 - 3.78 (m, 2H), 3.65 - 3.55 (m, 2H), 3.20 - 3.12 (m, 4H), 1.45 (s, 9H). IR (Neat): 3379, 1647, 1419, 1157, 1028, 866 cm"1. CI-MS (m/e): 475 (M+-32), 402, 376
Example 139:
(l-{4-[4-(2-Amino-acetyl)-piperazin-l-yl]-3-fluoro-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000183_0002
The title compound (93 mg, 95 %) was synthesized from [2-(4-{2-fluoro-4-[4- (methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]-phenyl}-piperazin-l-yl)-2-oxo- ethyl]-carbamic acid tert-butyl ester (120 mg, 0.24 mmol), obtained in example 138, by treating with trifluoroacetic acid.
Η NMR (200 MHz, DMSO): δ 9.70 (bs, IH), 8.65 and 8.62 (2s, IH, rotamers in the ratio 3:1), 8.30 - 8.01 (m, 2H), 7.90 - 7.68 (m, 2H), 7.22 (t, J = 8.9 Hz, IH), 4.72 and 4.43 (2d, J = 5.4 Hz, 2H, rotamers in the ratio 3:1), 3.94 and 3.84 (2s, 3H, rotamers in the ratio 1:2), 3.75 - 3.65 (m, 2H), 3.60 - 3.50 (m, 2H), 3.19 - 3.01 (m, 6H). IR fNeat): 3422, 1678, 1385, 1202, 1128, 1042, 833, 801, 721 cm"1. CI-MS (m/e): 408 (M++l), 376
Example 140:
(l-{3,5-Difluoro-4-[4-(pyridine-3-carbonyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000184_0001
The title compound (58 mg, 45%) was synthesized from [4-(4-azido-2,6-difluoro- phenyl)-piperazin-l-yl]-Pyridin-3-yl-methanone (130 mg, 0.38 mmol), obtained in preparation 75, by following the same procedure as described in example 1. Η NMR (200 MHz, DMSO): δ 9.75 - 9.61 (m, IH), 8.75 - 8.60 (m, 3H), 7.89 (d, J = 7.8 Hz, IH), 7.78 (d, J = 9.2 Hz, 2H), 7.50 (t, J = 5.3 Hz, IH), 4.72 and 4.45 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 3:1), 3.94 and 3.88 (2s, 3H, rotamers in the ratio 1:3), 3.81 - 3.60 (m, 2H), 3.55 - 3.39 (m, 2H), 3.39 - 3.10 (m, 4H).
IR (Neat): 3443, 2925, 1647, 1520, 1438, 1281, 1230, 1194, 1155, 1009, 852 cm"1. CI-MS (m e): 442 (MA 1), 314, 258
Example 141:
4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazine-l-carboximidothioic acid methyl ester, compound with acetonitrile
Figure imgf000185_0001
The title compound (50 mg, 16 %) was synthesized from [l-(3, 5- difluoro-4- piperazin-l-yl-phenyl)-lH-[l, 2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester (250 mg, 0.68 mmol), obtained in example 6, by following the procedure as described in example 135.
Η NMR (200 MHz, CDC13): δ 8.06 and 7.89 (2s, IH, rotamers in the ratio 3:1), 7.32 (d, J = 9.2 Hz, 2H), 6.95 - 6.85 (m, IH), 4.90 and 4.57 (2d, J = 5.7 Hz, 2H, rotamers in the ratio 3: 1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :3), 4.05 - 3.85 (m, 4H), 3.35 - 3.20 (m, 4H), 2.82 (s, 3H). IR (KBr): 3392, 2181, 1551, 1224, 1028 cm"1. CI-MS (m/e): 467 (M++l), 435
Example 142:
(l-{3,5-Difluoro-4-[4-(N-methylcarbamimidoyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester, compound with acetonitrile
Figure imgf000185_0002
To a stirred solution of 4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino-methyl)- [l,2,3]triazol-l-yl]-phenyl}-piperazine-l-carboximidothioic acid methyl ester (15 mg, 0.11 mmol), obtained in example 141, with acetonitrile was added dropwise methylamine in 40% water (0.02 mL) and stirred at 25-35 °C for 9 to 13 hours. The solvent was
removed under vacuum and the residue was purified by column chromatography (7:3 ethyl acetate/petroleum ether) to give the title product (20 mg, 80%>) Η NMR (200 MHz, CDCI3): δ 8.07, 7.94 (2s, IH, rotamers in the ratio 3:1), 7.29 (d, J = 10.1 Hz, 2H), 7.21 - 7.08 (m, IH), 5.43 - 5.39 (m, IH), 4.90 and 4.68 (2d, J = 5.7 Hz, 2H, rotamers in the ratio 3: 1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :3), 3.68 - 3.52 (m, 4H), 3.42 - 3.21 (m, 4H), 3.08 (d, J = 4.8 Hz, 3H). IR (Neat): 3281, 2925, 2967, 1578, 1430, 1286, 1229, 1120, 1030, 856, 756, 617, 558 cm" .
CI-MS (m/e): 450 (M++l), 418
Example 143: (l-{3,5-Difluoro-4-[4-(2-oxo-propyl)-piperazin-l-yI]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000186_0001
The title compound (65 mg, 45 %) was synthesized from l-[4-(4-azido-2,6- difluoro-phenyl)-piperazin-l-yl]-propan-2-one (100 mg, 0.34 mmol), obtained in preparation 76, by following the procedure as described in example 1. Η NMR (400 MHz, CDC1 ): δ 8.01 and 7.77 (2s, IH, rotamers in the ratio 3: 1), 7.27 (d, J = 10.4 Hz, 2H), 6.90 - 6.81 (m, IH), 4.90 and 4.64 (2d, J = 6.0 Hz, 2H, rotamers in the ratio 3: 1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :3), 3.37 - 3.32 (m, 4H), 3.26 (s, 2H), 2.65 - 2.53 (m, 4H), 2.19 (s, 3H).
IR (KBr): 3421, 2849, 1719, 1520, 1955, 1353, 1203, 1140, 1025, 843, 616 cm"1. CI-MS (m/e): 425 (M++l), 393
Example 144:
(l-{3,5-Difluoro-4-[4-(2-hydroxyimino-propyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-yImethyl)-thiocarbamic acid O-methyl ester
Figure imgf000186_0002
The title compound (20 mg, 45 %) was synthesized from (l-{3,5-difluoro-4-[4-(2- oxo-propyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester (45 mg, 0.14 mmol), obtained in preparation 77, by following the procedure as described in example 1.
Η NMR (400 MHz, DMSO + CDCI3): δ 10.33 (bs, IH), 9.31 - 9.30 (m, IH), 8.45 and 8.40 (2s, IH, rotamers in the ratio 3: 1), 7.52 (d, J = 9.9 Hz, 2H), 4.78 and 4.51 (2d, J = 5.9 Hz, 2H, rotamers in the ratio 3: 1), 4.01 and 3.94 (2s, 3H, rotamers in the ratio 1 :3), 3.35 - 3.23 (m, 4H), 2.56 - 2.53 (m, 6H), 1.86 (s, 3H). IR (KBr): 3444, 2925, 1635, 1457, 1040 cm"1. CI-MS (m/e): 440 (M++l), 408
Example 145:
(l-{4-[4-(3,5-Dihydroxy-benzoyl)-piperazin-l-yI]-3,5-difluoro-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000187_0001
The title compound (190 mg, 46 %) was synthesized from 3,5-dihydroxy benzoic acid (300 mg, 0.82 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH- [l,2,3]triazol-4-ylmethyl]-thiocarbamic acid O-methyl ester (300 mg, 0.82 mmol), obtained in example 6, by following the procedure as described in example 27. Η NMR (400 MHz, DMSO): δ 9.66 - 9.61 (m, IH), 8.71 and 8.67 (2s, IH, rotamers in the ratio 3: 1), 7.76 (d, J = 9.8 Hz, 2H), 6.27 (t, J = 2.0 Hz, IH), 6.22 (d, J = 2.2 Hz, 2H), 4.72 and 4.44 (2d, J = 5.7 Hz, 2H, rotamers in the ratio 3: 1), 3.95 and 3.88 (2s, 3H, rotamers in the ratio 1 :3), 3.80 - 3.41 (m, 4H), 3.21 - 3.10 (m, 4H). IR (KBr): 3263, 1583, 1518, 1442, 1337, 1280, 1230, 1154, 1033, 1007, 973, 858 cm"1. ES-MS (m/e): 527 (M++23), 505 (M++l).
Example 146:
(l-{3,5-Difluoro-4-[4-(2-pyridin-4-y_-aceryl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000187_0002
The title compound (200 mg, 81 %) was synthesized from l-[4-(4-azido-2, 6- difluoro-phenyl) - piperazin-l-yl]-2-pyridin-4-yl-ethanone (320 mg, 0.89 mmol), obtained in preparation 78, by following the procedure as described in example 1. Η NMR (400 MHz, CDC1 ): δ 8.58 (d, J = 5.9 Hz, 2H), 8.04 and 7.78 (2s, IH, rotamers in the ratio 4: 1), 7.29 (d, J = 9.1 Hz, 2H), 7.22 (d, J = 5.6 Hz, 2H), 6.91 - 6.85 (m, IH),
4.90 and 4.64 (2d, J = 5.6 Hz, 2H, rotamers in the ratio 4:1), 4.11 and 3.99 (2s, 3H, rotamers in the ratio 1 :5), 3.81 - 3.77 (m, 2H), 3.77 (s, 2H), 3.60 - 3.51 (m, 2H), 3.25 -
3.19 (m, 2H), 3.19 - 3.10 (m, 2H).
IR (KBr): 3443, 2923, 1630, 1519, 1455, 1203, 1038, 697 cm"1.
CI-MS (m/e): 456 (M+-31), 399
Example 147:
(l-{4-[4-(2-Acetylamino-acetyl)-piperazin-l-yI]-3,5-difluoro-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000188_0001
The title compound (200 mg, 63 %) was synthesized from N-acetyl glycine (95 mg, 0.82 mmol) and [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3] triazol-4- ylmethyl]-thiocarbamic acid O-methyl ester (250 mg, 0.68 mmol), obtained in example 6, by following the procedure as described in example 27.
Η NMR (400 MHz, DMSO): δ 9.65 (t, J = 5.6 Hz, IH), 8.71 and 8.67 (2s, IH, rotamers in the ratio 3: 1), 7.96 (t, J = 5.3 Hz, IH), 7.75 (d, J = 8.3 Hz, 2H), 4.72 and 4.43 (2d, J = 5.7 Hz, 2H, rotamers in the ratio 3: 1), 3.98 (d, J = 5.6 Hz, 2H), 3.95 and 3.88 (2s, 3H, rotamers in the ratio 1 :3), 3.60 - 3.51 (m, 4H), 3.20 - 3.10 (m, 4H), 1.87 (s, 3H). IR (KBr): 3301, 2925, 1648, 1520, 1446, 1230, 1033, 983, 940, 857 cm"1. CI-MS (m/e): 468 (M++l), 436, 394
Example 148:
[l-(3,5-Difluoro-4-{4-[2-(2-hydroxy-acety!amino)-acetyl]-piperazin-l-yl}-phenyl)-lH- [l,2,3]triazol-4-yImethyl]-thiocarbamic acid O-methyl ester
Figure imgf000188_0002
The title compound (1 10 mg, 50%) was synthesized from N-{2-[4-(4-azido-2,6- difluoro-phenyl)-piperazin-l-yl]-2-oxo-ethyl}-2-hydroxy-acetamide (160 mg, 0.46 mmol), obtained in preparation 81 , by following the procedure as described in example 1. Η NMR (400 MHz, DMSO): δ 9.65 (t, J = 5.8 Hz, IH), 8.72 and 8.67 (2s, IH, rotamers in the ratio 3: 1), 7.75 (d, J = 8.3 Hz, 2H), 7.74 - 7.73 (m, IH), 5.64 (t, J = 5.6 Hz, IH), 4.73 and 4.44 (2d, J = 5.8 Hz, 2H, rotamers in the ratio 3:1), 4.06 (d, I =5.1 Hz, 2H), 3.95 and 3.89 (2s, 3H, rotamers in the ratio 1:3), 3.86 (d, J = 5.6 Hz, 2H), 3.61 - 3.50 (m, 4H), 3.21 - 3.10 (m, 4H).
IR (KBr): 3354, 2922, 1654, 1518, 1449, 1367, 1286, 1235, 1209, 1129, 1084, 1030, 983, 857, 759, 615, 580 cm'1. ES-MS (m/e): 506 (M++23), 484 (M++l).
Example 149:
[2-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester
Figure imgf000189_0001
By following the procedure as described in example 82, the title compound (1.7 grams, 87%) was synthesized from {2-[4-(4-azido-2, 6-difluoro-phenyl)-piperazin-l-yl]- 2-oxo-ethyl}-carbamic acid tert-butyl ester (1.5 grams, 3.78 mmol), obtained in preparation 79.
Η NMR (400 MHz, DMSO): δ 8.06 and 7.82 (2s,lH, rotamers in the ratio 5:1), 7.31 (d, J= 9.2 Hz, 2H), 7.12 - 7.00 (m,lH), 5.62 -5.49 (m,lH), 4.91 and 4.66 (2d, J = 6.1 Hz, 2H, rotamers in the ratio 5: 1), 4.14 - 3.99 (m, 5H), 3.82 -3.71 (m, 2H), 3.60 - 3.50 (m, 2H), 3.30 - 3.18 (m, 4H), 1.46 (s, 9H).
IR (KBr): 3287, 2976, 1716, 1844, 1517, 1464, 1367, 1280, 1228, 1022 cm'1 ES-MS (m/e): 526(M++1), 426
Example 150:
(l-{3,5-Difluoro-4-[4-(2-ureido-acetyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester 3
Figure imgf000190_0001
[2-(4-{2,6-Difluoro-4-[4-(methox3 hiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (1.7 grams, 3.29 mmol), obtained in example 149, was treated with 60% TFA in DCM and stirred at 25-35
°C for 30 minutes and the reaction mixmre was co-evaporated with toluene (2 x 30 mL)
and extracted with ethyl acetate and concentrated to give (l-{4-[4-(2-amino-acetyl)- piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester, which was pure enough to be taken for further step directly. To a stirred solution of ( 1 - {4-[4-(2-amino-acetyl)-piperazin- 1 -yl]-3 ,5-difluoro-phenyl} - 1 H-
[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester (270 mg, 0.73 mmol) in dry DCM at 0 °C was added frimethylsilyl isocyanate (0.3 mL, 2.2mmol) dropwise and stirred at 25-35 °C for 9 to 13 hours. The solvent was removed under vacuum and the residue
was purified by column chromatography (1.5% Methanol in chloroform) to give the title product (150 mg, 44%).
Η NMR (400 MHz, DMSO): δ 9.65 (t, J = 5.6 Hz, IH), 8.71 and 8.67 (2s, IH, rotamers in the ratio 3:1), 7.75 (d, J = 9.9 Hz, 2H), 6.10 - 6.05 (m, IH), 5.68 (s, 2H), 4.73 and 4.44
(2d, J = 5.9 Hz, 2H, rotamers in the ratio 3:1), 3.95 and 3.88 (2s, 3H, rotamers in the ratio
1 :3), 3.92 (d, J = 5.1 Hz, 2H), 3.62 - 3.55 (m, 2H), 3.55- 3.50 (m, 2H), 3.20 - 3.10 (m,
4H).
IR (KBr): 3361, 2924, 1646, 1579, 1462, 1229, 1151, 1033, 817, 617 cm"1.
ES-MS (m/e): 469 (M++l)
Example 151:
(l-{3,5-Difluoro-4-[4-(2-phenyl-[l,3]dioxaπe-5-carbonyl)-piperazin-l-yl]-phenyl}-lJΪ- [l,2,3)triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000190_0002
To a suspension of [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol- 4 -ylmethyl] -thiocarbamic acid O-methyl ester (2.0 grams, 5.39 mmol) in DCM (30 mL) was added 2-phenyl-[l,3]dioxane-5-carboxylic acid (1.23 grams, 5.89 mmol) and _V- methylmorpholine (0.78 mL, 7.1 mmol) followed by the addition of l-(3- dimethylaminopropyl)-3 -ethyl carbodiimide.HCl (1.26 grams, 6.55 mmol) at 0 °C and stirred for 12 hours. The reaction mixmre was diluted with DCM; washed with water and brine solution successively and then dried over Na2S04. The DCM portion was concentrated and the resulting residue purified on silica gel (100-200 mesh) with CHCh/MeOH as eluent. The required compound was then dissolved in CHCU/MeOH. Charcoal was added and heated at 50 °C for 0.5 hour. Charcoal was filtered over celite and the filtrate concentrated and washed with petroleum ether. Title compound was obtained as light yellow solid (2.05 grams, 68%). MS (m/z): 559 (M++l), 527, 421.
Example 152:
(l-{3,5-Difluoro-4-[4-(3-hydroxymethyl-propionyl)-piperazin-l-yl]-phenyl}-lfl- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000191_0001
A cooled solution of aqueous HCI (50%>, 50 mL) was added to a solution of (1- {3,5-difluoro-4-[4-(2-phenyl-[l,3]dioxane-5-carbonyl)-piperazin-l-yl]-phenyl}-lH- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester (2.0 grams, 3.58 mmol), obtained in example 151, in methanol at 0 °C The temperamre was allowed to come to
25-35 °C and stirring continued for 12 hours. Reaction mixmre was neutralized with solid
NaΗC03 at 0 °C and then extracted with CHCI3. The organic layer was washed with water and brine solution successively and dried over Na2S04. The residue obtained upon concentration was purified over silica gel (100-200 mesh) with CHCb/MeOH as eluent.
Title compound was obtained as white solid (960 mg, 57%).
Melting Point : 178-180 °C .
Η NMR (CDCI3+DMSO- , 400 MHz): δ 8.76 & 8.63 (2t, J = 6.1 Hz, IH), H), 8.21 &
8.07 (2s in a ratio of 4: 1, IH), 7.48 (ά, J= 9.7 Hz, 2H), 4.85 & 4.56 (2d in a ratio of 4: 1, J = 5.6 Hz, 2H), 4.05-4.21 (m, IH), 4.03 & 3.96 (2s in a ratio of 1 :4, 3H), 3.85 (d, J = 5.6
Hz, 4H), 3.75-3.72 (m, 4H), 3.25 (bs, 2H), 3.20 (bs, 2H).
IR (KBr, cm"1): 3382, 3272, 1624, 1517, 1439, 1205, 1013, 981, 709.
MS (m/z): 471 (M++l), 439, 391, 352.
Example 153:
(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin -l-yl)-oxo-acetic acid methyl ester
Figure imgf000192_0001
To a suspension of [l-(3,5-difluoro-4-piperazin-l-yl-phenyl)-lH-[l,2,3]triazol-4- ylmethyl] -thiocarbamic acid O-methyl ester (1.0 gram 2.72 mmol), obtained in example 6, in DCM was added triethyl amine (0.46 mL, 3.54 mmol) followed by the addition of methyl oxalyl chloride (0.31 mL, 3.37 mmol) at 0 °C and stirred for 0.5 hour. The reaction mixture was diluted with DCM; washed with water and brine solution successively and dried over Na2S04. Organic portion was concentrated and purified on silica gel (100-200 mesh) with CHC^/MeOH as eluent. The title compound was obtained as white solid (865 mg, 70%). Melting Point: 178-180 °C
Η NMR (CDC1 , 200 MHz): δ 8.05 & 7.81 (2s in a ratio of 4:1, IH), 7.31 (d, J = 9.3 Hz, 2H), 6.91 (bs, IH), 4.93 & 4.65 (2d in a ratio of 4: 1, J = 5.9 Hz, 2H), 4.11 & 4.00 (2s in aratio of 1 :4, 3H), 3.90 (s, 3H), 3.72-3.82 (m, 2H), 3.55-3.65 (m, 2H), 3.15-3.35 (m, 4H). IR (KBr, cm"1): 3439, 3288, 1739, 1650, 1515. MS (m/z): 469 (M++l), 423.
Example 154:
(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenylj-piperazin -l-yl)-oxo-acetic acid
Figure imgf000192_0002
To a solution of (4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino-methyl)- [l,2,3]triazol-l-yl]-phenyl}-piperazin-l-yl)-oxo-acetic acid methyl ester (100 mg, 0.22 mmol), obtained in example 153, in THF was added lithium hydroxide (18 mg, 0.44 mmol) solution in water at 0 °C and stirred for 1 hour at 25-35 °C. Reaction mixmre was
diluted with water (2 mL) and pH of the solution was brought to 2 with 10%> aqueous.
HCI. Solid obtained was filtered and dissolved in aqueous.NaOH (13 mg, 0.33 mmol) solution. Aqueous layer was washed with ethyl acetate and acidified with 10% aquoes. HCI to pH 2. White solid obtained was filtered, washed with cold water and dried to obtain the title compound (60 mg, 62%).
Melting Point: 160-162 °C .
Η NMR (CDCl3+DMSO-< , 200 MHz): δ 8.85 (bs, 1NH), 8.25 & 8.13 (2s in a ratio of
4: 1, IH), 7.40 (d, J = 8.9 Hz, 2H), 4.85 & 4.59 (2d in a ratio of 4: 1, J = 5.0 Hz, 2H), 4.06
& 4.00 (2s in a ratio of 1 :4, 3H), 3.76 (bs, 2H), 3.66 (bs, 2H), 3.27 (bs, 4H).
IR(cm"'): 3249, 1724, 1628, 1522, 1202, 1026, 856.
MS (mz): 397, 365.
Example 155:
{l-[4-(4-Aminooxalyl-piperazin-l-yl)-3,4-difluoro-phenyl]-l T-[l,2,3]triazol- ylmethyl}-thiocarbamic acid O-methyl ester
Figure imgf000193_0001
To a solution of (4-{2,6-difluoro-4-[4-(methoxythiocarbonylamino-methyl)- [l,2,3]triazol-l-yl]-phenyl}-piperazin-l-yl)-oxo-acetic acid (100 mg, 0.27 mmol), obtained in example 154, in THF was added triethyl amine (0.05 mL, 0.34 mmol) followed by the addition of isobutylchloroformate at 0 °C and stirred for 15 minutes. Ammonia gas was then passed through the reaction mixmre for 15 minutes at 0 °C Reaction mixmre was diluted with ethylacetate, washed with water and brine solution successively and dried over Na2S04. Organic portion was concentrated and purified on silica gel (100-200 mesh) with CHCl3/MeOH as eluent. The title compound was obtained as white solid (70 mg, 70%). Melting Point: 190-192 °C. Η NMR (CDCI3, 200 MHz): δ 8.05 & 7.18 (2s in a ratio of 4:1, IH), 7.31 (d, J = 9.0 Hz,
2H), 7.21 (bs, IH), 7.07 (bs, IH), 6.92 (bs, IH), 4.91 & 4.66 (2d in a ratio of 4:1, J = 5.9
Hz, 2H), 4.20 - 4.30 (m, 2H), 4.11 & 4.00 (2s in a ratio of 1 :4, 3H), 3.72-3.85 (m, 2H),
3.29 (bs, 4H).
IR (KBr, cm"1): 3381, 2924, 1659, 1517, 1232, 1028, 616.
MS (m/z): 440 (M++l), 408.
The compounds mentioned below have been synthesized following any suitable procedure as defined above.
Example 156:
4-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-4-oxo-butyric acid methyl ester
Figure imgf000194_0001
White colour solid (62% yield).
Melting Point.: 140-142 °C
Η NMR (DMSO-^e, 200 MHz): δ 9.68 (bs, IH), 8.73 & 8.68 (2s in a ratio of 1:4, IH), 7.76 (d, J = 9.8 Hz, 2H), 4.73 & 4.43 (2d in a ratio of 4: 1, J= 5.6 Hz, 2H), 3.95 & 3.89 (2s in a ratio of 1 :4, 3H), 3.59 (s, 7H), 3.05-3.25 (m, 4H), 2.42-2.65 (m, 4H). IR (KBr, cm"1): 3245, 1720, 1641, 1518, 1454. MS (m/z): 483 (M++l), 451.
Example 157:
4-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-4-oxo-butyric acid
Figure imgf000194_0002
White solid (62% yield). Melting Point : 200-202 °C. Η NMR (CDCl3+DMSO-c?6, 200 MHz): δ 1 1.8 (hump, IH), 8.82 & 8.71 (2bs in a ratio of 1 :4, IH), 8.21 8c 8.08 (2s in a ratio of 4:1, IH), 7.88 (d, J = 9.3 Hz, 2H), 4.85 & 4.69 (2d in a ratio of 4: 1, J= 5.9 Hz, 2H), 4.06 & 3.99 (2s in a ratio of 1:4, 3H), 3.74 (bs, 2H), 3.65 (bs, 2H), 3.22 (bs, 4H), 2.50-2.85 (m, 4H). IR (KBr, cm"1): 3311, 1713, 1601 , 1521. MS (m/z): 369, 337.
Example 158:
(l-{4-[4-(3-Carbamoyl-propionyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-l_?y- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000195_0001
White solid (73% yield).
Melting Point: 180-182 °C .
Η NMR (CDC13, 200 MHz): δ 8.07 & 7.84 (2s in a ratio of 4: 1, IH), 7.31 (d, J = 9.5 Hz,
2H), 7.09 (bs, IH), 6.05 (bs, IH), 5.43 (bs, IH), 4.90 & 4.66 (2d in a ratio of 4:1, J = 5.9
Hz, 2H), 4.11 8c 4.00 (2s in a ratio of 1 :4, 3H), 3.70-3.79 (m, 2H), 3.61-3.69 (m, 2H),
3.11-3.32 (m, 4H), 2.51-2.82 (m, 4H).
IR (KBr, cm"1): 3393, 3220, 1636, 1519, 1432, 1204, 853, 613.
MS (m/z): 468 (M++l), 436, 419
Example 159:
3-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyI}-piperazin-l-yl)-4-oxo-propionic acid methyl ester
Figure imgf000195_0002
Melting Point: 130-132 °C Η NMR (CDCI3, 200 MHz): δ 8.07 & 7.83 (2s in a ratio of 4: 1, IH), 7.30 (d, J = 9.6 Hz, 2H), 7.02 (bs, IH), 4.90 & 4.65 (2d in a ratio of 4: 1, J= 5.9 Hz, 2H), 4.11 & 3.99 (2s in a ratio of 1 :4, 3H), 3.78 (bs, 5H), 3.60 & 3.54 (m, 4H), 3.25 (bs, 4H). IR (cm"'): 3252, 1745, 1637, 1519, 1208, 1018, 856, 706. MS (m z): 469 (M++l), 437.
Example 160:
3-(4-{2,6-Difluoro-4-[4-(methoxythiocarbonylamino-methyl)-[l,2,3]triazol-l-yl]- phenyl}-piperazin-l-yl)-4-oxo-propionic acid
Figure imgf000196_0001
Melting Point: 138-140 °C .
Η NMR (CDCI3+DMSO- , 200 MHz): δ 12.5 (hump, IH), 9.17 (bs, IH), 8.36 & 8.28
(2s in a ratio of 4:1, IH), 7.46 (d, J = 9.5 Hz, 2H), 4.82 & 4.54 (2d in a ratio of 4:1, J =
5.9 Hz, 2H), 4.04 & 3.96 (2s in a ratio of 1 :4, 3H), 3.73-3.62 (m, 4H), 3.49 (s, 2H), 3.24
(bs, 4H).
IR (KBr, cm"1): 3443, 3235, 1730, 1634, 1522, 1443, 1233, 859.
MS (m/z): 395, 379
Example 161:
(l-{4-[4-(2-Carbamoyl-acetyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-l_?7-[l,2,3]triazol- 4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000196_0002
Η NMR (DMSO-- 400 MHz): δ 9.65 (t, j = 5.9 Hz, IH), 8.72 & 8.67 (2s in a ratio of 4: 1, IH), 7.76 (d, J = 9.5 Hz, 2H), 7.45 (bs, IH), 6.99 (bs, IH), 4.73 & 4.44 (2d in a ratio of 4:1, J = 5.6 Hz, 2H), 3.95 & 3.89 (2s in a ratio of 1 :4, 3H), 3.58 (bs, 4H), 3.31 (s, 2H), 3.19 (bs, 2H), 3.11 (bs, 2H). MS (ES): 476 (M++22), 454 (M+), 335, 276. Example 162:
{l-[4-(4-Benzoyl-piperazin-l-yl)-3,5-difluoro-phenyl]-l _'-[l,2,3]triazol-4-ylmethyl}- thiocarbamic acid O-methyl ester:
Figure imgf000197_0001
Melting Point: 132-140 °C .
Η NMR (200 MHz, CDC13): δ 8.06 & 7.80 (2s in a ratio of 4: 1, IH), 7.44 (s, 5H), 7.31 (d, J= 6.18 Hz, 2H), 7.01 (bs, IH), 4.91 & 4.65 (2d in a ratio of 4:1, J= 5.9 Hz, 2H), 4.11 & 3.99 (2s in a ratio of 1 :4, 3H), 3.81-3.98 (m, 2H), 3.51-3.70 (m, 2H), 3.11-3.38 (m, 4H). IR (neat, cm"1): 1625, 1518, 1437. MS (m/e): 473 (M+), 441.
Example 163:
(l-{4- [4-(4-Amino-benzoyl)-piper azin-1 -yl] -3,5-difluoro-phenyl} -IH- [1 ,2,3] triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000197_0002
Melting Point: 176-178 °C.
Η NMR (200 MHz, CDC13): δ 8.05 & 7.80 (2s in a ratio of 4:1, IH), 7.18-7.38 (m, 4H), 7.08 & 6.90 (2 bs in a ratio of 1 :4, IH), 6.68 (d, J= 8.4 Hz, 2H), 4.91 & 4.65 (2d in a ratio of 4: l, J = 5.9 Hz, 2H), 4.1 1 & 3.99 (2s in a ratio of 1 :4, 3H), 3.65-3.85 (bs, 4H), 3.13- 3.28 (bs, 4H).
IR (KBr, cm-'): 3350, 1607, 1518, 1436. MS (m/e): 488 (M++l), 456, 424, 399.
Example 164:
(l-{4-[4-(3-Amino-benzoyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-l-9-[l,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester:
Figure imgf000198_0001
Melting Point: 116-118 °C.
Η NMR (200 MHz, CDC13): δ 8.05 & 7.80 (2s in a ratio of 4: 1 , IH), 7.05-7.36 (m, 4H), 6.82-6.95 (m, IH), 6.75 (t, J = 8.4 Hz, 2H), 4.89 & 4.65 (2d in a ratio of 4: 1, J = 5.9 Hz, 2H), 4.11 8c 3.99 (2s in a ratio of 1:4, 3H), 3.45-3.89 (m, 4H), 3.09-3.35 (m, 4H). IR (KBr, cm"1): 3357, 1623, 1518, 1463, 1437. MS (m e): 488 (M++l), 456, 411.
Example 165:
(l-{4-[4-(4-Chloro-benzoyl)-piperazin-l-yl]-3,5-difluoro-phenyI}-l_r7-[l,2,3]triazoI-4- ylmethyl)-thiocarbamic acid O-methyl ester:
Melting Point: 180-184 °C .
Η NMR (200 MHz, CDC13): δ 8.05 & 7.80 (2s in a ratio of 4: 1 , IH), 7.22-7.45 (m, 6H), 6.94 (bs, IH), 4.91 & 4.65 (2d in a ratio of 4:1, J= 5.9 Hz, 2H), 4.11 & 3.99 (2s in a ratio of 1 :4, 3H), 3.51-3.98 (m, 4H), 3.15-3.32 (m, 4H). IR (KBr, cm"1): 1638, 1519, 1433. MS (m/e): 507 (M+), 475, 391.
Example 166:
(l-{4-[4-(3,4-Dimethoxy-benzoyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-l_H- [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester:
3
Figure imgf000198_0003
Melting Point: 72-72 °C . Η NMR (200 MHz, CDC13): δ 8.06 & 7.81 (2s in a ratio of 4:1, IH), 7.21-7.35 (m, 2H), 6.81-7.08 (m, 3H), 4.91 & 4.65 (2d in a ratio of 4: 1, 7 = 5.9 Hz, 2H), 4.1 1 & 3.99 (2s in a ratio of 1 :4, 3H), 3.92 (s, 6H), 3.65-3.85 (m, 4H), 3.18-3.32 (m, 4H). IR (KBr, cm"1): 2926, 1626, 1518, 1463. MS (m/e): 533 (M++l), 501.
Example 167:
(l-{3,5-Difluoro-4-[4-(4-vinyl-benzoyl)-piperazin-l-yl)-phenyl}-l_?ϊ-[l,2,3]triazol-4- ylmethylj-thiocarbamic acid -methyl ester:
Figure imgf000199_0001
Melting Point: 150-152 °C .
Η NMR (200 MHz, CDCI3): δ 8.05 & 7.80 (2s in a ratio of 4:1, IH), 7.05-7.51 (m, 6H),
6.95 (bs, IH), 6.65-6.82 (m, IH), 5.73 (d, 7 = 17.4 Hz, IH), 5.33 (d, 7 = 10.7 Hz, IH),
4.91 & 4.65 (2d in a ratio of 4:1, 7 = 5.9 Hz, 2H), 4.11 & 3.99 (2s in a ratio of 1 :4, 3H),
3.51-3.98 (m, 4H), 3.15-3.35 (m, 4H).
IR (KBr, cm"1): 1636, 1560, 1519, 1432.
MS (m/e): 499 (M+), 467, 380, 278.
Example 168:
_V-(l-{4-[4-(2(_R),3-Dihydroxy-propionyl)-piperazin-l-yl)-3,5-difluoro-phenyl}-l_? -
[l,2,3]triazol-4-ylmethyl}-acetamide:
Figure imgf000199_0002
Melting Point: 182-184 °C.
Η NMR (200 MHz, DMSO- 6): δ 8.66 (s, IH), 8.44 (bs, IH), 7.75 (d, 7 = 9.8 Hz, 2H),
5.02 (bs, IH), 4.75 (bs, IH), 4.35 (d, 7 = 5.3 Hz, 3H), 3.41-3.73 (m, 6H), 3.05-3.29 (bs,
4H), 1.86 (s, 3H).
IR (KBr, cm"1): 1636, 1560, 1519, 1432.
MS (m/e): 425 (M++l), 393, 337. Example 169:
N-(l-{4-[4-(2(i?),3-Dihydroxy-propionyl)-piperazin-l-yl)-3,5-difluoro-phenyl}-l_?ϊ-
[l,2,3]triazol-4-ylmethyl}-thioacetamide: 3
Figure imgf000200_0001
Melting Point: 202-203 °C.
Η NMR (200 MHz, OMSO-d6): δ 10.50 (bs, IH), 8.78 (s, IH), 7.75 (d, 7 = 9.8 Hz, 2H),
5.00 (d, 7 = 7.0 Hz, IH), 4.83 (d, 7= 5.1 Hz, 2H), 4.74 (t, 7 = 5.8, IH), 4.28-4.47 (m, IH),
3.42-3.78 (m, 6H), 3.05-3.30, 2.44 (s, 3H).
IR (KBr, cm"1): 1629, 1517, 1457.
MS (m/e): 441 (M++l).
Example 170:
(l-{4-[4-(2(_R),3-Dihydroxy-propionyl)-piperazin-l-yl)-3,5-difluoro-phenyl}-l_?_r- [l,2,3]triazol-4-ylmethyl}-carbamic acid methyl ester:
Figure imgf000200_0002
Melting Point: 142-144 °C.
Η NMR (200 MHz, DMSO- t6): δ 8.67 (s, IH), 7.77 (d, 7 = 9.6 Hz, 2H), 5.02 (bs, IH),
4.75 (bs, IH), 4.37 (bs, IH), 4.31 (d, 7 = 5.6 Hz, 2H), 3.41-3.73 (m, 6H), 3.56 (s, 3H),
3.05-3.29 (bs, 4H).
IR (KBr, cm"1): 1636, 1560, 1519, 1432.
MS (m/e): 441 (M++l), 409.
Example 171: N-[l-(3,5-Difluoro-4-piperazin-l-yl-phenyl)-lΛ-[l,2,3]triazol-4-ylmethyI}-acetamide:
Figure imgf000200_0003
Melting Point: 212 °C .
Η NMR (200 MHz, DMSO-d6): δ 8.68 (s, IH), 8.51 (bs, IH), 7.76 (d, 7 = 9.8 Hz, 2H),
4.35 (d, 7= 5.6 Hz, 2H), 3.29 (bs, 4H), 3.04 (bs, 4H), 1.86 (s, 3H).
IR(KBr, cm"1): 3278, 2928, 1676, 1520.
MS (m/e): 337 (M++l).
Example 172:
N-[l-(3,5-Difluoro-4-piperazin-l-yl-phenyl)-l_?_ -[l,2,3]triazol-4-ylmethyl}- thioacetamide:
Figure imgf000201_0001
Melting Point: 210-212 °C
Η ΝMR (200 MHz, DMSO-d6): δ 10.56 (bs, IH), 8.79 (s, IH), 7.78 (d, 7 = 9.8 Hz, 2H),
4.84 (d, 7= 5.1 Hz, 2H), 3.32 (bs, 4H), 3.10 (bs, 4H), 2.45 (s, 3H).
IR(KBr, cm"1): 3437, 1518, 1559, 1037.
MS (m/e): 352 (M+), 324, 279, 241.
Example 173:
[l-(3,5-Difluoro-4-piperazin-l-yl-phenyl)-lJF/-[l,2,3]triazol-4-ylmethyl}-carbamic acid methyl ester:
Figure imgf000201_0002
Melting Point : 110 °C .
Η ΝMR (200 MHz, OMSO-d6): δ 8.65 (s, IH), 7.72 (d, 7 = 9.8 Hz, 2H), 4.30 (d, 7 = 5.9
Hz, 2H), 3.56 (s, 3H), 3.17 (bs, 4H), 2.82 (bs, 4H).
IR (KBr, cm"1): 1723, 1518, 1456, 1255.
MS (m/e): 353 (M++l), 321.
Example 174:
(l-{3,5-Difluoro-4-[4-(2-oxo-propionyl)-piperazin-l-yl]-phenyl}-lH-[l,2,3]triazol-4- ylmethyl}-thiocarbamic acid O-methyl ester:
Figure imgf000202_0001
Melting Point: 126-128 °C .
Η NMR (200 MHz, CDC13): δ 8.06 & 7.81 (2s in a ratio of 4: 1, IH), 7.32 (d, 7= 9.8 Hz,
2H), 6.93 (bs, IH), 4.89 & 4.12 (2d in a ratio of 4:1, 7 = 6.18 Hz, 2H), 4.12 & 4.00 (2s in a ratio of 1 :4, 3H), 3.72-3.85 (m, 2H), 3.58-3.3.70 (m, 2H), 3.18-3.32 (m, 4H), 2.48 (s,
3H).
IR (KBr, cm"1): 1722, 1645, 1516.
MS (m/e): 406 (M+-32), 395, 377, 335, 320.
Example 175:
(l-{3,5-Difluoro-4-[4-(2-hydroxy-propionyl)-piperazin-l-yl]-phenyI}-l_fϊ- [l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester: j
Figure imgf000202_0002
Melting Point: 130-132 °C
Η NMR (200 MHz, CDC13): δ 8.06 & 7.34 (2s in a ratio of 4: 1, IH), 7.32 (d, 7= 9.8 Hz, 2H), 6.96 (bs, IH), 4.91 & 4.66 (2d in a ratio of 4:1, 7 = 5.9 Hz, 2H), 4.51 (q, 7 = 6.4 Hz, IH), 4.11 & 3.99 (2s in a ratio of 1 :4, 3H), 3.68-3.92 (m, 2H), 3.56 (bs, 2H), 3.25 (bs, 4H), 1.37 (d, 7= 6.4 Hz, 3H). IR (KBr, cm"1): 3422, 1642, 1519. MS (m/e): 440 (M+), 408, 322
Example 176:
S-(l - {3,5-Difluor o-4-[4-(2-oxo-oxazolidine-5-carbonyl)-piper azin-1 -yl] -phenyl} ΛH-
[l,2,3]triazol-4-ylmethyl}-thiocarbamic acid O-methyl ester:
Figure imgf000202_0003
Melting Point : 158-160 °C Η NMR (400 MHz, CDC13): δ 8.06 & 7.84 (2s in a ratio of 4: 1, IH), 7.25-7.39 (m, 2H), 6.98 (t, 7 = 7.25 Hz, IH), 5.19-5.28 (m, 2H), 4.90 & 4.66 (2d in a ratio of 4:1, 7 = 6.2 Hz, 2H), 4.31-4.39 (m, IH), 4.11 & 3.99 (2s in a ratio of 1 :4, 3H), 3.82-4.00 (m, 2H), 3.62- 3.75 (m, 2H), 3.21-3.32 (m, 4H). IR (KBr, cm"1): 1756, 1640, 1520. MS (ES): 504 (M++Na), 482 (M++l).
Example 177:
{l-[3,5-Difluoro-4-(4-prop-2-ynyl-piperazine-l-yl)-phenyl]-l_7-[l,2,3]triazol-4- ylmethyl}-thiocarbamic acid O-methyl ester
Figure imgf000203_0001
Melting Point: 120-121 °C
Η NMR (400 MHz, CDCI3): δ 8.02 & 7.79 (2s in a ratio of 4: 1, IH), 7.22-7.31 (m, 2H),
6.93 (bs, IH), 4.91 & 4.89 (2d in a ratio of 4:1, 7 = 5.9 Hz, 2H), 4.1 1 & 3.99 (2s in a ratio of 1 :4, 3H), 3.38 (d, 7 = 2.4 Hz, 2H), 3.32 (bs, 4H), 2.68-2.78 (m, 4H), 2.29 (t, 7= 2.4 Hz,
IH).
IR (KBr, cm"1): 1518, 1455.
MS (m/e): 407 (M++l), 375, 288.
Example 178:
{l-[4-(4-Cyanomethyl-piperazin-l-yl)-3,5-Difluoro-phenyl]-l//-[l,2,3]triazol-4- ylmethyl}-thiocarbamic acid O-methyl ester ,
Figure imgf000203_0002
Melting Point: 130-131 °C .
Η NMR (400 MHz, CDCI3): δ 8.04 & 7.82 (2s in a ratio of 4:1, IH), 7.29 (d, 7 = 9.8 Hz, 2H), 7.00 (bs, IH), 4.90 & 4.66 (2d in a ratio of 4:1, 7 = 5.9 Hz, 2H), 3.58 (s, 2H), 3.26- 3.33 (m, 4H), 2.71-2.81 (m, 4H). IR (KBr, cm"1): 2837, 1517, 1455. MS (m/e): 408 (M++l), 381, 376, 349.
Example 179:
(l-{4-[4-(2-Bromo-acetyl)-piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2 ,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester
Figure imgf000204_0001
Bromoacetyl Bromide (2.354 grams, 11.7 mmol) was added drop wise (30 minutes) to a suspension of compound (2.8 grams, 11.7 mmol) obtained in example 6, and K2CO3 (0.967 grams, 7 mmol) in DCM (50 mL) at 0-5 °C. The reaction mixmre was then stirred for 2 hours at 25-35 °C, concentrated and extracted the product in ethyl acetate
(500 mL). The organic layer was washed with water (100 mL), brine (100 mL) and dried over Na2S04 and concentrated to get brownish semisolid mass. Product was purified by column chromatography (60-120 mesh silica, 15 % ethyl acetate in hexanes, to get the product (1.1 grams, 26%>) as a pale yellow solid.
Example 180-186
For secondary Amine: Secondary amine (1-1.5 equivalents) was added to a suspension of starting compound (1 equivalent) and K23 (2-3 equivalnets) in Acetonitrile (CH3CN) (40-50 v/w) at 25-30 °C . The reaction mixmre was stirred for (1-8 hours). Reaction was monitored by TLC and after the completion, product was extracted with ethyl acetate and usual workup gave nearly pure product which was taken to the next step without further purification.
For primary Amine: A solution of the starting material (1 equivalant) in CH3CN (20-30 v/w) was added drop wise to a suspension of primary amine (5-10 equivalents) & K2C03 (3-5 equivalents) in CH3CN (30-50 v/w) at 0-5 °C . Reaction mixmre was then stirred for (1-8 hours) at 25-35 °C and monitored by TLC. Product was extracted with
ethyl acetate and usual workup gave cmde product, which was further purified by column chromatography.
The following compounds were prepared by following the above procedure.
Figure imgf000205_0001
Figure imgf000206_0001
Example 187
Minimum Inhibiton Concentrations (MICs) were determined by broth microdilution technique as per the guidelines prescribed in the fifth edition of Approved Standards, NCCLS document M7-A5 Vol 20 - No 2, 2000 Nillinova, PA.
Initial stock solution of the test compound was prepared in DMSO. Subsequent two fold dilutions were carried out in sterile Mueller Hinton Broth (Difco) (MHB).
Frozen cultures stocks were inoculated into 50 ml sterile MHB in 250 ml Erlyn Meyer flasks.
Composition of MHB is as follows: Beef Extract Powder - 2.0 g/litre Acid Digest of Casein - 17.5 g/ litre Soluble Starch - 1.5 g/litre Final pH 7.3 + 0.1
Flasks were incubated for 4 to 5 h at 35 °C on a rotary shaker at 150 rpm. Inoculum was prepared by diluting the culmre in sterile MHB to obtain a mrbidity of 0.5 McFarland standard. This corresponds to 1-2 x 108 CFU/ml. The stock was further diluted in sterile broth to obtain 1-2 X 106 CFU/ml. 50 μl of the above diluted inoculum was added from 1-10 wells. The plates were incubated 9 to 13 hours at 37 °C.
MIC is read as the lowest concentration of the compound that completely inhibits growth of the organism in the microdilution wells as detected by the unaided eye.
Organism Culture o. DRCC No
Figure imgf000207_0001
ATCC: American Type Culmre Collection, USA NCTC: National Collections of Type Cultures, Colindale, UK DRCC: Dr. Reddy's Culmre Collection, Hyderabad, India. The in vitro antibacterial activity data is shown in TABLE 1.
Example 188:
• S.aureus ATCC 29213 and other tested strains were grown 9 to 13 hours on Columbia Blood agar (DIFCO).
• The inoculum was prepared by suspending the culmre in 0.9% saline and adjusted to 100 x LD50 dose in 10% Hog Gastric Mucin (DIFCO). 0.5ml was injected intraperitonially to Swiss albino mice weighing 18-22g (n=6)
• Test compounds were solubilised in suitable formulation and 0.25ml was administered intra venously or orally or sub-cutaneously at 1 hr and 5 hr post infection by BID or TID or single dose protocol
• The animals were observed for 5-7 days and the survival was noted.
• ED50 was calculated by probit analysis.
Abbreviations:
CHCI3: Chloroform
Na2C03: Sodium carbonate NaHC03: Sodiumbicarbonate
HCI: Hydrochloride
TFA: Trifluoro acetic acid
TBDMSO: tert-butyl-dimethyl-silanyloxy)-acetyl chloride
DCM: Dichloromethane
EDCI: l-[3-(dimethylamino)propyl]-3-ethyl- carbodiimide, hydrochloride
DMF: Dimethylformamide
THF: Tetrahydrofuran
(BOC)20: Di-tert-butyl Dicarbonate mL: Milli litres mmol: Milli moles
Et3SiH: Triethylsilane
BF3.OEt2: Boron trifluoride diethyl ether complex
CH3COOH: Trifluoroacetic acid
TMSC1: Trimethylsilyl chloride
Nal: Sodiumiodide
Me2SiI2: Diiododimethyl silane
Bu3SnH: Tri-n-butyl tin hydride
Cul: Cuprous (1) Iodide

Claims

We claim:
1. A compound of formula (I)
Figure imgf000209_0001
Where R1 is isoindole-1, 3-dione, azido, NHR5 where R5 represents
(a) Hydrogen,
(b) -c-R6
Q Where Q represents 'O' or 'S' R represents (i) Hydrogen,
Optionally substituted groups selected from, (ϋ) Alkyl, (iii) Cycloalkyl, (iv) Alkoxy, (v) Cycloalkoxy, (vi) Alkenyl, (vii) Alkenyloxy, (viii) Aryl, (ix) Aryloxy, (xii) Heteroaryl, (xiii) Heterocyclyl, (xii) Heteroaryloxy,
(xiii) -NH-R7, where R7 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, hydroxyalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, — C II — R8
Q ' wherein R8 is optionally substituted group selected from alkyl, alkoxy, cycloalkyl, alkenyl, alkenyloxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, and Q represents oxygen or sulfur; (xiv) -N-[alkyl]2, (xv) -N(RcRα), wherein Rc and Rd together form an optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xvi) -SR8, wherein R8 is as defined above, (xv) -S02-alkyl;
R2 and R3 at each occurrence are the same or different and are (ix) Hydrogen, (x) Halogen, (xi) Cyano, (xii) Nitro, (xiii) Amino
Optionally substituted groups selected from (xiv) Alkyl, (xv) Haloalkyl,
(xvi) 0Ra where Ra represents hydrogen or optionally substituted alkyl group; (xvii) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino;
'Z' represents N, C or CH;
' ' represents a bond or nobond;
R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, alkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, alkenyloxy, aryl, aryloxy, arylcarbonyl, aralkyl, aralkylcarbonyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heterocyclylalkyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, aralkoxyalkyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfmyl, arylsulfonyl, arylsulfanyl, arylsulfinyl, tert-butoxycarbonyl, (BOC), heteroarylsulfonyl
R and R independently represent hydrogen, oxo (=0), thioxo (=S), amino, cynao, halogen, alkyl, alkoxy or haloalkyl; Substituents on R4, R6, R7, R8, independently selected from halogen, nitro, cyano, amino, hydroxy, cyano, oxo (=0), thioxo (=S), =N-CN, =N-OR\ where Rx represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfmyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert- butyl-dimethyl-silanyloxy)-acetyl chloride (TBDMSO), tert-butoxycarbonyl (BOC), N- hydroxyformamide, carboxylic acids or its derivatives, phosphoric acid or its derivates. Further optional substituents on the optionally substituted groups defined above are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), thioxo (=S), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives. Substimtents on R2 and R3 independently selected from hydroxy, halogen, nitro, amino, alkyl, haloalkyl, alkoxy, =0, =S, cyano group, or carboxylic acid or its derivatives, their pharmaceutically acceptable salts their stereosiomers thereof, their prodmgs, their rotamers and their pharmaceutical compositions containing them.
Wherever substitutions are possible on the groups represented by R2, R3, R4, R5, R6, R7 and R8, they may take place 1 to 5 times, which may be same or different; 2. A compound as claimed in claim 1, wherein formula (I) as described by formula
(Ia) below:
Figure imgf000211_0001
Where R1 represents
— c- R6
Q
Where Q represents 'S'
R6 represents
(0 Hydrogen,
Optionally substituted groups selected from,
(ϋ) Alkyl,
(iii) Cycloalkyl,
(iv) Alkoxy,
(v) Cycloalkoxy,
(vi) Alkenyl, (vii) Alkenyloxy,
R2 and R3 at each occurrence are the same or different and are
(i) Hydrogen,
(ii) Halogen,
R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, aminocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, aryl, aryloxy, arylcarbonyl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcaarbonyl, tert-butoxycarbonyl (BOC), alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfmyl, arylsulfonyl, arylsulfanyl, arylsulfinyl, heteroarylsulfonyl
Substituents on R4 selected from halogen, nitro, cyano, amino, hydroxy, oxo (=0), =N-
CN, =N-ORx, where R represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfmyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert-butyl-dimethyl-silanyloxy)-acetyl chloride
(TBDMSO), tert-butoxycarbonyl (BOC), N-hydroxyformamide, carboxylic acids or its derivatives. The optional substituents on these groups are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives, phosphoric acid or its derivates;"
The substimtions on the possible groups represented by R4, may take place 1 to 5 times, which may be same or different;
3. The compound of formula (Ia) as claimed in claim 2, where R\ represents
— C-R6 S , wherein R represents alkyl or alkoxy group;
R2 and R3, which may be same or different, independently represent hydrogen or halogen;
R4 represents
R4 represents Hydrogen, Cyanq H,C > -
Figure imgf000213_0001
Figure imgf000213_0002
Figure imgf000213_0003
πo-y S
NH, • ...
Figure imgf000213_0004
n represens - ;
Hrf _ NC l, _ βr S,
Figure imgf000214_0001
Figure imgf000214_0002
Figure imgf000214_0003
Figure imgf000214_0004
Figure imgf000214_0005
Figure imgf000214_0006
Figure imgf000215_0001
Figure imgf000215_0002
Figure imgf000215_0003
4. The compound of formula (Ia) as claimed in claim 2, where Ri represents
-C-R6
S , wherein R represents alkyl or alkoxy group;
R2- and R3, which may be same or different, independently represent hydrogen or halogen;
R4 represents
Hydrogen, Cyano,
Figure imgf000216_0001
Figure imgf000216_0002
where R"' represents hydrogen or alkyl grou'p n represents 0-6;
Figure imgf000216_0003
Ry represents alkyl or aryl
The compound of formula (Ia) as claimed in claim 2, where R| represents
Figure imgf000217_0001
, wherein R6 represents alkyl or alkoxy group; R and R , which may be same or different, independently represent hydrogen or halogen; R represents cyano,
Figure imgf000217_0002
f A- a 4> .
Figure imgf000217_0003
Figure imgf000217_0004
OORy
Figure imgf000217_0006
Figure imgf000217_0005
Ry represents alkyl or aryl
6. A compound as claimed in claim 1, wherein formula (I) as described by formula (lb) below:
Figure imgf000218_0001
Where R1 represents
Figure imgf000218_0002
Where Q represents 'S'
R6 represents '
(i) Hydrogen,
Optionally substituted groups selected from,
(ii) Alkyl,
(iii) Cycloalkyl,
(iv) Alkoxy,
(v) Cycloalkoxy,
(vi) Alkenyl,
(vii) Alkenyloxy,
R2 and R3 at each occurrence are the same or different and are
(i) Hydrogen,
(ii) Halogen,
R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, aminocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, aryl, aryloxy, arylcarbonyl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcaarbonyl, tert-butoxycarbonyl (BOC), alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfinyl, arylsulfonyl, arylsulfanyl, arylsulfinyl, heteroarylsulfonyl
Substituents on R4 selected from halogen, nitro, cyano, amino, hydroxy, oxo (=0), =N- CN, =N-OR\ where R represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert-butyl-dimethyl-silanyloxy)-acetyl chloride
(TBDMSO), tert-butoxycarbonyl (BOC), N-hydroxyformamide, carboxylic acids or its derivatives. The optional substituents on these groups are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives, phosphoric acid or its derivates;
The substitutions on the possible groups represented by R4, may take place 1 to 5 times, which may be same or different; which is represented by compound of formula (Ia); their pharmaceutically acceptable salts their stereosiomers thereof, pharmaceutical compositions containing them
7. The compound of formula (lb), as defined in claim 6, where Ri represents
— C I I -R6
S , wherein R6 represents alkyl or alkoxy group;
2 3 -
R and R , which may be same or different, independently represent hydrogen or halogen; R4 represents
Hydrogen, Cyanq H3
Figure imgf000219_0001
Figure imgf000219_0002
Figure imgf000220_0001
Figure imgf000220_0002
Re=QH, OCH3, CH3, NH2
Figure imgf000220_0003
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000222_0002
Figure imgf000222_0003
8. The compound of formula (lb), as defined in claim 6, where Ri represents
— C-RD
S , wherein R6 represents alkyl or alkoxy group; R2 and R3, which may be same or different, independently represent hydrogen or halogen; R4 represents
Hydrogen, Cyano,
Figure imgf000223_0001
Figure imgf000223_0002
where R'" represents hydrogen or alkyl grou'p n represents 0-6;
ts
Figure imgf000223_0003
Figure imgf000223_0004
Rv represents
Figure imgf000223_0005
alkyl or aryl
Figure imgf000223_0006
Ry represents alkyl or aryl
9. The compound of formula (lb), as defined in claim 6, where Ri represents
-C-R°
II s , wherein R >6 represents alkyl or alkoxy group; R2 and R3, which may be same or different, independently represent hydrogen or halogen; R4 represents cyano,
Figure imgf000224_0001
Ry represents alkyl or aryl
10. The compound as claimed in claim 1,
Figure imgf000225_0001
Figure imgf000225_0002
Figure imgf000225_0003
Figure imgf000225_0004
Figure imgf000225_0005
Figure imgf000225_0006
Figure imgf000226_0001
Figure imgf000226_0002
Figure imgf000226_0003
Figure imgf000226_0004
Figure imgf000226_0005
Figure imgf000226_0006
Figure imgf000227_0001
Figure imgf000227_0002
Figure imgf000227_0003
Figure imgf000227_0004
Figure imgf000227_0005
Figure imgf000227_0006
.
Figure imgf000228_0001
Figure imgf000228_0002
Figure imgf000228_0003
Figure imgf000228_0004
Figure imgf000228_0005
Figure imgf000228_0006
Figure imgf000229_0001
^
Figure imgf000229_0002
:
Figure imgf000229_0003
Figure imgf000229_0004
Figure imgf000229_0005
Figure imgf000229_0006
Figure imgf000230_0001
Figure imgf000230_0003
Figure imgf000230_0004
Figure imgf000230_0005
Figure imgf000230_0006
.
Figure imgf000231_0001
.
Figure imgf000231_0002
Figure imgf000231_0003
Figure imgf000231_0004
Figure imgf000231_0005
Figure imgf000231_0006
Figure imgf000232_0001
Figure imgf000232_0002
Figure imgf000232_0003
.
Figure imgf000232_0004
Figure imgf000232_0005
Figure imgf000232_0006
Figure imgf000233_0001
Figure imgf000233_0002
Figure imgf000233_0003
Figure imgf000233_0004
Figure imgf000233_0005
Figure imgf000233_0006
Figure imgf000234_0001
.
Figure imgf000234_0002
Figure imgf000234_0003
Figure imgf000234_0004
Figure imgf000234_0005
Figure imgf000234_0006
Figure imgf000235_0001
Figure imgf000235_0002
Figure imgf000235_0003
,
Figure imgf000235_0004
H
Figure imgf000235_0005
Figure imgf000235_0006
Figure imgf000236_0001
Figure imgf000236_0002
Figure imgf000236_0003
Figure imgf000236_0004
Figure imgf000236_0005
Figure imgf000236_0006
Figure imgf000237_0001
Figure imgf000237_0002
Figure imgf000237_0003
Figure imgf000237_0004
Figure imgf000237_0005
Figure imgf000238_0001
Figure imgf000238_0002
.
Figure imgf000238_0003
Figure imgf000238_0004
Figure imgf000238_0005
Figure imgf000238_0006
Figure imgf000239_0001
Figure imgf000239_0002
Figure imgf000239_0003
Figure imgf000239_0004
Figure imgf000239_0005
Figure imgf000239_0006
Figure imgf000240_0001
Figure imgf000240_0002
their stereoisomers and their pharmaceutically acceptable salts thereof;
11. The compound as claimed in claim lis
Figure imgf000240_0003
Figure imgf000240_0004
Figure imgf000240_0005
Figure imgf000241_0001
Figure imgf000241_0002
Figure imgf000241_0003
=
Figure imgf000241_0004
Figure imgf000241_0005
Figure imgf000241_0006
Figure imgf000242_0001
Figure imgf000242_0002
Figure imgf000242_0003
Figure imgf000242_0004
their stereoisomers and their pharmaceutically acceptable salts thereof;
12. The compound as claimed in claim lis
Figure imgf000242_0005
Figure imgf000242_0006
Figure imgf000243_0001
Figure imgf000243_0002
Figure imgf000243_0003
Figure imgf000243_0004
Figure imgf000243_0005
,
Figure imgf000243_0006
Figure imgf000244_0001
Figure imgf000244_0002
Figure imgf000244_0003
*
their stereoisomers and their pharmaceutically acceptable salts thereof; 13. The compound as claimed in claim lis
Figure imgf000244_0004
Figure imgf000244_0005
Figure imgf000244_0006
Figure imgf000245_0001
Figure imgf000245_0002
Figure imgf000245_0003
Figure imgf000245_0004
Figure imgf000245_0005
.
Figure imgf000245_0006
,
Figure imgf000246_0001
Figure imgf000246_0002
Figure imgf000246_0003
Figure imgf000246_0004
their stereoisomers and their pharmaceutically acceptable salts thereof; 14. The compound as claimed in claim lis
Figure imgf000246_0005
Figure imgf000246_0006
Figure imgf000247_0001
Figure imgf000247_0002
Figure imgf000247_0003
Figure imgf000247_0004
CH
Figure imgf000247_0005
Figure imgf000247_0006
Figure imgf000248_0001
Figure imgf000248_0002
Figure imgf000248_0003
their stereoisomers and their pharmaceutically acceptable salts thereof;
15. A process for the preparation of compound of formula (I), which is represented by compound of formula (Ia) and (lb) respectively
Figure imgf000248_0004
Where R1 is isoindole-1, 3-dione, azido, NHR5 where R5 represents (a) Hydrogen,
Figure imgf000248_0005
Where Q represents 'O' or 'S'
R6 represents
(i) Hydrogen,
Optionally substituted groups selected from, (ϋ) Alkyl,
(iii) Cycloalkyl,
(iv) Alkoxy,
(v) Cycloalkoxy,
(vi) Alkenyl,
(vii) Alkenyloxy,
(viii) Aryl,
(ix) Aryloxy,
(xiv) Heteroaryl,
(xv) Heterocyclyl,
(xii) Heteroaryloxy,
(xiii) -NH-R7, where R7 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, hydroxyalkyl, alkoxy, cycloalkoxy, alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, — C I I — R8
Q ' wherein R8 is optionally substituted group selected from alkyl, alkoxy, cycloalkyl, alkenyl, alkenyloxy, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaryloxy, and Q represents oxygen or sulfur; (xiv) -N-[alkyl]2,
(xv) -N(RcRd), wherein Rc and Rd together form an optionally substituted 5 or 6 member heterocycle ring containing nitrogen and optionally having one or two additional hetero atoms selected from O, S or N; (xvi) -SR8, wherein R8 is as defined above, (xvii) -S02-alkyl;
R and R at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen, (iii) Cyano, (iv) Nitro, (v) Amino
Optionally substituted groups selected from (vi) Alkyl, (vii) Haloalkyl, (viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; (ix) -NR where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino; 'Z' represents N, C or CH;
' ' represents a bond or nobond;
R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, alkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, alkenyloxy, aryl, aryloxy, arylcarbonyl, aralkyl, aralkylcarbonyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heterocyclylalkyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, aralkoxyalkyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfinyl, arylsulfonyl, arylsulfanyl, arylsulfmyl, tert-butoxycarbonyl, (BOC), heteroarylsulfonyl
R and R independently represent hydrogen, oxo (=0), thioxo (=S), amino, cynao, halogen, alkyl, alkoxy or haloalkyl;
Substituents on R4, R6, R7, R8, independently selected from halogen, nitro, cyano, amino, hydroxy, cyano, oxo (=0), thioxo (=S), =N-CN, =N-OR\ where R represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert- butyl-dimethyl-silanyloxy)-acetyl chloride (TBDMSO), tert-butoxycarbonyl (BOC), N- hydroxyformamide, carboxylic acids or its derivatives, phosphoric acid or its derivates. Further optional substituents on the optionally substituted groups defined above are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), thioxo (=S), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives. Substimtents on R2 and R3 independently selected from hydroxy, halogen, nitro, amino, alkyl, haloalkyl, alkoxy, =0, =S, cyano group, or carboxylic acid or its derivatives, their pharmaceutically acceptable salts their stereosiomers thereof, pharmaceutical compositions containing them.
Wherever substitutions are possible on the groups represented by R2, R3, R4, R5, R6, R7 and R8, they may take place 1 to 5 times, which may be same or different; which comprises:
Figure imgf000251_0001
Where Rb represents R or R4, wherein R represents 't-butoxy carbonyl group (protecting group) and R4 is as defined above.
16. A pharmaceutical composition comprising (a) an antibacterially effective amount of the compound of formula (I) as claimed in claim 1 and (b) a pharmaceutically acceptable carrier, diluent, excipient or solvate.
Figure imgf000251_0002
17. The pharmaceutical composition of claim 16, which is a tablet, a capsule, a powder, a syrup, a solution or a suspension.
18. A method for inhibiting the growth of bacteria in humans and non-human mammals suffering bacterial infections, which comprises administering to a subject suffering such infection an antibacterially effective dose of the compound of claim 1.
19. The method according to claim 1 , wherein the bacterial infection is caused by the drug susceptible or resistance bacterial pathogens.
20. A compound of formula (2f)
Figure imgf000252_0001
(21) where Rb represents R or R4; where in R represents tert-butoxy carbonyl (BOC) R4 represents hydrogen, cyano, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylammoalklyl, acyl, haloacyl, alkylcarbonyl, alkoxycarbonyl,, hydroxyalkylcarbonyl, alkoxyalkyl, alkenyloxy, aryl, aryloxy, arylcarbonyl, aralkyl, aralkylcarbonyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaralkylcarbonyl, heterocyclylalkyl, heteroaryloxy, cycloalkoxy, heteroarylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, aralkyl, aralkylcarbonyl, aralkoxyalkylcarbonyl, aralkoxyalkyl, aralkoxyalkylcarbonyl, alkenylcarbonyl, alkylsulfonyl, alkylsulfanyl, alkylsulfinyl, arylsulfonyl, arylsulfanyl, arylsulfmyl, tert-butoxycarbonyl, (BOC), heteroarylsulfonyl
R and R3 at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen, (iii) Cyano, (iv) Nitro, (v) Amino
Optionally substituted groups selected from (vi) Alkyl, (vii) Haloalkyl,
(viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; (ix) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino;
R and R independently represent hydrogen, oxo (=0), thioxo (=S), amino, cynao, halogen, alkyl, alkoxy or haloalkyl;
Substiments on R4 independently selected from halogen, nitro, cyano, amino, hydroxy, cyano, oxo (=0), thioxo (=S), =N-CN, =N-ORx, where Rx represents hydrogen, alkyl or aryl; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, alkenyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, hydroxyalkyl, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, acyl, aryl, aralkyl, aralkoxy, heteroaryl, (tert-butyl-dimethyl- silanyloxy)-acetyl chloride (TBDMSO), tert-butoxycarbonyl (BOC), N- hydroxyformamide, carboxylic acids or its derivatives, phosphoric acid or its derivates. Further optional substiments on the optionally substituted groups defined above are selected from halogen, hydroxyl, cyano, amino, nitro, oxo (=0), thioxo (=S), hydroxyalkyl, alkylamino, aminoalkyl, carboxylic acid or its derivatives. Substimtents on R2 and R3 independently selected from hydroxy, halogen, nitro, amino, alkyl, haloalkyl, alkoxy, =0, =S, cyano group, or carboxylic acid or its derivatives.
Wherever substitutions are possible on the groups represented by R2, R3 and R4, they may take place 1 to 5 times, which may be same or different. 21. A compound of formula (2k)
Figure imgf000253_0001
where R represents teri f-butoxy carbonyl (BOC)
R2 and R at each occurrence are the same or different and are
(i) Hydrogen,
(ϋ) Halogen,
(iii) Cyano,
(iv) Nitro,
(v) Amino
Optionally substituted groups selected from
(vi) Alkyl,
(vii) Haloalkyl, (viii) 0Ra where Ra represents hydrogen or optionally substituted alkyl group; (ix) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino;
R and R independently represent hydrogen, oxo (=0), thioxo (=S), amino, cynao, halogen, alkyl, alkoxy or haloalkyl;
Substimtents on R2 and R3 independently selected from hydroxy, halogen, nitro, amino, alkyl, haloalkyl, alkoxy, =0, =S, cyano group, or carboxylic acid or its derivatives.
Wherever substitutions are possible on the groups represented by R2 and R3 they may take place 1 to 5 times, which may be same or different. 22. A compound of formula (21)
Figure imgf000254_0001
(21) where R represents tert-butoxy carbonyl (BOC) R2 and R at each occurrence are the same or different and are (i) Hydrogen, (ii) Halogen, (iii) Cyano, (iv) Nitro, (v) Amino
Optionally substituted groups selected from (vi) Alkyl, (vii) Haloalkyl,
(viii) ORa where Ra represents hydrogen or optionally substituted alkyl group; (ix) -NRb where Rb represents hydrogen or optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, hydroxyalkyl, alkyl carbonyl, alkoxycarbonyl, alkoxyalkyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, amino alkyl, alkylamino, aryl amino;
R and R independently represent hydrogen, oxo (=0), thioxo (=S), amino, cynao, halogen, alkyl, alkoxy or haloalkyl; Substimtents on R2 and R3 independently selected from hydroxy, halogen, nitro, amino, alkyl, haloalkyl, alkoxy, =0, =S, cyano group, or carboxylic acid or its derivatives.
Wherever substitutions are possible on the groups represented by R2 and R3 they may take place 1 to 5 times, which may be same or different.
23. The compound of claim 1 , which is (l-{4-[4-(2(S),3-Dihydroxy-propionyl)- piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid - methyl ester or a salt there of
24. The compound of claim 1, (l-{3,5-Difluoro-4-[4-(2(R),3(S),4-trihydroxy-butyryl) -piperazin-l-yl]-phenyl}-lH [l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester or a salt there of
25. The compound of claim 1, which is (l-{4-[l-(2,3-Dihydroxy-propionyl)-l,2,3,6- tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}-l -[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O-methyl ester or a salt there of
26. The compound of claim 1, which is {l-[4-(4-Aminooxalyl-piperazin-l-yl)-3,4- difluoro-phenyl]-lH-[l,2,3]triazol-ylmethyl}-thiocarbamic acid O-methyl ester or a salt there of
27. The compound of claim 1, which is (l-{4-[4-(2(R),3-Dihydroxy-propionyl)- piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester or a salt there of
28. The compound of claim 1 , which is (l-{3,5-Difluoro-4-[4-(3-hydroxymethyl- propionyl)-piperazin-l-yl]-phenyl}-lH-[l ,2,3]triazol-4-ylmethyl)-thiocarbamic acid O- methyl ester or a salt there of
29. The compound of claim 1, which is (l-{4-[l-(2(S), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}-lH-[l,2,3] triazol-4-ylmethyl)- thiocarbamic acid O-methyl ester or a salt there of
30. The compound of claim 1, which is (l-{4-[l-(2(R), 3-Dihydroxy-propionyl)-l, 2, 3, 6-tetrahydro-pyridin-4-yl]-3,5-difluoro-phenyl}-lH-[l, 2, 3] triazol-4-ylmethyl)- thiocarbamic acid O-methyl ester or a salt there of
31. The compound of claim 1, which is (l-{4-[4-(3(S),4-Dihydroxy-butyryl)- piperazin-l-yl]-3,5-difluoro-phenyl}-lH-[l,2,3]triazol-4-ylmethyl)-thiocarbamic acid - methyl ester or a salt there of
32. The compound of claim 1, which is (l-{3,5-Difluoro-4-[l-(3-hydroxy-2- hydroxymethyl-propionyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-phenyl}-l H-[l ,2,3]triazol-4- ylmethyl)-thiocarbamic acid O-methyl ester or a salt there of
PCT/IB2005/000343 2004-02-17 2005-02-11 Triazole compounds as antibacterial agents and pharmaceutical compositions containing them WO2005082892A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN120/CHE/2004 2004-02-17
IN120CH2004 2004-02-17

Publications (2)

Publication Number Publication Date
WO2005082892A2 true WO2005082892A2 (en) 2005-09-09
WO2005082892A3 WO2005082892A3 (en) 2006-03-23

Family

ID=34897727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000343 WO2005082892A2 (en) 2004-02-17 2005-02-11 Triazole compounds as antibacterial agents and pharmaceutical compositions containing them

Country Status (1)

Country Link
WO (1) WO2005082892A2 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082910A1 (en) * 2006-01-19 2007-07-26 Laboratorios Salvat, S.A. Dicarbonylic compounds with antibacterial activity
EP1876168A1 (en) * 2006-07-04 2008-01-09 Evonik Degussa GmbH Method for manufacturing beta amino alpha hydroxy carboxylic acid amides
US7521470B2 (en) 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7763608B2 (en) 2006-05-05 2010-07-27 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
WO2016049524A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9810690B2 (en) 2015-10-19 2017-11-07 Araxes Pharma Llc Method for screening inhibitors of Ras
US9840516B2 (en) 2013-10-10 2017-12-12 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US9926267B2 (en) 2013-03-15 2018-03-27 Araxes Pharma Llc Covalent inhibitors of K-Ras G12C
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US10111874B2 (en) 2014-09-18 2018-10-30 Araxes Pharma Llc Combination therapies for treatment of cancer
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US11013741B1 (en) 2018-04-05 2021-05-25 Sumitomo Dainippon Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009328A1 (en) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
WO1997030995A1 (en) * 1996-02-24 1997-08-28 Zeneca Limited Antibiotic oxazolidinone derivatives
WO2001040222A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
WO2003008395A1 (en) * 2001-07-20 2003-01-30 Laboratorios S.A.L.V.A.T., S.A. Substituted isoxazoles and the use thereof as antibiotics
WO2003059894A1 (en) * 2002-01-18 2003-07-24 Dr.Reddy's Laboratories Ltd. Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009328A1 (en) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
WO1997030995A1 (en) * 1996-02-24 1997-08-28 Zeneca Limited Antibiotic oxazolidinone derivatives
WO2001040222A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
WO2003008395A1 (en) * 2001-07-20 2003-01-30 Laboratorios S.A.L.V.A.T., S.A. Substituted isoxazoles and the use thereof as antibiotics
WO2003059894A1 (en) * 2002-01-18 2003-07-24 Dr.Reddy's Laboratories Ltd. Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153670B2 (en) 2004-06-18 2012-04-10 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7521470B2 (en) 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US8377974B2 (en) 2004-06-18 2013-02-19 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2007082910A1 (en) * 2006-01-19 2007-07-26 Laboratorios Salvat, S.A. Dicarbonylic compounds with antibacterial activity
US7763608B2 (en) 2006-05-05 2010-07-27 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7767697B2 (en) 2006-05-05 2010-08-03 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US8349873B2 (en) 2006-05-05 2013-01-08 Millennium Pharmaceuticals, Inc. Factor XA inhibitors
US8063077B2 (en) 2006-05-05 2011-11-22 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP1876168A1 (en) * 2006-07-04 2008-01-09 Evonik Degussa GmbH Method for manufacturing beta amino alpha hydroxy carboxylic acid amides
CN101100443B (en) * 2006-07-04 2012-04-25 赢创德固赛有限公司 Process for preparing beta-amino-alpha-hydroxycarboxamides
US7612237B2 (en) 2006-07-04 2009-11-03 Degussa Gmbh Process for preparing β-amino-α-hydroxycarboxamides
US8440862B2 (en) 2006-07-04 2013-05-14 Evonik Degussa Gmbh Process for preparing β-amino-α-hydroxycarboxamides
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
US10752594B2 (en) 2013-03-14 2020-08-25 Sumitomo Dainippon Pharma Oncology, Inc. JAK1 and ALK2 inhibitors and methods for their use
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US10919850B2 (en) 2013-03-15 2021-02-16 Araxes Pharma Llc Covalent inhibitors of KRas G12C
US9926267B2 (en) 2013-03-15 2018-03-27 Araxes Pharma Llc Covalent inhibitors of K-Ras G12C
US10273207B2 (en) 2013-03-15 2019-04-30 Araxes Pharma Llc Covalent inhibitors of kras G12C
US9840516B2 (en) 2013-10-10 2017-12-12 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US10370386B2 (en) 2013-10-10 2019-08-06 Araxes Pharma Llc Substituted quinolines as inhibitors of KRAS G12C
US10927125B2 (en) 2013-10-10 2021-02-23 Araxes Pharma Llc Substituted cinnolines as inhibitors of KRAS G12C
US11878985B2 (en) 2013-10-10 2024-01-23 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US10111874B2 (en) 2014-09-18 2018-10-30 Araxes Pharma Llc Combination therapies for treatment of cancer
JP2017528498A (en) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Inhibitors of KRAS G12C mutant protein
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2016049524A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10829458B2 (en) 2015-04-10 2020-11-10 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10351550B2 (en) 2015-07-22 2019-07-16 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US9810690B2 (en) 2015-10-19 2017-11-07 Araxes Pharma Llc Method for screening inhibitors of Ras
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US11021470B2 (en) 2015-11-16 2021-06-01 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10723738B2 (en) 2016-09-29 2020-07-28 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US11377441B2 (en) 2017-05-25 2022-07-05 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US11013741B1 (en) 2018-04-05 2021-05-25 Sumitomo Dainippon Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
US11400091B2 (en) 2018-04-05 2022-08-02 Sumitomo Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

Also Published As

Publication number Publication date
WO2005082892A3 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2005082892A2 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
JP5475841B2 (en) Tri-, tetra-substituted-3-aminopyrrolidine derivatives
US7875715B2 (en) Compounds for the treatment of multi-drug resistant bacterial infections
JP2008542249A (en) Aminopiperidine quinoline with antibacterial activity and its stereo-analogues
AU2099995A (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
EP2913330A1 (en) Condensed derivatives of imidazole useful as pharmaceuticals
CA2616977A1 (en) Oxazolidinone-quinolone hybrids as antibacterial compounds
JPWO2007129745A1 (en) Heteroarylamide lower carboxylic acid derivatives
AU784314B2 (en) Piperidinyloxy and pyrrolidinyloxyphenyl oxazolidinones as antibacterials
EP2800748A1 (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
RU2737892C1 (en) Hydroxyalkylthiadiazole derivatives
SG176014A1 (en) 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
JP5511824B2 (en) Novel oxazolidinone derivative having cyclic amidoxime or cyclic amidrazon group and pharmaceutical composition containing the same
FR2928150A1 (en) NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONES DERIVATIVES, THEIR PREPARATION AND APPLICATION AS ANTI-BACTERIANS
KR101169359B1 (en) Novel Oxazolidinone derivatives with cyclic amidrazone and Pharmaceutical Compositions thereof
EP2913333A1 (en) 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents
US8952010B2 (en) Amino group-containing pyrrolidinone derivative
JP5063032B2 (en) Tri-, tetra-substituted-3-aminopyrrolidine derivatives
TW202225165A (en) Pyrrole derivatives and preparation method and use thereof
CA3168355A1 (en) Macrocyclic indole derivatives as inhibitors of mcl-1
KR20120081579A (en) Novel oxazolidinone derivatives with cyclic amidrazone and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase